


WEST Search History

DATE: Monday, May 17, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L20	3D6 AND humanized AND antibody	41
<input type="checkbox"/>	L19	L18 AND polyclonal antibody	20
<input type="checkbox"/>	L18	L17 AND beta-amyloid	80
<input type="checkbox"/>	L17	L16 AND amyloid	90
<input type="checkbox"/>	L16	(3D6 AND monoclonal antibody)	156
<input type="checkbox"/>	L15	L13 AND amyloid	93
<input type="checkbox"/>	L14	L13 AND beta	134
<input type="checkbox"/>	L13	L12 AND antibody	165
<input type="checkbox"/>	L12	(3D6)	348
<input type="checkbox"/>	L11	L10 AND 3D6	19
<input type="checkbox"/>	L10	(530/387.1,387.2,387.3,387.9,388.1,388.15.CCLS.)	5185
<input type="checkbox"/>	L9	Yednock-T.IN.	5
<input type="checkbox"/>	L8	Yednock-Ted.IN.	3
<input type="checkbox"/>	L7	Yednock.IN.	37
<input type="checkbox"/>	L6	Saldanha-J.IN.	10
<input type="checkbox"/>	L5	Saldanha-Jose.IN.	17
<input type="checkbox"/>	L4	Saldanha.IN.	149
<input type="checkbox"/>	L3	Basi-G.IN.	3
<input type="checkbox"/>	L2	Basi-Guriq.IN.	4
<input type="checkbox"/>	L1	(Basi.IN.)	56

END OF SEARCH HISTORY



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for beta-amyloid AND antibody AND 3D6 Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 20 Sort Send to Text

Text Version

☐ 1: [Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E.](#) Related Articles, Links



Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

Amyloid. 2000 Dec;7(4):245-58.

PMID: 11132093 [PubMed - indexed for MEDLINE]

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts


ClinicalTrials.gov

PubMed Central

Privacy Policy

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act | Disclaimer](#)

May 12 2004 06:43:50



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Book
 Search PubMed for 3D6 Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities

PubMed Services

Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Cubby

Related Resources

Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text
 Items 1-42 of 42 One page.

1: [Oldoni I, Weiblen R, Inkelmann MA, Flores EF.](#) [Related Articles, Links](#)

Production and characterization of monoclonal antibodies to a Brazilian bovine herpesvirus type 5.
 Braz J Med Biol Res. 2004 Feb;37(2):213-21. Epub 2004 Jan 30.
 PMID: 14762576 [PubMed - in process]

2: [Nguyen TH, Loux N, Dagher I, Vons C, Carey K, Briand P, Hadchouel M, Franco D, Jouanneau J, Schwall R, Weber A.](#) [Related Articles, Links](#)

Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met.
 Cancer Gene Ther. 2003 Nov;10(11):840-9.
 PMID: 14605670 [PubMed - in process]

3: [Liu X, Zhen Y.](#) [Related Articles, Links](#)

Antitumor effects of monoclonal antibody Fab' fragment-containing immunoconjugates.
 Chin Med Sci J. 2002 Mar;17(1):1-6.
 PMID: 12894876 [PubMed - indexed for MEDLINE]

4: [Bacskaí BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT.](#) [Related Articles, Links](#)

Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.
 J Neurosci. 2002 Sep 15;22(18):7873-8.
 PMID: 12223540 [PubMed - indexed for MEDLINE]

5: [Elmore LW, Domson K, Moore JR, Kornstein M, Burks RT.](#) [Related Articles, Links](#)

Expression of c-kit (CD117) in benign and malignant human endometrial epithelium.
 Arch Pathol Lab Med. 2001 Jan;125(1):146-51.
 PMID: 11151069 [PubMed - indexed for MEDLINE]



















6: [Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E.](#) [Related Articles, Links](#)

















Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.
 Amyloid. 2000 Dec;7(4):245-58.
 PMID: 11132093 [PubMed - indexed for MEDLINE]











7: [Wang W, Zhou J, Xu L, Zhen Y.](#) [Related Articles, Links](#)

Antineoplastic effect of intracellular expression of a single-chain antibody directed against type IV collagenase.
 J Environ Pathol Toxicol Oncol. 2000;19(1-2):61-8.
 PMID: 10905509 [PubMed - indexed for MEDLINE]

8: [Cavacini LA, Wisniewski A, Peterson JE, Montefiori D, Emes C, Duval M, Kingsbury G, Wang A, Scadden D, Posner MR.](#) [Related Articles, Links](#)

-  **A human anti-HIV autoantibody enhances EBV transformation and HIV infection.**
Clin Immunol. 1999 Dec;93(3):263-73.
PMID: 10600338 [PubMed - indexed for MEDLINE]
-  **9:** [Jackson LR, Trudel LJ, Fox JG, Lipman NS.](#) [Related Articles, Links](#)
-  **Monoclonal antibody production in murine ascites. II. Production characteristics.**
Lab Anim Sci. 1999 Feb;49(1):81-6.
PMID: 10090099 [PubMed - indexed for MEDLINE]
-  **10:** [Zhou YY, Li CL.](#) [Related Articles, Links](#)
-  **Spin-triplet contribution to zero-field splittings for 3d4 and 3d6 ions at tetragonal sites.**
Phys Rev B Condens Matter. 1993 Dec 1;48(22):16489-16499. No abstract available.
PMID: 10008231 [PubMed - as supplied by publisher]
-  **11:** [Jiang CY, Du ML, Zhou YY.](#) [Related Articles, Links](#)
-  **Contributions to zero-field splitting from spin triplets of 3d4 and 3d6 ions in tetragonal symmetry.**
Phys Rev B Condens Matter. 1994 Jul 1;50(2):949-954. No abstract available.
PMID: 9975761 [PubMed - as supplied by publisher]
-  **12:** [Cavacini LA, Emes CL, Wisniewski AV, Power J, Lewis G, Montefiori D, Posner MR.](#) [Related Articles, Links](#)
-  **Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.**
AIDS Res Hum Retroviruses. 1998 Sep 20;14(14):1271-80.
PMID: 9764911 [PubMed - indexed for MEDLINE]
-  **13:** [Kunert R, Ruker F, Katinger H.](#) [Related Articles, Links](#)
-  **Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5.**
AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1115-28.
PMID: 9737583 [PubMed - indexed for MEDLINE]
-  **14:** [Duperray A, Languino LR, Plescia J, McDowall A, Hogg N, Craig AG, Berendt AR, Altieri DC.](#) [Related Articles, Links](#)
-  **Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging.**
J Biol Chem. 1997 Jan 3;272(1):435-41.
PMID: 8995280 [PubMed - indexed for MEDLINE]
-  **15:** [Woodside DG, Teague TK, McIntyre BW.](#) [Related Articles, Links](#)
-  **Specific inhibition of T lymphocyte coactivation by triggering integrin beta 1 reveals convergence of beta 1, beta 2, and beta 7 signaling pathways.**
J Immunol. 1996 Jul 15;157(2):700-6.
PMID: 8752919 [PubMed - indexed for MEDLINE]
-  **16:** [Stigler RD, Ruker F, Katinger D, Elliott G, Hohne W, Henklein P, Ho JX, Keeling K, Carter DC, Nugal E, et al.](#) [Related Articles, Links](#)
-  **Interaction between a Fab fragment against gp41 of human immunodeficiency virus 1 and its peptide epitope: characterization using a peptide epitope library and molecular modeling.**
Protein Eng. 1995 May;8(5):471-9.
PMID: 8532669 [PubMed - indexed for MEDLINE]
-  **17:** [Chen YH, Susanna A, Bock G, Steindl F, Katinger H, Dierich MP.](#) [Related Articles, Links](#)

-  HIV-1 gp41 shares a common immunologic determinant with human T, B and monocyte cell lines.
Immunol Lett. 1994 Mar;39(3):219-22.
PMID: 7518416 [PubMed - indexed for MEDLINE]
-  **18:** [Unterluggauer F, Doblhoff-Dier O, Tauer C, Jungbauer A, Gaida T, Reiter M, Schmatz C, Zach N, Katinger H.](#) [Related Articles, Links](#)
[Stable, continuous large-scale production of human monoclonal HIV-1 antibody using a computer-controlled pilot plant.](#)
Biotechniques. 1994 Jan;16(1):140-7.
PMID: 8136128 [PubMed - indexed for MEDLINE]
-  **19:** [Salem RR, Wolf BC, Sears HF, Lavin PT, Ravikumar TS, DeCoste D, D'Emilia JC, Herlyn M, Schlom J, Gottlieb LS, et al.](#) [Related Articles, Links](#)
[Expression of colorectal carcinoma-associated antigens in colonic polyps.](#)
J Surg Res. 1993 Sep;55(3):249-55.
PMID: 8412106 [PubMed - indexed for MEDLINE]
-  **20:** [Marschang P, Gurtler L, Totsch M, Thielens NM, Arlaud GJ, Hittmair A, Katinger H, Dierich MP.](#) [Related Articles, Links](#)
 HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells.
AIDS. 1993 Jul;7(7):903-10.
PMID: 7689323 [PubMed - indexed for MEDLINE]
-  **21:** [Reisbach G, Bartke I, Kempkes B, Kostka G, Ellwart J, Birner A, Thalmeier K, Mailhammer R, Bornkamm GW, Ullrich A, et al.](#) [Related Articles, Links](#)
 Characterization of hemopoietic cell populations from human cord blood expressing c-kit.
Exp Hematol. 1993 Jan;21(1):74-9.
PMID: 7678090 [PubMed - indexed for MEDLINE]
-  **22:** [Borth N, Heider R, Assadian A, Katinger H.](#) [Related Articles, Links](#)
 Growth and production kinetics of human x mouse and mouse hybridoma cells at reduced temperature and serum content.
J Biotechnol. 1992 Sep;25(3):319-31.
PMID: 1382458 [PubMed - indexed for MEDLINE]
-  **23:** [Churn SB, Yaghmai A, Povlishock J, Rafiq A, DeLorenzo RJ.](#) [Related Articles, Links](#)
 Global forebrain ischemia results in decreased immunoreactivity of calcium/calmodulin-dependent protein kinase II.
J Cereb Blood Flow Metab. 1992 Sep;12(5):784-93.
PMID: 1324253 [PubMed - indexed for MEDLINE]
-  **24:** [Cloeckaert A, Zygmunt MS, de Wergifosse P, Dubray G, Limet JN.](#) [Related Articles, Links](#)
 Demonstration of peptidoglycan-associated Brucella outer-membrane proteins by use of monoclonal antibodies.
J Gen Microbiol. 1992 Jul;138 (Pt 7):1543-50.
PMID: 1380979 [PubMed - indexed for MEDLINE]
-  **25:** [Groopman JD, Skipper PL, Donahue PR, Trudel LJ, Wildschutte M, Kadlubar FF, Tannenbaum SR.](#) [Related Articles, Links](#)
 Monoclonal antibodies and rabbit antisera recognizing 4-aminobiphenyl--DNA adducts and application to immunoaffinity chromatography.
Carcinogenesis. 1992 Jun;13(6):917-22.
PMID: 1600611 [PubMed - indexed for MEDLINE]
-  **26:** [Ruker F, Ebert V, Kohl J, Steindl F, Riegler H, Katinger H.](#) [Related Articles, Links](#)
Expression of a human monoclonal anti-HIV-1 antibody in CHO cells.

-  [Ann N Y Acad Sci. 1991 Dec 27;646:212-9.](#)
PMID: 1809191 [PubMed - indexed for MEDLINE]
-  **27:** [Kohl J, Ruker F, Himmler G, Razazzi E, Katinger H.](#) [Related Articles, Links](#)
Cloning and expression of an HIV-1 specific single-chain Fv region fused to Escherichia coli alkaline phosphatase.
[Ann N Y Acad Sci. 1991 Dec 27;646:106-14.](#)
PMID: 1809181 [PubMed - indexed for MEDLINE]
-  **28:** [Ohsako S, Kurohmaru M, Nishida T, Hayashi Y.](#) [Related Articles, Links](#)
Analysis of various antigens in golden hamster testis by monoclonal antibodies.
[J Vet Med Sci. 1991 Dec;53\(6\):969-74.](#)
PMID: 1790231 [PubMed - indexed for MEDLINE]
-  **29:** [Larcher C, Broker M, Huemer HP, Solder B, Schulz TF, Hofbauer JM, Wachter H, Dierich MP.](#) [Related Articles, Links](#)
Characterization of monoclonal antibodies to human immunodeficiency virus type 1 gp41 by HIV-1 polypeptides expressed in Escherichia coli.
[FEMS Microbiol Immunol. 1990 Sep;2\(2\):103-10.](#)
PMID: 1701654 [PubMed - indexed for MEDLINE]
-  **30:** [Wolf BC, Salem RR, Sears HF, Horst DA, Lavin PT, Herlyn M, Itzkowitz SH, Schlom J, Steele GD Jr.](#) [Related Articles, Links](#)
The expression of colorectal carcinoma-associated antigens in the normal colonic mucosa. An immunohistochemical analysis of regional distribution.
[Am J Pathol. 1989 Jul;135\(1\):111-9.](#)
PMID: 2476033 [PubMed - indexed for MEDLINE]
-  **31:** [Lipoldova M, Boylston AW, Yssel H, Owen MJ.](#) [Related Articles, Links](#)
T-cell receptor V beta 5 usage defines reactivity to a human T-cell receptor monoclonal antibody.
[Immunogenetics. 1989;30\(3\):162-8.](#)
PMID: 2476387 [PubMed - indexed for MEDLINE]
-  **32:** [Miyazaki H, Kozutsumi H, Kato T, Hoshi S, Tamura S, Kubota M, Suzuki T.](#) [Related Articles, Links](#)
Production of monoclonal antibodies against human erythropoietin and their use in the purification of human urinary erythropoietin.
[J Immunol Methods. 1988 Oct 26;113\(2\):261-7.](#)
PMID: 2459256 [PubMed - indexed for MEDLINE]
-  **33:** [Hodges RS, Heaton RJ, Parker JM, Molday L, Molday RS.](#) [Related Articles, Links](#)
Antigen-antibody interaction. Synthetic peptides define linear antigenic determinants recognized by monoclonal antibodies directed to the cytoplasmic carboxyl terminus of rhodopsin.
[J Biol Chem. 1988 Aug 25;263\(24\):11768-75.](#)
PMID: 2457026 [PubMed - indexed for MEDLINE]
-  **34:** [Borst J, Spits H, Voordouw A, de Vries E, Boylston A, de Vries JE.](#) [Related Articles, Links](#)
A family of T-cell receptor molecules expressed on T-cell clones with different specificities for allomajor histocompatibility antigens.
[Hum Immunol. 1986 Dec;17\(4\):426-42.](#)
PMID: 2432049 [PubMed - indexed for MEDLINE]
-  **35:** [Yssel H, Blanchard D, Boylston A, De Vries JE, Spits H.](#) [Related Articles, Links](#)
T cell clones which share T cell receptor epitopes differ in phenotype, function and specificity.

Eur J Immunol. 1986 Oct;16(10):1187-93.
PMID: 2429845 [PubMed - indexed for MEDLINE]

-  **36:** [Boylston AW, Borst J, Yssel H, Blanchard D, Spits H, de Vries JE](#). [Related Articles, Links](#)



Properties of a panel of monoclonal antibodies which react with the human T cell antigen receptor on the leukemic line HPB-ALL and a subset of normal peripheral blood T lymphocytes.

J Immunol. 1986 Jul 15;137(2):741-4.
PMID: 2424978 [PubMed - indexed for MEDLINE]

-  **37:** [Hicks D, Molday RS](#). [Related Articles, Links](#)



Differential immunogold-dextran labeling of bovine and frog rod and cone cells using monoclonal antibodies against bovine rhodopsin.


Exp Eye Res. 1986 Jan;42(1):55-71.
PMID: 2420630 [PubMed - indexed for MEDLINE]

-  **38:** [Borst J, Boylston AW, de Vries JE, Spits H](#). [Related Articles, Links](#)



Human T cell lines differing in phenotype and specificity are reactive with the same anti-idiotypic antibody.


J Immunol. 1986 Jan;136(2):601-8.
PMID: 2416817 [PubMed - indexed for MEDLINE]

-  **39:** [Boylston AW, Cosford P](#). [Related Articles, Links](#)



Growth of normal human T lymphocytes induced by monoclonal antibody to the T cell antigen receptor.

Eur J Immunol. 1985 Jul;15(7):738-42.
PMID: 3874082 [PubMed - indexed for MEDLINE]

-  **40:** [Liu YS, Tobias RJ, Zurawski VR Jr](#). [Related Articles, Links](#)



A more specific, simpler radioimmunoassay for carcinoembryonic antigen, with use of monoclonal antibodies.

Clin Chem. 1985 Feb;31(2):191-5.
PMID: 3967348 [PubMed - indexed for MEDLINE]

-  **41:** [Uede T, Ibayashi Y, Koda H, Kikuchi K](#). [Related Articles, Links](#)



Construction of rat-mouse T-cell hybridomas that constitutively produce rat IL-2.

Hybridoma. 1985 Summer;4(2):103-14.
PMID: 3874144 [PubMed - indexed for MEDLINE]

-  **42:** [MacKenzie D, Molday RS](#). [Related Articles, Links](#)




Organization of rhodopsin and a high molecular weight glycoprotein in rod photoreceptor disc membranes using monoclonal antibodies.

J Biol Chem. 1982 Jun 25;257(12):7100-5.
PMID: 7085619 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** Sort **Send to** **Text**
Items 1-42 of 42 One page.

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

May 12 2004 06:43:50



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for 10D5 Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Text Version

Items 1-11 of 11

One page.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: Yamaguchi H, Harada A.

Related Articles, Links



Supramolecular formation of antibodies with viologen dimers: utilization for amplification of methyl viologen detection signals in surface plasmon resonance sensor.

Biomacromolecules. 2002 Nov-Dec;3(6):1163-9.

PMID: 12425652 [PubMed - indexed for MEDLINE]

☐ 2: Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT

Related Articles, Links



Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.

J Neurosci. 2002 Sep 15;22(18):7873-8.

PMID: 12223540 [PubMed - indexed for MEDLINE]

☐ 3: Ramos DM, But M, Regezi J, Schmidt BL, Atakilit A, Dang D, Ellis D, Jordan R, Li X.

Related Articles, Links



Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma.

Matrix Biol. 2002 Apr;21(3):297-307.

PMID: 12009335 [PubMed - indexed for MEDLINE]

☐ 4: Parvizi J, Van Hoesen GW, Damasio A.

Related Articles, Links



The selective vulnerability of brainstem nuclei to Alzheimer's disease.

Ann Neurol. 2001 Jan;49(1):53-66.

PMID: 11198297 [PubMed - indexed for MEDLINE]

☐ 5: Parvizi J, Van Hoesen GW, Damasio A.

Related Articles, Links



Selective pathological changes of the periaqueductal gray matter in Alzheimer's disease.

Ann Neurol. 2000 Sep;48(3):344-53.

PMID: 10976641 [PubMed - indexed for MEDLINE]

☐ 6: Jackson T, Sheppard D, Denyer M, Blakemore W, King AM.

Related Articles, Links



The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus.

J Virol. 2000 Jun;74(11):4949-56.

PMID: 10799568 [PubMed - indexed for MEDLINE]

☐ 7: Frenkel D, Balass M, Katchalski-Katzir E, Solomon B.

Related Articles, Links



High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation.


J Neuroimmunol. 1999 Mar 1;95(1-2):136-42.

PMID: 10229123 [PubMed - indexed for MEDLINE]

☐ 8: Frenkel D, Balass M, Solomon B.


Related Articles, Links


N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents

-  the epitope of its anti-aggregating antibodies.
J Neuroimmunol. 1998 Aug 1;88(1-2):85-90.
PMID: 9688328 [PubMed - indexed for MEDLINE]


 **9:** [Huang X, Wu J, Spong S, Sheppard D.](#)

[Related Articles, Links](#)

-  The integrin alphavbeta6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin.
J Cell Sci. 1998 Aug;111 (Pt 15):2189-95.
PMID: 9664040 [PubMed - indexed for MEDLINE]


 **10:** [Johnstone EM, Babbey LE, Stephenson D, Paul DC, Santerre RF, Clemens JA, Williams DC, Little SP.](#)

[Related Articles, Links](#)

-  Nuclear and cytoplasmic localization of the beta-amyloid peptide (1-43) in transfected 293 cells.
Biochem Biophys Res Commun. 1996 Mar 27;220(3):710-8.
PMID: 8607830 [PubMed - indexed for MEDLINE]

 **11:** [Walker LC, Price DL, Voytko ML, Schenk DB.](#)

[Related Articles, Links](#)

-  Labeling of cerebral amyloid in vivo with a monoclonal antibody.
J Neuropathol Exp Neurol. 1994 Jul;53(4):377-83.
PMID: 8021711 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** Sort **Send to** **Text**
Items 1-11 of 11 One page.

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

May 12 2004 06:43:50

Welcome to STN International! Enter x:x
* * * * * Welcome to STN International * * * * *
* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:55:26 ON 17 MAY 2004

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 11:55:36 ON 17 MAY 2004

FILE 'ANABSTR' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOSIS' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 11:55:36 ON 17 MAY 2004

FILE 'CAPLUS' ENTERED AT 11:55:36 ON 17 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 11:55:36 ON 17 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 11:55:36 ON 17 MAY 2004

COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 11:55:36 ON 17 MAY 2004

FILE 'FOMAD' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 11:55:36 ON 17 MAY 2004

FILE 'HEALSAFE' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemi

FILE 'LIFESCI' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 11:55:36 ON 17 MAY 2004

FILE 'NIOSHTIC' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 11:55:36 ON 17 MAY 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.

FILE 'NUTRACEUT' ENTERED AT 11:55:36 ON 17 MAY 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 11:55:36 ON 17 MAY 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 11:55:36 ON 17 MAY 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 Prouis Science

FILE 'TOXCENTER' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 11:55:36 ON 17 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:55:36 ON 17 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 11:55:36 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S 3D6
63 FILES SEARCHED...
L1 2786 3D6

=> DUP REM L1
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY 98% COMPLETE FOR L1
PROCESSING COMPLETED FOR L1
L2 2449 DUP REM L1 (337 DUPLICATES REMOVED)

=> S L2 AND antibody
21 FILES SEARCHED...
36 FILES SEARCHED...
60 FILES SEARCHED...
L3 325 L2 AND ANTIBODY

=> D L3 1-325

L3 ANSWER 1 OF 325 AGRICOLA Compiled and distributed by the National Agricultural Library of the Department of Agriculture of the United States of America. It contains copyrighted materials. All rights reserved.
(2004) on STN

AN 2000:4580 AGRICOLA

DN IND22009396

TI Monoclonal ***antibody*** production in murine ascites. II. Production characteristics.

AU Jackson, L.R.; Trudel, L.J.; Fox, J.G.; Lipman, N.S.

CS Biogen, Inc., Cambridge, MA.

SO Laboratory animal science, Feb 1999. Vol. 49, No. 1. p. 81-86
Publisher: Cordova, Tenn. : American Association for Laboratory Animal Science.

CODEN: LBASAE; ISSN: 0023-6764

NTE Includes references

CY Tennessee; United States

DT Article

FS U.S. Imprints not USDA, Experiment or Extension

LA English

L3 ANSWER 2 OF 325 AGRICOLA Compiled and distributed by the National Agricultural Library of the Department of Agriculture of the United States of America. It contains copyrighted materials. All rights reserved.
(2004) on STN

AN 92:115808 AGRICOLA

DN IND92071156

TI Demonstration of peptidoglycan-associated Brucella outer-membrane proteins by use of monoclonal ***antibodies***

AU Cloeckaert, A.; Zygmunt, M.S.; Wergifosse, P. de; Dubray, G.; Limet, J.N.

CS Catholic University of Louvain, Brussels, Belgium

AV DNAL (448.3 J823)

SO The Journal of general microbiology, July 1992. Vol. 138, No. pt.7. p. 1543-1550

Publisher: Reading : Society for General Microbiology.

CODEN: JGMIAN; ISSN: 0022-1287

NTE Includes references.

DT Article

FS Non-U.S. Imprint other than FAO

LA English

L3 ANSWER 3 OF 325 BIOBUSINESS COPYRIGHT 2004 BIOSIS on STN

AN 85:580 BIOBUSINESS

DN 0010784

TI A MORE SPECIFIC, SIMILAR RADIOIMMUNOASSAY FOR CARCINOEMBRYONIC ANTIGEN, WITH USE OF MONOCLONAL ***ANTIBODIES***

AU LIU Y-S V; TOBIAS R J; ZURAWSKI V R JR

CS CENTOCOR, 244 GREAT VALLEY PARKWAY, MALVERN, PA. 19355.

SO CLINICAL CHEMISTRY, (1985) VOL.31, NO.2, P.191-195.

FS NONUNIQUE

LA ENGLISH

L3 ANSWER 4 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

AN 2004:197007 BIOSIS

DN PREV200400197566

TI gamma - Secretase involvement in hypoxia - induced increase of K!+ channel currents in rat cerebellar granule neurones.

AU Freir, D. B. [Reprint Author]; Webster, N. J.; Plant, L. D.; Boyle, J. P.; Peers, C.; Pearson, H. A.

CS Sch. of Biomed. Sci., Univ. of Leeds, Leeds, UK

SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003)
Vol. 2003, pp. Abstract No. 295.4. <http://sfn.scholarone.com>. e-file.
Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 14 Apr 2004

L3 ANSWER 5 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 2004:195531 BIOSIS
 DN PREV200400196090
 TI Passive immunization of APPV717F transgenic mice with mid - domain - or
 amino - terminal - reactive anti - Abetaantibodies produce differential
 effects on immunoreactive Abeta burden and fibrillar (thioflavin - S
 positive) plaque deposits.
 AU Gitter, B. D. [Reprint Author]; Hepburn, D. L. [Reprint Author]; Cummins,
 D. J.; Brown-Augsburger, P. L.; Bales, K. R. [Reprint Author]; Bailey, D.
 L.; Ballard, D. W.; Brazelton, A. D.; Czilli, D. L. [Reprint Author];
 Schirtzinger, L. M.; Yue, X. M.; Farnen, M. W.; Devanarayan, V.; Paul, S.
 M. [Reprint Author]; Galbreath, E. J.
 CS Neurosci. Res, Lilly Res. Labs, Indianapolis, IN, USA
 SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003)
 Vol. 2003, pp. Abstract No. 201.9. <http://sfn.scholarone.com>. e-file.
 Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New
 Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
 DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 14 Apr 2004
 Last Updated on STN: 14 Apr 2004

L3 ANSWER 6 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 2004:194330 BIOSIS
 DN PREV200400194890
 TI Comparative efficacy of different immunotherapeutic approaches in reducing
 AD - like neuropathology.
 AU Seubert, P. [Reprint Author]; Games, D. [Reprint Author]; Khan, K.
 [Reprint Author]; Buttini, M. [Reprint Author]; Bard, F. [Reprint Author];
 Guido, T. [Reprint Author]; Grajeda, H. [Reprint Author]; Barbour, R.
 [Reprint Author]; Nguyen, M. [Reprint Author]; Kling, K. [Reprint Author];
 Vasquez, N. [Reprint Author]; Schenk, D. [Reprint Author]; Hagen, M.;
 Eldridge, J.
 CS So. San Francisco, CA, USA
 SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003)
 Vol. 2003, pp. Abstract No. 133.3. <http://sfn.scholarone.com>. e-file.
 Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New
 Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
 DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 14 Apr 2004
 Last Updated on STN: 14 Apr 2004

L3 ANSWER 7 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 2004:175867 BIOSIS
 DN PREV200400177964
 TI Production and characterization of monoclonal ***antibodies*** to a
 Brazilian bovine herpesvirus type 5.
 AU Oldoni, I.; Weiblen, R.; Inkelmann, M. A.; Flores, E. F. [Reprint Author]
 CS Departamento de Medicina, Veterinaria Preventiva, Universidade Federal de
 Santa Maria, 97105-900, Santa Maria, RS, Brazil
 flores@ccr.ufsm.br
 SO Brazilian Journal of Medical and Biological Research, (February 2004) Vol.
 37, No. 2, pp. 213-221. print.
 CODEN: BJMRDK. ISSN: 0100-879X.
 DT Article
 LA English
 ED Entered STN: 31 Mar 2004
 Last Updated on STN: 31 Mar 2004

L3 ANSWER 8 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 2004:37649 BIOSIS
 DN PREV200400038213
 TI Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus
 vector displaying single-chain variable fragment ***antibody***
 against c-Met.
 AU Nguyen, Tuan Huy; Loux, Nathalie; Dagher, Ibrahim; Vons, Corinne; Carey,
 Ken; Briand, Pascale; Hadchouel, Michelle; Franco, Dominique; Jouanneau,
 Jacqueline; Schwall, Ralph; Weber, Anne [Reprint Author]
 CS Research, EMI 00-20 Hopital A. Beclere, 157 Rue de la Porte de Trivaux,
 92141, Clamart, France
 anne.weber@abc.ap-hop-paris.fr

ISSN: 0929-1903 (ISSN print).
DT Article
LA English
ED Entered STN: 7 Jan 2004
Last Updated on STN: 7 Jan 2004

L3 ANSWER 9 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:492999 BIOSIS
DN PREV200300492874
TI Evaluation of monoclonal ***antibody*** ***3D6*** in BALB/c nude
mice with human lung cancer.
AU Jia, B. [Reprint Author]; Dai, Y.; Du, J. [Reprint Author]; Wang, F.
[Reprint Author]
CS Medical Isotopes Research Center, School of Basic Medical Science, Peking
University, 38 Xueyuan Road, Beijing, 100083, China
Wangfan@bjmu.edu.cn
SO Journal of Labelled Compounds and Radiopharmaceuticals, (August 2003) Vol.
46, No. Supplement 1, pp. S392. print.
Meeting Info.: 15th International Symposium on Radiopharmaceutical
Chemistry. Sydney, Australia. August 10-14, 2003.
ISSN: 0362-4803 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 22 Oct 2003
Last Updated on STN: 22 Oct 2003

L3 ANSWER 10 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:14498 BIOSIS
DN PREV200300014498
TI Antitumor effects of the conjugates of pingyangmycin linked to monoclonal
antibody ***3D6*** and its Fab' fragment on hepatoma in mice
AU Liu Xiu-jun [Reprint Author]; Jiang Min [Reprint Author]; Liu Xiao-yun
[Reprint Author]; Zhen Yong-Su [Reprint Author]
CS Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
and Peking Union Medical College, Beijing, 100050, China
SO Zhongguo Kangshengsu Zazhi, (2002) Vol. 27, No. 8, pp. 496-501. print.
CODEN: ZKZAEY. ISSN: 1001-8689.
DT Article
LA Chinese
ED Entered STN: 25 Dec 2002
Last Updated on STN: 25 Dec 2002

L3 ANSWER 11 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2002:572097 BIOSIS
DN PREV200200572097
TI Antibiotics acting on matrix metalloproteinases.
AU Wang Feng-qiang [Reprint author]; Jiang Min [Reprint author]; Zhen Yong-Su
[Reprint author]
CS Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
and Peking Union Medical College, Beijing, 100050, China
SO Zhongguo Kangshengsu Zazhi, (2002) Vol. 27, No. 7, pp. 434-438, 448.
print.
CODEN: ZKZAEY. ISSN: 1001-8689.
DT Article
LA Chinese
ED Entered STN: 7 Nov 2002
Last Updated on STN: 7 Nov 2002

L3 ANSWER 12 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2002:517566 BIOSIS
DN PREV200200517566
TI Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in
vivo by immunotherapy.
AU Bacskai, Brian J.; Kajdasz, Stephen T.; McLellan, Megan E.; Games, Dora;
Seubert, Peter; Schenk, Dale; Hyman, Bradley T. [Reprint author]
CS Alzheimer's Disease Research Unit, Massachusetts General Hospital, 114
16th Street, Charlestown Navy Yard 2450, Charlestown, MA, 02129, USA
bhyman@partners.org
SO Journal of Neuroscience, (September 15, 2002) Vol. 22, No. 18, pp.
7873-7878. print.
CODEN: JNRSDS. ISSN: 0270-6474.
DT Article
LA English
ED Entered STN: 9 Oct 2002

L3 ANSWER 13 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2002:372789 BIOSIS
DN PREV200200372789
TI Antitumor effects of monoclonal ***antibody*** Fab'
fragment-containing immunoconjugates.
AU Liu Xiaoyun; Zhen Yongsu [Reprint author]
CS Institute of Medicinal Biotechnology, CAMS and PUMC, Beijing, 100050,
China
SO Chinese Medical Sciences Journal, (March, 2002) Vol. 17, No. 1, pp. 1-6.
print.
ISSN: 1001-9294.
DT Article
LA English
ED Entered STN: 3 Jul 2002
Last Updated on STN: 3 Jul 2002

L3 ANSWER 14 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:562501 BIOSIS
DN PREV200100562501
TI Multiple mechanisms are involved in clearance of amyloid-beta by
immunotherapy.
AU Bacskai, B. J. [Reprint author]; Kajdasz, S. T. [Reprint author];
McLellan, M. E. [Reprint author]; Games, D.; Seubert, P.; Schenk, D.;
Hyman, B. T. [Reprint author]
CS Dept Neurology, Mass General Hospital, Charlestown, MA, USA
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 1807.
print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San
Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 5 Dec 2001
Last Updated on STN: 25 Feb 2002

L3 ANSWER 15 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:468726 BIOSIS
DN PREV200100468726
TI An immunoconjugate targeting matrix metalloproteinase shows highly potent
cytotoxicity and anti-angiogenic activity.
AU Zhen, Yong-Su [Reprint author]; Liu, Xiao-Yun [Reprint author]; Wang,
Xin-Hua [Reprint author]; Liu, Xiu-jun [Reprint author]
CS Chinese Acad. Med. Sci., Beijing, China
SO Proceedings of the American Association for Cancer Research Annual
Meeting, (March, 2001) Vol. 42, pp. 290. print.
Meeting Info.: 92nd Annual Meeting of the American Association for Cancer
Research. New Orleans, LA, USA. March 24-28, 2001.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 3 Oct 2001
Last Updated on STN: 23 Feb 2002

L3 ANSWER 16 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:223921 BIOSIS
DN PREV200100223921
TI Expression of c-Kit (CD117) in benign and malignant human endometrial
epithelium.
AU Elmore, Lynne W. [Reprint author]; Domson, Kelly; Moore, Jonathan R.;
Kornstein, Michael; Burks, R. Tucker
CS Department of Pathology, Medical College of Virginia at Virginia
Commonwealth University, Richmond, VA, 23298, USA
SO Archives of Pathology and Laboratory Medicine, (January, 2001) Vol. 125,
No. 1, pp. 146-151. print.
CODEN: ARPAAQ. ISSN: 0363-0153.
DT Article
LA English
ED Entered STN: 9 May 2001
Last Updated on STN: 18 Feb 2002

L3 ANSWER 17 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:121222 BIOSIS

TI Intraneuronal Abeta42 immunoreactivity in Down syndrome brain.
 AU Mori, C. [Reprint author]; Spooner, E. T.; Lu, M.; Wisniewski, K.;
 CS Wisniewski, T.; Yamaguchi, H.; Saido, T. C.; Selkoe, D. J.; Lemere, C. A.
 SO Brigham " Women's Hospital, Harvard Medical School, Boston, MA, USA
 Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
 No.-764.7. print.
 Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New
 Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
 ISSN: 0190-5295.
 DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 7 Mar 2001
 Last Updated on STN: 15 Feb 2002

L3 ANSWER 18 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 2001:80301 BIOSIS
 DN PREV200100080301
 TI Dissociation between age-related and age-independent memory deficits in
 the PDAPP mouse.
 AU Morris, R. G.; Chen, G.; Chen, K. S.; Knox, J.; Inglis, J.; Martin, S. J.;
 CS Justice, A.; Games, D.; Freedman, S. B.
 SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
 No.-275.4. print.
 Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New
 Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
 ISSN: 0190-5295.
 DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 14 Feb 2001
 Last Updated on STN: 12 Feb 2002

L3 ANSWER 19 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 2000:368395 BIOSIS
 DN PREV2000000368395
 TI Antineoplastic effect of intracellular expression of a single-chain
 antibody directed against type IV collagenase.
 AU Wang, Weigang; Zhou, Jinghua; Xu, Linna; Zhen, Yongsu [Reprint author]
 CS Department of Oncology, Institute of Medicinal Biotechnology, Chinese
 Academy of Medical Sciences and Peking Union Medical College, Beijing,
 100050, China
 SO Journal of Environmental Pathology Toxicology and Oncology, (2000) Vol.
 19, No. 1-2, pp. 61-68. print.
 CODEN: JEPOEC. ISSN: 0731-8898.
 DT Article
 LA English
 ED Entered STN: 23 Aug 2000
 Last Updated on STN: 8 Jan 2002

L3 ANSWER 20 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 2000:245001 BIOSIS
 DN PREV2000000245001
 TI Antitumor effects of novel immunoconjugates with downsized-molecule
 prepared by linking lidamycin to Fab' and scFv ***antibody***
 AU Liu, Xiao Yun [Reprint author]; Li, S. Q.; Jiang, M.; Zhen, Y. S.
 CS Inst for Med Bio, Chinese Acad of Med Sci, Beijing, China
 SO Proceedings of the American Association for Cancer Research Annual
 Meeting, (March, 2000) No. 41, pp. 290-291. print.
 Meeting Info.: 91st Annual Meeting of the American Association for Cancer
 Research. San Francisco, California, USA. April 01-05, 2000.
 ISSN: 0197-016X.
 DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 14 Jun 2000
 Last Updated on STN: 5 Jan 2002

L3 ANSWER 21 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 2000:76243 BIOSIS
 DN PREV2000000076243
 TI A human anti-HIV autoantibody enhances EBV transformation and HIV
 infection.
 AU Cavacini, Lisa A. [Reprint author]; Wisnewski, Adam [Reprint author];
 Peterson, Jennifer E. [Reprint author]; Montefiori, David; Emes, Charlotte

[Reprint author]; Wang, Anlai [Reprint author]; Scadden, David [Reprint author]; Posner, Marshall R. [Reprint author]
 CS Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, and
 SO Harvard Medical School, Boston, MA, USA
 Clinical Immunology (Orlando), (Dec., 1999) Vol. 93, No. 3, pp. 263-273.
 print.
 ISSN: 1521-6616.
 DT Article
 LA English
 ED Entered STN: 23 Feb 2000
 Last Updated on STN: 3 Jan 2002

L3 ANSWER 22 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1999:209028 BIOSIS
 DN PREV199900209028
 TI Monoclonal ***antibody*** production in murine ascites: I. Clinical
 and pathologic features.
 AU Jackson, Lynn R. [Reprint author]; Trudel, Laura J.; Fox, James G.;
 Lipman, Neil S.
 CS Biogen, Inc., 14 Cambridge Center, Cambridge, MA, 02142, USA
 SO Laboratory Animal Science, (Feb., 1999) Vol. 49, No. 1. print.
 CODEN: LBASAE. ISSN: 0023-6764.
 DT Article
 LA English
 ED Entered STN: 26 May 1999
 Last Updated on STN: 26 May 1999

L3 ANSWER 23 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1999:13917 BIOSIS
 DN PREV199900013917
 TI Capture of human monoclonal ***antibodies*** from cell culture
 supernatant by ion exchange media exhibiting high charge density.
 AU Necina, Roman; Amatschek, Karin; Jungbauer, A. [Reprint author]
 CS Inst. Appl. Microbiol., Univ. Agric. For. Biotechnol., Nussdorferlaende
 11, A-1190 Vienna, Austria
 SO Biotechnology and Bioengineering, (Dec. 20, 1998) Vol. 60, No. 6, pp.
 689-698. print.
 CODEN: BIBIAU. ISSN: 0006-3592.
 DT Article
 LA English
 ED Entered STN: 11 Jan 1999
 Last Updated on STN: 11 Jan 1999

L3 ANSWER 24 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1998:480733 BIOSIS
 DN PREV199800480733
 TI Functional and molecular characterization of human monoclonal
 antibody reactive with immunodominant region of HIV type 1
 glycoprotein 41.
 AU Cavacini, Lisa A. [Reprint author]; Emes, Charlotte L.; Wisniewski, Adam
 V.; Power, Jennifer; Lewis, George; Montefiori, David; Posner, Marshall R.
 CS Beth Israel Deaconess Med. Cent., 21-27 Burlington Ave., P.O. Box 15709,
 Boston, MA 02215, USA
 SO AIDS Research and Human Retroviruses, (Sept. 20, 1998) Vol. 14, No. 14,
 pp. 1271-1280. print.
 CODEN: ARHRE7. ISSN: 0889-2229.
 DT Article
 LA English
 ED Entered STN: 5 Nov 1998
 Last Updated on STN: 5 Nov 1998

L3 ANSWER 25 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1998:443408 BIOSIS
 DN PREV199800443408
 TI Molecular characterization of five neutralizing anti-HIV type 1
 antibodies : Identification of nonconventional D segments in the
 human monoclonal ***antibodies*** 2G12 and 2F5.
 AU Kunert, Renate [Reprint author]; Ruker, Florian; Katinger, Hermann
 CS Inst. Applied Microbiol., Univ. Agricultural Sciences, Muthgasse 18, Haus
 B, A-1190 Vienna, Austria
 SO AIDS Research and Human Retroviruses, (Sept. 1, 1998) Vol. 14, No. 13, pp.
 1115-1128. print.
 CODEN: ARHRE7. ISSN: 0889-2229.
 DT Article
 LA English

Last Updated on STN: 21 Oct 1998

L3 ANSWER 26 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1997:61863 BIOSIS
DN PREV199799361066
TI Molecular identification of a novel fibrinogen binding site on the first
domain of ICAM-1 regulating leukocyte-endothelium bridging.
AU Duperray, Alain; Languino, Lucia R.; Plescia, Janet; McDowall, Alison;
Hogg, Nancy; Craig, Alister G.; Berendt, Anthony R.; Altieri, Dario C.
[Reprint author]
CS Yale Univ. Sch. Med., BCMM 436B, 295 Congress Ave., New Haven, CT 06536,
USA
SO Journal of Biological Chemistry, (1997) Vol. 272, No. 1, pp. 435-441.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 11 Feb 1997
Last Updated on STN: 11 Feb 1997

L3 ANSWER 27 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1995:438091 BIOSIS
DN PREV199598452391
TI Interaction between a Fab fragment against gp41 of human immunodeficiency
virus 1 and its peptide epitope: Characterization using a peptide epitope
library and molecular modeling.
AU Stigler, Rolf-Dietrich; Rueker, Florian; Katinger, Dietmar; Elliott,
Graham; Hoehne, Wolfgang; Henklein, Peter; Ho, Joseph X.; Keeling, Kim;
Carter, Dan C.; Nugel, Elsa; Kramer, Achim; Porstmann, Tomas;
Schneider-Mergener, Jens [Reprint author]
CS Inst. Med. Immunologie, Universitaetsklin. Charite, Humboldt-Univ. zu
Berlin, Schumannstrasse 20-21, 10098 Berlin, Germany
SO Protein Engineering, (1995) Vol. 8, No. 5, pp. 471-479.
CODEN: PRENE9. ISSN: 0269-2139.
DT Article
LA English
ED Entered STN: 10 Oct 1995
Last Updated on STN: 10 Oct 1995

L3 ANSWER 28 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1994:271698 BIOSIS
DN PREV199497284698
TI HIV-1 gp41 shares a common immunologic determinant with human T, B and
monocyte cell lines.
AU Chen, Ying-Hua; Susanna, Alex; Boeck, Guenther; Steindl, Franz; Katinger,
Hermann; Dierich, Manfred P. [Reprint author]
CS Inst. Hygiene, Fritz-Pregl-Strasse 3, A-6010 Innsbruck, Austria
SO Immunology Letters, (1994) Vol. 39, No. 3, pp. 219-222.
CODEN: IMLED6. ISSN: 0165-2478.
DT Article
LA English
ED Entered STN: 24 Jun 1994
Last Updated on STN: 24 Jun 1994

L3 ANSWER 29 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1994:128940 BIOSIS
DN PREV199497141940
TI Stable, continuous large-scale production of human monoclonal HIV-1
antibody using a computer-controlled pilot plant.
AU Unterluggauer, F. [Reprint author]; Doblhoff-Dier, O.; Tauer, C.;
Jungbauer, A.; Gaida, T.; Reiter, M.; Schmatz, C.; Zach, N.; Katinger, H.
CS Inst. Applied Microbiol., Univ. Agric. and Forestry, Nussdorfer Laende 11,
A-1190 Vienna, Austria
SO Biotechniques, (1994) Vol. 16, No. 1, pp. 140-144, 146-147.
CODEN: BTNQDO. ISSN: 0736-6205.
DT Article
LA English
ED Entered STN: 24 Mar 1994
Last Updated on STN: 24 Mar 1994

L3 ANSWER 30 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1993:587931 BIOSIS
DN PREV199497007301
TI Expression of colorectal carcinoma-associated antigens in colonic polyps.
AU Salem, Ronald R. [Reprint author]; Wolf, Barbara C. [Reprint author];
Sears, Henry F. [Reprint author]; Lavin, Philip T. [Reprint author];

author]; D'Emilia, John C. [Reprint author]; Herlyn, Meenhard; Schlom, Jeffrey
CS Dep. Surg., Lab. Cancer Biol., New England Deaconess Hosp., Harvard Med.
Sch., Boston, MA 02138, USA
SO Journal of Surgical Research, (1993) Vol. 55, No. 3, pp. 249-255.
CODEN: JSGRA2. ISSN: 0022-4804.
DT Article
LA English
ED Entered STN: 28 Dec 1993
Last Updated on STN: 28 Dec 1993

L3 ANSWER 31 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1993:410131 BIOSIS
DN PREV199396075856
TI HIV-1 and HIV-2 isolates differ in their ability to activate the
complement system on the surface of infected cells.
AU Marschang, Peter [Reprint author]; Guertler, Lutz; Toetsch, Martin;
Thielens, Nicole M.; Arlaud, Gerard J.; Hittmair, Anton; Katinger,
Hermann; Dierich, Manfred P.
CS Inst. Hygiene, Fritz-Pregl-Str. 3, 6020 Innsbruck, Austria
SO AIDS (Philadelphia), (1993) Vol. 7, No. 7, pp. 903-910.
CODEN: AIDSET. ISSN: 0269-9370.
DT Article
LA English
ED Entered STN: 8 Sep 1993
Last Updated on STN: 8 Sep 1993

L3 ANSWER 32 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1992:504534 BIOSIS
DN PREV199294123059; BA94:123059
TI GLOBAL FOREBRAIN ISCHEMIA RESULTS IN DECREASED IMMUNOREACTIVITY OF
CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II.
AU CHURN S B [Reprint author]; YAGHMAI A; POVLISHOCK J; RAFIQ A; DELORENZO R
J
CS DEP NEUROLOGY, MED COLL VA, BOX 599 MCV STATION, RICHMOND, VA 23298, USA
SO Journal of Cerebral Blood Flow and Metabolism, (1992) Vol. 12, No. 5, pp.
784-793.
CODEN: JCBMDN. ISSN: 0271-678X.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 9 Nov 1992
Last Updated on STN: 10 Nov 1992

L3 ANSWER 33 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1992:391924 BIOSIS
DN PREV199294064099; BA94:64099
TI MONOCLONAL ***ANTIBODIES*** AND RABBIT ANTISERA RECOGNIZING 4
AMINOBIIPHENYL-DNA ADDUCTS AND APPLICATION TO IMMUNOAFFINITY
CHROMATOGRAPHY.
AU GROOPMAN J D [Reprint author]; SKIPPER P L; DONAHUE P R; TRUDEL L J;
WILDSCHUTTE M; KADLUBAR F F; TANNENBAUM S R
CS DEP ENVIRONMENTAL HEALTH SCIENCES, JOHNS HOPKINS UNIV, SCH HYGIENE PUBLIC
HEALTH, 615 NORTH WOLFE STREET, BALTIMORE, MD 21205, USA
SO Carcinogenesis (Oxford), (1992) Vol. 13, No. 6, pp. 917-922.
CODEN: CRNGDP. ISSN: 0143-3334.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 24 Aug 1992
Last Updated on STN: 24 Aug 1992

L3 ANSWER 34 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1992:119275 BIOSIS
DN PREV199293065075; BA93:65075
TI ANALYSIS OF VARIOUS ANTIGENS IN GOLDEN HAMSTER TESTIS BY MONOCLONAL
ANTIBODIES
AU OHSAGO S [Reprint author]; KUOHMARU M; NISHIDA T; HAYASHI Y
CS DEP VETERINARY ANATOMY, FAC AGRIC, UNIVERSITY TOKYO, BUNKYO-KU, TOKYO 113,
JAPAN
SO Journal of Veterinary Medical Science, (1991) Vol. 53, No. 6, pp. 969-974.
CODEN: JVMSEQ. ISSN: 0916-7250.
DT Article
FS BA
LA ENGLISH

Last Updated on STN: 1 Mar 1992

L3 ANSWER 35 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1990:517848 BIOSIS
DN PREV199090135124; BA90:135124
TI CHARACTERIZATION OF MONOCLONAL ***ANTIBODIES*** TO HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 GP41 BY HIV-1 POLYPEPTIDES EXPRESSED IN
ESCHERICHIA-COLI.
AU LARCHER C [Reprint author]; BROEKER M; HUEMER H P; SOELDER B; SCHULZ T F;
HOFBAUER J M; WACHTER H; DIERICH M P
CS INST HYGIENE, UNIV INNSBRUCK, FRITZ-PREGL-STR 3, A-6020 INNSBRUCK, AUSTRIA
SO FEMS (Federation of European Microbiological Societies) Microbiology
Immunology, (1990) Vol. 64, No. 2, pp. 103-110.
ISSN: 0920-8534.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 19 Nov 1990
Last Updated on STN: 19 Nov 1990

L3 ANSWER 36 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1989:514312 BIOSIS
DN PREV198988130455; BA88:130455
TI T-CELL RECEPTOR V-BETA-5 USAGE DEFINES REACTIVITY TO A HUMAN T-CELL
RECEPTOR MONOCLONAL ***ANTIBODY***
AU LIPOLDOVA M [Reprint author]; BOYLSTON A W; YSSEL H; OWEN M J
CS IMPERIAL CANCER RES FUND, ST BARTHOLOMEW'S HOSP, DOMINION HOUSE,
BARTHOLOMEW CLOSE, LONDON EC1A 7BE, UK
SO Immunogenetics, (1989) Vol. 30, No. 3, pp. 162-168.
CODEN: IMNGBK. ISSN: 0093-7711.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 15 Nov 1989
Last Updated on STN: 15 Nov 1989

L3 ANSWER 37 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1989:495013 BIOSIS
DN PREV198988121550; BA88:121550
TI THE EXPRESSION OF COLORECTAL CARCINOMA-ASSOCIATED ANTIGENS IN THE NORMAL
COLONIC MUCOSA AN IMMUNOHISTOCHEMICAL ANALYSIS OF REGIONAL DISTRIBUTION.
AU WOLF B C [Reprint author]; SALEM R R; SEARS H F; HORST D A; LAVIN P T;
HERLYN M; ITZKOWITZ S H; SCHLOM J; STEEL G D JR
CS LAB CANCER BIOL, NEW ENGLAND DEACONESS HOSP, 50 BINNEY ST, BOSTON, MASS
02115, USA
SO American Journal of Pathology, (1989) Vol. 135, No. 1, pp. 111-120.
CODEN: AJPA44. ISSN: 0002-9440.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 2 Nov 1989
Last Updated on STN: 2 Nov 1989

L3 ANSWER 38 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1989:27208 BIOSIS
DN PREV198987015208; BA87:15208
TI PRODUCTION OF MONOCLONAL ***ANTIBODIES*** AGAINST HUMAN ERYTHROPOIETIN
AND THEIR USE IN THE PURIFICATION OF HUMAN URINARY ERYTHROPOIETIN.
AU MIYAZAKI H [Reprint author]; KOZUTSUMI H; KATO T; HOSHI S; TAMURA S;
KUBOTA M; SUZUKI T
CS PHARM LAB, KIRIN BREWERY CO LTD, MAEBASHI, GUNMA 371, JPN
SO Journal of Immunological Methods, (1988) Vol. 113, No. 2, pp. 261-268.
CODEN: JIMMBG. ISSN: 0022-1759.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 20 Dec 1988
Last Updated on STN: 20 Dec 1988

L3 ANSWER 39 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1988:439941 BIOSIS
DN PREV198886092039; BA86:92039
TI ANTIGEN- ***ANTIBODY*** INTERACTION SYNTHETIC PEPTIDES DEFINE LINEAR
ANTIGENIC DETERMINANTS RECOGNIZED BY MONOCLONAL ***ANTIBODIES***
DIRECTED TO THE CYTOPLASMIC CARBOXYL TERMINUS OF RHODOPSIN.

S
 CS DEP BIOCHEM, UNIV ALBERTA, EDMONTON, ALBERTA T6G 2H7, CAN
 SO Journal of Biological Chemistry, (1988) Vol. 263, No. 24, pp. 11768-11775.
 CODEN: JBCHA3. ISSN: 0021-9258.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 4 Oct 1988
 Last Updated on STN: 4 Oct 1988

L3 ANSWER 40 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1987:85748 BIOSIS
 DN PREV198783044326; BA83:44326
 TI A FAMILY OF T CELL RECEPTOR MOLECULES EXPRESSED ON T CELL CLONES WITH
 DIFFERENT SPECIFICITIES FOR ALLOMAJOR HISTOCOMPATIBILITY ANTIGENS.
 AU BORST J [Reprint author]; SPITS H; VOORDOUW A; DE VRIES E; BOYLSTON A; DE
 CS DIV IMMUNOL, NETHERLANDS CANCER INST PLESMANLAAN 121, 10666 CX AMSTERDAM,
 SO Human Immunology, (1986) Vol. 17, No. 4, pp. 426-442.
 CODEN: HUIMDQ. ISSN: 0198-8859.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 7 Feb 1987
 Last Updated on STN: 7 Feb 1987

L3 ANSWER 41 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1987:65782 BIOSIS
 DN PREV198783034108; BA83:34108
 TI T CELL CLONES WHICH SHARE T CELL RECEPTOR EPITOPES DIFFER IN PHENOTYPE
 FUNCTION AND SPECIFICITY.
 AU YSSEL H [Reprint author]; BLANCHARD D; BOYLSTON A; DE VRIES J E; SPITS H
 CS UNICET, CENTRE DE RECHERCHES, 27 CHEMIN DES PEUPLIERS, BP 11, F-69572
 SO European Journal of Immunology, (1986) Vol. 16, No. 10, pp. 1187-1194.
 CODEN: EJIMAF. ISSN: 0014-2980.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 24 Jan 1987
 Last Updated on STN: 24 Jan 1987

L3 ANSWER 42 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1986:378452 BIOSIS
 DN PREV198682073428; BA82:73428
 TI PROPERTIES OF A PANEL OF MONOCLONAL ***ANTIBODIES*** WHICH REACT WITH
 THE HUMAN T CELL ANTIGEN RECEPTOR ON THE LEUKEMIC LINE HPB-ALL AND A
 SUBSET OF NORMAL PERIPHERAL BLOOD T LYMPHOCYTES.
 AU BOYLSTON A W [Reprint author]; BORST J; YSSEL H; BLANCHARD D; SPITS H; DE
 CS PATHOL DEP, ST MARY'S HOSP MED SCH, LONDON W2 1PG, ENGLAND, UK
 SO Journal of Immunology, (1986) Vol. 137, No. 2, pp. 741-744.
 CODEN: JOIMA3. ISSN: 0022-1767.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 20 Sep 1986
 Last Updated on STN: 20 Sep 1986

L3 ANSWER 43 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1986:286053 BIOSIS
 DN PREV198682029916; BA82:29916
 TI THE USE OF A MONOCLONAL ***ANTIBODY*** SPECIFIC FOR THE AMINO-TERMINAL
 REGION OF SOUTHERN BEAN MOSAIC VIRUS AS A PROBE OF VIRUS STRUCTURE.
 AU MACKENZIE D J [Reprint author]; TREMAINE J H
 CS RESEARCH STN, AGRIC CAN, 6660 NW MARINE DR, VANCOUVER, BRITISH COLUMBIA,
 SO Journal of General Virology, (1986) Vol. 67, No. 4, pp. 727-736.
 CODEN: JGVIAY. ISSN: 0022-1317.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 4 Jul 1986
 Last Updated on STN: 4 Jul 1986

L3 ANSWER 44 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1986:258982 BIOSIS
 DN PREV198682013731; BA82:13731
 TI DIFFERENTIAL IMMUNOGOLD-DEXTRAN LABELING OF BOVINE AND FROG ROD AND CONE
 CELLS USING MONOCLONAL ***ANTIBODIES*** AGAINST BOVINE RHODOPSIN.
 AU HICKS D [Reprint author]; MOLDAI R S
 CS DEPARTMENT BIOCHEMISTRY, UNIVERSITY BRITISH COLUMBIA, VANCOUVER, BC V6T
 1W5, CANADA
 SO Experimental Eye Research, (1986) Vol. 42, No. 1, pp. 55-72.
 CODEN: EXERA6. ISSN: 0014-4835.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 21 Jun 1986
 Last Updated on STN: 21 Jun 1986

L3 ANSWER 45 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1986:171816 BIOSIS
 DN PREV198681082232; BA81:82232
 TI HUMAN T CELL LINES DIFFERING IN PHENOTYPE AND SPECIFICITY ARE REACTIVE
 WITH THE SAME ANTI-IDIOTYPIC ***ANTIBODY***
 AU BORST J [Reprint author]; BOYLSTON A W; DE VRIES J E; SPITS H
 CS DIV IMMUNOLOGY, NETH CANCER INST, ANTONI VAN LEEUWENHOEK HUIS, PLESMANLAAN
 121, 1066 CX AMSTERDAM, NETH
 SO Journal of Immunology, (1986) Vol. 136, No. 2, pp. 601-608.
 CODEN: JOIMA3. ISSN: 0022-1767.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 26 Apr 1986
 Last Updated on STN: 26 Apr 1986

L3 ANSWER 46 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1985:407367 BIOSIS
 DN PREV198580077359; BA80:77359
 TI GROWTH OF NORMAL HUMAN T LYMPHOCYTES INDUCED BY MONOCLONAL
 ANTIBODY TO THE T CELL ANTIGEN RECEPTOR.
 AU BOYLSTON A W [Reprint author]; COSFORD P
 CS DEP PATHOLOGY, ST MARY'S HOSPITAL MED SCH, NORFOLK PLACE, PADDINGTON,
 LONDON W21PG, GB, UK
 SO European Journal of Immunology, (1985) Vol. 15, No. 7, pp. 738-742.
 CODEN: EJIMAF. ISSN: 0014-2980.
 DT Article
 FS BA
 LA ENGLISH

L3 ANSWER 47 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1985:388721 BIOSIS
 DN PREV198580058713; BA80:58713
 TI DETERMINANT HETEROGENEITY OF L-1 L-2 AND L-3 ANTIGEN MOLECULES ON HUMAN T
 CELLS AS DEFINED BY MONOCLONAL ***ANTIBODIES*** AND THEIR ROLES IN T
 CELL-MEDIATED IMMUNE FUNCTIONS.
 AU TAKEI T [Reprint author]; ISHII Y
 CS DEP PATHOL, SAPPORO MED COLL
 SO Sapporo Medical Journal, (1985) Vol. 54, No. 3, pp. 281-300.
 CODEN: SIJSAR. ISSN: 0036-472X.
 DT Article
 FS BA
 LA JAPANESE

L3 ANSWER 48 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1985:308182 BIOSIS
 DN PREV198579088178; BA79:88178
 TI A MORE SPECIFIC SIMILAR RADIOIMMUNOASSAY FOR CARCINOEMBRYONIC ANTIGEN WITH
 USE OF MONOCLONAL ***ANTIBODIES***
 AU LIU Y-S V [Reprint author]; TOBIAS R J; ZURAWSKI V R JR
 CS CENTOCOR, 244 GREAT VALLEY PARKWAY, MALVERN, PA 19355, USA
 SO Clinical Chemistry, (1985) Vol. 31, No. 2, pp. 191-195.
 CODEN: CLCHAU. ISSN: 0009-9147.
 DT Article
 FS BA
 LA ENGLISH

L3 ANSWER 49 OF 325 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1983:195706 BIOSIS

TI ORGANIZATION OF RHOD OPSIN AND A HIGH MOLECULAR WEIGHT GLYCO PROTEIN IN
 ROD PHOTO RECEPTOR DISC MEMBRANES USING MONO CLONAL ***ANTIBODIES***
 AU MACKENZIE D [Reprint author]; MOLDAY R S
 CS DEP BIOCHEMISTRY, UNIV BRITISH COLUMBIA, VANCOUVER, BRITISH COLUMBIA V6T
 1W5 CANADA
 SO Journal of Biological Chemistry, (1982) Vol. 257, No. 12, pp. 7100-7105.
 CODEN: JBCHA3. ISSN: 0021-9258.
 DT Article
 FS BA
 LA ENGLISH

L3 ANSWER 50 OF 325 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 2003-09778 BIOTECHDS
 TI New humanized forms of mouse ***3D6*** ***antibodies***, useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
 of or reducing Abeta plaque in the brain;
 vector-mediated humanized ***antibody*** gene transfer and
 expression in host cell for recombinant protein production and disease
 therapy
 AU TSURUSHITA N; VASQUEZ M
 PA LILLY and CO ELI
 PI WO 2002088306 7 Nov 2002
 AI WO 2002-US11853 26 Apr 2002
 PRAI US 2001-287539 30 Apr 2001; US 2001-287539 30 Apr 2001
 DT Patent
 LA English
 OS WPI: 2003-183835 [18]

L3 ANSWER 51 OF 325 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 2002-19245 BIOTECHDS
 TI Novel light/heavy chain of humanized immunoglobulin for treating
 amyloidogenic disease, has ***3D6*** /10D5 variable region
 complementarity determining regions and variable framework region from
 human acceptor immunoglobulin;
 humanized ***antibody*** production by ***antibody***
 engineering for use in Alzheimer disease prevention, diagnosis,
 imaging, and therapy
 AU BASI G; SALDANHA J; YEDNOCK T
 PA NEURALAB LTD; WYETH
 PI WO 2002046237 13 Jun 2002
 AI WO 2000-US46587 6 Dec 2000
 PRAI US 2000-251892 6 Dec 2000
 DT Patent
 LA English
 OS WPI: 2002-519658 [55]

L3 ANSWER 52 OF 325 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 1996-02092 BIOTECHDS
 TI Isolated ligand for T cell surface molecule, especially CTLA4;
 antigen-specific apoptosis using a T-lymphocyte CTLA4 human monoclonal
 antibody, for application in graft rejection inhibition and
 autoimmune disease therapy
 AU Gribben J G; Freeman G J; Nadler L M; Rennert P; Jellis C L; Greenfield
 E; Gray G
 PA Repligen; Dana-Farber-Cancer-Inst.
 LO Cambridge, MA, USA; Boston, MA, USA.
 PI WO 9533770 14 Dec 1995
 AI WO 1995-US6726 2 Jun 1995
 PRAI US 1994-253783 3 Jun 1994
 DT Patent
 LA English
 OS WPI: 1996-040187 [04]

L3 ANSWER 53 OF 325 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 1993-09567 BIOTECHDS
 TI Isoprotein analysis by ionexchange chromatography using a linear pH
 gradient combined with a salt gradient;
 monoclonal ***antibody*** purification (conference paper)
 AU Kaltenbrunner O; Tauer C; Brunner J; *Jungbauer A
 LO Institut fuer angewandte Mikrobiologie, Universitaet fuer Bodenkultur,
 Nussdorfer Laende 11, A-1190 Vienna, Austria.
 SO J.Chromatogr.; (1993) 639, 1, 41-49
 CODEN: JOCRAM
 DT Journal

L3 ANSWER 54 OF 325 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 1993-04124 BIOTECHDS
 TI New D-arabinitol-dehydrogenase enzyme;
 produced by *Candida shehatae* or *Candida tropicalis*, which is incapable
 of oxidizing D-mannitol, is useful for detecting *Candida* infections;
 monoclonal ***antibody***
 PA Syntex
 PI EP 522875 13 Jan 1993
 AI EP 1992-306371 10 Jul 1992
 PRAI US 1991-731218 12 Jul 1991
 DT Patent
 LA English
 OS WPI: 1993-010684 [02]

L3 ANSWER 55 OF 325 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 1992-08168 BIOTECHDS
 TI Microencapsulation of hybridomas by cellulose sulfate-
 polydimethylallylammonium chloride procedure;
 hybridoma encapsulation and cell culture for mouse and human
 monoclonal ***antibody*** preparation
 AU Groot-Wassink T; Dautzenberg H; Grunow R; von Baehr R
 LO Bereich Medizin (Charite) der Humboldt-Universitaet zu Berlin, Institut
 fuer Medizinische Immunologie, Schumannstrasse 20/21, PSF 150, O-1040
 Berlin, Germany.
 SO Acta Biotechnol.; (1992) 12, 3, 169-78
 CODEN: ACBTDD
 DT Journal
 LA English

L3 ANSWER 56 OF 325 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 1992-07605 BIOTECHDS
 TI Expression of a human monoclonal anti-HIV-1 ***antibody*** in CHO
 cells;
 production of human recombinant monoclonal ***antibody*** specific
 for HIV virus-1 gp41 by expression of heavy chain and light chain from
 vector pair in CHO cell culture (conference paper)
 AU Rueker F; Ebert V; Kohl J; Steindl F; Riegler H; Kattinger H
 LO Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur,
 Nussdorfer Laende 11, A-1190 Vienna, Austria.
 SO Ann.N.Y.Acad.Sci.; (1991) 646, 212-19
 CODEN: ANYAA9
 DT Journal
 LA English

L3 ANSWER 57 OF 325 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 1992-07389 BIOTECHDS
 TI Cloning and expression of an HIV-1 specific single-chain Fv region fused
 to *Escherichia coli* alkaline phosphatase;
 anti-HIV virus-1 recombinant monoclonal ***antibody*** fragment
 production and purification following ***antibody*** engineering
 (conference paper)
 AU Kohl J; *Rueker F; Himmler G; Razazzi E; Kattinger H
 LO Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur,
 Nussdorfer Laende 11, A-1190 Vienna, Austria.
 SO Ann.N.Y.Acad.Sci.; (1991) 646, 106-14
 CODEN: ANYAA9
 DT Journal
 LA English

L3 ANSWER 58 OF 325 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 1992-03259 BIOTECHDS
 TI Recombinant protein which binds to complex viral antigen of HIV virus-1;
 human recombinant ***antibody*** containing variable region of
 human monoclonal ***antibody***; DNA sequence; useful in
 detection, quantification, purification of HIV virus-1 antigen
 PA Jungbauer A
 PI WO 9118983 12 Dec 1991
 AI WO 1991-AT67 28 May 1991
 PRAI AT 1990-1178 29 May 1990
 DT Patent
 LA German
 OS WPI: 1992-007468 [01]

L3 ANSWER 59 OF 325 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN

TI Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-chains of a human monoclonal ***antibody*** specific to HIV-1 - gp41;
 HIV virus-1 gp41; heavy and light chain DNA sequence
 AU Flegenhauer M; Kohl J; *Rueker F
 LO Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur, Peter Jordanstrasse 82, A-1190 Wien, Austria.
 SO Nucleic Acids Res.; (1990) 18, 16, 4927
 CODEN: NARHAD
 DT Journal
 LA English

L3 ANSWER 60 OF 325 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
 AN 2003:36798162 BIOTECHNO
 TI Fibrinogen mediates bladder cancer cell migration in an ICAM-1-dependent pathway
 AU Roche Y.; Pasquier D.; Rambeaud J.-J.; Seigneurin D.; Duperray A.
 CS Dr. A. Duperray, Unite INSERM 578, Institut Albert Bonniot, Domaine de la Merci, 38706 La Tronche Cedex, Grenoble, France.
 E-mail: Alain.Duperray@ujf-grenoble.fr
 SO Thrombosis and Haemostasis, (01 JUN 2003), 89/6 (1089-1097), 32
 reference(s)
 CODEN: THHADQ ISSN: 0340-6245
 DT Journal; Article
 CY Germany, Federal Republic of
 LA English
 SL English

L3 ANSWER 61 OF 325 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
 AN 2002:36033256 BIOTECHNO
 TI Immunological approaches as therapy for Alzheimer's disease
 AU Solomon B.
 CS B. Solomon, Department of Molecular Microbiology, George S. Wise Fac. of Life Sciences, Tel-Aviv University, Ramat Aviv, Tel-Aviv 69978, Israel.
 E-mail: beka@post.tau.ac.il
 SO Expert Opinion on Biological Therapy, (2002), 2/8 (907-917), 85
 reference(s)
 CODEN: EOBT2 ISSN: 1471-2598
 DT Journal; General Review
 CY United Kingdom
 LA English
 SL English

L3 ANSWER 62 OF 325 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
 AN 2001:32679499 BIOTECHNO
 TI Characterization of a monoclonal ***antibody*** against neopterin using an enzyme-linked immunosorbent assay with penicillinase as label
 AU Malakaneh M.; Rasaee M.J.; Rahbarizadeh F.; Madani R.; Forozandeh M.M.; Khabiri K.; Alimohammadian M.H.
 CS Dr. M.J. Rasaee, Department of Biochemistry, School of Medical Sciences, Tarbiat Modarres University, P.O. Box 14155-4838, Tehran, Iran.
 E-mail: rasaee mj@yahoo.com
 SO Hybridoma, (2001), 20/2 (117-121), 32 reference(s)
 CODEN: HYBRDY ISSN: 0272-457X
 DT Journal; Article
 CY United States
 LA English
 SL English

L3 ANSWER 63 OF 325 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
 AN 2000:31001699 BIOTECHNO
 TI Standardization of measurement of .beta.-amyloid((1-42)) in cerebrospinal fluid and plasma
 AU Vanderstichele H.; Van Kerschaver E.; Hesse C.; Davidsson P.; Buyse M.-A.; Andreasen N.; Minthon L.; Wallin A.; Blennow K.; Vanmechelen E.
 CS Dr. H. Vanderstichele, Innogenetics NV, Box 4, Industriepark Zwijnaarde 7, B-9052 Ghent, Belgium.
 E-mail: hugovdr@innogenetics.be
 SO Amyloid, (2000), 7/4 (245-258), 51 reference(s)
 CODEN: AIJIET ISSN: 1350-6129
 DT Journal; Article
 CY United Kingdom
 LA English
 SL English

AN 1991:22266099 BIOTECHNO
TI Expression of a human monoclonal anti-HIV-1 ***antibody*** in CHO
cells
AU Ruker F.; Ebert V.; Kohl J.; Steindl F.; Riegler H.; Katinger H.
CS Inst. fur Angewandte Mikrobiologie, Universitat fur Bodenkultur,
Nussdorfer Lande 11,A-1190 Vienna, Austria.
SO Annals of the New York Academy of Sciences, (1991), 646/- (212-219)
CODEN: ANYAAO ISSN: 0077-8923
DT Journal; Conference Article
CY United States
LA English
SL English

L3 ANSWER 65 OF 325 CABA COPYRIGHT 2004 CABI on STN
AN 2003:116703 CABA
DN 20033091492
TI Cloning and nucleotide sequencing of ScFv gene against Cryptosporidium
parvum sporozoite
AU Yin JiGang; Zhang XiChen; Zhu Ping; Zhang GuoLi; Li JianHua; He HongXuan;
Tian ZongCheng; Yang Ju; Yin, J. G.; Zhang, X. C.; Zhu, P.; Zhang, G. L.;
Li, J. H.; He, H. X.; Tian, Z. C.; Yang, J.
CS Faculty of Military Veterinary, Quartermaster University of PLA, Changchun
130062, China.
SO Chinese Journal of Veterinary Science, (2003) Vol. 23, No. 2, pp. 166-169.
10 ref.
Publisher: Editorial Board Chinese Journal of Veterinary Science.
Changchun
ISSN: 1005-4545
CY China
DT Journal
LA Chinese
SL English
ED Entered STN: 20030707
Last Updated on STN: 20030707

L3 ANSWER 66 OF 325 CABA COPYRIGHT 2004 CABI on STN
AN 2003:108107 CABA
DN 20033077660
TI Preparation and characterization of monoclonal ***antibodies***
against surface antigens of Cryptosporidium parvum sporozoites
AU Yin JiangAng; Zhang XiChen; Li JianHua; Wang YanZhao; He HongXuan; Yin, J.
A.; Zhang, X. C.; Li, J. H.; Wang, Y. Z.; He, H. X.
CS The Quartermaster University of PLA, Changchun 130062, China.
SO Acta Parasitologica et Medica Entomologica Sinica, (2003) Vol. 10, No. 1,
pp. 11-15. 10 ref.
Publisher: Editorial Board of Acta Parasitologica et Medica Entomologica
Sinica. Beijing
ISSN: 1005-0507
CY China
DT Journal
LA Chinese
SL English
ED Entered STN: 20030707
Last Updated on STN: 20030707

L3 ANSWER 67 OF 325 CABA COPYRIGHT 2004 CABI on STN
AN 97:137303 CABA
DN 19972214088
TI Antigen analysis of egg drop syndrome 76 virus by using monoclonal
antibodies
AU Yang KeJun; Kong DeYing; Xin ChaoAn; Yang, K. J.; Kong, D. Y.; Xin, C. A.
CS Department of Animal Medicine, South China Agricultural University,
Guangzhou, Guangdong 510642, China.
SO Chinese Journal of Veterinary Medicine, (1996) Vol. 22, No. 5, pp. 3-6. 12
ref.
DT Journal
LA Chinese
SL English
ED Entered STN: 19971112
Last Updated on STN: 19971112

L3 ANSWER 68 OF 325 CANCERLIT on STN
AN 93114405 CANCERLIT
DN 93114405 PubMed ID: 7678090
TI Characterization of hemopoietic cell populations from human cord blood

AU Reilsbach G; Bartke I; Kempkes B; Kostka G; Ellwart J; Birner A; Thalmeier
 K; Mailhammer R; Bornkamm G W; Ullrich A; +
 CS GSF-Institute of Experimental Hematology, Munich, Germany.
 SO EXPERIMENTAL HEMATOLOGY, (1993 Jan) 21 (1) 74-9.
 Journal code: 0402313. ISSN: 0301-472X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS MEDLINE; Priority Journals
 OS MEDLINE 93114405
 EM 199301
 ED Entered STN: 19941107
 Last Updated on STN: 19960517

L3 ANSWER 69 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:919088 CAPLUS
 DN 140:234388
 TI Anti-collagenase IV monoclonal ***antibody*** ***3D6*** and
 lidamycin for diagnosing and treating colon and other digestive tract
 neoplasm
 IN Zhen, Yongsu; Wang, Fengqiang; Li, Liang; Liu, Xiujun; Shang, Baiyang
 PA Institute of Medical and Biological Technology, Chinese Academy of Medical
 Sciences, Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 16 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1389472	A	20030108	CN 2002-125314	20020724
PRAI	CN 2002-125314		20020724		

L3 ANSWER 70 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:453253 CAPLUS
 DN 136:406839
 TI Conjugate of monoclonal ***antibody*** and pingyangmycin using
 cyclodextrin as coupling agent
 IN Zhen, Yongsu; Liu, Xiaoyun; Liu, Xiujun; Li, Yi
 PA Inst. of Medical Biological Technology, Chinese Academy of Medical
 Sciences, Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 10 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1305847	A	20010801	CN 2001-101936	20010118
PRAI	CN 2001-101936		20010118		

L3 ANSWER 71 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:179103 CAPLUS
 DN 136:198924
 TI conjugate of lidamycin with active fragment of monoclonal ***antibody***
 IN Zhen, Yongsu; Liu, Xiaoyun; Shao, Rongguang; Shang, Boyang
 PA Inst. of Medical Bio-Technology, Chinese Academy of Medical Sciences,
 Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 17 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1306008	A	20010801	CN 2001-101937	20010118
	CN 1128157	B	20031119		
PRAI	CN 2001-101937		20010118		

L3 ANSWER 72 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:231762 CAPLUS
 DN 134:227345
 TI Anti-matrix metalloprotease monoclonal ***antibody*** Fab'-medicine
 conjugate and its antitumor action
 IN Zhen, Yongsu; Liu, Xiaoyun; Xu, Linna; Shang, Boyang

SO Sciences, Peop. Rep. China
Faming Zhuanti Shenqing Gongkai Shuomingshu, 14 pp.
CODEN: CNXXEV

DT Patent
LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1268377	A	20001004	CN 2000-103497	20000315
PRAI	CN 2000-103497		20000315		

L3 ANSWER 73 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:65029 CAPLUS

DN 134:91120

TI Monoclonal ***antibody*** Fab'-pingyangmycin conjugate and its anticancer action

IN Zhen, Yongsu; Liu, Xiaoyun; Wang, Weigang; Liu, Xiujun

PA Inst. of Biomedicinal Technology, Chinese Academy of Medical Sciences, Peop. Rep. China

SO Faming Zhuanti Shenqing Gongkai Shuomingshu, 9 pp.
CODEN: CNXXEV

DT Patent
LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1255378	A	20000607	CN 1999-110806	19990721
	CN 1110322	B	20030604		
PRAI	CN 1999-110806		19990721		

L3 ANSWER 74 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:249109 CAPLUS

DN 130:293622

TI Process for detecting, extracting or removing human or mammalian cells with a disturbed cellular cycle regulation or unlimited proliferation or tumor-forming ability

IN Abken, Hinrich

PA Germany

SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2

DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9918235	A1	19990415	WO 1998-EP6384	19981007
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 19821506	A1	19990415	DE 1998-19821506	19980513
	EP 1021564	A1	20000726	EP 1998-954373	19981007
	R: AT, CH, DE, DK, ES, FR, GB, IT, LI				
	JP 2001519169	T2	20011023	JP 2000-515027	19981007
PRAI	DE 1997-19744335	A	19971007		
	DE 1997-19749118	A	19971106		
	DE 1998-19821506	A	19980513		
	WO 1998-EP6384	W	19981007		

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 75 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:184272 CAPLUS

DN 130:223588

TI Preparation and properties of biomolecules containing an elastomeric peptide

IN Relersen, Herald; Rees, Anthony; Korsnes, Lars

PA Dynal As, Norway

SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911661	A1	19990311	WO 1998-GB2602	19980828

DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2301981 AA 19990311 CA 1998-2301981 19980828
 AU 9888755 A1 19990322 AU 1998-88755 19980828
 AU 759080 B2 20030403
 EP 1009761 A1 20000621 EP 1998-940427 19980828
 R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, PT, IE, FI
 BR 9811421 A 20000822 BR 1998-11421 19980828
 JP 2001514263 T2 20010911 JP 2000-508699 19980828
 NZ 503097 A 20020328 NZ 1998-503097 19980828
 PRAI GB 1997-18463 A 19970829
 WO 1998-GB2602 W 19980828
 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 76 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:291603 CAPLUS
 DN 129:94197
 TI Production of monoclonal ***antibodies*** against bovine parvovirus
 AU Mahmoud, Mervat M.; Karim, Ikram A.; Shalaby, M. A.
 CS Animal Health Research Institute, Giza, Egypt
 SO Veterinary Medical Journal Giza (1997), 45(4), 449-455
 CODEN: VMJGEA; ISSN: 1110-1423
 PB Cairo University, Faculty of Veterinary Medicine
 DT Journal
 LA English
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 77 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:59054 CAPLUS
 DN 128:124544
 TI Hepatocyte growth factor receptor agonists and uses thereof
 IN Hillan, Kenneth J.; Schwall, Ralph H.; Tabor, Kelly H.
 PA Genentech, Inc., USA
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9800543	A1	19980108	WO 1997-US10688	19970620
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2258153	AA	19980108	CA 1997-2258153	19970620
AU 9734949	A1	19980121	AU 1997-34949	19970620
AU 729029	B2	20010125		
EP 922102	A1	19990616	EP 1997-931275	19970620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000515735	T2	20001128	JP 1998-504193	19970620
US 6099841	A	20000808	US 1997-884669	19970627
ZA 9705851	A	19990104	ZA 1997-5851	19970701
PRAI US 1996-21215P	P	19960703		
WO 1997-US10688	W	19970620		
RE.CNT 9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L3 ANSWER 78 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1995:950241 CAPLUS
 DN 124:6696
 TI BiP binding sequences in ***antibodies***
 AU Knarr, Gerhard; Gething, Mary-Jane; Modrow, Susanne; Buchner, Johannes

93040, Germany
SO Journal of Biological Chemistry (1995), 270(46), 27589-94
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English

L3 ANSWER 79 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:467394 CAPLUS
DN 115:67394
TI The effect of a monoclonal ***antibody*** on specific steps of the
reaction sequence of the calcium-magnesium ATPase from sarcoplasmic
reticulum
AU Mata, Ana M.; Colyer, John; Michelangeli, Francesco; Lee, Anthony G.;
East, J. Malcolm
CS Dep. Biochem., Univ. Southampton, Southampton, SO9 3TU, UK
SO Biochemical Society Transactions (1991), 19(2), 205S
CODEN: BCSTB5; ISSN: 0300-5127
DT Journal
LA English

L3 ANSWER 80 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:196651 CAPLUS
DN 112:196651
TI Pilot production of human monoclonal ***antibodies*** against HIV-1
AU Jungbauer, Alois; Steindl, Franz; Grunow, Roland; Porstmann, Tomas; Ernst,
Wolfgang; Purtscher, Martin; Reiter, Manfred; Tauer, Christa; Wenisch,
Elisabeth; Katinger, Hermann
CS Inst. Angew. Mikrobiol., Univ. Bodenkult., Vienna, A-1190, Austria
SO Zeitschrift fuer Klinische Medizin (1985) (1990), 45(4), 351-4
CODEN: ZKMEEF; ISSN: 0233-1608
DT Journal
LA German

L3 ANSWER 81 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:137344 CAPLUS
DN 112:137344
TI Human monoclonal anti-human immunodeficiency virus type 1 (anti-HIV-1)
antibodies
IN Katinger, Hermann; Von Baehr, Ruediger; Jungbauer, Alois; Porstmann,
Tomas; Steindl, Franz J.; Grunow, Roland; Buchacher, Andrea
PA CL Pharma A.-G., Austria
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8904370	A1	19890518	WO 1988-EP1072	19881114
	W: JP, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 355140	A1	19900228	EP 1989-900809	19881114
	EP 355140	B1	19960320		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02502251	T2	19900726	JP 1989-500718	19881114
	AT 135743	E	19960415	AT 1989-900809	19881114
	US 5831034	A	19981103	US 1994-293842	19940822
	US 5753503	A	19980519	US 1994-347966	19941201
PRAI	US 1987-120489	A	19871113		
	WO 1988-EP1072	W	19881114		
	US 1990-583505	B1	19900917		
	US 1991-693730	B1	19910430		
	US 1993-97170	B1	19930723		
	US 1993-105360	B1	19930810		

L3 ANSWER 82 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:524927 CAPLUS
DN 109:124927
TI The mechanism of inhibition of the calcium-magnesium-ATPase by monoclonal
antibodies
AU Colyer, J.; Michelangeli, F.; Lee, A. G.; East, J. M.
CS Dep. Biochem., Univ. Southampton, Southampton, SO9 3TU, UK
SO Biochemical Society Transactions (1988), 16(6), 967-8
CODEN: BCSTB5; ISSN: 0300-5127

LA English

L3 ANSWER 83 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1988:488831 CAPLUS
 DN 109:88831
 TI Effect of monoclonal ***antibodies*** raised against calcium-magnesium ATPase from rabbit skeletal muscle sarcoplasmic reticulum on ATPase activity and its correlation with epitope location
 AU Mata, Ana M.; Colyer, John; Tunwell, Richard E. A.; Lee, Anthony G.; East, J. Malcolm
 CS Dep. Biochem., Univ. Southampton, Southampton, SO9 3TU, UK
 SO Biochemical Society Transactions (1988), 16(5), 771-2
 CODEN: BCSTB5; ISSN: 0300-5127
 DT Journal
 LA English

L3 ANSWER 84 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:634639 CAPLUS
 DN 107:234639
 TI Immunometric assay for high-molecular-weight carcinoembryonic antigen, kits for the immunoassay, and their use in colorectal cancer diagnosis
 IN Schoemaker, Hubert J. P.; Brennan, Suzanne E.; Schlom, Jeffrey; Brock, Paul
 PA Centocor, Inc., USA
 SO Eur. Pat. Appl., 17 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 225709	A2	19870616	EP 1986-308212	19861022
	EP 225709	A3	19880907		
	EP 225709	B1	19920527		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 790261	A0	19880601	US 1985-790261	19851022
	JP 62201364	A2	19870905	JP 1986-251574	19861022
	CA 1291422	A1	19911029	CA 1986-521283	19861022
	AT 76690	E	19920615	AT 1986-308212	19861022
PRAI	US 1985-790261		19851022		
	EP 1986-308212		19861022		

L3 ANSWER 85 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:420274 CAPLUS
 DN 107:20274
 TI Detection in plasma of derivatives of crosslinked fibrin, using monoclonal ***antibodies***
 AU Whitaker, A. N.; Masci, P. P.; Dunstan, A.; Elms, M. J.; Bunce, I. H.; Bundesen, P. J.; Rylatt, D. B.; Webber, A. J.
 CS Princess Alexandra Hosp., Univ. Queensland, Queensland, Australia
 SO International Congress Series (1986), 722(Fibrinogen Its Deriv.), 265-72
 CODEN: EXMDA4; ISSN: 0531-5131
 DT Journal
 LA English

L3 ANSWER 86 OF 325 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1969:479219 CAPLUS
 DN 71:79219
 TI Quantitative studies of the specificity of antipneumococcal ***antibodies***, types III and VIII. IV. Binding of labeled hexasaccharides derived from S3 by anti-S3 ***antibodies*** and their Fab fragments
 AU Katz, Moshe; Pappenheimer, Alwin M., Jr.
 CS Harvard Univ., Cambridge, MA, USA
 SO Journal of Immunology (1969), 103(3), 491-5
 CODEN: JOIMA3; ISSN: 0022-1767
 DT Journal
 LA English

L3 ANSWER 87 OF 325 DISSABS COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved on STN
 AN 93:59597 DISSABS Order Number: AARC313016 (not available for sale by UMI)
 TI CLONING AND EXPRESSION OF A SINGLE-CHAIN PROTEIN IN ESCHERICHIA COLI
 KOLONIERUNG UND EXPRESSION EINES ANTIGENBINDENDEN PROTEINS IN ESCHERICHIA

AU KOHL, JOHANN [DR.NAT.]
 CS UNIVERSITAET FUER BODENKULTUR WIEN (AUSTRIA) (5808)
 SO Dissertation Abstracts International, (1991) Vol. 54, No. 4C, p. 1078.
 Order No.: AARC313016 (not available for sale by UMI). 58 pages.
 DT Dissertation
 FS DAI
 LA English
 ED Entered STN: 19931214
 Last Updated on STN: 19931214

L3 ANSWER 88 OF 325 DISSABS COPYRIGHT (C) 2004 ProQuest Information and
 Learning Company; All Rights Reserved on STN
 AN 93:38865 DISSABS Order Number: AAR9320691
 TI APPLICATION OF MONOCLONAL ***ANTIBODIES*** IN THE STUDY OF MYCOPLASMA
 GALLISEPTICUM SURFACE EPITOPES AND AS A DIAGNOSTIC TOOL
 AU GARCIA, MARICARMEN [PH.D.]; KLEVEN, STANLEY H. [advisor]
 CS UNIVERSITY OF GEORGIA (0077)
 SO Dissertation Abstracts International, (1993) Vol. 54, No. 3B, p. 1314.
 Order No.: AAR9320691. 118 pages.
 DT Dissertation
 FS DAI
 LA English
 ED Entered STN: 19930817
 Last Updated on STN: 19930817

L3 ANSWER 89 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABR54947 Protein DGENE
 TI Amplifying nucleic acid by contacting engineered nucleic acid strand
 having predetermined sequence at one end and sequence complementary to
 predetermined sequence at other end, with primer having predetermined
 sequence -
 IN Bowdish K S; Frederickson S; Maruyama T; Lin Y; Renshaw M
 PA (ALEX-N) ALEXION PHARM INC.
 PI WO 2003025202 A2 20030327 68p
 AI WO 2002-US29889 20020919
 PRAI US 2001-323455P 20010919
 DT Patent
 LA English
 OS 2003-313359 [30]
 DESC IgG light chain clone HBL4a ***3D6*** SEQ ID NO:173.

L3 ANSWER 90 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABR54930 Protein DGENE
 TI Amplifying nucleic acid by contacting engineered nucleic acid strand
 having predetermined sequence at one end and sequence complementary to
 predetermined sequence at other end, with primer having predetermined
 sequence -
 IN Bowdish K S; Frederickson S; Maruyama T; Lin Y; Renshaw M
 PA (ALEX-N) ALEXION PHARM INC.
 PI WO 2003025202 A2 20030327 68p
 AI WO 2002-US29889 20020919
 PRAI US 2001-323455P 20010919
 DT Patent
 LA English
 OS 2003-313359 [30]
 DESC IgG lambda clone HBL4a ***3D6*** SEQ ID NO:156.

L3 ANSWER 91 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP58275 Protein DGENE
 TI New humanized forms of mouse ***3D6*** ***antibodies***, useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
 of or reducing Abeta plaque in the brain -
 IN Tsurushita N; Vasquez M
 PA (ELIL) LILLY & CO ELI.
 PI WO 2002088306 A2 20021107 54p
 AI WO 2002-US11853 20020426
 PRAI US 2001-287539P 20010430
 DT Patent
 LA English
 OS 2003-183835 [18]
 CR N-PSDB: ABZ24633; ABZ24635
 DESC Humanised ***3D6*** ***antibody*** heavy chain.

L3 ANSWER 92 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
 of or reducing Abeta plaque in the brain -
 IN Tsurushita N; Vasquez M
 PA (ELIL) LILLY & CO ELI.
 PI WO 2002088306 A2 20021107 54p
 AI WO 2002-US11853 20020426
 PRAI US 2001-287539P 20010430
 DT Patent
 LA English
 OS 2003-183835 [18]
 CR N-PSDB: ABZ24632; ABZ24634
 DESC Humanised ***3D6*** ***antibody*** light chain.

L3 ANSWER 93 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP58273 Protein DGENE
 TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
 of or reducing Abeta plaque in the brain -
 IN Tsurushita N; Vasquez M
 PA (ELIL) LILLY & CO ELI.
 PI WO 2002088306 A2 20021107 54p
 AI WO 2002-US11853 20020426
 PRAI US 2001-287539P 20010430
 DT Patent
 LA English
 OS 2003-183835 [18]
 DESC Humanised ***3D6*** ***antibody*** heavy chain.

L3 ANSWER 94 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP58272 Protein DGENE
 TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
 of or reducing Abeta plaque in the brain -
 IN Tsurushita N; Vasquez M
 PA (ELIL) LILLY & CO ELI.
 PI WO 2002088306 A2 20021107 54p
 AI WO 2002-US11853 20020426
 PRAI US 2001-287539P 20010430
 DT Patent
 LA English
 OS 2003-183835 [18]
 DESC Humanised ***3D6*** ***antibody*** light chain.

L3 ANSWER 95 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP58271 Protein DGENE
 TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
 of or reducing Abeta plaque in the brain -
 IN Tsurushita N; Vasquez M
 PA (ELIL) LILLY & CO ELI.
 PI WO 2002088306 A2 20021107 54p
 AI WO 2002-US11853 20020426
 PRAI US 2001-287539P 20010430
 DT Patent
 LA English
 OS 2003-183835 [18]
 DESC Humanised ***3D6*** ***antibody*** heavy chain variable region.

L3 ANSWER 96 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP58270 Protein DGENE
 TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
 of or reducing Abeta plaque in the brain -
 IN Tsurushita N; Vasquez M
 PA (ELIL) LILLY & CO ELI.
 PI WO 2002088306 A2 20021107 54p
 AI WO 2002-US11853 20020426
 PRAI US 2001-287539P 20010430
 DT Patent

OS 2003-183835 [18]
DESC Humanised ***3D6*** ***antibody*** light chain variable region.

L3 ANSWER 97 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP58269 Protein DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
(pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Humanised ***3D6*** ***antibody*** heavy chain variable region.

L3 ANSWER 98 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP58268 Protein DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
(pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Humanised ***3D6*** ***antibody*** light chain variable region.

L3 ANSWER 99 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP58267 Peptide DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
(pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Mouse monoclonal ***antibody*** ***3D6*** heavy chain CDR3.

L3 ANSWER 100 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP58266 Peptide DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
(pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Mouse monoclonal ***antibody*** ***3D6*** heavy chain CDR2.

L3 ANSWER 101 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP58265 Peptide DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
(pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
of or reducing Abeta plaque in the brain -
IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.

AI WO 2002-US11853 20020426
 PRAI US 2001-287539P 20010430
 DT Patent
 LA English
 OS 2003-183835 [18]
 DESC Mouse monoclonal ***antibody*** ***3D6*** heavy chain CDR1.

L3 ANSWER 102 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP58264 Peptide DGENE
 TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
 of or reducing Abeta plaque in the brain -
 IN Tsurushita N; Vasquez M
 PA (ELIL) LILLY & CO ELI.
 PI WO 2002088306 A2 20021107 54p
 AI WO 2002-US11853 20020426
 PRAI US 2001-287539P 20010430
 DT Patent
 LA English
 OS 2003-183835 [18]
 DESC Mouse monoclonal ***antibody*** ***3D6*** light chain CDR3.

L3 ANSWER 103 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP58263 Peptide DGENE
 TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
 of or reducing Abeta plaque in the brain -
 IN Tsurushita N; Vasquez M
 PA (ELIL) LILLY & CO ELI.
 PI WO 2002088306 A2 20021107 54p
 AI WO 2002-US11853 20020426
 PRAI US 2001-287539P 20010430
 DT Patent
 LA English
 OS 2003-183835 [18]
 DESC Mouse monoclonal ***antibody*** ***3D6*** light chain CDR2.

L3 ANSWER 104 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP58262 Peptide DGENE
 TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
 of or reducing Abeta plaque in the brain -
 IN Tsurushita N; Vasquez M
 PA (ELIL) LILLY & CO ELI.
 PI WO 2002088306 A2 20021107 54p
 AI WO 2002-US11853 20020426
 PRAI US 2001-287539P 20010430
 DT Patent
 LA English
 OS 2003-183835 [18]
 DESC Mouse monoclonal ***antibody*** ***3D6*** light chain CDR1.

L3 ANSWER 105 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABG76936 Protein DGENE
 TI Novel light/heavy chain of humanized immunoglobulin for treating
 amyloidogenic disease, has ***3D6*** /10D5 variable region
 complementarity determining regions and variable framework region from
 human acceptor immunoglobulin -
 IN Basi G; Saldanha J; Yednock T
 PA (NEUR-N) NEURALAB LTD.
 (AMHP) WYETH.
 PI WO 2002046237 A2 20020613 171p
 AI WO 2001-US46587 20011206
 PRAI US 2000-251892P 20001206
 DT Patent
 LA English
 OS 2002-519658 [55]
 DESC Humanised ***antibody*** associated protein #5.

L3 ANSWER 106 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABG76930 Protein DGENE
 TI Novel light/heavy chain of humanized immunoglobulin for treating

complementarity determining regions and variable framework region from human acceptor immunoglobulin -

IN Basi G; Saldanha J; Yednock T
PA (NEUR-N) NEURALAB LTD.
(AMHP) WYETH.
PI WO 2002046237 A2 20020613 171p
AI WO 2001-US46587 20011206
PRAI US 2000-251892P 20001206
DT Patent
LA English
OS 2002-519658 [55]
DESC Humanised ***antibody*** associated protein #4.

L3 ANSWER 107 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG76929 Protein DGENE
TI Novel light/heavy chain of humanized immunoglobulin for treating amyloidogenic disease, has ***3D6*** /10D5 variable region complementarity determining regions and variable framework region from human acceptor immunoglobulin -

IN Basi G; Saldanha J; Yednock T
PA (NEUR-N) NEURALAB LTD.
(AMHP) WYETH.
PI WO 2002046237 A2 20020613 171p
AI WO 2001-US46587 20011206
PRAI US 2000-251892P 20001206
DT Patent
LA English
OS 2002-519658 [55]
DESC Humanised ***antibody*** associated protein #3.

L3 ANSWER 108 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG76927 Protein DGENE
TI Novel light/heavy chain of humanized immunoglobulin for treating amyloidogenic disease, has ***3D6*** /10D5 variable region complementarity determining regions and variable framework region from human acceptor immunoglobulin -

IN Basi G; Saldanha J; Yednock T
PA (NEUR-N) NEURALAB LTD.
(AMHP) WYETH.
PI WO 2002046237 A2 20020613 171p
AI WO 2001-US46587 20011206
PRAI US 2000-251892P 20001206
DT Patent
LA English
OS 2002-519658 [55]
DESC Humanised ***antibody*** associated protein #2.

L3 ANSWER 109 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG76926 Protein DGENE
TI Novel light/heavy chain of humanized immunoglobulin for treating amyloidogenic disease, has ***3D6*** /10D5 variable region complementarity determining regions and variable framework region from human acceptor immunoglobulin -

IN Basi G; Saldanha J; Yednock T
PA (NEUR-N) NEURALAB LTD.
(AMHP) WYETH.
PI WO 2002046237 A2 20020613 171p
AI WO 2001-US46587 20011206
PRAI US 2000-251892P 20001206
DT Patent
LA English
OS 2002-519658 [55]
DESC Humanised ***antibody*** associated protein #1.

L3 ANSWER 110 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW19507 protein DGENE
TI Testing compounds for an effect on an Alzheimer's disease marker - uses non-human transgenic animals which can control expression of major forms of beta-amyloid precursor protein

IN Games K D; McConlogue L C; Rydel R E; Schenk D B; Seubert P A
PA (ATHE-N) ATHENA NEUROSCIENCES INC.
PI WO 9640896 A1 19961219 139p
AI WO 1996-US9857 19960607
PRAI US 1995-480653 19950607
DT Patent

OS 1997-052309 [05]
DESC Immunogen for raising monoclonal ***antibody*** ***3D6*** for
A-beta recognition.

L3 ANSWER 111 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW19494 protein DGENE
TI Transgenic mammal comprising DNA encoding A-beta-contg. protein - useful
as animal model to test potential Alzheimer's disease treatments
IN McConlogue L C; Seubert P A
PA (ATHE-N) ATHENA NEUROSCIENCES INC.
PI WO 9640895 A1 19961219 116p
AI WO 1996-US9679 19960607
PRAI US 1995-486538 19950607
US 1995-486018 19950607

DT Patent
LA English
OS 1997-052308 [05]
DESC Immunogen for raising monoclonal ***antibody*** ***3D6*** for
A-beta recognition.

L3 ANSWER 112 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52521 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 CDR-H2.

L3 ANSWER 113 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52537 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 heavy chain complementarity determining region 1.

L3 ANSWER 114 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52536 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 heavy chain complementarity determining region 1.

L3 ANSWER 115 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52535 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***

V-region
 IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI EP 592106 A1 19940413 230p
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC Gloop-2 heavy chain complementarity determining region 1.

L3 ANSWER 116 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52534 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI EP 592106 A1 19940413 230p
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC ***3D6*** light chain complementarity determining region 3.

L3 ANSWER 117 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52533 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI EP 592106 A1 19940413 230p
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC 36-71 light chain complementarity determining region 3.

L3 ANSWER 118 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52532 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI EP 592106 A1 19940413 230p
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC D1.3 light chain complementarity determining region 3.

L3 ANSWER 119 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52531 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI EP 592106 A1 19940413 230p
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909

LA English
 OS 1994-120230 [15]
 DESC Gloop-2 light chain complementarity determining region 3.

L3 ANSWER 120 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52530 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region
 IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI EP 592106 A1 19940413 230p
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC ***3D6*** light chain complementarity determining region 2.

L3 ANSWER 121 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52529 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region
 IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI EP 592106 A1 19940413 230p
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC 36-71 light chain complementarity determining region 2.

L3 ANSWER 122 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52528 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region
 IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI EP 592106 A1 19940413 230p
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC D1.3 light chain complementarity determining region 2.

L3 ANSWER 123 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52527 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region
 IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI EP 592106 A1 19940413 230p
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC Gloop-2 light chain complementarity determining region 2.

L3 ANSWER 124 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52526 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised

with improved therapeutic efficiency by presenting human surface on V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ****3D6**** light chain complementarity determining region 1.

L3 ANSWER 125 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52525 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 light chain complementarity determining region 1.

L3 ANSWER 126 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52524 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 light chain complementarity determining region 1.

L3 ANSWER 127 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52523 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 light chain complementarity determining region 1.

L3 ANSWER 128 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52522 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907

DT Patent
LA English
OS 1994-120230 [15]
DESC F19.9 CDR-H2.

L3 ANSWER 129 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52546 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ***3D6*** heavy chain complementarity determining region 3.

L3 ANSWER 130 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52545 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 heavy chain complementarity determining region 3.

L3 ANSWER 131 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52544 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 heavy chain complementarity determining region 3.

L3 ANSWER 132 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52543 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 heavy chain complementarity determining region 3.

L3 ANSWER 133 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52542 Peptide DGENE

antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ***3D6*** heavy chain complementarity determining region 2.

L3 ANSWER 134 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52541 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 heavy chain complementarity determining region 2.

L3 ANSWER 135 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52540 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 heavy chain complementarity determining region 2.

L3 ANSWER 136 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52539 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 heavy chain complementarity determining region 2.

L3 ANSWER 137 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52538 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI EP 592106 A1 19940413 230p

PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC ***3D6*** heavy chain complementarity determining region 1.

L3 ANSWER 138 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR20059 Protein DGENE
 TI Recombinant protein which binds to complex viral antigen and HIV-1 -
 contains variable region of ***antibody*** derived from ***3D6***
 cell line, used for detecting HIV-1 antigen
 IN Felgenhauer M; Himmler G; Kohl J; Steindl F
 PA (JUNG-I) JUNGBAUER A.
 PI WO 9118983 A 19911212 52p
 AI WO 1991-1000067 19910528
 PRAI AT 1990-1178 19900529
 DT Patent
 LA German
 OS 1992-007468 [01]
 CR N-PSDB: AAQ20068
 DESC Recombinant sc3D6 anti-HIV gp160 ***antibody*** .

L3 ANSWER 139 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR20058 Protein DGENE
 TI Recombinant protein which binds to complex viral antigen and HIV-1 -
 contains variable region of ***antibody*** derived from ***3D6***
 cell line, used for detecting HIV-1 antigen
 IN Felgenhauer M; Himmler G; Kohl J; Steindl F
 PA (JUNG-I) JUNGBAUER A.
 PI WO 9118983 A 19911212 52p
 AI WO 1991-1000067 19910528
 PRAI AT 1990-1178 19900529
 DT Patent
 LA German
 OS 1992-007468 [01]
 CR N-PSDB: AAQ20067
 DESC Light chain of ***3D6*** anti-HIV ***antibody*** .

L3 ANSWER 140 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR20057 Protein DGENE
 TI Recombinant protein which binds to complex viral antigen and HIV-1 -
 contains variable region of ***antibody*** derived from ***3D6***
 cell line, used for detecting HIV-1 antigen
 IN Felgenhauer M; Himmler G; Kohl J; Steindl F
 PA (JUNG-I) JUNGBAUER A.
 PI WO 9118983 A 19911212 52p
 AI WO 1991-1000067 19910528
 PRAI AT 1990-1178 19900529
 DT Patent
 LA German
 OS 1992-007468 [01]
 CR N-PSDB: AAQ20066
 DESC Heavy chain of ***3D6*** anti-HIV ***antibody*** .

L3 ANSWER 141 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABZ24637 DNA DGENE
 TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
 of or reducing Abeta plaque in the brain -
 IN Tsurushita N; Vasquez M
 PA (ELIL) LILLY & CO ELI.
 PI WO 2002088306 A2 20021107 54p
 AI WO 2002-US11853 20020426
 PRAI US 2001-287539P 20010430
 DT Patent
 LA English
 OS 2003-183835 [18]
 DESC Mouse heavy chain variable region 3' PCR primer.

L3 ANSWER 142 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABZ24636 DNA DGENE
 TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
 for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
 (pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation

IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
DESC Mouse light chain variable region 3' PCR primer.

L3 ANSWER 143 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABZ24635 cDNA DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
(pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
of or reducing Abeta plaque in the brain -

IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
CR P-PSDB: ABP58275
DESC Humanised ***3D6*** ***antibody*** heavy chain gene.

L3 ANSWER 144 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABZ24634 DNA DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
(pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
of or reducing Abeta plaque in the brain -

IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
CR P-PSDB: ABP58274
DESC Humanised ***3D6*** ***antibody*** light chain gene.

L3 ANSWER 145 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABZ24633 cDNA DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
(pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
of or reducing Abeta plaque in the brain -

IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]
CR P-PSDB: ABP58275
DESC Humanised ***3D6*** ***antibody*** heavy chain cDNA.

L3 ANSWER 146 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABZ24632 cDNA DGENE
TI New humanized forms of mouse ***3D6*** ***antibodies*** , useful
for treating Down's syndrome, (pre-)clinical Alzheimer's disease or
(pre-)clinical cerebral amyloid angiopathy, or for inhibiting formation
of or reducing Abeta plaque in the brain -

IN Tsurushita N; Vasquez M
PA (ELIL) LILLY & CO ELI.
PI WO 2002088306 A2 20021107 54p
AI WO 2002-US11853 20020426
PRAI US 2001-287539P 20010430
DT Patent
LA English
OS 2003-183835 [18]

DESC Humanised ***3D6*** ***antibody*** light chain cDNA.
 L3 ANSWER 147 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAQ20068 DNA DGENE
 TI Recombinant protein which binds to complex viral antigen and HIV-1 -
 contains variable region of ***antibody*** derived from ***3D6***
 cell line, used for detecting HIV-1 antigen
 IN Felgenhauer M; Himmler G; Kohl J; Steindl F
 PA (JUNG-I) JUNGBAUER A.
 PI WO 9118983 A 19911212 52p
 AI WO 1991-1000067 19910528
 PRAI AT 1990-1178 19900529
 DT Patent
 LA German
 OS 1992-007468 [01]
 CR P-PSDB: AAR20059
 DESC Encodes recombinant sc3D6 anti-HIV gp160 ***antibody*** .
 L3 ANSWER 148 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAQ20067 DNA DGENE
 TI Recombinant protein which binds to complex viral antigen and HIV-1 -
 contains variable region of ***antibody*** derived from ***3D6***
 cell line, used for detecting HIV-1 antigen
 IN Felgenhauer M; Himmler G; Kohl J; Steindl F
 PA (JUNG-I) JUNGBAUER A.
 PI WO 9118983 A 19911212 52p
 AI WO 1991-1000067 19910528
 PRAI AT 1990-1178 19900529
 DT Patent
 LA German
 OS 1992-007468 [01]
 CR P-PSDB: AAR20058
 DESC Encodes light chain of ***3D6*** anti-HIV ***antibody*** .
 L3 ANSWER 149 OF 325 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAQ20066 DNA DGENE
 TI Recombinant protein which binds to complex viral antigen and HIV-1 -
 contains variable region of ***antibody*** derived from ***3D6***
 cell line, used for detecting HIV-1 antigen
 IN Felgenhauer M; Himmler G; Kohl J; Steindl F
 PA (JUNG-I) JUNGBAUER A.
 PI WO 9118983 A 19911212 52p
 AI WO 1991-1000067 19910528
 PRAI AT 1990-1178 19900529
 DT Patent
 LA German
 OS 1992-007468 [01]
 CR P-PSDB: AAR20057
 DESC Encodes heavy chain of ***3D6*** ***antibody*** .
 L3 ANSWER 150 OF 325 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2003-14919 DRUGU M
 TI Epitope and isotype specificities of ***antibodies*** to beta-amyloid
 peptide for protection against Alzheimer's disease-like neuropathology.
 AU Bard F; Barbour R; Cannon C; Fox M; Games D; Guido T; Hoenow K; Hu K;
 Johnson Wood K
 CS Elan
 LO San Francisco, Cal., USA
 SO Proc.Natl.Acad.Sci.U.S.A. (100, No. 4, 2023-28, 2003) 4 Fig. 2 Tab. 24
 Ref.
 CODEN: PNASA6 ISSN: 0027-8424
 AV Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA
 94080, U.S.A. (22 authors). (e-mail: frederique.bard@elan.com).
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature
 L3 ANSWER 151 OF 325 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2002-42727 DRUGU P
 TI Immunological concept in the treatment of Alzheimer's disease.
 AU Solomon B
 CS Univ.Tel-Aviv
 LO Tel Aviv, Isr.
 SO Drug Dev.Res. (56, No. 2, 163-67, 2002) 39 Ref.

AV Department of Molecular Microbiology and Biotechnology, George S. Wise
 Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Tel-Aviv
 69978, Israel. (e-mail: beka@post.tau.ac.il).
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature

L3 ANSWER 152 OF 325 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2002-42726 DRUGU T P
 TI Beta-amyloid immunization approaches for Alzheimer's disease.
 AU Imbimbo B P
 CS Chiesi
 LO Parma, It.
 SO Drug Dev.Res. (56, No. 2, 150-62, 2002) 4 Fig. 75 Ref.
 CODEN: DDREDK ISSN: 0272-4391
 AV Research and Development Department, Chiesi Farmaceutici, Via Palermo
 26/A, 43100 Parma, Italy. (e-mail: b.imbimbo@chiesigroup.com).
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature

L3 ANSWER 153 OF 325 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2002-13564 DRUGU M
 TI Passive intranasal monoclonal ***antibody*** prophylaxis against
 murine Pneumocystis carinii pneumonia.
 AU Gigliotti F; Haidaris C G; Wright T W; Harmsen A G
 CS Univ.Rochester; Trudeau-Inst.
 LO Rochester; Saranac Lake, N.Y., USA
 SO Infect.Immun. (70, No. 3, 1069-74, 2002) 4 Fig. 1 Tab. 19 Ref.
 CODEN: INFIBR ISSN: 0019-9567
 AV Department of Pediatrics, University of Rochester School of Medicine and
 Dentistry, Rochester NY 14642, U.S.A. (e-mail:
 Francis_Gigliotti@urmc.rochester.edu).
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature

L3 ANSWER 154 OF 325 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2000-36596 DRUGU P
 TI Peripherally administered ***antibodies*** against amyloid
 beta-peptide enter the central nervous system and reduce pathology in a
 mouse model of Alzheimer disease.
 AU Bard F; Cannon C; Barbour R; Burke R L; Games D; Grajeda H; Guido T; Hu
 K; Huang J; Johnson Wood K
 LO San Francisco, Cal., USA
 SO Nat.Med. (6, No. 8, 916-19, 2000) 3 Fig. 1 Tab. 10 Ref.
 CODEN: MAMEF ISSN: 1078-8956
 AV Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco,
 California 94080, U.S.A. (23 authors). (e-mail: fbard@elanpharma.com).
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature

L3 ANSWER 155 OF 325 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2000-31155 DRUGU P
 TI Antitumor effects of novel immunoconjugates with downsized-molecule
 prepared by linking lidamycin to Fab' and scFv ***antibody***.
 AU Liu X Y; Li S Q; Jiang M; Zhen Y S
 CS Chinese-Acad.Med.Sci.
 LO Beijing, China
 SO Proc.Am.Assoc.Cancer Res. (41, 91 Meet., 290-91, 2000) ISSN:
 0197-016X
 AV Inst. for Med Bio, Chinese Acad of Med Sci, China.
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature

L3 ANSWER 156 OF 325 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 1985-37973 DRUGU P M
 TI Rationale for Development of a Synthetic Vaccine Against Plasmodium

AU Zavala F; Tam J P; Hollingdale M R; Cochrane A H; Quakyi I; Nussenzweig R
S
LO New York, New York, Rockville, Maryland, United States; Legon, Gha
SO Science (228, No. 4706, 1436-40, 1985) 2 Fig. 2 Tab. 23 Ref.
CODEN: SCIEAS ISSN: 0036-8075
AV Department of Medical and Molecular Parasitology, New York University
Medical Center, New York 10021, U.S.A. (7 authors).
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature

L3 ANSWER 157 OF 325 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 2004037115 EMBASE
TI Society for Neuroscience - 33rd Annual Meeting: Alzheimer's and
Parkinson's diseases 8-12 November 2003, New Orleans, LA, USA.
AU Garvey R.; De La Rue S.
CS R. Garvey, Thomson Current Drugs, Middlesex House, 34-42 Cleveland Street,
London W1T 4JE, United Kingdom. redmond.garvey@thomson.com
SO IDrugs, (2003) 6/12 (1111-1113).
ISSN: 1369-7056 CODEN: IDRUFN
CY United Kingdom
DT Journal; Conference Article
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
030 Pharmacology
038 Adverse Reactions Titles
LA English

L3 ANSWER 158 OF 325 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): A21387 GenBank (R)
GenBank ACC. NO. (GBN): A21387
GenBank VERSION (VER): A21387.1 GI:583511
CAS REGISTRY NO. (RN): 389191-84-8
SEQUENCE LENGTH (SQL): 776
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Patent
DATE (DATE): 12 Jul 1994
DEFINITION (DEF): Plasmid DNA with human cDNA insert.
SOURCE: synthetic construct.
ORGANISM (ORGN): synthetic construct
artificial sequence
NUCLEIC ACID COUNT (NA): 184 a 178 c 221 g 193 t
REFERENCE: 1 (bases 1 to 776)
AUTHOR (AU):
TITLE (TI): RECOMBINANT PROTEIN WHICH BINDS TO A COMPLEX VIRAL
ANTIGEN OF HIV-1
JOURNAL (SO): Patent: WO 9118983-A 3 12-DEC-1991;

FEATURES (FEAT):
Feature Key Location Qualifier
=====+=====+=====

source	1..776	/organism="synthetic construct" /db-xref="taxon:32630"
CDS	14..760	/codon-start=1 /transl-table=11 /product="Fv-fragment of antibody 3D6" /protein-id="CAA01551.1" /db-xref="GI:583512" /translation="MEVQLVESGGGLVQPGRS LSCAASGFTFNDYAMHWVRQAPGK GLEWVSGISWDSSSIGYADSVKGRFTISR DNAKN SLYLQMNLSLRAEDMALYYCVKGRD YYDSGGYFTVAFDIWGQGTMTVSSGGG SGGGSDIQMTQSPSTLSASVGD VTITCRASQISRWLAWYQQKPGKPKLLI YKAS SLESGVPSRFSGSGSGTEFTLTIS SLQPDDEFATYYCQYNSYSFGPGTKVDIKR"

SEQUENCE (SEQ):
1 aaaagaattc cccatggaag tgcagctggt ggagtctggg ggaggcttgg tacagcctgg
61 caggtccctg agactctcct gtgcagcctc tggattcacc tttaatgatt atgccatgca

```

181 taġtāgtafā ggctatgcgġ āctctġtgaa ġġġccġāttc accāctcca ġagācāacġc
241 caagaactcc ctgtatctgc aaatgaacag tctgagagct gaggacatgg ccttatatta
301 ctgtgtaaaa ggcagagatt actatgatag tgggtggttat ttcacgggttg cttttgatatt
361 ctggggccaa gggacaatgg tcaccgtctc ttcaggtggc ggtggctcgg gcggtgggtgg
421 gtcgggtggc ggcggatctg acatccagat gaccagctct ccttccacc cgtctgcatc
481 tġtaggagac agagtcacca tcaattgccc ggcagtcag agtattagta ggtgggtggc
541 ctgggtatcag cagaaaccag ggaagtccc taagctcctg atctataagg catctagttt
601 agaaagtggg gtcccacaa ggttcagcgg cagtggatct gggacagaat tcactctcac
661 catcagcagc ctgcagcctg atgattttgc aacttattac tgccaacagt ataatagta
721 ttctttcggc cctgggacca aagtggatat caaacgataa gcttctgcac catctg

```

L3 ANSWER 159 OF 325 GENBANK.RTM. COPYRIGHT 2004 on STN

```

LOCUS (LOC): A21386 GenBank (R)
GenBank ACC. NO. (GBN): A21386
GenBank VERSION (VER): A21386.1 GI:583509
CAS REGISTRY NO. (RN): 389191-83-7
SEQUENCE LENGTH (SQL): 945
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Patent
DATE (DATE): 12 Jul 1994
DEFINITION (DEF): Plasmid DNA with human cDNA insert.
SOURCE: synthetic construct.
ORGANISM (ORGN): synthetic construct
artificial sequence
NUCLEIC ACID COUNT (NA): 229 a 274 c 226 g 216 t
REFERENCE: 1 (bases 1 to 945)
AUTHOR (AU):
TITLE (TI): RECOMBINANT PROTEIN WHICH BINDS TO A COMPLEX VIRAL
ANTIGEN OF HIV-1
JOURNAL (SO): Patent: WO 9118983-A 2 12-DEC-1991;

```

```

FEATURES (FEAT):
Feature Key Location Qualifier
=====+=====+=====
source 1..945 /organism="synthetic construct"
/db-xref="taxon:32630"
CDS 28..732 /codon-start=1
/transl-table=11
/product="3D6 antibody light
chain"
/protein-id="CAA01550.1"
/db-xref="GI:583510"
/translation="MDMRVPAQLLGLLLLWLPGA
KCDIQMTQSPSTLSASVGDRTIT
CRASQSIISRWLAWYQQKPKVPLLIYKASSLES
GVPSRFSGSGSGTEFTLTISLQ
DDFATYYCQQYNSYSFGPGTKVDIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFY
PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS
LSSTLTLSKADYEKHKVYACEVTH
QGLSPVTKSFNRGEC"

```

```

SEQUENCE (SEQ):
1 gtgaattcga gctcgggtacc ccacagcatg gacatgaggg tccccgctca gctcctgggg
61 ctccctgctgc tctggctccc aggtgccaaa tgtgacatcc agatgaccca gtctccttcc
121 accctgtctg catctgtagg agacagagtc accatcactt gccggggccag tcagagtatt
181 agtaggtggg tggcctggta tcagcagaaa ccagggaag tccctaagct cctgatctat
241 aaggcatcta gtttagaaag tgggggtccca tcaaggttca gcggcagtg atctgggaca
301 gaattcactc tcaccatcag cagcctgcag cctgatgatt ttgcaactta ttactgccaa
361 cagtataata gttattcttt cggccctggg accaaagtgg atatcaaacg aactgtggct
421 gcaccatctg tcttcatctt cccgccatct gatgagcagt tgaatctgg aactgcctct
481 gttgtgtgcc tgctgaataa cttctatccc agagaggcca aagtaacagt gaaggtggat
541 aacgccctcc aatcgggtaa ctcccaggag agtgtcacag agcaggacag caaggacagc
601 acctacagcc tcagcagcac cctgacgctg agcaaagcag actacgagaa acacaaagtc
661 tacgcctgcg aagtcaccca tcagggcctg agctcgcccg tcacaaagag cttcaacagg
721 ggagagtgtt agcacctgct cctcagttcc agcctgaccc cctcccatcc tttggcctct
781 gacccttttt ccacagggga cctaccccta ttgcggtcct ccagctcatc tttcacctca
841 cccccctcct cctccttggc ttaattatg ctaatgttgg aggagaatga ataaataaag
901 tgaatgggga tcctctagag tcgacctgca ggcattgcaag cttgg

```

L3 ANSWER 160 OF 325 GENBANK.RTM. COPYRIGHT 2004 on STN

```

LOCUS (LOC): A21385 GenBank (R)
GenBank ACC. NO. (GBN): A21385

```

CAS REGISTRY NO. (RN): 389191-86-0
 SEQUENCE LENGTH (SQL): 1549
 MOLECULE TYPE (CI): mRNA; linear
 DIVISION CODE (CI): Patent
 DATE (DATE): 19 Dec 1994
 DEFINITION (DEF): Plasmid DNA with human cDNA insert.
 SOURCE: synthetic construct.
 ORGANISM (ORGN): synthetic construct
 artificial sequence
 NUCLEIC ACID COUNT (NA): 362 a 463 c 417 g 307 t
 REFERENCE: 1 (bases 1 to 1549)
 AUTHOR (AU):
 TITLE (TI): RECOMBINANT PROTEIN WHICH BINDS TO A COMPLEX VIRAL
 ANTIGEN OF HIV-1
 JOURNAL (SO): Patent: WO 9118983-A 1 12-DEC-1991;

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..1549	/organism="synthetic construct" /db-xref="taxon:32630"
CDS	101..1528	/codon-start=1 /translation="heavy chain antibody 3D6" /protein-id="CAA01549.1" /db-xref="GI:583508" /translation="MELGLSWIFLLAILKGVQCE VQLVESGGGLVQPGKSLRLSCAAS GFTTFNDYAMHWVRQAPGKGLEWVSGISWDSSSIG YADSVKGRFTISRDNKNSLYLQM NSLRAEDMALYYCVKGRDYYDSGGYFTVAFDIWG QGTMTVTSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTGPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVS LTCLVKGFPYSDIAVEWESNGQPENNYKTTPPV LDSGFSFLYSKLTVDKSRWQQGNV FSCSVMEALHNHYTQKSLSLSPGK"

SEQUENCE (SEQ):

```

1  gtgaattcga gctcgggtacc cggggatcct ctagagtcacc agccctgaga ttcccaggtg
61  ttccattca gtgatcagca ctgaacacag aggactcacc atggagttgg gactgagctg
121 gattttcctt ttggctattt taaaagggtgt ccagtgtgaa gtgcagctgg tggagctcgg
181 gggaggcctg gtacagcctg gcaggtccct gagactctcc tgtgcagctg cttgattcac
241 ctttaatatg tatgccatgc actgggtccg gcaagctcca gggaagggcc tggagtgggt
301 ctcaggtata agttgggata gtagtagtat aggctatgcg gactctgtga agggccgatt
361 caccatctcc agagacaacg ccaagaactc cctgtatctg caaatgaaca gtctgagagc
421 tgaggacatg gccttatatt actgtgtaaa aggcagagat tactatgata gtggtggtta
481 ttccacggtt gcttttgata tctggggcca agggacaatg gtcaccgtct cttcagcctc
541 caccaagggc ccatcggtct tccccctggc accctcctcc aagagcactc ctggggggcac
601 agcagccctg ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa
661 ctcaggcgcc ctgaccagcg gcgtgcacac cttcccggtc gtcctacagt cctcaggact
721 ctactccctc agcagcgtgg tgaccgtgcc ctccagcagc ttggggcacc agacctacat
781 ctgcaacgtg aatcacaaag ccagcaaacac caaggtggac aagaaagtgt agcccaaate
841 ttgtgacaaa actcacacat gcccaccgtg cccagcactt gaactcctgg ggggaccgtc
901 agtcttcttc tcccccccaa aacccaagga caccctcatg atctcccgga cccctgaggt
961 cacatgcgtg gtggtggacg tgagccacga agaccctgag gtcaagtcca actggtacgt
1021 ggacggcgtg gaggtgcata atgccaagac aaagccgcgg gaggagcagt acaactccac
1081 gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta
1141 caagtgcgaag gtctccaaca aagccctccc agcccccatc gagaaaacca tctccaaagc
1201 caaagggcag ccccgagaac cacaggtgta caccctgccc ccattcccgg atgagctgac
1261 caagaaccag gtcagcctga cctgcctggg caaaggtctc tatcccagcg acatcgccgt
1321 ggagtgaggag agcaatgggc agccggagaa caactacaag accacgcctc ccgtgtctga
1381 ctccgacggc tccttcttcc tctacagcaa gctcaccgtg gacaagagca ggtggcagca
1441 ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa
1501 gaggctctcc ctgtctccgg gtaaatgaga cctgcaggca tgcaagctt

```

GenBank ACC. NO. (GBN): D14172
 GenBank VERSION (VER): D14172.1 GI:784932
 CAS REGISTRY NO. (RN): 384577-20-2
 SEQUENCE LENGTH (SQL): 341
 MOLECULE TYPE (CI): mRNA; linear
 DIVISION CODE (CI): Rodents
 DATE (DATE): 24 Jan 2003
 DEFINITION (DEF): Mus musculus mRNA, immunoglobulin heavy chain variable region (anti-CD8 monoclonal ***antibody***), partial sequence, clone:TD- ***3D6*** .

KEYWORDS (ST): VH region
 SOURCE: Mus musculus (house mouse)
 ORGANISM (ORGN): Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
 Euteleostomi; Mammalia; Eutheria; Rodentia;
 Sciurognathi; Muridae; Murinae; Mus

NUCLEIC ACID COUNT (NA): 97 a 83 c 89 g 72 t

COMMENT:

On Apr 26, 1995 this sequence version replaced gi:498370.

REFERENCE: 1 (bases 1 to 341)
 AUTHOR (AU): Sato,T.; Kon,S.
 TITLE (TI): Analysis of the immunoglobulin heavy chain variable region of hybridomas producing anti-CD8 monoclonal antibodies

JOURNAL (SO): Sapporo Med. J., 62, 31-41 (1993)

OTHER SOURCE (OS): CA 121:80571

REFERENCE: 2 (bases 1 to 341)

AUTHOR (AU): Kon,S.

TITLE (TI): Direct Submission

JOURNAL (SO): Submitted (25-JAN-1993) Shinichiro Kon, Sapporo Medical College, Department of Pathology; South1, West17, Chuo-ku, Sapporo 060, Japan (Tel:011-611-2111(ex.2311), Fax:011-643-2310)

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..341	/organism="Mus musculus" /strain="BALB/c" /db-xref="taxon:10090" /clone="TD-3D6" /cell-type="hybridoma (TD series)"
V-region	<1..>341	/product="anti-CD8 monoclonal antibody" /db-xref="IMGT/LIGM:D14172"
misc-feature	1..89	/note="FR1"
misc-feature	90..104	/note="CDR1"
misc-feature	105..146	/note="FR2"
misc-feature	147..197	/note="CDR2"
misc-feature	198..293	/note="FR3"
misc-feature	294..317	/note="CDR3"
misc-feature	318..341	/note="FR4"

SEQUENCE (SEQ):

```

1 aggtccaact gcagcagctct ggagctgaac tgatgaagcc tggggcctca gtgaagatat
61 cctgcaaggc tactggcaac acattcagaa ccaactggat agagtgggta aaacagagggc
121 ctggacatgg ccttgagtgg attggagaga ttttacctgg aagtggtagt accaactacc
181 atgagaagtt caaggataag gccacattca ctgcagacat atcctccaac acagcctaca
241 tacaactcag cagcctgaca tctgaggact ctgccgtcta ttactgtgca agactgagtg
301 attccaagtt tgcttactgg ggcgcagggg ccacggtcac c

```

L3 ANSWER 162 OF 325 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): HS3D6LCV GenBank (R)
 GenBank ACC. NO. (GBN): X53612
 GenBank VERSION (VER): X53612.1 GI:23868
 CAS REGISTRY NO. (RN): 140555-39-1
 SEQUENCE LENGTH (SQL): 381
 MOLECULE TYPE (CI): mRNA; linear
 DIVISION CODE (CI): Primates
 DATE (DATE): 3 Apr 1995
 DEFINITION (DEF): Human mRNA for ***3D6*** light chain variable region.
 SOURCE: human.
 ORGANISM (ORGN): Homo sapiens

Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo

NUCLEIC ACID COUNT (NA): 92 a 101 c 95 g 93 t

COMMENT:

This comes from serum of a HIV-1 positive individual.

REFERENCE: 1 (bases 1 to 381)

AUTHOR (AU): Rueker, F.

TITLE (TI): Direct Submission

JOURNAL (SO): Submitted (26-JUN-1990) Rueker F., Institut fuer
Angewandte Mikrobiologie, Universitaet fuer
Bodenkultur, Peter Jordanstr. 82, A-1190 Wien, Austria
2 (bases 1 to 381)

REFERENCE:

AUTHOR (AU): Felgenhauer, M.; Kohl, J.; Rueker, F.

TITLE (TI): Nucleotide sequences of the cDNAs encoding the
V-regions of H- and L-chains of a human monoclonal
antibody specific to HIV-1-gp41

JOURNAL (SO): Nucleic Acids Res., 18 (16), 4927 (1990)

OTHER SOURCE (OS): CA 113:166692

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..381	/organism="Homo sapiens" /isolate="monoclonal antibody 3D6" /db-xref="taxon:9606" /cell-line="3D6." /cell-type="rearranged lymphoblastoid"
sig-peptide	1..66	
CDS	1..>381	/codon-start=1 /product="kappa light chain V-region" /protein-id="CAA37674.1" /db-xref="GI:762937" /translation="MDMRVPAQLLGLLLLWLPGA KCDIQMTQSPSTLSASVGDRTIT CRASQSIISRWLAWYQQKPGKVPKLLIYKASSLES GVPSRFSGSGSGTEFTLTISLQP DDFATYYCQQYNSYSFGPGTKVDIK" /note="variable region (AA 23 - 127)"
V-region	67..>381	

SEQUENCE (SEQ):

```
1 atggacatga gggccccgc tcagtcctgc gggctcctgc tgctctggct cccaggtgcc
61 aaatgtgaca tccagatgac ccagtcctct tccaccctgt ctgcatctgt aggagacaga
121 gtcaccatca cttgccgggc cagtcagagt attagtaggt ggttggcctg gtatcagcag
181 aaaccaggga aagtccttaa gtcctgatc tataaggcat ctagttaga aagtggggtc
241 ccatcaaggt tcagcggcag tggatctggg acagaattca ctctcaccat cagcagcctg
301 cagcctgatg attttgcaac ttattactgc caacagtata atagttattc tttcggccct
361 gggaccaaa gggatataca a
```

L3 ANSWER 163 OF 325 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): HS3D6HCV GenBank (R)

GenBank ACC. NO. (GBN): X53613

GenBank VERSION (VER): X53613.1 GI:23865

CAS REGISTRY NO. (RN): 139841-87-5

SEQUENCE LENGTH (SQL): 435

MOLECULE TYPE (CI): mRNA; linear

DIVISION CODE (CI): Primates

DATE (DATE): 3 Apr 1995

DEFINITION (DEF): Human mRNA for ***3D6*** heavy chain variable
region.

SOURCE: human.

ORGANISM (ORGN): Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo

NUCLEIC ACID COUNT (NA): 99 a 87 c 130 g 119 t

COMMENT:

This comes from serum of a HIV-1 positive individual.

REFERENCE: 1 (bases 1 to 435)

AUTHOR (AU): Rueker, F.

TITLE (TI): Direct Submission

JOURNAL (SO): Submitted (26-JUN-1990) Rueker F., Institut fuer

REFERENCE: Bodenkultur, Peter Jordanstr. 82, A-1190 Wien, Austria
 2 (bases 1 to 435)
 AUTHOR (AU): Felgenhauer, M.; Kohl, J.; Ruker, F.
 TITLE (TI): Nucleotide sequences of the cDNAs encoding the
 V-regions of H- and L-chains of a human monoclonal
 antibody specific to HIV-1-gp41
 JOURNAL (SO): Nucleic Acids Res., 18 (16), 4927 (1990)
 OTHER SOURCE (OS): CA 113:166692

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..435	/organism="Homo sapiens" /isolate="monoclonal antibody 3D6" /db-xref="taxon:9606" /cell-line="3D6." /cell-type="rearranged lymphoblastoid"
sig-peptide	1..57	
CDS	1..>435	/codon-start=1 /product="kappa light chain V-region" /protein-id="CAA37675.1" /db-xref="GI:762936" /translation="MELGLSWIFLLAILKGVQCE VQLVESGGGLVQPGRSLRLSCAAS GFTFNDYAMHWVRQAPGKGLEWVSGISWDS SSIGYADSVKGRFTISRDNAKNSLYLQM NSLRAEDMALYYCVKGRDYYDSGGYFTVAF DIWGQGTMTVTVSS"
V-region	58..>435	/note="variable region (AA 20 - 145)"

SEQUENCE (SEQ):

```

1 atggagttgg gactgagctg gattttcctt ttggctatatt taaaaggtgt ccagtgtgaa
61 gtgcagctgg tggagtctgg gggaggcctt gtacagcctg gcaggtccct gagactctcc
121 tgtgcagcct ctggattcac ctttaatatg tatgccatgc actgggtccg gcaagctcca
181 gggaagggcc tggagtgggt ctcaggtata agttgggata gtagtagtat aggctatgcg
241 gactctgtga agggccgatt caccatctcc agagacaacg ccaagaactc cctgtatctg
301 caaatgaaca gtctgagagc tgaggacatg gccttatatt actgtgtaaa aggcagagat
361 tactatgata gtggtgggta tttcacggtt gcttttgata tctggggcca agggacaatg
421 gtcaccgtct cttca
```

L3 ANSWER 164 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 10580555 IFIPAT;IFIUDB;IFICDB
 TI HUMANIZED ***ANTIBODIES*** THAT RECOGNIZE BETA AMYLOID PEPTIDE
 IN Basi Guriq; Saldanha Jose (GB); Yednock Ted
 PA Elan Pharmaceuticals Inc (49246)
 PI US 2004087777 A1 20040506
 AI US 2003-388389 20030312
 RLI US 2001-10942 20011206 CONTINUATION-IN-PART PENDING
 PRAI US 2000-251892P 20001206 (Provisional)
 FI US 2004087777 20040506
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION
 CLMN 158
 GI 14 Figure(s).

FIG. 1 depicts an alignment of the amino acid sequences of the light chain of mouse ***3D6***, humanized ***3D6***, Kabat ID 109230 and germline A19 ***antibodies***. CDR regions are indicated by arrows. Bold italics indicate rare murine residues. Bold indicates packing (VH+VL) residues. Solid fill indicates canonical/CDR interacting residues. Asterisks indicate residues selected for backmutation in humanized ***3D6***, version 1.
 FIG. 2 depicts an alignment of the amino acid sequences of the heavy chain of mouse ***3D6***, humanized ***3D6***, Kabat ID 045919 and germline VH3-23 ***antibodies***. Annotation is the same as for FIG. 1.
 FIG. 3 graphically depicts the A beta binding properties of ***3D6***, chimeric ***3D6*** and 10D5.
 FIG. 3A is a graph depicting binding of A beta to chimeric ***3D6*** (PK1614) as compared to murine ***3D6***.
 FIG. 3B is a graph depicting competition of biotinylated ***3D6*** versus unlabeled ***3D6***, PK1614 and 10D5 for binding to A beta.

alphacarbon backbone trace. VH is shown in as a stippled line, and VL is shown as a solid line. CDR regions are indicated in ribbon form.

FIG. 5 graphically depicts the A beta binding properties of chimeric ***3D6*** and humanized ***3D6***.

FIG. 5A depicts ELISA results measuring the binding of humanized 3D6v1 and chimeric ***3D6*** to aggregated A beta.

FIG. 5B depicts ELISA results measuring the binding of humanized 3D6v1 and humanized 3D6v2 to aggregated A beta.

FIG. 6 is a graph quantitating the binding of humanized ***3D6*** and chimeric ***3D6*** to A beta plaques from brain sections of PDAPP mice.

FIG. 7 is a graph showing results of a competitive binding assay testing the ability of humanized ***3D6*** versions 1 and 2, chimeric ***3D6***, murine ***3D6***, and 10D5 to compete with murine ***3D6*** for binding to A beta.

FIG. 8 graphically depicts of an ex vivo phagocytosis assay testing the ability of humanized 3D6v2, chimeric ***3D6***, and human IgG to mediate the uptake of A beta by microglial cells.

FIG. 9 depicts an alignment of the 10D5 VL and ***3D6*** VL amino acid sequences. Bold indicates residues that match 10D5 exactly.

FIG. 10 depicts an alignment of the 10D5 VH and ***3D6*** VH amino acid sequences. Bold indicates residues that match 10D5 exactly.

L3 ANSWER 165 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 10575540 IFIPAT;IFIUDB;IFICDB
 TI HUMANIZED ***ANTIBODIES*** THAT RECOGNIZE BETA AMYLOID PEPTIDE
 IN Basi Guriq; Saldanha Jose (GB)
 PA Elan Pharmaceuticals Inc (49246)
 PI US 2004082762 A1 20040429
 AI US 2003-388214 20030312
 PRAI US 2002-363751P 20020312 (Provisional)
 FI US 2004082762 20040429
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION

CLMN 115

GI 9 Figure(s).

FIGS. 1A-B depicts an alignment of the amino acid sequences of the light chain of mouse 12B4 (mature peptide, SEQ ID NO:2), humanized 12B4 (mature peptide, SEQ ID NO:6), Kabat ID 005036 (mature peptide, SEQ ID NO:32) and germline A19 (X63397, mature peptide, SEQ ID NO:30) ***antibodies***. CDR regions are stippled and overlined. The single backmutation of a human right-arrow mouse residue is indicated by the asterisk. The importance of the shaded residues is shown in the legend. Numbered from the first methionine, not Kabat numbering.

FIGS. 2A-B depicts an alignment of the amino acid sequences of the heavy chain of mouse 12B4 (mature peptide, SEQ ID NO:4), humanized 12B4 (version 1) (mature peptide, SEQ ID NO:8), Kabat ID 000333 (mature peptide, SEQ ID NO:34), and germline VH4-39 and VH4-61 ***antibodies*** (mature peptides, SEQ ID NOs: 38 and 36, respectively). Annotation is the same as for FIG. 1. Numbered from the first methionine, not Kabat numbering.

FIGS. 3A-D depicts the nucleotide and amino acid sequence for humanized 12B4VLv1 compared with chimeric 12B4VL (identical variable region sequences as murine 12B4VL, SEQ ID NOs: 1 and 2, respectively); germline A19 sequences (SEQ ID NOs: 29 and 30, respectively); and Kabat ID 005036 (SEQ ID NOs: 31 and 32, respectively).

FIGS. 4A-D depicts the nucleotide and amino acid sequence for humanized 12B4VHv1 compared with chimeric 12B4VH (identical variable region sequences as murine 12B4VH, SEQ ID NOs: 3 and 4, respectively); Kabat ID 000333 (SEQ ID NOs: 33 and 34, respectively); and germline VH4-61 (SEQ ID NOs: 35 and 36, respectively).

FIG. 5 graphically depicts the ELISA results from two independent experiments measuring the binding of chimeric 12B4, ***3D6***, and chimeric ***3D6*** to A beta (panels A and B, respectively).

FIG. 6 graphically depicts competitive ELISA binding confirming functional activity of 12B4 and chimeric 12B4 as compared to ***3D6***, chimeric ***3D6***, and 10D5. Chimeric 12B4 (open triangles) competes with equal potency with its non biotinylated murine counterpart (open inverted triangles) for binding of biotinylated murine 12B4 to A beta 1-42 peptide.

FIG. 7 graphically depicts an ex vivo phagocytosis assay testing the ability of chimeric 12B4, ***3D6***, and human IgG1 to mediate the uptake of A beta by microglial cells on PDAPP brain sections.

FIG. 8 graphically depicts the results from two independent ex vivo

chimeric 12B4, humanized ***3D6*** , and human IgG1 to mediate the uptake of A beta by microglial cells on AD brain sections. FIG. 9 is a schematic representation of the PCR-mediated assembly of humanized 12B4, version 1. FIG. 9A depicts the assembly of the VL regions. FIG. 9B depicts the assembly of the VH regions.

L3 ANSWER 166 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 10574435 IFIPAT;IFIUDB;IFICDB
 TI PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
 IN Schenk Dale B
 PA Athena Neurosciences Inc
 Neuralab Ltd BM
 (33043)
 PI US 2004081657 A1 20040429
 AI US 2003-429216 20030502
 RLI US 1998-201430 19981130 CONTINUATION PENDING
 PRAI US 1997-67740P 19971202 (Provisional)
 US 1998-80970P 19980407 (Provisional)
 FI US 2004081657 20040429
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION
 CLMN 63
 GI 15 Figure(s).

FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
 FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific mA beta ***3D6*** , was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
 FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APPspecific mA beta 8E5, was determined by quantitative computerassisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
 FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
 FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0. 14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
 FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
 FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS and AN1792-treated mice.
 FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS and AN1792-treated mice.
 FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
 FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (upper panel) or PBS-treated (lower panel).
 FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
 FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBStreated control group.
 FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
 FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
 FIG. 15: A beta levels in the cortex of 12-month old PDAPP mice treated

L3 ANSWER 167 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 10421072 IFIPAT;IFIUDB;IFICDB
 TI HUMANIZED ***ANTIBODIES*** THAT RECOGNIZE BETA AMYLOID PEPTIDE
 IN Basi Gurig; Saldanha Jose (GB); Yednock Ted
 PA Elan Pharmaceuticals Inc (49246)
 PI US 2003165496 A1 20030904
 AI US 2001-10942 20011206
 PRAI US 2000-251892P 20001206 (Provisional)
 FI US 2003165496 20030904
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION
 CLMN 158
 GI 10 Figure(s).
 FIG. 1 depicts an alignment of the amino acid sequences of the light chain of mouse ***3D6***, humanized ***3D6***, Kabat ID 109230 and germline A19 ***antibodies***. CDR regions are indicated by arrows. Bold italics indicate rare murine residues. Bold indicates packing (VH+VL) residues. Solid fill indicates canonical/CDR interacting residues. Asterisks indicate residues selected for backmutation in humanized ***3D6***, version 1.
 FIG. 2 depicts an alignment of the amino acid sequences of the heavy chain of mouse ***3D6***, humanized ***3D6***, Kabat ID 045919 and germline VH3-23 ***antibodies***. Annotation is the same as for FIG. 1.
 FIG. 3 graphically depicts the A beta binding properties of ***3D6***, chimeric ***3D6*** and 10D5. FIG. 3A is a graph depicting binding of A beta to chimeric ***3D6*** (PK1614) as compared to murine ***3D6***. FIG. 3B is a graph depicting competition of biotinylated ***3D6*** versus unlabeled ***3D6***, PK1614 and 10D5 for binding to A beta.
 FIG. 4 depicts a homology model of ***3D6*** VH and VL, showing alphacarbon backbone trace. VH is shown in as a stippled line, and VL is shown as a solid line. CDR regions are indicated in ribbon form.
 FIG. 5 graphically depicts the A beta binding properties of chimeric ***3D6*** and humanized ***3D6***. FIG. 5A depicts ELISA results measuring the binding of humanized 3D6v1 and chimeric ***3D6*** to aggregated A beta. FIG. 5B depicts ELISA results measuring the binding of humanized 3D6v1 and humanized 3D6v2 to aggregated A beta.
 FIG. 6 is a graph quantitating the binding of humanized ***3D6*** and chimeric ***3D6*** to A beta plaques from brain sections of PDAPP mice.
 FIG. 7 is a graph showing results of a competitive binding assay testing the ability of humanized ***3D6*** versions 1 and 2, chimeric ***3D6***, murine ***3D6***, and 10D5 to compete with murine ***3D6*** for binding to A beta.
 FIG. 8 graphically depicts of an ex vivo phagocytosis assay testing the ability of humanized 3D6v2, chimeric ***3D6***, and human IgG to mediate the uptake of A beta by microglial cells.
 FIG. 9 depicts an alignment of the 10D5 VL and ***3D6*** VL amino acid sequences. Bold indicates residues that match 10D5 exactly.
 FIG. 10 depicts an alignment of the 10D5 VH and ***3D6*** VH amino acid sequences. Bold indicates residues that match 10D5 exactly.

L3 ANSWER 168 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 10374168 IFIPAT;IFIUDB;IFICDB
 TI HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF
 IN Schwall Ralph H; Tabor Kelly H
 PA Unassigned Or Assigned To Individual (68000)
 PI US 2003118587 A1 20030626
 AI US 2002-232408 20020903
 RLI WO 1996-US8094 19960531 Section 371 PCT Filing PENDING
 US 1998-952235 19980217 CONTINUATION 6207152
 US 2000-669971 20000926 CONTINUATION 6468529
 FI US 2003118587 20030626
 US 6207152
 US 6468529
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION

CLMN 40
 GI 14 Figure(s).
 FIGS. 1A and 1B show the amino acid sequences (and encoding nucleotides) for the light chain (FIG. 1A) and heavy chain (FIG. 1B), respectively,

FIG. 2 is a graph showing the inhibition of HGF binding to c-MetIgG fusion protein by monoclonal ***antibody*** 1A3.3.13.
 FIG. 3 is a bar diagram showing the stimulatory effect of monoclonal ***antibodies*** ***3D6***, 6G1. and 1A3.3.13 on human mammary epithelial cells in a proliferation assay.
 FIG. 4 is a bar diagram showing the stimulatory effect of monoclonal ***antibodies*** ***3D6***, 05-237 and 05-238 on mink lung cells : a proliferation assay.
 FIG. 5 is a bar diagram showing the inhibitory effect of monoclonal ***antibody*** 1A3.3.13 Fab fragments on BaF3-hmet.8 cells in a proliferation assay.
 FIGS. 6A and 6B are FACS analysis graphs showing binding specificity of monoclonal ***antibody*** 5D5 to BaF3-hmet.8 cells expressing c-Met.
 FIG. 7 is a graph showing the inhibition of HGF binding to c-MetIgG fusion protein by monoclonal ***antibody*** 5D5 and by 5D5 Fab.
 FIGS. 8A and 8B are graphs showing the inhibitory effect of 5D5 Fab on BaF3-hmet.8 cells in a proliferation assay.
 FIG. 9 is a graph showing the inhibitory effect of 5D5 Fab on a human breast carcinoma cell line (MDA-MB-435) which expresses cMet.
 FIGS. 10A and 10B are bar diagrams showing the inhibitory effect of 5D5 Fab on c-Met tyrosine phosphorylation.
 FIGS. 11A-11C are graphs comparing inhibitory effects of NK1 (FIG. 11A), 5D5 Fab (FIG. 11B), and 5D5 Fab and rhuHGF (FIG. 11C) on BaF3-hmet.8 cells in a proliferation assay conducted in the presence or absence of heparin.
 FIG. 12 is a restriction map of plasmid p5D5 containing the discistronic operon for expression of the chimera 5D5 Fab.
 FIG. 13 is a graph showing the inhibition of HGF binding to cMet-IgG fusion protein by recombinant 5D5 Fab.
 FIGS. 14A-14D are graphs comparing the inhibitory effect of recombinant 5D5 Fab and recombinant anti-VEGF Fab (control Fab) on BaF3-hmet.8 cells in a proliferation assay conducted in the presence or absence of heparin.

L3 ANSWER 169 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 10264702 IFIPAT;IFIUDB;IFICDB
 TI IN VIVO MULTIPHOTON DIAGNOSTIC DETECTION AND IMAGING OF A
 NEURODEGENERATIVE DISEASE
 IN Backsai Brian; Christie Richard; Hyman Bradley T; Webb Watt W; Zipfel
 Warren R
 PA Unassigned Or Assigned To Individual (68000)
 PI US 2003009104 A1 20030109
 AI US 2001-1643 20011031
 PRAI US 2000-245306P 20001102 (Provisional)
 FI US 2003009104 20030109
 DT Utility; Patent Application - First Publication
 FS ELECTRICAL
 APPLICATION

CLMN 34
 GI 25 Figure(s).

FIGS. 1A-C show different embodiments for imaging neurodegenerative disease in accordance with the present invention. FIG. 1A illustrates the manner in which a patient's skull is imaged. In FIG. 1B, imaging is carried out with a spectroscopic system. FIG. 1C illustrates imaging with a single mode optical fiber and terminal lens.
 FIGS. 2A-E show the preparation of a skull for in vivo imaging. FIG. 2A shows the gross appearance of skull through dissecting microscope prior to imaging. The pial vasculature is visible through the intact but thinned region of skull. Anterior and midline sutures are also visible in the image. Scale marks are spaced 1 mm apart. FIG. 2B is a schematic diagram of the microscope objective during imaging. The thinned area of skull is bathed in a pool of artificial cerebrospinal fluid (light gray), retained by a ring of bone wax (dark gray). A small break is made in the lateral wall of the thinned area to allow for thioflavine S entry. FIG. 2C is the in vivo visualization of thioflavine S-positive ("ThioS") amyloid in a 15-month old Tg2576 mouse. Single optical section near the surface of the skull. Thioflavine S-positive amyloid angiopathy is visible ring the pial arteriole in this image. The fainter autofluorescence of the skull bone is visible in the lower right corner, and the fibrous autofluorescence of the dura is visible as a band at lower right. FIG. 2D shows another optical section from the same z-series as in FIG. 2C, but 50 μ m deeper into the brain, showing a thioflavine S-positive amyloid deposit in layer 1 of the mouse cortex. FIG. 2E shows the perpendicular volume rendering of the entire stack of images, with the skull visible at the top, the amyloid-encrusted pial vessel just beneath, and the thioflavine S-positive plaque deep in the living brain.

vessel and the skull. The approximate levels of optical sections shown in FIGS. 2C and 2D are represented by dotted lines. The scale bars in FIGS. 2C-E are 25 μ m.

FIGS. 3A-C confirm the thioflavine S-positive structures were indeed senile plaques. This was demonstrated by applying thioflavine S and an anti-amyloid-beta monoclonal ***antibody***, cy3labeled 10D5 (Elan Pharmaceuticals, South San Francisco, Calif.), to the surface of a fixed but intact Tg2576 brain. In FIG. 3A, the fluorescence emission in the range 380-480 nm shows Thioflavine S staining the amyloid core of a plaque about 40 μ m deep into the brain. In FIG. 3B, emission in the 560-650 nm range shows the Cy3-10 D5 staining of the same A beta surrounding the thioflavine S positive core. Scale bar =10 μ m. FIG. 3C shows glial fibrillary acidic protein immunoreactivity in a section through the area imaged by multiphoton microscopy 2 days previously. Sparse immunoreactive astrocytes, not substantially different from adjacent (non-imaged) cortex, suggest minimal tissue response to imaging. Scale=100 μ m.

FIGS. 4A-E show the in vivo imaging of thioflavine S positive amyloid deposition in a Tg2576 mouse. FIG. 4A is a 3 x 3 montage of 60 x fields acquired on initial imaging day. Optical sections were obtained every 2 micrometers for a distance of 200 micrometers from the inner surface of the skull; images were aligned in the x, y, and z axes, then projected onto a single image revealing amyloid angiopathy and senile plaques. Scale bar=100 μ m. FIG. 4B shows the in vivo imaging of a thioflavine S-positive plaque approximately 40 μ m deep to the skull surface. This image is a single optical section through the body of the plaque. Scale bar=10 μ m. FIG. 4C shows the same plaque as in FIG. 4B, reimaged two days later under identical imaging conditions. FIG. 4D is a single optical section showing thioflavine S-positive amyloid angiopathy associated with a pial arteriole. Scale bar=20 μ m. FIG. 4E shows the same arteriole imaged in FIG. 4D after two days.

FIGS. 5A-B show the analysis of variability of plaque measurements. In FIG. 5A, the percent change (average \pm standard deviation) for all plaque measurements binned into 0.5 month groups shows no trend in either the average measure or the variability of measurement over the time interval examined. N's for each measurement are noted above the standard deviation bars. FIG. 5B is a linear regression plot of initial measurement and subsequent measurement for all time intervals, showing tight correlation for all plaque sizes. The slope of the line approaches unity (0.98) with a correlation coefficient ($R^2=0.89$).

FIG. 6 shows a subpopulation of plaques change size over time. The images are 2-channel volume rendered stacks of thioflavine S plaques (red) and fluorescein angiograms (green) taken from the same animal at the initial imaging session (left images) and 104 days later (right images). Four clearly imaged plaques can be seen in these volumes, labeled A-D. The autofluorescence of the dura appears at the upper edge of the volume stacks, and appears slightly different in the images here and in FIG. 7, because the image stacks are not exactly coincident at their initial depth. The graph below represents the percent change in diameter for each plaque. The plaques labeled A and B increase in size by about 50%, plaque C remains the same size, and plaque D decreases by 40%. Scale bar=20 μ m.

FIGS. 7A-B show the appearance of a novel plaque in the imaged region. FIG. 7A is a volume rendering of a set of 3 plaques during an initial imaging session. FIG. 7B is a volume rendering of the same region, imaged 64 days later, showing the initial plaques joined by a novel thioflavine S-positive plaque. The fibrous autofluorescence at lower left is dura mater. Scale bar=50 μ m.

FIG. 8 is a simplified schematic representation of the experimental paradigm. An anesthetized mouse is placed in a head-open device that is then mounted on the stage of a multiphoton microscope. Texas red-labeled dextran is injected in the tail vein as an angiographic contrast agent. Thioflavine S is applied to the surface of the brain through an open craniotomy. After thioflavine-S is washed out, imaging reveals both microvascular anatomy and amyloid deposits.

FIG. 9 shows examples of the co-occurrence of amyloid angiopathy and microvascular anatomy. A semiquantitative rating scale (none, mild, moderate, severe) was employed as illustrated in this figure.

FIG. 10 shows the measurement of vessel diameter. A random start point was placed, and then the diameter of vessels measured every thirty micrometers thereafter throughout the image series. At each measuring point, the diameter of the vessel as well as the presence or absence of amyloid was noted.

FIG. 11 shows the measurement of vessel diameter as noted with regard to FIG. 10. There is a significant difference between amyloid-containing and

severe (n=6) vessels.

*=p less-than 0.01.

FIG. 12 shows an example of mild amyloid angiopathy occurring near the branch points of vessels. The method for measuring distance is illustrated with an overlay of random points from which the distance from the nearest branch point is measured.

FIG. 13 shows the distance of amyloid deposits from nearest branch point. Measurements were carried out as described with reference to FIG. 12. The significant differences were seen in both mild (n=75 vessel segments, p less-than 0.005) and moderate (n=73 vessel segments, p less-than 0.005) vessels, with amyloid tending to occur near branch points. A smaller difference, not reaching statistical significance was seen in severely affected vessels (n=59).

FIG. 14 shows the thioS positive amyloid angiopathy in the Tg2576 mouse. The intact fixed brain of a 16 month old Tg2576 mouse was stained with thioS (0.005%) and imaged using twophoton excitation at 750 nm. This image is a montage of 4 x 8 zseries collected with a 20 x objective. The midline of the brain is at the top of the figure, and the brain was oriented with the anterior pole to the left. Extreme curvature at the lateral edge of the brain interfered with montage generation, distorting the lowermost portion of the image. The middle cerebral artery emerges from behind the lateral edge of the brain on the right, and courses towards the midline. ThioS positive vessel-associated amyloid, as well as superficial parenchymal thioS-positive plaques are clearly visible. Surface venules are seen as negatively stained background profiles. Scale bar(upper right)=600 μ m.

FIGS. 15A-B shows that the overexpression of mutant amyloid precursor protein ("APP") does not disrupt smooth muscle cells independent of amyloid deposition. Phalloidin-labeled smooth muscle cells in young (6 month) Tg2576 animals are arranged neatly around the circumference of the vessel, with no apparent space between adjacent cells. FIG. 15A shows the phalloidin-stained smooth muscle cells in a pial vessel from a Tg-animal. FIG. 15B shows smooth muscle cells in a pial vessel of a Tg+ animal. Scale bar=20 μ m.

FIGS. 16A-F show the effect of amyloid deposition on smooth muscle cells in 14 month old and 22 month old Tg2567 animals. FIG. 16A shows phalloidin-labeled smooth muscle cells in the wall of a pial arteriole in a 14 month old Tg2576 animal. FIG. 16B shows thioS-positive amyloid surrounding the vessels. Smooth muscle cells are clearly disrupted in areas of amyloid deposition as compared to unaffected regions of the same vessel. Smooth muscle cells surrounded by amyloid are disorganized and isolated, though there is no apparent loss of cells along the length of the vessel. FIG. 16D shows smooth muscle cell staining in a 24 month old Tg2576 animal. FIG. 16E shows thioS-positive amyloid surrounding the vessel. At this age, overt loss of smooth muscle cells along the length of the vessel is evident, along with disruption of remaining cells. Regions of the vessel unaffected by amyloid, however, retain normal smooth muscle cell organization. (See FIG. 16C and F). Superimposed color images showing both phalloidin and thio S staining. Scale bar=20 μ m.

FIG. 17 shows the quantitation of smooth muscle cell density in amyloid-laden versus amyloid-free vessels in 14 mo and 24 mo Tg2576 mice. Smooth muscle cell linear density was measured as described. Density was measured in affected and unaffected vessels from both age groups. The 24 month old amyloid-laden set of vessels has significantly smaller smooth muscle cell density (p less-than 0.01, ANOVA) than either the amyloid-free vessels from the same animal or amyloid-free vessels from younger transgenic and non-transgenic animals.

FIG. 18 shows the response of pial vessels to ACh and SNP. Maximal percent dilation in response to ACh (10^{-6} M) and SNP (0.5×10^{-6} M) in 14 month old Tg+ (n=4 of 5, one outlier excluded) and Tg- (n=3 of 3) mice. Bars are mean \pm SD. *, p less-than 0.05 by ANOVA.

FIGS. 19A-D show the in vivo imaging of amyloid-beta deposits in 20 month old homozygous PDAPP mice. Reconstructions of stacks of Z series images taken at 5 micron steps with a 20X objective (FIGS. 19A-B) and 2 micron steps with a 60 x objective (FIGS. 19C-D) starting from just below the cortical surface to approximately 150 microns below the surface. Amyloid beta is visualized with a dilute solution of fluorescein labeled monoclonal ***antibody*** 10D5. (FIGS. 19A and C) Initial imaging session shows numerous 10D5 immunoreactive amyloid-beta plaques in the neuropil and associated with vessels in one representative animal (FIGS. 19B and D). Three days later exactly the same sites were re-imaged with fluorescein10D5. Surprisingly, very little of the neuropil amyloid-beta remains, directly showing reversal of previously existing amyloid-beta deposits. Note that the vessel associated amyloid-beta is not clearly altered. Magnification bar=50 μ m in FIGS. 19A and B, 25 μ m in FIGS.

FIGS. 20A-D ascertain whether the apparent clearance of amyloid-beta was due to application of an anti-amyloid beta ***antibody*** or to the surgical preparation, imaging, and other nonspecific factors by replacing 10D5 in the first imaging session with 16B5, a monoclonal ***antibody*** directed against human tau that does not cross react with rodent tau (Sobey et al., "Effect of Nitric Oxide and Potassium Channel Agonists and Inhibitors on Basilar Artery Diameter," Am J Physiol 72:H256-H262 (1997), which is hereby incorporated by reference), and used thioflavine S as the imaging agent. FIGS. 20A and 20B, respectively, show a thioflavine S positive plaque in the first imaging session and 3 days after application of 10D5. FIG. 20C depicts a thioflavine S positive plaque in a 16B5 treated animal does not change 3 days later (FIG. 20D). Magnification bar=20 mu m.

FIGS. 21A-B show the histological analysis of imaged brains from 20 mo. old homozygous PDAPP mice using directly labeled ***antibody*** ***3D6***, showing an extraordinarily high level of amyloid-beta deposits throughout the cortex and hippocampal formation. There was a marked diminution of amyloid-beta staining at the site of 10D5 application. FIG. 21A depicts the immunostaining with biotinylated ***3D6***, an anti-amyloid-beta monoclonal ***antibody*** that has a distinct epitope (aa 1-5) compared to 10D5 (aa 3-6), which shows a 100-200 micron deep area that was essentially devoid of diffuse amyloid-beta deposits, in contrast to the intense deposits found in adjacent sections or medial or lateral to the site. FIG. 21B shows that there were no changes in ***3D6*** immunoreactive amyloid-beta plaques observed after initial treatment with 16B5 application. Magnification bar=200 mu m.

FIGS. 22A-B show that marked local microglial activation, as assessed with biotin labeled tomato lectin (Sigma Chemical Co., St. Louis, Mo.), occurred three days after skull preparation and imaging in both (FIG. 22A) the 10D5 and (FIG. 22B) the 16B5 groups. Magnification bar=200 mu m.

FIGS. 23A-B show confocal thin optical sections (0.2 micron) that were reconstructed to illustrate the intimate relationship of microglia with remaining amyloid-beta three days after treatment with 10D5-fluorescein. FIG. 23A depicts fluorescein labeled tomato lectin, which detects microglia, and biotin labeled ***3D6*** detected with Cy3 avidin, which detects amyloid-beta. A marked microglial response surrounding remaining amyloid-beta plaques was observed. As indicated in FIG. 23B, distal to the site, for example in temporal lobe, the association of microglia with amyloid-beta is much more modest. Magnification bar=20 mu m.

FIG. 24A shows the autofluorescence of neurofibrillary tangles and lipofusion droplets from post-mortem brain tissue in a human Alzheimer's Disease patient. FIG. 24B shows the fluorescence of neurofibrillary tangles from post-mortem brain tissue in a human Alzheimer's Disease patient using an ***antibody*** against the tau protein; this demonstrates the fluorescence in FIG. 24A is attributable to the tau protein. !

L3 ANSWER 170 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10193017 IFIPAT;IFIUDB;IFICDB
TI HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF;
SPECIFICALLY BINDS TO HEPATOCYTE GROWTH FACTOR RECEPTOR; FOR TREATING
CANCER

IN Schwall Ralph H; Tabor Kelly H
PA Unassigned Or Assigned To Individual (68000)

PI US 2002136721 A1 20020926

AI US 2001-995693 20011129

RLI WO 1996-US8094 19960531 Section 371 PCT Filing UNKNOWN

US 1998-952235 19980217 CONTINUATION 6207152

US 2000-669971 20000926 CONTINUATION PENDING

FI US 2002136721 20020926

US 6207152

DT Utility; Patent Application - First Publication

FS CHEMICAL
APPLICATION

CLMN 40

GI 14 Figure(s).

FIGS. 1A and 1B show the amino acid sequences (and encoding nucleotides) for the light chain (FIG. 1A) and heavy chain (FIG. 1B), respectively, of monoclonal ***antibody*** 5D5 Fab.

FIG. 2 is a graph showing the inhibition of HGF binding to c-MetIgG fusion protein by monoclonal ***antibody*** 1A33.13.

FIG. 3 is a bar diagram showing the stimulatory effect of monoclonal ***antibodies*** ***3D6***, 6G1, and 1A3.3.13 on human mammary

FIG. 4 is a bar diagram showing the stimulatory effect of monoclonal
 antibodies ***3D6***, 05-237 and 05-238 on mink lung cells :
 a proliferation assay.
 FIG. 5 is a bar diagram showing the inhibitory effect of monoclonal
 antibody 1A3.3.13 Fab fragments on BaF3-hmet.8 cells in a
 proliferation assay.
 FIG. 6A and 6B are FACS analysis graphs showing binding specificity of
 monoclonal ***antibody*** 5D5 to BaF3-hmet.8 cells expressing c-Met.
 FIG. 7 is a graph showing the inhibition of HGF binding to c-MetIgG fusion
 protein by monoclonal ***antibody*** 5D5 and by 5D5 Fab.
 FIGS. 8A and 8B are graphs showing the inhibitory effect of 5D5 Fab on
 BaF3-hmet.8 cells in a proliferation assay.
 FIG. 9 is a graph showing the inhibitory effect of 5D5 Fab on a human
 breast carcinoma cell line (MDA-MB-435) which expresses cMet.
 FIGS. 10A and 10B are bar diagrams showing the inhibitory effect of 5D5
 Fab on c-Met tyrosine phosphorylation.
 FIGS. 11A-11C are graphs comparing inhibitory effects of NK1 (FIG. 11A),
 5D5 Fab (FIG. 11B). and 5D5 Fab and rhuHGF (FIG. 11C) on BaF3-hmet.8
 cells in a proliferation assay conducted in the presence or absence of
 heparin.
 FIG. 12 is a restriction map of plasmid p5D5 containing the discistronic
 operon for expression of the chimera 5D5 Fab.
 FIG. 13 is a graph showing the inhibition of HGF binding to cMet-IgG
 fusion protein by recombinant 5D5 Fab.
 FIGS. 14A-14D graphs comparing the inhibitory effect of recombinant 5D5
 Fab and recombinant anti-VEGF Fab (control Fab) on BaF3-hmet8 cells in a
 proliferation assay conducted in the presence or absence of heparin.

L3 ANSWER 171 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 04049335 IFIPAT;IFIUDB;IFICDB
 TI METHODS OF INHIBITING T CELL PROLIFERATION OR IL-2 ACCUMULATION WITH
 CTLA4-SPECIFIC ***ANTIBODIES***
 IN Freeman Gordon J; Gray Gary S; Greenfield Edward; Gribben John G; Jellis
 Cindy L; Nadler Lee M; Rennert Paul
 PA Dana-Farber Cancer Institute Inc
 Repligen Corp
 (10790, 11804)
 PI US 6719972 B1 20040413
 AI US 1994-253783 19940603
 FI US 6719972 20040413
 DT Utility; Granted Patent - Utility, no Pre-Grant Publication
 FS CHEMICAL
 GRANTED
 CLMN 11
 GI 2 Drawing Sheet(s), 4 Figure(s).
 FIG. 1A is a graphic representation of T cell responses (proliferation,
 IL-2 production or apoptosis) by activated DR7specific T cell clones upon
 rechallenge with antigen (t-DR7) and the indicated second signals,
 demonstrating induction of apoptosis by an anti-CTLA4 monoclonal
 antibody (mAb).
 FIG. 1B is a graphic representation of T cell responses (proliferation,
 IL-2 production or apoptosis) by normal peripheral blood CD4+ T cell
 blasts upon rechallenge with antiCD3 and the indicated second signals,
 demonstrating induction of apoptosis by an anti-CTLA4 mAb.
 FIG. 2A is a graphic representation of T cell responses (proliferation,
 IL-2 production or apoptosis) by activated DR7specific T cell clones upon
 rechallenge with cells expressing antigen alone (t-DR7) or cells
 expressing both antigen and either B7-1 (tDR7/B7-1) or B7-2 (tDR7/B7-2),
 demonstrating that neither B7-1 nor B7-2 induces antigen apoptosis.
 FIG. 2B is a graphic representation of T cell responses (proliferation,
 IL-2 production or apoptosis) by activated DR7specific T cell clones upon
 rechallenge with the indicated cells together with the indicated mAbs or
 fusion proteins, demonstrating that antigen specific apoptosis is induced
 by a non-B7-1, non-B7-2 CTLA4 binding ligand.

L3 ANSWER 172 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 04038728 IFIPAT;IFIUDB;IFICDB
 TI TRANSGENIC MOUSE ASSAY TO DETERMINE THE EFFECT OF A BETA
 ANTIBODIES AND A BETA FRAGMENTS ON ALZHEIMER'S DISEASE
 CHARACTERISTICS
 IN Schenk Dale B
 PI US 6710226 B1 20040323
 AI US 2000-723384 20001127
 RLI US 1999-322289 19990528 CONTINUATION PENDING
 US 1998-201430 19981130 CONTINUATION-IN-PART PENDING

US 1998-80970P 19980407 (Provisional)
FI US 6710226 20040323
DT Utility; Granted Patent - Utility, no Pre-Grant Publication
FS CHEMICAL
GRANTED

CLMN 32

GI 16 Drawing Sheet(s), 22 Figure(s).

- FIG. 1: ***Antibody*** titer after injection of transgenic mice with A beta 1-42.
- FIG. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A beta-specific monoclonal ***antibody*** ***3D6***, was determined by computer-assisted quantitative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.
- FIG. 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APP-specific monoclonal 8E5, was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.
- FIG. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.
- FIG. 5: Geometric mean ***antibody*** titers to A beta 1-42 following immunization with a range of eight doses of AN1792 containing 0.14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 mu g.
- FIG. 6: Kinetics of ***antibody*** response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.
- FIG. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.
- FIG. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.
- FIG. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.
- FIG. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (upper panel) or PBS-treated (lower panel).
- FIG. 11: Total A beta levels in the cortex. A scatterplot of individual A beta profiles in mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
- FIG. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A beta peptide conjugates A beta 1-5, A beta 1-12, and A beta 13-28; the full length A beta aggregates AN1792 (A beta 1-42) and AN1528 (A beta 1-40) and the PBS-treated control group.
- FIG. 13: Geometric mean titers of A beta-specific ***antibody*** for groups of mice immunized with A beta or APP derivatives combined with Freund's adjuvant.
- FIG. 14: Geometric mean titers of A beta-specific ***antibody*** for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.
- FIGS. 15A-E: A beta levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A beta level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.
- FIG. 15A: The values for mice for the PBS-treated control group and the untreated control group.
- FIG. 15B: The values for mice in the AN1528/alum and AN1528/MPL treatment groups.
- FIG. 15C: The values for mice in the AN1528/QS21 and AN1792/ Freund's adjuvant treatment groups.
- FIG. 15D: The values for mice in the AN1792/Thimerosal and AN1792/alum treatment groups.
- FIG. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.
- FIG. 16: Mean titer of mice treated with polyclonal ***antibody*** to A beta.
- FIG. 17: Mean titer of mice treated with monoclonal ***antibody***

FIG. 18: Mean titer of mice treated with monoclonal ***antibody***
2F12 to A beta .

L3 ANSWER 173 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
AN 03572420 IFIPAT;IFIUDB;IFICDB
TI METHOD FOR DETECTING CANDIDA INFECTION; ARABINITOL OXIDOREDUCTASE; FOR
USE IN THE DIAGNOSIS OF MICROORGANISMAL INFECTION
IN Miyada Charles Garrett; Quong Melanie W; Switchenko Arthur C; Wong
Man-Ying Laurie
PA Dade Behring Marburg GmbH DE (46971)
PI US 6287833 B1 20010911
AI US 1995-472599 19950607
RLI US 1991-731218 19910712 CONTINUATION ABANDONED
US 1994-184764 19940121 CONTINUATION ABANDONED
US 1995-400417 19950303 DIVISION 5451517
FI US 6287833 20010911
US 5451517
DT Utility
FS CHEMICAL
GRANTED
MRN 009168 MFN: 0310
009178 0174
009472 0001
009507 0015
010121 0426
010121 0451
CLMN 7

L3 ANSWER 174 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
AN 03565000 IFIPAT;IFIUDB;IFICDB
TI METHOD FOR DETECTING CANDIDA INFECTION; DETERMINATION OF D-ARABINITOL
USING D-ARABINITOL DEHYDROGENASE
IN Miyada Charles Garrett; Quong Melanie W; Switchenko Arthur C; Wong
Man-Ying Laurie
PA Dade Behring Marburg GmbH DE (46971)
PI US 6280988 B1 20010828
AI US 1995-487946 19950607
RLI US 1991-731218 19910712 CONTINUATION ABANDONED
US 1994-184764 19940121 CONTINUATION ABANDONED
US 1995-400417 19950303 DIVISION 5451517
FI US 6280988 20010828
US 5451517
DT Utility
FS CHEMICAL
GRANTED
MRN 009168 MFN: 0310
009178 0174
009472 0001
009507 0015
010121 0426
010121 0451
CLMN 6

L3 ANSWER 175 OF 325 IFIPAT COPYRIGHT 2004 IFI on STN
AN 02981273 IFIPAT;IFIUDB;IFICDB
TI HUMAN MONOCLONAL ANTI-HIV-I- ***ANTIBODIES*** ; CAPABLE OF SELECTIVELY
BINDING TO GP41 OF ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS TYPE
1
IN von Baehr Ruediger (DE); Grunow Roland (DE); Jungbauer Alois A (AT);
Katinger Hermann W D (AT); Porstmann Tomas (DE); Steindl Franz J (AT)
PA Unassigned Or Assigned To Individual (68000)
PI US 5753503 A 19980519
AI US 1994-347966 19941201
RLI US 1990-583505 19900917 CONTINUATION ABANDONED
US 1993-97170 19930723 CONTINUATION ABANDONED
US 1993-105360 19930810 CONTINUATION ABANDONED
US 1987-120489 19871113 DIVISION ABANDONED
FI US 5753503 19980519
DT Utility
FS CHEMICAL
GRANTED
CLMN 7
GI 5 Drawing Sheet(s), 8 Figure(s).

L3 ANSWER 176 OF 325 LIFESCI COPYRIGHT 2004 CSA on STN

TI Demonstration of peptidoglycan-associated Brucella outer-membrane
 proteins by use of monoclonal ***antibodies***
 AU Coeckaert, A.; Zygmunt, M.S.; de Wergifosse, P.; Dubray, G.; Limet, J.N.
 CS Unit Exp. Med., Catholic Univ. Louvain, 75 Ave. Hippocrate, B-1200
 Brussels, Belgium
 SO J. GEN. MICROBIOL., (1992) vol. 138, no. 7, pp. 1543-1550.
 DT Journal
 FS J; M; F
 LA English
 SL English

L3 ANSWER 177 OF 325 LIFESCI COPYRIGHT 2004 CSA on STN
 AN 88:57297 LIFESCI
 TI Production of monoclonal ***antibodies*** against human erythropoietin
 and their use in the purification of human urinary erythropoietin.
 AU Miyazaki, H.; Kozutsumi, H.; Kato, T.; Hoshi, S.; Tamura, S.; Kubota, M.;
 Suzuki, T.
 CS Pharm. Lab., Kirin Brewery Co., Ltd., Maebashi, Gunma 371, Japan
 SO J. IMMUNOL. METHODS., (1988) vol. 113, no. 3, pp. 261-267.
 DT Journal
 FS F
 LA English
 SL English

L3 ANSWER 178 OF 325 LIFESCI COPYRIGHT 2004 CSA on STN
 AN 86:33498 LIFESCI
 TI Characterization of three different rat T-cell clones with specificity to
 Listeria monocytogenes : Phenotype, specific proliferation, lymphokine
 production, and protective capacity in vivo.
 AU Stolpmann, R.M.; Sperling, U.; Hahn, H.
 CS Inst. Med. Mikrobiol., Freie Univ., Berlin, FRG
 SO CELL. IMMUNOL., (1986) vol. 101, no. 2, pp. 548-557.
 DT Journal
 FS J; F
 LA English
 SL English

L3 ANSWER 179 OF 325 MEDLINE on STN
 AN 91077155 MEDLINE
 DN PubMed ID: 1701654
 TI Characterization of monoclonal ***antibodies*** to human
 immunodeficiency virus type 1 gp41 by HIV-1 polypeptides expressed in
 Escherichia coli.
 AU Larcher C; Broker M; Huemer H P; Solder B; Schulz T F; Hofbauer J M;
 Wachter H; Dierich M P
 CS Institut fur Hygiene, University of Innsbruck, Austria.
 SO FEMS microbiology immunology, (1990 Sep) 2 (2) 103-10.
 Journal code: 8901230. ISSN: 0920-8534.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; AIDS
 EM 199101
 ED Entered STN: 19910322
 Last Updated on STN: 19970203
 Entered Medline: 19910129

L3 ANSWER 180 OF 325 NTIS COPYRIGHT 2004 NTIS on STN
 AN 1988(15):00270 NTIS Order Number: PB88-167978/XAB
 TI Immunometric Assay for High Molecular Weight Carcinoembryonic Antigen.
 Patent Application
 IN Schlom, J.
 PA Department of Health and Human Services, Washington, DC. (068119000)
 NR PB88-167978/XAB; PAT-APPL-6-790 261
 26p; Filed 22 Oct 85
 AI US 1985-790261 19851022
 DT Patent
 CY United States
 LA English
 AV This Government-owned invention available for U.S. licensing and,
 possibly, for foreign licensing. Copy of application available NTIS.
 Order this product from NTIS by: phone at 1-800-553-NTIS (U.S.
 customers); (703)605-6000 (other countries); fax at (703)605-6900; and
 email at orders@ntis.gov. NTIS is located at 5285 Port Royal Road,
 Springfield, VA, 22161, USA.

OS GRA&I8811

L3 ANSWER 181 OF 325 PASCAL COPYRIGHT 2004 INIST-CNRS. ALL RIGHTS
RESERVED. on STN

AN 1992-0540032 PASCAL

TIEN Demonstration of peptidoglycan-associated Brucella outer-membrane
proteins by use of monoclonal ***antibodies***

AU CLOACKAERT A.; ZYGMUNT M. S.; DE WERGIFOSSE P.; DUBRAY G.; LIMET J. N.

CS Catholic univ. Louvain, unit exp. medicine, 1200 Brussels, Belgium

SO JGM. Journal of general microbiology, (1992), 138(p.7), 1543-1550, refs.
1 p.

DT Journal

BL Analytic

CY United Kingdom

LA English

AV INIST-4410, 354000020157910310

L3 ANSWER 182 OF 325 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN

AN 94:100602 SCISEARCH

GA The Genuine Article (R) Number: MQ935

TI STABLE, CONTINUOUS LARGE-SCALE PRODUCTION OF HUMAN MONOCLONAL HIV-1
ANTIBODY USING A COMPUTER-CONTROLLED PILOT-PLANT

AU UNTERLUGGAUER F (Reprint); DOBLHOFFDIER O; TAUER C; JUNGBAUER A; GAIDA T;
REITER M; SCHMATZ C; ZACH N; KATINGER H

CS UNIV AGR & FORESTRY, INST APPL MICROBIOL, NUSSDORFER LANDE 11, A-1190
VIENNA, AUSTRIA (Reprint)

CYA AUSTRIA

SO BIOTECHNIQUES, (JAN 1994) Vol. 16, No. 1, pp. 140.
ISSN: 0736-6205.

DT Article; Journal

FS LIFE

LA ENGLISH

REC Reference Count: 25
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 183 OF 325 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN

AN 93:5268 SCISEARCH

GA The Genuine Article (R) Number: KD862

TI GROWTH AND PRODUCTION KINETICS OF HUMAN X MOUSE AND MOUSE HYBRIDOMA CELLS
AT REDUCED TEMPERATURE AND SERUM CONTENT

AU BORTH N (Reprint); HEIDER R; ASSADIAN A; KATINGER H

CS UNIV AGR VIENNA, INST APPL MICROBIOL, NUSSDORFER LANDE 11, A-1190 VIENNA,
AUSTRIA (Reprint)

CYA AUSTRIA

SO JOURNAL OF BIOTECHNOLOGY, (SEP 1992) Vol. 25, No. 3, pp. 319-331.
ISSN: 0168-1656.

DT Article; Journal

FS AGRI

LA ENGLISH

REC Reference Count: 36
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 184 OF 325 TOXCENTER COPYRIGHT 2004 ACS on STN

AN 2002:432063 TOXCENTER

DN EMIC-87667

TI Monoclonal ***antibodies*** and rabbit antisera recognizing
4-aminobiphenyl--DNA adducts and application to immunoaffinity
chromatography.

AU Groopman J D; Skipper P L; Donahue P R; Trudel L J; Wildschutte M;
Kadlubar F F; Tannenbaum S R

CS Department of Environmental Health Sciences, Johns Hopkins University,
School of Hygiene and Public Health, Baltimore, MD 21205.

NC K04 CA01517 (CA)
P01-ES00597 (ES)

SO Carcinogenesis, (1992 Jun) 13 (6) 917-22.
Journal Code: C9T. ISSN: 0143-3334.

DT Journal; Article; (JOURNAL ARTICLE)

FS EMIC

OS EMIC MED-92289027

LA English

ED Entered STN: 20021200
Last Updated on STN: 20021200

L3 ANSWER 185 OF 325 TOXCENTER COPYRIGHT 2004 ACS on STN

AN 1998:106834 TOXCENTER

DN CA12811124544M
 TI Hepatocyte growth factor receptor agonists and uses thereof
 AU Hillan, Kenneth J.; Schwall, Ralph H.; Tabor, Kelly H.
 CS ASSIGNEE: Genentech, Inc.
 PI WO 98543 A1 8 Jan 1998
 SO (1998) PCT Int. Appl., 48 pp.
 CODEN: PIXXD2.
 CY UNITED STATES
 DT Patent
 FS CAPLUS
 OS CAPLUS 1998:59054
 LA English
 ED Entered STN: 20011116
 Last Updated on STN: 20020605

L3 ANSWER 186 OF 325 TOXCENTER COPYRIGHT 2004 ACS on STN
 AN 1990:125644 TOXCENTER
 CP Copyright 2004 ACS
 DN CA11215137344R
 TI Human monoclonal anti-human immunodeficiency virus type 1 (anti-HIV-1)
 antibodies
 AU Katinger, Hermann; Von Baehr, Ruediger; Jungbauer, Alois; Porstmann, Tomas; Steindl, Franz J.; Grunow, Roland; Buchacher, Andrea
 CS ASSIGNEE: CL Pharma A.-G.
 PI WO 894370 A1 18 May 1989
 SO (1989) PCT Int. Appl., 35 pp.
 CODEN: PIXXD2.
 CY AUSTRIA
 DT Patent
 FS CAPLUS
 OS CAPLUS 1990:137344
 LA English
 ED Entered STN: 20011116
 Last Updated on STN: 20021022

L3 ANSWER 187 OF 325 USPATFULL on STN
 AN 2004:120070 USPATFULL
 TI Degraded tpo agonist ***antibody***
 IN Tsuchiya, Masayuki, Shizuoka-ken, JAPAN
 Ohtomo, Toshihiko, Shizuoka-ken, JAPAN
 Yabuta, Naohiro, Ibaraki, JAPAN
 Tsunoda, Hiroyuki, Ibaraki, JAPAN
 Orita, Tetsuro, Ibaraki, JAPAN
 PI US 2004091475 A1 20040513
 AI US 2003-399518 A1 20030417 (10)
 WO 2001-JP9259 20011022
 PRAI JP 2000-321821 20001020
 JP 2001-277314 20010912
 DT Utility
 FS APPLICATION
 LN.CNT 5325
 INCL INCLM: 424/132.100
 INCLS: 530/387.300
 NCL NCLM: 424/132.100
 NCLS: 530/387.300
 IC [7]
 ICM: A61K039-395
 ICS: C07K016-44

L3 ANSWER 188 OF 325 USPATFULL on STN
 AN 2004:108368 USPATFULL
 TI Novel glyphosate N-acetyltransferase (GAT) genes
 IN Castle, Linda A., Mountain View, CA, UNITED STATES
 Siehl, Dan, Menlo Park, CA, UNITED STATES
 Giver, Lorraine, Sunnyvale, CA, UNITED STATES
 Minshull, Jeremy, Los Altos, CA, UNITED STATES
 Ivy, Cristina, Encinitas, CA, UNITED STATES
 Chen, Yong Hong, Foster City, CA, UNITED STATES
 Patten, Phillip A., Menlo Park, CA, UNITED STATES
 Gorton, Rebecca, Irvine, CA, UNITED STATES
 Duck, Nicholas B., Apex, NC, UNITED STATES
 McCutchen, Billy Fred, Clive, IA, UNITED STATES
 Kemble, Roger, Wake Forest, NC, UNITED STATES
 PA Verdia, Inc. (U.S. corporation)
 Pioneer Hi-Bred International, Inc. (U.S. corporation)

AI US 2003-427692 A1 20030430 (10)
RLI Continuation-in-part of Ser. No. US 2001-4357, filed on 29 Oct 2001,
PENDING
PRAI US 2002-377719P 20020430 (60)
US 2002-377175P 20020501 (60)
US 2000-244385P 20001030 (60)
DT Utility
FS APPLICATION
LN.CNT 7542
INCL INCLM: 536/023.200
INCLS: 435/069.100; 435/006.000; 435/193.000; 435/320.100; 435/419.000
NCL NCLM: 536/023.200
NCLS: 435/069.100; 435/006.000; 435/193.000; 435/320.100; 435/419.000
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-10; C12N005-04

L3 ANSWER 189 OF 325 USPATFULL on STN
AN 2004:101757 USPATFULL
TI Lactam compound
IN Koenig, Thomas Mitchell, Camby, IN, UNITED STATES
Mitchell, David, Indianapolis, IN, UNITED STATES
Nissen, Jeffrey Scott, Indianapolis, IN, UNITED STATES
PI US 2004077627 A1 20040422
AI US 2003-415057 A1 20030903 (10)
WO 2001-US27796 20011102
DT Utility
FS APPLICATION
LN.CNT 1843
INCL INCLM: 514/212.070
INCLS: 540/523.000
NCL NCLM: 514/212.070
NCLS: 540/523.000
IC [7]
ICM: A61K031-55
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 190 OF 325 USPATFULL on STN
AN 2004:77121 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting beta-amyloid
peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, R. Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James A., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
Mcdaniel, Stacey L., Indianapolis, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2004058900 A1 20040325
AI US 2003-336767 A1 20030106 (10)
RLI Division of Ser. No. US 2001-915342, filed on 27 Jul 2001, PENDING
Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25655
INCL INCLM: 514/183.000
INCLS: 514/212.020; 514/317.000; 514/284.000; 514/212.070; 514/221.000;
514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000
NCL NCLM: 514/183.000

514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000

IC [7]
ICM: A61K031-553
ICS: A61K031-55; A61K031-554; A61K031-551; A61K031-5513; A61K031-473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 191 OF 325 USPATFULL on STN
AN 2004:76615 USPATFULL
TI Agonist ***antibodies***
IN Fukushima, Naoshi, Gotemba-shi, Shizuoka-ken, JAPAN
Tsuchiya, Masayuki, Gotemba-shi, Shizuoka-ken, JAPAN
Oheda, Masayoshi, Gotemba-shi, Shizuoka-ken, JAPAN
Uno, Shinsuke, Gotemba-shi, Shizuoka-ken, JAPAN
Kikuchi, Yasufumi, Gotemba-shi, Shizuoka-ken, JAPAN
Ohtomo, Toshihiko, Gotemba-shi, Shizuoka-ken, JAPAN
PI US 2004058393 A1 20040325
AI US 2003-257864 A1 20030624 (10)
WO 2001-JP3288 20010417
PRAI JP 2000-115246 20000417
JP 2000-321821 20001020
JP 2000-321822 20001020
WO 2001-JP1912 20010312
DT Utility
FS APPLICATION
LN.CNT 4382
INCL INCLM: 435/007.200
INCLS: 530/388.250
NCL NCLM: 435/007.200
NCLS: 530/388.250
IC [7]

ICM: G01N033-53
ICS: G01N033-567; C07K016-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 192 OF 325 USPATFULL on STN
AN 2004:65895 USPATFULL
TI Protein/(poly)peptide libraries
IN Knappik, Achim, Grarelfing, GERMANY, FEDERAL REPUBLIC OF
Pack, Peter, Munchen, GERMANY, FEDERAL REPUBLIC OF
Ge, Liming, Munchen, GERMANY, FEDERAL REPUBLIC OF
Moroney, Simon, Munchen, GERMANY, FEDERAL REPUBLIC OF
Pluckthun, Andreas, Zurich, SWITZERLAND
PA Morphosys AG, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6706484 B1 20040316
AI US 2000-490153 20000124 (9)
RLI Division of Ser. No. US 1998-25769, filed on 18 Feb 1998 Continuation of
Ser. No. WO 1996-EP3647, filed on 19 Aug 1996
PRAI EP 1995-113021 19950818
DE 1997-U29702923 19970219
DT Utility
FS GRANTED
LN.CNT 8910
INCL INCLM: 435/007.100
INCLS: 435/069.100; 435/069.300; 435/069.700; 435/320.100; 536/023.100;
530/350.000
NCL NCLM: 435/007.100
NCLS: 435/069.100; 435/069.300; 435/069.700; 435/320.100; 530/350.000;
536/023.100

IC [7]
ICM: C12P021-06
ICS: G01N033-53; C07K001-00
EXF 435/69.1; 435/69.3; 435/69.7; 435/320.1; 435/7.1; 435/DIG.2; 435/DIG.15;
435/DIG.47; 536/23.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 193 OF 325 USPATFULL on STN
AN 2004:63731 USPATFULL
TI Novel nucleic acids and secreted polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Yang, Yonghong, San Jose, CA, UNITED STATES
Weng, Gezhi, Piedmont, CA, UNITED STATES
Zhang, Jie, Campbell, CA, UNITED STATES
Ren, Feiyan, Cupertino, CA, UNITED STATES
Xue, Aidong, Sunnyvale, CA, UNITED STATES
Wang, Jian-Rui, Cupertino, CA, UNITED STATES

Ghosh, Malabika J., Sunnyvale, CA, UNITED STATES
 Wang, Dunrui, Poway, CA, UNITED STATES
 Zhao, Qing A., San Jose, CA, UNITED STATES
 Wang, Zhiwei, Sunnyvale, CA, UNITED STATES
 PI US 2004048249 A1 20040311
 AI US 2002-112944 A1 20020328 (10)
 RLI Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-491404, filed on 25 Jan
 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-496914, filed
 on 3 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US
 2000-515126, filed on 28 Feb 2000, ABANDONED Continuation-in-part of
 Ser. No. US 2000-519705, filed on 7 Mar 2000, ABANDONED
 Continuation-in-part of Ser. No. US 2000-540217, filed on 31 Mar 2000,
 ABANDONED Continuation-in-part of Ser. No. US 2000-552929, filed on 18
 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-577408,
 filed on 18 May 2000, ABANDONED
 PRAI US 2001-306971P 20010721 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 23809
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 435/455.000;
 530/350.000; 536/023.200
 NCL NCLM: 435/006.000
 NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 435/455.000;
 530/350.000; 536/023.200
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47;
 C12N015-85
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 194 OF 325 USPATFULL on STN
 AN 2004:63342 USPATFULL
 TI ***Antibodies*** to human mcp-1
 IN Hiestand, Peter, Allscwil, SWITZERLAND
 Hofstetter, Hans, Riehen, SWITZERLAND
 Payne, Trevor Glyn, Nedlands, AUSTRALIA
 Urfer, Roman, Foster City, CA, UNITED STATES
 Di Padova, Franco E, Birsfelden, SWITZERLAND
 PI US 2004047860 A1 20040311
 AI US 2003-312022 A1 20030718 (10)
 WO 2001-EP7468 20010629
 PRAI GB 2000-1638 20000630
 DT Utility
 FS APPLICATION
 LN.CNT 1372
 INCL INCLM: 424/144.100
 INCLS: 530/388.220
 NCL NCLM: 424/144.100
 NCLS: 530/388.220
 IC [7]
 ICM: A61K039-395
 ICS: C07K016-28
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 195 OF 325 USPATFULL on STN
 AN 2004:59929 USPATFULL
 TI ***Antibodies*** to vertebrate serrate proteins and fragments
 IN Ish-Horowicz, David, Oxford, UNITED KINGDOM
 Henrique, Domingos Manuel Pinto, Oxford, UNITED KINGDOM
 Lewis, Julian Hart, Oxford, UNITED KINGDOM
 Myat, Anna Mary, Oxford, UNITED KINGDOM
 Fleming, Robert J., Rochester, NY, United States
 Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
 Mann, Robert S., Hamden, CT, United States
 Gray, Grace E., New Haven, CT, United States
 PA Yale University, New Haven, CT, United States (U.S. corporation)
 Imperial Cancer Research Technology, Ltd., London, UNITED KINGDOM
 (non-U.S. corporation)
 PI US 6703489 B1 20040309
 AI US 1998-195524 19981119 (9)
 RLI Division of Ser. No. US 1996-611729, filed on 6 Mar 1996, now patented,
 Pat. No. US 6004924 Continuation-in-part of Ser. No. US 1995-400159,
 filed on 7 Mar 1995, now patented, Pat. No. US 5869282

FS GRANTED
LN.CNT 6515
INCL INCLM: 530/399.000
INCLS: 530/389.100; 530/387.100; 530/388.850; 530/388.100; 424/130.100;
424/141.100; 424/156.100; 536/023.100; 536/023.530; 536/024.500
NCL NCLM: 530/399.000
NCLS: 424/130.100; 424/141.100; 424/156.100; 530/387.100; 530/388.100;
530/388.850; 530/389.100; 536/023.100; 536/023.530; 536/024.500
IC [7]
ICM: A61K038-24
ICS: A61K039-395; C07K016-00; C12P021-06; C07H021-04
EXF 530/387.1; 530/399; 530/388.1; 530/388.85; 530/389.1; 424/130.1;
424/141.1; 424/156.1; 536/23.1; 536/23.53; 536/24.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 196 OF 325 USPATFULL on STN
AN 2004:58174 USPATFULL
TI Novel nucleic acids and polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Asundi, Vinod, Foster City, CA, UNITED STATES
Wehrman, Tom, Stanford, CA, UNITED STATES
Ren, Feiyan, Cupertino, CA, UNITED STATES
Zhou, Ping, Cupertino, CA, UNITED STATES
Zhao, Qing A., San Jose, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
Zhang, Jie, Campbell, CA, UNITED STATES
Xue, Aidong, Sunnyvale, CA, UNITED STATES
Wang, Jian-Rui, Cupertino, CA, UNITED STATES
Wang, Dunrui, Poway, CA, UNITED STATES
PI US 2004044181 A1 20040304
AI US 2003-363616 A1 20030715 (10)
WO 2001-US27093 20010831
DT Utility
FS APPLICATION
LN.CNT 17667
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 197 OF 325 USPATFULL on STN
AN 2004:57970 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting beta-amyloid
peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2004043977 A1 20040304
AI US 2003-336687 A1 20030106 (10)
RLI Division of Ser. No. US 2001-915362, filed on 27 Jul 2001, GRANTED, Pat.
No. US 6541466 Division of Ser. No. US 1997-996422, filed on 22 Dec

PRAI US 1996-64851P 19961223 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25738
 INCL INCLM: 514/183.000
 INCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000;
 514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000;
 540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000;
 546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000;
 514/662.000; 564/454.000
 NCL NCLM: 514/183.000
 NCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000;
 514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000;
 540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000;
 546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000;
 514/662.000; 564/454.000
 IC [7]
 ICM: A61K031-5513
 ICS: A61K031-551; A61K031-55; A61K031-4706; A61K031-473; A61K031-445;
 A61K031-366; A61K031-137
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 198 OF 325 USPATFULL on STN
 AN 2004:57416 USPATFULL
 TI Humanized ***antibodies*** that sequester Abeta peptide
 IN Holtzman, David M., St. Louis, MO, UNITED STATES
 DeMattos, Ronald, Noblesville, IN, UNITED STATES
 Bales, Kelly R., Indianapolis, IN, UNITED STATES
 Paul, Steven M., Carmel, IN, UNITED STATES
 Tsurushita, Naoya, Palo Alto, CA, UNITED STATES
 Vasquez, Maximiliano, Palo Alto, CA, UNITED STATES
 PI US 2004043418 A1 20040304
 AI US 2002-226435 A1 20020821 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 2136
 INCL INCLM: 435/007.100
 INCLS: 530/388.150; 424/133.100
 NCL NCLM: 435/007.100
 NCLS: 530/388.150; 424/133.100
 IC [7]
 ICM: A61K039-395
 ICS: G01N033-53; C07K016-44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 199 OF 325 USPATFULL on STN
 AN 2004:46723 USPATFULL
 TI Protein/(poly)peptide libraries
 IN Knappik, Achim, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
 Pack, Peter, Munchen, GERMANY, FEDERAL REPUBLIC OF
 Ge, Liming, Munchen, GERMANY, FEDERAL REPUBLIC OF
 Moroney, Simon, Munchen, GERMANY, FEDERAL REPUBLIC OF
 Pluckthun, Andreas, Zurich, GERMANY, FEDERAL REPUBLIC OF
 PA Morphosys AG, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
 PI US 6696248 B1 20040224
 AI US 2000-490070 20000124 (9)
 RLI Division of Ser. No. US 1998-25769, filed on 18 Feb 1998, now patented,
 Pat. No. US 6300064 Continuation of Ser. No. WO 1996-EP3647, filed on 19
 Aug 1996
 PRAI EP 1995-1130210 19950818
 DE 1997-U29702923 19970219
 DT Utility
 FS GRANTED
 LN.CNT 9073
 INCL INCLM: 435/006.000
 INCLS: 435/320.100; 536/023.100; 536/024.100; 536/024.500
 NCL NCLM: 435/006.000
 NCLS: 435/320.100; 536/023.100; 536/024.100; 536/024.500
 IC [7]
 ICM: C12Q001-68
 ICS: C12N015-00; C12N015-63; C07H021-04
 EXF 435/6; 435/320.1; 435/DIG.1; 536/23.1; 536/24.1; 536/24.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 200 OF 325 USPATFULL on STN

TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use
 IN Wu, Jing, San Mateo, CA, United States
 Tung, Jay S., Belmont, CA, United States
 Thorsett, Eugene D., Moss Beach, CA, United States
 Pleiss, Michael A., Sunnyvale, CA, United States
 Nissen, Jeffrey S., Indianapolis, IN, United States
 Neitz, R. Jeffrey, San Francisco, CA, United States
 Latimer, Lee H., Oakland, CA, United States
 John, Varghese, San Francisco, CA, United States
 Freedman, Stephen, Walnut Creek, CA, United States
 Britton, Thomas C., Carmel, IN, United States
 Audia, James A., Indianapolis, IN, United States
 Reel, Jon K., Carmel, IN, United States
 Mabry, Thomas E., Indianapolis, IN, United States
 Dressman, Bruce A., Indianapolis, IN, United States
 Cwi, Cynthia L., Indianapolis, IN, United States
 Droste, James J., Indianapolis, IN, United States
 Henry, Steven S., New Palastine, IN, United States
 McDaniel, Stacey L., Indianapolis, IN, United States
 Scott, William Leonard, Indianapolis, IN, United States
 Stucky, Russell D., Indianapolis, IN, United States
 Porter, Warren J., Indianapolis, IN, United States
 PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 B1 20040127
 AI US 6683075
 RLI US 2003-336806 20030106 (10)
 Division of Ser. No. US 2001-915564, filed on 27 Jul 2001 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997
 PRAI US 1996-64851P 19961223 (60)
 DT Utility
 FS GRANTED
 LN.CNT 19986
 INCL INCLM: 514/220.000
 INCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/517.000; 540/518.000
 NCL NCLM: 514/220.000
 NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/517.000; 540/518.000
 IC [7]
 ICM: A61K031-55
 ICS: C07D487-04; C07D243-12; C07D243-24; C07D487-00
 EXF 540/496; 540/497; 540/498; 540/499; 540/504; 540/517; 540/518; 514/220; 514/221
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 201 OF 325 USPATFULL on STN
 AN 2004:21475 USPATFULL
 TI Anti-cryptosporidium parvum preparations
 IN Riggs, Michael W., Tucson, AZ, United States
 Perryman, Lance E., Cary, NC, United States
 PA North Carolina State University, Raleigh, NC, United States (U.S. corporation)
 PI US 6682737 B1 20040127
 AI US 2000-557324 20000425 (9)
 RLI Continuation of Ser. No. US 1997-828943, filed on 27 Mar 1997, now patented, Pat. No. US 6110463
 PRAI US 1996-14410P 19960329 (60)
 US 1996-21465P 19960710 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1356
 INCL INCLM: 424/151.100
 INCLS: 424/157.100; 424/535.000; 424/807.000; 435/007.220; 435/070.210; 435/329.000; 435/342.000; 530/388.600; 530/389.100; 530/822.000; 530/832.000
 NCL NCLM: 424/151.100
 NCLS: 424/157.100; 424/535.000; 424/807.000; 435/007.220; 435/070.210; 435/329.000; 435/342.000; 530/388.600; 530/389.100; 530/822.000; 530/832.000
 IC [7]
 ICM: A61K039-395
 ICS: A61K035-20; C07K016-20; C12N005-20

424/535; 424/807; 424/157.1; 435/7.22; 435/70.21; 435/452; 435/329;
435/342; 435/947; 530/388.6; 530/389.1; 530/395; 530/822; 530/832
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 202 OF 325 USPATFULL on STN
AN 2004:18840 USPATFULL
TI Differential diagnosis of neurodegeneration
IN VanMechelen, Eugene, Nazareth Eke, BELGIUM
Vanderstichele, Hugo, Gent, BELGIUM
Van De Voorde, Andre, Lokeren, BELGIUM
PA INNOGENETICS N.V. (non-U.S. corporation)
PI US 2004014142 A1 20040122
AI US 2003-445366 A1 20030522 (10)
RLI Division of Ser. No. US 2000-720707, filed on 29 Dec 2000, ABANDONED A
371 of International Ser. No. WO 1999-EP4483, filed on 29 Jun 1999,
UNKNOWN
PRAI EP 1998-870148 19980703
EP 1998-870236 19981103
EP 1999-870069 19990409
DT Utility
FS APPLICATION
LN.CNT 2706
INCL INCLM: 435/007.100
INCLS: 435/007.200
NCL NCLM: 435/007.100
NCLS: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 203 OF 325 USPATFULL on STN
AN 2004:7845 USPATFULL
TI Hydroxyalkanoyl aminopyrazoles and related compounds
IN Tung, Jay S., Belmont, CA, UNITED STATES
Guinn, Ashley C., Pacifica, CA, UNITED STATES
Thorsett, Gene, Half Moon Bay, CA, UNITED STATES
Pleiss, Mike A., Sunnyvale, CA, UNITED STATES
PI US 2004006085 A1 20040108
AI US 2003-355700 A1 20030131 (10)
PRAI US 2002-353214P 20020201 (60)
DT Utility
FS APPLICATION
LN.CNT 1738
INCL INCLM: 514/249.000
INCLS: 514/253.010; 514/254.110; 514/317.000; 514/278.000; 514/316.000;
514/363.000; 514/400.000; 514/419.000; 514/464.000; 514/534.000;
514/616.000; 514/406.000; 544/360.000; 544/353.000; 544/386.000;
514/255.010; 544/377.000; 546/186.000; 546/020.000; 548/138.000;
548/328.500; 548/367.400; 560/155.000; 564/155.000; 514/389.000;
548/318.100
NCL NCLM: 514/249.000
NCLS: 514/253.010; 514/254.110; 514/317.000; 514/278.000; 514/316.000;
514/363.000; 514/400.000; 514/419.000; 514/464.000; 514/534.000;
514/616.000; 514/406.000; 544/360.000; 544/353.000; 544/386.000;
514/255.010; 544/377.000; 546/186.000; 546/020.000; 548/138.000;
548/328.500; 548/367.400; 560/155.000; 564/155.000; 514/389.000;
548/318.100
IC [7]
ICM: A61K031-498
ICS: A61K031-495; A61K031-496; A61K031-4747; A61K031-4545; A61K031-433;
A61K031-4172; A61K031-4152; A61K031-165

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 204 OF 325 USPATFULL on STN
AN 2003:332380 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting .beta.-amyloid
peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Pleiss, Michael A., Sunnyvale, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Neitz, R. Jeffrey, San Francisco, CA, United States

John, Varghese, San Francisco, CA, United States
 Freedman, Stephen, Walnut Creek, CA, United States
 Britton, Thomas C., Carmel, IN, United States
 Audia, James A., Indianapolis, IN, United States
 Reel, Jon K., Carmel, IN, United States
 Mabry, Thomas E., Indianapolis, IN, United States
 Dressman, Bruce A., Indianapolis, IN, United States
 Cwi, Cynthia L., Indianapolis, IN, United States
 Droste, James J., Indianapolis, IN, United States
 Henry, Steven S., New Palestine, IN, United States
 McDaniel, Stacey L., Indianapolis, IN, United States
 Scott, William Leonard, Indianapolis, IN, United States
 Stucky, Russell D., Indianapolis, IN, United States
 Porter, Warren J., Indianapolis, IN, United States
 PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6667305 B1 20031223
 AI US 2003-336745 20030106 (10)
 RLI Division of Ser. No. US 2002-915379, filed on 27 Jul 2002, now patented, Pat. No. US 6579867 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997
 PRAI US 1996-64851P 19961223 (60)
 DT Utility
 FS GRANTED
 LN.CNT 19309
 INCL INCLM: 514/220.000
 INCLS: 514/221.000
 NCL NCLM: 514/220.000
 NCLS: 514/221.000
 IC [7]
 ICM: A61P025-28
 EXF 514/220; 514/221
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 205 OF 325 USPATFULL on STN
 AN 2003:330543 USPATFULL
 TI Immunological methods and compositions for the treatment of Alzheimer's disease
 IN St. George-Hyslop, Peter H., Toronto, CANADA
 McLaurin, JoAnne, Toronto, CANADA
 PA Hospital for Sick Children and University of Toronto (non-U.S. corporation)
 PI US 2003232758 A1 20031218
 AI US 2003-411544 A1 20030410 (10)
 PRAI US 2002-373914P 20020419 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2487
 INCL INCLM: 514/012.000
 INCLS: 530/324.000; 435/069.100; 435/320.100; 435/325.000; 536/023.100
 NCL NCLM: 514/012.000
 NCLS: 530/324.000; 435/069.100; 435/320.100; 435/325.000; 536/023.100
 IC [7]
 ICM: A61K038-17
 ICS: C07K014-47; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 206 OF 325 USPATFULL on STN
 AN 2003:325042 USPATFULL
 TI Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
 IN Audia, James E., Indianapolis, IN, UNITED STATES
 Britton, Thomas C., Carmel, IN, UNITED STATES
 Droste, James J., Indianapolis, IN, UNITED STATES
 Folmer, Beverly K., Newark, DE, UNITED STATES
 Huffman, George W., Carmel, IN, UNITED STATES
 John, Varghese, San Francisco, CA, UNITED STATES
 Latimer, Lee H., Oakland, CA, UNITED STATES
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
 Porter, Warren J., Indianapolis, IN, UNITED STATES
 Reel, Jon K., Carmel, IN, UNITED STATES
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
 Tung, Jay S., Belmont, CA, UNITED STATES

Eid, Clārck Norman, Cheshire, CT, UNITED STATES
 Scott, William Leonard, Indianapolis, IN, UNITED STATES

PI US 2003229024 A1 20031211
 AI US 2002-309569 A1 20021203 (10)
 RLI Continuation of Ser. No. US 2001-789487, filed on 20 Feb 2001, PENDING
 Continuation of Ser. No. US 1997-976289, filed on 21 Nov 1997, GRANTED,
 Pat. No. US 6191166

PRAI US 1996-108166P 19961122 (60)
 US 1997-64859P 19970228 (60)
 US 1997-108161P 19970228 (60)
 US 1997-98558P 19970228 (60)

DT Utility
 FS APPLICATION
 LN.CNT 14968
 INCL INCLM: 514/017.000
 INCLS: 514/018.000; 514/019.000; 530/328.000; 530/329.000; 530/330.000;
 530/331.000

NCL NCLM: 514/017.000
 NCLS: 514/018.000; 514/019.000; 530/328.000; 530/329.000; 530/330.000;
 530/331.000

IC [7]
 ICM: A61K038-08
 ICS: A61K038-06; A61K038-05; C07K007-08; C07K007-06; C07K005-04
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 207 OF 325 USPATFULL on STN
 AN 2003:321588 USPATFULL
 TI Mice comprising engrafted functional human hepatocytes
 IN Kay, Mark A., Los Altos, CA, United States
 Ohashi, Kazuo, Palo Alto, CA, United States
 PA The Board of Trustees of the Leland Stanford Junior University, Palo
 Alto, CA, United States (U.S. corporation)

PI US 6660905 B1 20031209
 AI US 2000-614658 20000712 (9)
 PRAI US 1999-143897P 19990714 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1586
 INCL INCLM: 800/008.000
 INCLS: 424/093.100; 530/388.100; 530/388.150; 530/388.200

NCL NCLM: 800/008.000
 NCLS: 424/093.100; 530/388.100; 530/388.150; 530/388.200

IC [7]
 ICM: A01K067-00
 ICS: A01K067-033; A01K063-00; C07K016-00; C12P021-08
 EXF 800/18; 800/21; 800/22; 800/26; 800/3; 800/8; 424/93.1; 530/388.1;
 530/388.15; 530/388.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 208 OF 325 USPATFULL on STN
 AN 2003:318635 USPATFULL
 TI Novel nucleic acids and polypeptides
 IN Tang, Y. Tom, San Jose, CA, UNITED STATES
 Yang, Yonghong, San Jose, CA, UNITED STATES
 Wang, Zhiwei, Sunnyvale, CA, UNITED STATES
 Weng, Gezhi, Piedmont, CA, UNITED STATES
 Ma, Yunging, Santa Clara, CA, UNITED STATES

PI US 2003224379 A1 20031204
 AI US 2002-243552 A1 20020912 (10)
 RLI Continuation-in-part of Ser. No. WO 2000-US35017, filed on 22 Dec 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-552317, filed on 25 Apr
 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed
 on 21 Jan 2000, PENDING

PRAI WO 2001-US2623 20010125
 WO 2001-US3800 20010205
 WO 2001-US4927 20010226
 WO 2001-US4941 20010305
 WO 2001-US8631 20010330
 WO 2001-US8656 20010416
 WO 2001-US14827 20010516
 US 2001-322511P 20010913 (60)

DT Utility
 FS APPLICATION
 LN.CNT 13810
 INCL INCLM: 435/006.000

NCL NCLM: 536/023.200
NCLS: 435/006.000
435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200

IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-47; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 209 OF 325 USPATFULL on STN

AN 2003:309076 USPATFULL

TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Pleiss, Michael A., Sunnyvale, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Neitz, R. Jeffrey, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Freedman, Stephen, Walnut Creek, CA, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James A., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Henry, Steven S., New Palestine, IN, United States
McDaniel, Stacey L., Indianapolis, IN, United States
Scott, William Leonard, Indianapolis, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)

PI US 6653303 B1 20031125

AI US 2003-336824 20030106 (10)

RLI Division of Ser. No. US 2001-915480, filed on 27 Jul 2001, now patented,
Pat. No. US 6544978 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997

PRAI US 1996-64851P 19961223 (60)

DT Utility

FS GRANTED

LN.CNT 19893

INCL INCLM: 514/220.000
INCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000;
540/504.000; 540/513.000; 540/518.000

NCL NCLM: 514/220.000
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000;
540/504.000; 540/513.000; 540/518.000

IC [7]
ICM: A61K031-55
ICS: C07D487-00; C07D491-00; C07D487-04; C07D243-12
EXF 514/220; 514/221; 540/496; 540/497; 540/498; 540/499; 540/504; 540/513;
540/518

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 210 OF 325 USPATFULL on STN

AN 2003:302865 USPATFULL

TI Modified VEGF Oligonucleotides for Inhibition of tumor growth

IN Smyth, Adrienne P., Charlton, MA, United States

Robinson, Gregory S., Acton, MA, United States

PA Hybridon, Inc., Cambridge, MA, United States (U.S. corporation)

PI US 6649596 B1 20031118

AI US 1998-124304 19980729 (9)

RLI Continuation-in-part of Ser. No. US 1996-629730, filed on 9 Apr 1996,
now abandoned Continuation-in-part of Ser. No. US 1995-569926, filed on
8 Dec 1995, now patented, Pat. No. US 5641756

DT Utility

FS GRANTED

LN.CNT 1377

INCL INCLM: 514/044.000

NCL NCLM: 514/044.000
 NCLS: 435/006.000; 435/325.000; 435/375.000; 536/024.500
 IC [7]
 ICM: C07H021-04
 ICS: C21N015-85; C21N015-86; C12Q001-68; A61K048-00
 EXF 514/44; 435/6; 435/91.1; 435/91.3; 435/325; 435/375; 536/23.1; 536/24.5;
 536/23.2; 536/24.3; 536/24.31; 536/24.33
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 211 OF 325 USPATFULL on STN
 AN 2003:279186 USPATFULL
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
 compositions comprising same, and methods for inhibiting .beta.-amyloid
 peptide release and/or its synthesis by use of such compounds
 IN Wu, Jing, San Mateo, CA, United States
 Tung, Jay S., Belmont, CA, United States
 Thorsett, Eugene D., Moss Beach, CA, United States
 Pleiss, Michael A., Sunnyvale, CA, United States
 Nissen, Jeffrey S., Indianapolis, IN, United States
 Neitz, R. Jeffrey, San Francisco, CA, United States
 Latimer, Lee H., Oakland, CA, United States
 John, Varghese, San Francisco, CA, United States
 Freedman, Stephen, Walnut Creek, CA, United States
 Britton, Thomas C., Carmel, IN, United States
 Audia, James A., Indianapolis, IN, United States
 Reel, Jon K., Carmel, IN, United States
 Mabry, Thomas E., Indianapolis, IN, United States
 Dressman, Bruce A., Indianapolis, IN, United States
 Cwi, Cynthia L., Indianapolis, IN, United States
 Droste, James J., Indianapolis, IN, United States
 Henry, Steven S., New Palestine, IN, United States
 McDaniel, Stacey L., Indianapolis, IN, United States
 Scott, William Leonard, Indianapolis, IN, United States
 Stucky, Russell D., Indianapolis, IN, United States
 Porter, Warren J., Indianapolis, IN, United States
 PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6635632 B1 20031021
 AI US 1997-996422 19971222 (8)
 PRAI US 1996-64851P 19961223 (60)
 DT Utility
 FS GRANTED
 LN.CNT 22179
 INCL INCLM: 514/212.030
 INCLS: 514/212.040; 514/212.070; 514/212.080
 NCL NCLM: 514/212.030
 NCLS: 514/212.040; 514/212.070; 514/212.080
 IC [7]
 ICM: A61K031-55
 ICS: A61P025-28
 EXF 514/212.03; 514/212.04; 514/212.07; 514/212.08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 212 OF 325 USPATFULL on STN
 AN 2003:271536 USPATFULL
 TI Compounds, compositions and methods for modulating beta-amyloid
 production
 IN Connop, Bruce P., Vancouver, CANADA
 Grant, Amelia, Vancouver, CANADA
 MacDonald, David, Surrey, CANADA
 Nathwani, Parimal S., Burnaby, CANADA
 Reiner, Peter B., Vancouver, CANADA
 Zhang, Zaihui, Richmond, CANADA
 PA Active Pass Pharmaceuticals, Inc., Vancouver, CANADA (non-U.S.
 corporation)
 PI US 2003191144 A1 20031009
 AI US 2002-325667 A1 20021219 (10)
 RLI Continuation-in-part of Ser. No. US 2002-170224, filed on 12 Jun 2002,
 PENDING
 PRAI US 2001-309257P 20010731 (60)
 US 2001-297845P 20010612 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3629

NCL NCLM: 514/269.000
IC [7]
ICM: A61K031-513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 213 OF 325 USPATFULL on STN
AN 2003:271511 USPATFULL
TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
PI US 2003191119 A1 20031009
AI US 2002-314221 A1 20021209 (10)
RLI Division of Ser. No. US 2001-984834, filed on 31 Oct 2001, PENDING
Continuation of Ser. No. US 1999-303655, filed on 3 May 1999, GRANTED,
Pat. No. US 6333351 Continuation of Ser. No. US 1997-976179, filed on 21
Nov 1997, GRANTED, Pat. No. US 6117901
PRAI US 1996-98551P 19961122 (60)
DT Utility
FS APPLICATION
LN.CNT 3753
INCL INCLM: 514/227.800
INCLS: 514/357.000; 514/235.500; 514/563.000; 514/616.000
NCL NCLM: 514/227.800
NCLS: 514/357.000; 514/235.500; 514/563.000; 514/616.000
IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-44; A61K031-198; A61K031-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 214 OF 325 USPATFULL on STN
AN 2003:260805 USPATFULL
TI .beta.-secretase enzyme compositions and methods
IN Anderson, John P., San Francisco, CA, United States
Basi, Guriqbal, Palo Alto, CA, United States
Doan, Minh Tam, Hayward, CA, United States
Frigon, Normand, Milbrae, CA, United States
John, Varghese, San Francisco, CA, United States
Power, Michael, Fremont, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
Tatsuno, Gwen, Oakland, CA, United States
Tung, Jay, Belmont, CA, United States
Wang, Shuwen, Hersey, PA, United States
McConlogue, Lisa, Burlingame, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6627739 B1 20030930
AI US 2000-724566 20001128 (9)
RLI Continuation of Ser. No. US 2000-501708, filed on 10 Feb 2000
PRAI US 1999-119571P 19990210 (60)
US 1999-139172P 19990615 (60)
DT Utility
FS GRANTED
LN.CNT 4793
INCL INCLM: 530/387.900
INCLS: 530/388.100; 530/388.260; 530/389.100; 530/389.200
NCL NCLM: 530/387.900
NCLS: 530/388.100; 530/388.260; 530/389.100; 530/389.200
IC [7]
ICM: C07K016-40
EXF 530/387.9; 530/388.1; 530/388.26; 530/389.1; 530/389.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 215 OF 325 USPATFULL on STN
AN 2003:232567 USPATFULL
TI Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

Dressman, Bruce A., Indianapolis, IN, UNITED STATES
 Shi, Qing, Carmel, IN, UNITED STATES
 PI US 2003162768 A1 20030828
 US 6696438 B2 20040224
 AI US 2002-317081 A1 20021212 (10)
 RLI Division of Ser. No. US 1999-338180, filed on 22 Jun 1999, GRANTED, Pat.
 No. US 6528505
 PRAI US 1998-160067P 19980622 (60)
 US 1998-155238P 19980930 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 7196
 INCL INCLM: 514/211.050
 INCLS: 514/212.050; 514/212.070; 514/220.000; 514/221.000; 540/490.000;
 540/496.000; 540/500.000; 540/504.000
 NCL NCLM: 514/220.000
 NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000;
 540/504.000; 540/517.000; 540/518.000
 IC [7]
 ICM: A61K031-554
 ICS: A61K031-553; A61K031-55; A61K031-5513; A61K031-551
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 216 OF 325 USPATFULL on STN
 AN 2003:228237 USPATFULL
 TI Screening compounds for the ability to alter the production of
 amyloid-.beta. peptide
 IN Citron, Martin, Thousands Oaks, CA, United States
 Selkoe, Dennis J., Jamaica Plain, MA, United States
 Seubert, Peter A., San Francisco, CA, United States
 Schenk, Dale, Burlingame, CA, United States
 PA Brigham and Women's Hospital, Boston, MA, United States (U.S.
 corporation)
 Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 PI US 6610493 B1 20030826
 AI US 1996-665649 19960618 (8)
 RLI Continuation-in-part of Ser. No. US 1993-79511, filed on 17 Jun 1993,
 now patented, Pat. No. US 5766846
 DT Utility
 FS GRANTED
 LN.CNT 2054
 INCL INCLM: 435/007.100
 INCLS: 435/007.200; 435/007.210; 435/007.230; 435/007.800; 435/007.920
 NCL NCLM: 435/007.100
 NCLS: 435/007.200; 435/007.210; 435/007.230; 435/007.800; 435/007.920
 IC [7]
 ICM: G01N033-53
 EXF 435/7.1; 435/7.2; 435/7.21; 435/7.23; 435/7.8; 435/7.92; 530/387.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 217 OF 325 USPATFULL on STN
 AN 2003:220259 USPATFULL
 TI Deoxyamino acid compounds, pharmaceutical compositions comprising same,
 and methods for inhibiting beta-amyloid peptide release and/or its
 synthesis by use of such compounds
 IN Audia, James E., Indianapolis, IN, UNITED STATES
 Thompson, Richard C., Frankfort, IN, UNITED STATES
 Wilkie, Stephen C., Indianapolis, IN, UNITED STATES
 Britton, Thomas C., Carmel, IN, UNITED STATES
 Porter, Warren J., Indianapolis, IN, UNITED STATES
 Huffman, George W., Carmel, IN, UNITED STATES
 Latimer, Lee H., Oakland, CA, UNITED STATES
 PI US 2003153550 A1 20030814
 AI US 2002-267017 A1 20021007 (10)
 RLI Division of Ser. No. US 1999-337484, filed on 21 Jun 1999, GRANTED, Pat.
 No. US 6509331
 PRAI US 1998-155265P 19980622 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6533
 INCL INCLM: 514/211.050
 INCLS: 514/221.000; 514/220.000; 514/212.040; 514/212.050; 514/151.000;
 540/490.000; 540/496.000; 540/500.000; 540/522.000; 540/523.000;
 540/520.000

NCLS: 514/221.000; 514/220.000; 514/212.040; 514/212.050; 514/151.000;
540/490.000; 540/496.000; 540/500.000; 540/522.000; 540/523.000;
540/520.000

IC [7]

ICM: A61K031-655

ICS: A61K031-55; A61K031-553; A61K031-5513; A61K031-551

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 218 OF 325 USPATFULL on STN

AN 2003:214379 USPATFULL

TI Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

IN Audia, James E., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Thompson, Richard C., Frankfort, IN, UNITED STATES
Wilkie, Stephen C., Indianapolis, IN, UNITED STATES
Stack, Douglas R., Fishers, IN, UNITED STATES
Shi, Qing, Carmel, IN, UNITED STATES

PI US 2003149022 A1 20030807

AI US 2002-326081 A1 20021223 (10)

RLI Division of Ser. No. US 1999-338121, filed on 22 Jun 1999, PENDING

PRAI US 1998-160067P 19980622 (60)

US 1998-150704P 19980930 (60)

DT Utility

FS APPLICATION

LN.CNT 7927

INCL INCLM: 514/211.040

INCLS: 514/212.040; 514/220.000; 514/212.050; 514/221.000

NCL NCLM: 514/211.040

NCLS: 514/212.040; 514/220.000; 514/212.050; 514/221.000

IC [7]

ICM: A61K031-55

ICS: A61K031-553; A61K031-554; A61K031-5513

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 219 OF 325 USPATFULL on STN

AN 2003:213754 USPATFULL

TI Screening compounds for the ability to alter the production of amyloid-beta peptide (x-41)

IN Citron, Martin, Thousand Oaks, CA, UNITED STATES
Selkoe, Dennis J., Jamaica Plain, MA, UNITED STATES
Seubert, Peter A., San Francisco, CA, UNITED STATES
Schenk, Dale B., Burlingame, CA, UNITED STATES

PA Athena Neurosciences, Inc. a Delaware corporation, South San Francisco, CA, UNITED STATES (U.S. corporation)

PI US 2003148392 A1 20030807

AI US 2002-335035 A1 20021230 (10)

RLI Continuation of Ser. No. US 1996-665649, filed on 18 Jun 1996, PENDING

Continuation-in-part of Ser. No. US 1993-79511, filed on 17 Jun 1993,

GRANTED, Pat. No. US 5766846 Division of Ser. No. US 1992-965972, filed on 26 Oct 1992, ABANDONED

Continuation-in-part of Ser. No. US 1992-911647, filed on 10 Jul 1992, ABANDONED

DT Utility

FS APPLICATION

LN.CNT 1904

INCL INCLM: 435/007.200

INCLS: 435/007.930

NCL NCLM: 435/007.200

NCLS: 435/007.930

IC [7]

ICM: G01N033-53

ICS: G01N033-567; G01N033-537; G01N033-543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 220 OF 325 USPATFULL on STN

AN 2003:213718 USPATFULL

TI Novel APP mutation associated with an unusual Alzheimer's disease pathology

IN Cruts, Mare, Antwerpen, BELGIUM
Jonghe, Chris De, Edegem, BELGIUM
Singh, Samir Kumar, Edegem, BELGIUM
Broeckhoven, Christine van, Edegem, BELGIUM

PI US 2003148356 A1 20030807

AI US 2003-337970 A1 20030106 (10)

DT Utility
FS APPLICATION
LN.CNT 1415
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/252.300; 435/320.100; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/226.000; 435/252.300; 435/320.100; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12N001-21; C12P021-02; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 221 OF 325 USPATFULL on STN
AN 2003:200445 USPATFULL
TI Modified ***antibodies*** with human milk fat globule specificity & uses
IN do Couto, Fernando J.R., Pleasanton, CA, UNITED STATES
Ceriani, Roberto L., Lafayette, CA, UNITED STATES
Peterson, Jerry A., Lafayette, CA, UNITED STATES
Padlan, Eduardo A., Kensington, CA, UNITED STATES
PI US 2003138428 A1 20030724
AI US 2001-947839 A1 20010906 (9)
RLI Division of Ser. No. US 1997-976288, filed on 21 Nov 1997, GRANTED, Pat. No. US 6315997 Division of Ser. No. US 1993-129930, filed on 30 Sep 1993, GRANTED, Pat. No. US 5804187 Continuation-in-part of Ser. No. US 1992-977696, filed on 16 Nov 1992, GRANTED, Pat. No. US 5792852

DT Utility
FS APPLICATION
LN.CNT 5365
INCL INCLM: 424/155.100
INCLS: 530/388.800; 435/344.000
NCL NCLM: 424/155.100
NCLS: 530/388.800; 435/344.000
IC [7]
ICM: A61K039-395
ICS: C12N005-06; C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 222 OF 325 USPATFULL on STN
AN 2003:188395 USPATFULL
TI Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Droste, James, Indianapolis, IN, UNITED STATES

PI US 2003130188 A1 20030710
AI US 2002-246558 A1 20020919 (10)
RLI Division of Ser. No. US 1998-32019, filed on 27 Feb 1998, PENDING
DT Utility
FS APPLICATION
LN.CNT 11320
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 514/019.000; 514/400.000; 514/419.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 514/019.000; 514/400.000; 514/419.000
IC [7]
ICM: A61K038-10
ICS: A61K038-08; A61K038-06; A61K038-05; A61K031-4172; A61K031-405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 223 OF 325 USPATFULL on STN
AN 2003:181505 USPATFULL
TI Compounds, compositions and methods for modulating beta-amyloid production
IN Connop, Bruce P., Vancouver, CANADA
Grant, Amelia, Vancouver, CANADA
Nathwani, Parimal S., Burnaby, CANADA
PA Active Pass Pharmaceuticals, Inc., Vancouver, CANADA, V5Z 4H5 (non-U.S. corporation)

AI US 2002-170224 A1 20020612 (10)
PRAI US 2001-309257P 20010731 (60)
US 2001-297845P 20010612 (60)
DT Utility
FS APPLICATION
LN.CNT 2198
INCL INCLM: 514/255.060
INCLS: 514/255.050; 544/405.000; 544/408.000
NCL NCLM: 514/255.060
NCLS: 514/255.050; 544/405.000; 544/408.000
IC [7]
ICM: A61K031-4965
ICS: C07D043-02; C07D241-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 224 OF 325 USPATFULL on STN
AN 2003:159820 USPATFULL
TI Methods of inhibiting amyloid toxicity
IN Prenner, Irene Griswald, Brisbane, CA, UNITED STATES
Wright, Sarah, San Francisco, CA, UNITED STATES
Yednock, Theodore, Forest knolls, CA, UNITED STATES
Rydel, Russell, Belmont, CA, UNITED STATES
PI US 2003109435 A1 20030612
AI US 2002-190548 A1 20020709 (10)
PRAI US 2001-304315P 20010709 (60)
US 2001-341772P 20011217 (60)
DT Utility
FS APPLICATION
LN.CNT 2361
INCL INCLM: 514/012.000
INCLS: 424/146.100
NCL NCLM: 514/012.000
NCLS: 424/146.100
IC [7]
ICM: A61K038-17
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 225 OF 325 USPATFULL on STN
AN 2003:152328 USPATFULL
TI Compositions and methods for the therapy and diagnosis of lung cancer
IN Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2003103994 A1 20030605
AI US 2002-114666 A1 20020401 (10)
RLI Continuation-in-part of Ser. No. US 2001-895828, filed on 28 Jun 2001,
PENDING
DT Utility
FS APPLICATION
LN.CNT 10295
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 226 OF 325 USPATFULL on STN
AN 2003:143058 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting .beta.-amyloid
peptide release and/or its synthesis by use of such compounds
IN Thompson, Richard C., Frankfort, IN, United States
Wilkie, Stephen, Indianapolis, IN, United States
Stack, Douglas R., Fishers, IN, United States
VanMeter, Eldon E., Greenwood, IN, United States
Shi, Qing, Carmel, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Henry, Steven S., New Palestine, IN, United States

Stucky, Russell D., Indianapolis, IN, United States
 Porter, Warren J., Indianapolis, IN, United States
 PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6569851 B1 20030527
 AI US 1999-338191 19990622 (9)
 PRAI US 1998-160067P 19980622 (60)
 DT Utility
 FS GRANTED
 LN.CNT 12808
 INCL INCLM: 514/219.000
 INCLS: 514/220.000; 514/221.000; 540/509.000; 540/517.000; 540/518.000;
 540/558.000; 540/559.000; 540/560.000; 540/561.000
 NCL NCLM: 514/219.000
 NCLS: 514/220.000; 514/221.000; 540/509.000; 540/517.000; 540/518.000;
 540/558.000; 540/559.000; 540/560.000; 540/561.000
 IC [7]
 ICM: C07D243-24
 ICS: C07D223-18; C07D223-16; C07D243-14; A61K031-55
 EXF 540/509; 540/558; 540/559; 540/560; 540/561; 540/517; 540/518; 514/221;
 514/219; 514/220
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 227 OF 325 USPATFULL on STN
 AN 2003:126723 USPATFULL
 TI Basal cell markers in breast cancer and uses thereof
 IN Botstein, David, Belmont, CA, UNITED STATES
 Brown, Patrick O., Stanford, CA, UNITED STATES
 Perou, Charles M., Carrboro, NC, UNITED STATES
 Ring, Brian, Foster City, CA, UNITED STATES
 Ross, Douglas, Burlingame, CA, UNITED STATES
 Seitz, Rob, Hampton Cove, AL, UNITED STATES
 van de Rijn, Jan Matthijs, LaHanda, CA, UNITED STATES
 PI US 2003086934 A1 20030508
 AI US 2001-916849 A1 20010726 (9)
 PRAI US 2000-220967P 20000726 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6518
 INCL INCLM: 424/185.100
 INCLS: 435/006.000; 435/007.230
 NCL NCLM: 424/185.100
 NCLS: 435/006.000; 435/007.230
 IC [7]
 ICM: C12Q001-68
 ICS: G01N033-574; A61K039-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 228 OF 325 USPATFULL on STN
 AN 2003:120996 USPATFULL
 TI Novel glyphosate N-acetyl transferase (GAT) genes
 IN Castle, Linda A., Mountain View, CA, UNITED STATES
 Siehl, Dan, Menlow Park, CA, UNITED STATES
 Giver, Lorraine J., Santa Clara, CA, UNITED STATES
 Minshull, Jeremy, Menlo Park, CA, UNITED STATES
 Ivy, Cristina, Los Altos, CA, UNITED STATES
 Chen, Yong Hong, Foster City, CA, UNITED STATES
 Duck, Nicholas B., Apex, NC, UNITED STATES
 PA Maxygen, Inc., Redwood City, CA, UNITED STATES, 94063 (U.S. corporation)
 PI US 2003083480 A1 20030501
 AI US 2001-4357 A1 20011029 (10)
 PRAI US 2000-244385P 20001030 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 11334
 INCL INCLM: 536/023.100
 NCL NCLM: 536/023.100
 IC [7]
 ICM: C07H021-02
 ICS: C07H021-04
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 229 OF 325 USPATFULL on STN
 AN 2003:120174 USPATFULL

the CA125 epitope
IN O'Brien, Timothy J., Little Rock, AR, UNITED STATES
PI US 2003082655 A1 20030501
AI US 2002-237920 A1 20020909 (10)
RLI Continuation of Ser. No. US 1998-69471, filed on 29 Apr 1998, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 611
INCL INCLM: 435/007.230
INCLS: 530/388.800
NCL NCLM: 435/007.230
NCLS: 530/388.800
IC [7]
ICM: G01N033-574
ICS: C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 230 OF 325 USPATFULL on STN
AN 2003:109100 USPATFULL
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same,
and methods for inhibiting .beta.-amyloid peptide release and/or its
synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Thompson, Richard C., Frankfort, IN, United States
Wilkie, Stephen C., Indianapolis, IN, United States
Stack, Douglas R., Fishers, IN, United States
Shi, Qing, Carmel, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
corporation)
Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)
PI US 6552013 B1 20030422
AI US 1999-338121 19990622 (9)
PRAI US 1998-160067P 19980622 (60)
US 1998-150704P 19980930 (60)
DT Utility
FS GRANTED
LN.CNT 7962
INCL INCLM: 514/212.040
INCLS: 514/212.070; 540/522.000; 540/523.000
NCL NCLM: 514/212.040
NCLS: 514/212.070; 540/522.000; 540/523.000
IC [7]
ICM: C07D243-24
ICS: C07D223-18; C07D223-16; C07D409-12; A61K031-55
EXF 514/212.04; 514/212.07; 540/522; 540/523
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 231 OF 325 USPATFULL on STN
AN 2003:99221 USPATFULL
TI Immunogenic peptide composition for the prevention and treatment of
Alzheimer's Disease
IN Wang, Chang Yi, Cold Spring Harbor, NY, UNITED STATES
PI US 2003068325 A1 20030410
AI US 2001-865294 A1 20010525 (9)
DT Utility
FS APPLICATION
LN.CNT 2076
INCL INCLM: 424/185.100
INCLS: 435/226.000
NCL NCLM: 424/185.100
NCLS: 435/226.000
IC [7]
ICM: A61K039-00
ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 232 OF 325 USPATFULL on STN
AN 2003:60218 USPATFULL
TI Cyclic amino acid compounds pharmaceutical compositions comprising same
and methods for inhibiting .beta.-amyloid peptide release and/or its
synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States

PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6528505 B1 20030304
 AI US 1999-338180 19990622 (9)
 PRAI US 1998-160067P 19980622 (60)
 US 1998-155238P 19980930 (60)
 DT Utility
 FS GRANTED
 LN.CNT 7113
 INCL INCLM: 514/212.040
 INCLS: 514/212.070; 540/522.000; 540/523.000
 NCL NCLM: 514/212.040
 NCLS: 514/212.070; 540/522.000; 540/523.000
 IC [7]
 ICM: C07D223-14
 ICS: C07D243-06; C07D243-10; C07D243-12; A61K031-55
 EXF 540/522; 540/523; 514/212.04; 514/212.07
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 233 OF 325 USPATFULL on STN
 AN 2003:23331 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of colon cancer
 IN Jiang, Yuqiu, Kent, WA, UNITED STATES
 PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
 PI US 2003017167 A1 20030123
 AI US 2001-904456 A1 20010711 (9)
 RLI Continuation-in-part of Ser. No. US 2001-878722, filed on 8 Jun 2001,
 PENDING
 PRAI US 2001-290240P 20010510 (60)
 US 2000-256571P 20001218 (60)
 US 2000-210821P 20000609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 8237
 INCL INCLM: 424/185.100
 INCLS: 514/044.000; 435/007.230; 435/006.000; 435/325.000; 435/320.100;
 435/069.100; 536/023.200
 NCL NCLM: 424/185.100
 NCLS: 514/044.000; 435/007.230; 435/006.000; 435/325.000; 435/320.100;
 435/069.100; 536/023.200
 IC [7]
 ICM: C12Q001-68
 ICS: G01N033-574; C07H021-04; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 234 OF 325 USPATFULL on STN
 AN 2003:20224 USPATFULL
 TI Deoxyamino acid compounds, pharmaceutical compositions comprising same,
 and methods for inhibiting .beta.-amyloid peptide release and/or its
 synthesis by use of such compounds
 IN Audia, James E., Indianapolis, IN, United States
 Thompson, Richard C., Frankfort, IN, United States
 Wilkie, Stephen C., Indianapolis, IN, United States
 Britton, Thomas C., Carmel, IN, United States
 Porter, Warren J., Indianapolis, IN, United States
 Huffman, George W., Carmel, IN, United States
 Latimer, Lee H., Oakland, CA, United States
 PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6509331 B1 20030121
 AI US 1999-337484 19990621 (9)
 PRAI US 1998-155265P 19980622 (60)
 DT Utility
 FS GRANTED
 LN.CNT 6167
 INCL INCLM: 514/212.040
 INCLS: 514/212.070; 540/522.000; 540/523.000
 NCL NCLM: 514/212.040
 NCLS: 514/212.070; 540/522.000; 540/523.000
 IC [7]
 ICM: C07D487-00
 ICS: C07D491-00; C07D498-00; C07D513-00; A61K031-55
 EXF 540/522; 540/523; 514/212.04; 514/212.07

L3 ANSWER 235 OF 325 USPATFULL on STN
 AN 2003:13325 USPATFULL
 TI Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
 IN Thorsett, Eugene D., Moss Beach, CA, United States
 Porter, Warren J., Indianapolis, IN, United States
 Nissen, Jeffrey S., Indianapolis, IN, United States
 Latimer, Lee H., Oakland, CA, United States
 Audia, James E., Indianapolis, IN, United States
 Droste, James, Indianapolis, IN, United States
 PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
 Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6506782 B1 20030114
 AI US 1998-32019 19980227 (9)
 DT Utility
 FS GRANTED
 LN.CNT 9870
 INCL INCLM: 514/364.000
 NCL NCLM: 514/364.000
 IC [7]
 ICM: A61K031-4245
 EXF 514/364
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 236 OF 325 USPATFULL on STN
 AN 2002:308378 USPATFULL
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
 IN Wu, Jing, San Mateo, CA, UNITED STATES
 Tung, Jay S., Belmont, CA, UNITED STATES
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES
 Latimer, Lee H., Oakland, CA, UNITED STATES
 John, Varghese, San Francisco, CA, UNITED STATES
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES
 Britton, Thomas C., Carmel, IN, UNITED STATES
 Audia, James E., Indianapolis, IN, UNITED STATES
 Reel, Jon K., Carmel, IN, UNITED STATES
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
 Droste, James J., Indianapolis, IN, UNITED STATES
 Henry, Steven S., New Palestine, IN, UNITED STATES
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES
 Scott, William Leonard, Indianapolis, IN, UNITED STATES
 Stucky, Russell D., Indianapolis, IN, UNITED STATES
 Porter, Warren J., Indianapolis, IN, UNITED STATES
 PI US 2002173504 A1 20021121
 AI US 2001-915519 A1 20010727 (9)
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
 PRAI US 1996-64851P 19961223 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25650
 INCL INCLM: 514/212.040
 INCLS: 514/327.000; 514/424.000; 514/659.000
 NCL NCLM: 514/212.040
 NCLS: 514/327.000; 514/424.000; 514/659.000
 IC [7]
 ICM: A61K031-55
 ICS: A61K031-445; A61K031-4015; A61K031-13
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 237 OF 325 USPATFULL on STN
 AN 2002:291111 USPATFULL
 TI Compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis
 IN Wu, Jing, San Mateo, CA, United States
 Tung, Jay S., Belmont, CA, United States

Reel, Jon K., Carmel, IN, United States
 Porter, Warren J., Indianapolis, IN, United States
 Nissen, Jeffrey S., Indianapolis, IN, United States
 Mabry, Thomas E., Indianapolis, IN, United States
 Latimer, Lee H., Oakland, CA, United States
 John, Varghese, San Francisco, CA, United States
 Folmer, Beverly K., Newark, DE, United States
 Droste, James J., Indianapolis, IN, United States
 Britton, Thomas C., Carmel, IN, United States
 Audia, James E., Indianapolis, IN, United States
 PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
 AI US 6476263 B1 20021105
 RLI US 2001-826412 20010403 (9)
 Continuation of Ser. No. US 1998-164448, filed on 30 Sep 1998, now patented, Pat. No. US 6211235 Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997, now patented, Pat. No. US 6191166
 PRAI US 1996-108166P 19961122 (60)
 US 1997-64859P 19970228 (60)
 US 1997-108161P 19970228 (60)
 US 1997-98558P 19970228 (60)
 DT Utility
 FS GRANTED
 LN.CNT 12409
 INCL INCLM: 564/152.000
 INCLS: 564/153.000; 564/159.000; 564/160.000; 564/161.000; 564/041.000; 560/041.000; 562/450.000
 NCL NCLM: 564/152.000
 NCLS: 560/041.000; 562/450.000; 564/041.000; 564/153.000; 564/159.000; 564/160.000; 564/161.000
 IC [7]
 ICM: C07C233-00
 EXF 564/152; 564/153; 564/159; 564/160; 564/161; 560/41; 562/450
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 238 OF 325 USPATFULL on STN
 AN 2002:287132 USPATFULL
 TI Modulation of Abeta levels by beta-secretase BACE2
 IN Cordell, Barbara, Palo Alto, CA, UNITED STATES
 Schimmoller, Frauke, Menlo Park, CA, UNITED STATES
 Liu, Yu-Wang, Santa Clara, CA, UNITED STATES
 Quon, Diana Hom, Redwood City, CA, UNITED STATES
 PI US 2002159991 A1 20021031
 US 6713276 B2 20040330
 AI US 2001-886143 A1 20010620 (9)
 PRAI US 2000-215729P 20000628 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1421
 INCL INCLM: 424/094.630
 NCL NCLM: 435/023.000
 NCLS: 435/024.000; 435/069.200
 IC [7]
 ICM: A61K038-48
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 239 OF 325 USPATFULL on STN
 AN 2002:275738 USPATFULL
 TI Hepatocyte growth factor receptor antagonists and uses thereof
 IN Schwall, Ralph H., Pacifica, CA, United States
 Tabor, Kelly H., Hillsborough, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 6468529 B1 20021022
 AI US 2000-669971 20000926 (9)
 RLI Continuation of Ser. No. US 952235, now patented, Pat. No. US 6207152
 Continuation-in-part of Ser. No. US 1995-460368, filed on 2 Jun 1995, now patented, Pat. No. US 5686292
 DT Utility
 FS GRANTED
 LN.CNT 2994
 INCL INCLM: 424/130.100
 INCLS: 424/130.100; 424/133.100; 424/134.100; 424/135.100; 424/138.100; 424/141.100

IC NCLS: 424/133.100; 424/134.100; 424/135.100; 424/138.100; 424/141.100
[7]
ICM: A61K039-395
EXF 424/133.1; 424/134.1; 424/135.1; 424/138.1; 424/141.1; 536/23.53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 240 OF 325 USPATFULL on STN
AN 2002:273410 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James A., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002151538 A1 20021017
US 6579867 B2 20030617
AI US 2001-915379 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26543
INCL INCLM: 514/212.040
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 241 OF 325 USPATFULL on STN
AN 2002:265874 USPATFULL
TI Mucin-1 specific binding members and methods of use thereof
IN Hoogenboom, Hendricus R.J.M., Hertogsingel, NETHERLANDS
Henderikx, Maria P.G., Wijngaardstraat, BELGIUM
PI US 2002146750 A1 20021010
AI US 2001-822698 A1 20010330 (9)
RLI Continuation-in-part of Ser. No. US 2000-538913, filed on 30 Mar 2000, PENDING
DT Utility
FS APPLICATION
LN.CNT 4442
INCL INCLM: 435/007.230
INCLS: 424/155.100; 435/069.500; 530/351.000; 424/085.100
NCL NCLM: 435/007.230
NCLS: 424/155.100; 435/069.500; 530/351.000; 424/085.100
IC [7]
ICM: G01N033-574
ICS: C12P021-02; A61K039-395; C07K014-52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 242 OF 325 USPATFULL on STN
AN 2002:251790 USPATFULL
TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES

Mabry, Thomas E., Indianapolis, IN, UNITED STATES
 Latimer, Lee H., Oakland, CA, UNITED STATES
 John, Varghese, San Francisco, CA, UNITED STATES
 Fang, Lawrence Y., Foster City, CA, UNITED STATES
 Audia, James E., Indianapolis, IN, UNITED STATES

PI US 2002137743 A1 20020926
 US 6642261 B2 20031104
 AI US 2001-984834 A1 20011031 (9)
 RLI Continuation of Ser. No. US 1999-303655, filed on 3 May 1999, PATENTED
 Continuation of Ser. No. US 1997-976179, filed on 21 Nov 1997, PATENTED
 DT Utility
 FS APPLICATION
 LN.CNT 3784
 INCL INCLM: 514/227.500
 INCLS: 514/237.800; 514/252.120; 514/357.000; 514/534.000; 514/561.000;
 544/059.000; 544/159.000; 544/400.000; 546/336.000; 560/041.000;
 560/155.000
 NCL NCLM: 514/357.000
 NCLS: 546/336.000
 IC [7]
 ICM: A61K031-54
 ICS: A61K031-535; A61K031-495; A61K031-44; A61K031-198
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 243 OF 325 USPATFULL on STN
 AN 2002:251785 USPATFULL
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
 compositions comprising same, and methods for inhibiting beta-amyloid
 peptide release and/or its synthesis by use of such compounds
 IN Wu, Jing, San Mateo, CA, UNITED STATES
 Tung, Jay S., Belmont, CA, UNITED STATES
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES
 Latimer, Lee H., Oakland, CA, UNITED STATES
 John, Varghese, San Francisco, CA, UNITED STATES
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES
 Britton, Thomas C., Carmel, IN, UNITED STATES
 Audia, James E., Indianapolis, IN, UNITED STATES
 Reel, Jon K., Carmel, IN, UNITED STATES
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
 Droste, James J., Indianapolis, IN, UNITED STATES
 Henry, Steven S., New Palestine, IN, UNITED STATES
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES
 Scott, William Leonard, Indianapolis, IN, UNITED STATES
 Stucky, Russell D., Indianapolis, IN, UNITED STATES
 Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002137738 A1 20020926
 US 6559141 B2 20030506
 AI US 2001-915564 A1 20010727 (9)
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
 PRAI US 1996-64851P 19961223 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 26049
 INCL INCLM: 514/212.030
 INCLS: 514/327.000; 514/424.000; 514/659.000
 NCL NCLM: 514/211.060
 NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;
 540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;
 540/527.000
 IC [7]
 ICM: A61K031-55
 ICS: A61K031-445; A61K031-4015; A61K031-13
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 244 OF 325 USPATFULL on STN
 AN 2002:246898 USPATFULL
 TI Transgenic mice expressing human APP and TGF-.beta. demonstrate
 cerebrovascular amyloid deposits
 IN Mucke, Lennart, Foster City, CA, United States
 Wyss-Coray, Tony, Berkeley, CA, United States

PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6455757 B1 20020924
AI US 1999-262519 19990304 (9)
RLI Continuation-in-part of Ser. No. US 1997-947295, filed on 8 Oct 1997
DT Utility
FS GRANTED
LN.CNT 1966
INCL INCLM: 800/012.000
INCLS: 800/003.000; 800/018.000
NCL NCLM: 800/012.000
NCLS: 800/003.000; 800/018.000
IC [7]
ICM: A01K067-00
ICS: A01K067-027; A01K067-033; G01N033-00
EXF 800/3; 800/12; 800/14; 800/18; 514/44; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 245 OF 325 USPATFULL on STN
AN 2002:228326 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting beta-amyloid
peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002123486 A1 20020905
US 6632811 B2 20031014
AI US 2001-915342 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26177
INCL INCLM: 514/212.020
INCLS: 514/659.000
NCL NCLM: 514/220.000
NCLS: 514/221.000
IC [7]
ICM: A61K031-55
ICS: A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 246 OF 325 USPATFULL on STN
AN 2002:214264 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting beta-amyloid
peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES

Audia, James E., Indianapolis, IN, UNITED STATES
 Reel, Jon K., Carmel, IN, UNITED STATES
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
 Droste, James J., Indianapolis, IN, UNITED STATES
 Henry, Steven S., New Palestine, IN, UNITED STATES
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES
 Scott, William Leonard, Indianapolis, IN, UNITED STATES
 Stucky, Russell D., Indianapolis, IN, UNITED STATES
 Porter, Warren J., Indianapolis, IN, UNITED STATES
 PI US 2002115652 A1 20020822
 US 6541466 B2 20030401
 AI US 2001-915362 A1 20010727 (9)
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
 PRAI US 1996-64851P 19961223 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25618
 INCL INCLM: 514/212.010
 INCLS: 514/248.000; 514/258.000; 514/279.000; 514/410.000; 514/659.000
 NCL NCLM: 514/211.060
 NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;
 540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;
 540/527.000
 IC [7]
 ICM: A61K031-55
 ICS: A61K031-519; A61K031-5025; A61K031-4745; A61K031-407; A61K031-13
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 247 OF 325 USPATFULL on STN
 AN 2002:206646 USPATFULL
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
 compositions comprising same, and methods for inhibiting beta-Amyloid
 peptide release and/or its synthesis by use of such compounds
 IN Wu, Jing, San Mateo, CA, UNITED STATES
 Tung, Jay S., Belmont, CA, UNITED STATES
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES
 Latimer, Lee H., Oakland, CA, UNITED STATES
 Varghese, John, San Francisco, CA, UNITED STATES
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES
 Britton, Thomas C., Carmel, IN, UNITED STATES
 Audia, James E., Indianapolis, IN, UNITED STATES
 Reel, Jon K., Carmel, IN, UNITED STATES
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
 Droste, James J., Indianapolis, IN, UNITED STATES
 Henry, Steven S., New Palestine, IN, UNITED STATES
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES
 Scott, William Leonard, Indianapolis, IN, UNITED STATES
 Stucky, Russell D., Indianapolis, IN, UNITED STATES
 Porter, Warren J., Indianapolis, IN, UNITED STATES
 PI US 2002111343 A1 20020815
 AI US 2001-915547 A1 20010727 (9)
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
 PRAI US 1996-64851P 19961223 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25803
 INCL INCLM: 514/212.030
 INCLS: 514/327.000; 514/424.000; 514/659.000
 NCL NCLM: 514/212.030
 NCLS: 514/327.000; 514/424.000; 514/659.000
 IC [7]
 ICM: A61K031-55
 ICS: A61K031-445; A61K031-4015; A61K031-13
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 248 OF 325 USPATFULL on STN
 AN 2002:193026 USPATFULL
 TI METHOD FOR IDENTIFYING ALZHEIMER'S DISEASE THERAPEUTICS USING TRANSGENIC

IN GAMES, KATE DORA, BELMONT, CA, UNITED STATES
 SCHENK, DALE BERNARD, BURLINGAME, CA, UNITED STATES
 MCCONLOGUE, LISA CLAIRE, SAN FRANCISCO, CA, UNITED STATES
 SEUBERT, PETER ANDREW, SAN FRANCISCO, CA, UNITED STATES
 RYDEL, RUSSELL E., BELMONT, CA, UNITED STATES

PI US 2002104104 A1 20020801
 US 6717031 B2 20040406

AI US 1998-149718 A1 19980908 (9)

RLI Continuation-in-part of Ser. No. US 1996-660487, filed on 7 Jun 1996,
 ABANDONED Continuation-in-part of Ser. No. US 1995-480653, filed on 7
 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1996-659797,
 filed on 7 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US
 1995-486538, filed on 7 Jun 1995, ABANDONED

DT Utility
 FS APPLICATION
 LN.CNT 4514

INCL INCLM: 800/003.000
 INCLS: 435/354.000; 435/029.000; 800/012.000; 800/018.000

NCL NCLM: 800/012.000
 NCLS: 435/006.000; 435/007.100; 800/003.000; 800/018.000

IC [7]
 ICM: A01K067-027
 ICS: C12Q001-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 249 OF 325 USPATFULL on STN

AN 2002:191195 USPATFULL

TI Human tumor necrosis factor receptor-like 2 (TR2) ***antibodies***

IN Harrop, Jeremy A., Malvern, PA, UNITED STATES
 Holmes, Stephen D., Epsom, UNITED KINGDOM
 Reddy, Manjula P., Phoenixville, PA, UNITED STATES
 Truneh, Alemseged, West Chester, PA, UNITED STATES

PA SmithKline Beecham Corporation (U.S. corporation)

PI US 2002102258 A1 20020801

AI US 2001-20787 A1 20011214 (10)

RLI Continuation of Ser. No. US 1999-403815, filed on 26 Oct 1999, ABANDONED
 A 371 of International Ser. No. WO 1998-US9744, filed on 12 May 1998,
 UNKNOWN

PRAI US 1997-46249P 19970512 (60)

DT Utility
 FS APPLICATION
 LN.CNT 1098

INCL INCLM: 424/143.100

NCL NCLM: 424/143.100

IC [7]
 ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 250 OF 325 USPATFULL on STN

AN 2002:188237 USPATFULL

TI Method for detecting candida infection

IN Miyada, Charles Garrett, Mountain View, CA, United States
 Switchenko, Arthur C., Palo Alto, CA, United States
 Quong, Melanie W, La Jolla, CA, United States
 Wong, Man-Ying Laurie, Fremont, CA, United States

PA Dade Behring Marburg GmbH, Marburg, GERMANY, FEDERAL REPUBLIC OF
 (non-U.S. corporation)

PI US 6426204 B1 20020730

AI US 1995-476394 19950607 (8)

RLI Division of Ser. No. US 1995-400417, filed on 3 Mar 1995, now patented,
 Pat. No. US 5451517 Continuation of Ser. No. US 1994-184764, filed on 21
 Jan 1994, now abandoned Continuation of Ser. No. US 1991-731218, filed
 on 12 Jul 1991, now abandoned

DT Utility
 FS GRANTED
 LN.CNT 1052

INCL INCLM: 435/190.000
 INCLS: 435/026.000; 435/034.000; 435/255.400; 435/921.000; 435/924.000

NCL NCLM: 435/190.000
 NCLS: 435/026.000; 435/034.000; 435/255.400; 435/921.000; 435/924.000

IC [7]
 ICM: C12N009-04

EXF 435/26; 435/34; 435/190; 435/255.4; 435/921; 435/924

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:186091 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of lung cancer
 IN Wang, Tongtong, Medina, WA, UNITED STATES
 McNeill, Patricia D., Federal Way, WA, UNITED STATES
 Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
 Carter, Darrick, Seattle, WA, UNITED STATES
 Henderson, Robert A., Edmonds, WA, UNITED STATES
 Kalos, Michael D., Seattle, WA, UNITED STATES
 PI US 2002099012 A1 20020725
 AI US 2001-895828 A1 20010628 (9)
 PRAI US 2000-215696P 20000629 (60)
 US 2000-227142P 20000822 (60)
 US 2000-230481P 20000906 (60)
 US 2000-257729P 20001221 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 10022
 INCL INCLM: 514/012.000
 INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/183.000;
 530/350.000; 536/023.100
 NCL NCLM: 514/012.000
 NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/183.000;
 530/350.000; 536/023.100
 IC [7]
 ICM: A61K038-17
 ICS: C12Q001-68; C07H021-04; C12N009-00; C12N005-06; C12P021-02;
 C07K014-435

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 252 OF 325 USPATFULL on STN
 AN 2002:172330 USPATFULL
 TI Prevention and treatment of degenerative diseases by glutathione and
 phase II detoxification enzymes
 IN Zhang, Yuesheng, Tucson, AZ, UNITED STATES
 Ho, Tony W., Malvern, PA, UNITED STATES
 Li, Yun, Tucson, AZ, UNITED STATES
 PI US 2002091087 A1 20020711
 AI US 2001-897934 A1 20010705 (9)
 PRAI US 2000-215812P 20000705 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1287
 INCL INCLM: 514/018.000
 INCLS: 514/023.000; 514/506.000; 514/717.000; 514/733.000; 514/731.000
 NCL NCLM: 514/018.000
 NCLS: 514/023.000; 514/506.000; 514/717.000; 514/733.000; 514/731.000
 IC [7]
 ICM: A61K038-06
 ICS: A61K031-7024; A61K031-26; A61K031-075; A61K031-05

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 253 OF 325 USPATFULL on STN
 AN 2002:133883 USPATFULL
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
 compositions comprising same, and methods for inhibiting beta-amyloid
 peptide release and/or its synthesis by use of such compounds
 IN Wu, Jing, San Mateo, CA, UNITED STATES
 Tung, Jay S., Belmont, CA, UNITED STATES
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES
 Latimer, Lee H., Oakland, CA, UNITED STATES
 John, Varghese, San Francisco, CA, UNITED STATES
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES
 Britton, Thomas C., Carmel, IN, UNITED STATES
 Audia, James E., Indianapolis, IN, UNITED STATES
 Reel, Jon K., Carmel, IN, UNITED STATES
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
 Droste, James J., Indianapolis, IN, UNITED STATES
 Henry, Steven S., New Palestine, IN, UNITED STATES
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES
 Scott, William Leonard, Indianapolis, IN, UNITED STATES

Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002068741 A1 20020606
 AI US 2001-915263 A1 20010726 (9)
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
 PRAI US 1996-64851P 19961223 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25726
 INCL INCLM: 514/248.000
 INCLS: 514/257.000; 514/258.000; 514/280.000; 514/290.000; 514/299.000;
 514/410.000; 514/411.000
 NCL NCLM: 514/248.000
 NCLS: 514/257.000; 514/258.000; 514/280.000; 514/290.000; 514/299.000;
 514/410.000; 514/411.000
 IC [7]
 ICM: A61K031-517
 ICS: A61K031-502; A61K031-498; A61K031-473; A61K031-403
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 254 OF 325 USPATFULL on STN
 AN 2002:129982 USPATFULL
 TI N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions
 comprising same, and methods for inhibiting alpha- amyloid peptide
 release and/or its synthesis by use of such compounds
 IN Audia, James E., Indianapolis, IN, United States
 Folmer, Beverly K., Newark, DE, United States
 John, Varghese, San Francisco, CA, United States
 Latimer, Lee H., Oakland, CA, United States
 Nissen, Jeffrey S., Indianapolis, IN, United States
 Reel, Jon K., Carmel, IN, United States
 Thorsett, Eugene D., Moss Beach, CA, United States
 Whitesitt, Celia A., Greenwood, IN, United States
 PA Athena Neurosciences, Inc., San Francisco, CA, United States (U.S.
 corporation)
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6399628 B1 20020604
 AI US 1999-266908 19990312 (9)
 RLI Continuation of Ser. No. US 1997-975977, filed on 21 Nov 1997, now
 patented, Pat. No. US 5965614
 PRAI US 1996-104593P 19961122 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2944
 INCL INCLM: 514/311.000
 INCLS: 514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000;
 514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000;
 514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000;
 548/540.000; 549/366.000; 549/439.000; 549/451.000; 549/496.000;
 560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000
 NCL NCLM: 514/311.000
 NCLS: 514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000;
 514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000;
 514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000;
 548/540.000; 549/366.000; 549/439.000; 549/451.000; 549/496.000;
 560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000
 IC [7]
 ICM: C07D215-38
 ICS: C07D277-82; C07D209-20; C07D319-14; C07D317-44; C07D307-02;
 C07C229-28
 EXF 514/311; 514/367; 514/413; 514/423; 514/452; 514/465; 514/467; 514/471;
 514/529; 514/533; 514/538; 514/550; 514/567; 546/171; 548/161; 548/496;
 548/540; 549/366; 549/439; 549/451; 549/496; 560/43; 560/45; 560/161;
 562/433; 562/457
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 255 OF 325 USPATFULL on STN
 AN 2002:129948 USPATFULL
 TI Modified VEGF oligonucleotides
 IN Robinson, Gregory S., Acton, MA, United States
 PA Hybridon, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 6399586 B1 20020604
 AI US 1999-320911 19990527 (9)
 RLI Continuation of Ser. No. US 1998-124304, filed on 29 Jul 1998, now
 abandoned Continuation of Ser. No. US 1996-761708, filed on 6 Dec 1996
 Continuation-in-part of Ser. No. US 1996-629730, filed on 9 Apr 1996,

8 Dec 1995, now patented, Pat. No. US 5641756 Continuation-in-part of
Ser. No. US 1995-398945, filed on 2 Mar 1995, now patented, Pat. No. US
5639872 Continuation-in-part of Ser. No. US 1995-378860, filed on 26 Jan
1995, now patented, Pat. No. US 5731294 Continuation-in-part of Ser. No.
US 1993-98942, filed on 27 Jul 1993

DT Utility
FS GRANTED

LN.CNT 1274

INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/091.100; 435/091.310; 435/375.000; 435/325.000;
536/023.100; 536/023.200; 536/024.500; 536/024.300; 536/024.310;
536/024.330

NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/091.100; 435/091.310; 435/325.000; 435/375.000;
536/023.100; 536/023.200; 536/024.300; 536/024.310; 536/024.330;
536/024.500

IC [7]
ICM: A61K048-00
ICS: C07H021-04

EXF 435/6; 435/91.1; 435/91.3; 435/375; 435/325; 536/23.1; 536/23.2;
536/24.5; 536/24.3; 536/24.31; 536/24.33; 514/44

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 256 OF 325 USPATFULL on STN

AN 2002:106291 USPATFULL

TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting B-amyloid
peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002055500 A1 20020509

AI US 2001-916440 A1 20010730 (9)

RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING

PRAI US 1996-64851P 19961223 (60)

DT Utility
FS APPLICATION

LN.CNT 25439

INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 514/659.000

NCL NCLM: 514/212.030
NCLS: 514/327.000; 514/424.000; 514/659.000

IC [7]
ICM: A61K031-55
ICS: A61K031-45; A61K031-4015; A61K031-13

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 257 OF 325 USPATFULL on STN

AN 2002:99458 USPATFULL

TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting B-amyloid
peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES

Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002052359 A1 20020502
US 6544978 B2 20030408
AI US 2001-915480 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)

DT Utility
FS APPLICATION
LN.CNT 25908

INCL INCLM: 514/212.010
INCLS: 514/327.000; 514/424.000; 514/519.000; 514/529.000; 514/683.000;
514/676.000

NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;
540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;
540/527.000

IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-40; A61K031-215; A61K031-275

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 258 OF 325 USPATFULL on STN

AN 2002:99421 USPATFULL

TI Methods and compounds for inhibiting beta-amyloid peptide release and/or
its synthesis

IN Audia, James E., Indianapolis, IN, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Folmer, Beverly K., Newark, DE, UNITED STATES
Huffman, George W., Carmel, IN, UNITED STATES
Varghese, John, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Wu, Jing, San Mateo, CA, UNITED STATES
Eid, Clark Norman, Cheshire, CT, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES

PI US 2002052322 A1 20020502

AI US 2001-789487 A1 20010220 (9)

RLI Continuation of Ser. No. US 1997-976289, filed on 21 Nov 1997, GRANTED,
Pat. No. US 6191166

PRAI US 1996-108166P 19961122 (60)
US 1997-108161P 19970228 (60)
US 1997-98558P 19970228 (60)
US 1997-64859P 19970228 (60)

DT Utility
FS APPLICATION

LN.CNT 14911

INCL INCLM: 514/018.000
INCLS: 514/019.000; 514/400.000; 514/563.000; 514/419.000

NCL NCLM: 514/018.000
NCLS: 514/019.000; 514/400.000; 514/563.000; 514/419.000

IC [7]
ICM: A61K038-06
ICS: A61K031-05; A61K031-4172; A61K031-405; A61K031-198

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:85701 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting beta-amyloid
peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James A., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Indianapolis, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002045747 A1 20020418
AI US 2001-916282 A1 20010730 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26053
INCL INCLM: 540/450.000
INCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000
NCL NCLM: 540/450.000
NCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000
IC [7]
ICM: A61K031-551
ICS: C07D243-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 260 OF 325 USPATFULL on STN
AN 2002:72987 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Clapper, Jonathan D., Seattle, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
PI US 2002040127 A1 20020404
AI US 2001-878722 A1 20010608 (9)
PRAI US 2000-256571P 20001218 (60)
US 2000-210821P 20000609 (60)
US 2001-290240P 20010510 (60)
DT Utility
FS APPLICATION
LN.CNT 8110
INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/320.100; 435/325.000; 435/069.100
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/320.100; 435/325.000; 435/069.100
IC [7]
ICM: C07K014-705
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 261 OF 325 USPATFULL on STN
AN 2002:16575 USPATFULL
TI NEW MONOCLONAL ***ANTIBODIES*** WHICH IDENTIFY THE GLYCOPROTEIN
CARRYING THE CA125 EPI TOPE
IN O'BRIEN, TIMOTHY J., LITTLE ROCK, AR, UNITED STATES
PI US 2002009451 A1 20020124
AI US 1998-69471 A1 19980429 (9)
RLI Continuation of Ser. No. US 1996-626675, filed on 2 Apr 1996, GRANTED,
Pat. No. US 5976818 Continuation of Ser. No. US 1994-343357, filed on 22

DT Dec 1991, ABANDONED
FS Utility
LN.CNT APPLICATION
INCL 611
INCLM: 424/156.100
INCLS: 435/007.100; 424/178.100
NCLM: 424/156.100
NCLS: 435/007.100; 424/178.100
IC [7]
ICM: G01N033-53
ICS: A61K039-395; G01N033-574; A61K039-40; A61K039-42; A61K039-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 262 OF 325 USPATFULL on STN
AN 2001:235274 USPATFULL
TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Fang, Lawrence Y., Foster City, CA, United States
Audia, James E., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6333351 B1 20011225
AI US 1999-303655 19990503 (9)
RLI Continuation of Ser. No. US 1997-976179, filed on 21 Nov 1997, now patented, Pat. No. US 6117901
PRAI US 1996-98551P 19961122 (60)
US 1996-19790P 19960614 (60)
DT Utility
FS GRANTED
LN.CNT 3252
INCL INCLM: 514/538.000
INCLS: 560/037.000; 514/432.000; 514/452.000; 549/023.000; 549/362.000
NCLM: 514/538.000
NCLS: 514/432.000; 514/452.000; 549/023.000; 549/362.000; 560/037.000
IC [7]
ICM: C07C229-06
ICS: A61K031-24; A61K031-38; A61K031-335
EXF 560/37; 514/538; 514/432; 514/452; 549/23; 549/362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 263 OF 325 USPATFULL on STN
AN 2001:226429 USPATFULL
TI Assays for detecting .beta.-secretase inhibition
IN Anderson, John P., San Francisco, CA, United States
Jacobson-Croak, Kirsten L., San Bruno, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6329163 B1 20011211
AI US 1998-54334 19980402 (9)
RLI Continuation of Ser. No. US 1995-485152, filed on 7 Jun 1995, now abandoned
DT Utility
FS GRANTED
LN.CNT 735
INCL INCLM: 435/023.000
INCLS: 435/004.000; 435/024.000; 435/007.100; 435/007.950; 436/518.000
NCLM: 435/023.000
NCLS: 435/004.000; 435/007.100; 435/007.950; 435/024.000; 436/518.000
IC [7]
ICM: C12Q001-37
ICS: G01N033-53
EXF 435/7.1; 435/7.2; 435/23; 435/70.21; 435/240.27; 435/961; 435/4; 435/24; 435/7.95; 436/516; 436/518; 436/529; 436/530; 436/547; 436/548; 436/155; 436/161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:202194 USPATFULL
 TI Use of modified ***antibodies*** with human milk fat globule specificity
 IN do Couto, Fernando J.R., Pleasanton, CA, United States
 Ceriani, Roberto L., Lafayette, CA, United States
 Peterson, Jerry A., Lafayette, CA, United States
 Padlan, Eduardo A., Kensington, CA, United States
 PA Cancer Research Fund, San Francisco, CA, United States (U.S. corporation)
 PI US 6315997 B1 20011113
 AI US 1997-976288 19971121 (8)
 RLI Division of Ser. No. US 1993-129930, filed on 30 Sep 1993, now patented, Pat. No. US 5804187 Continuation-in-part of Ser. No. US 1992-977696, filed on 16 Nov 1992, now patented, Pat. No. US 5792852
 DT Utility
 FS GRANTED
 LN.CNT 4677
 INCL INCLM: 424/134.100
 INCLS: 424/133.100; 424/135.100; 424/138.100; 424/178.100; 424/182.100
 NCL NCLM: 424/134.100
 NCLS: 424/133.100; 424/135.100; 424/138.100; 424/178.100; 424/182.100
 IC [7]
 ICM: A61K039-395
 EXF 424/133.1; 424/134.1; 424/135.1; 424/138.1; 424/178.1; 424/182.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 265 OF 325 USPATFULL on STN
 AN 2001:197049 USPATFULL
 TI N(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
 IN Wu, Jing, San Mateo, CA, United States
 Thorsett, Eugene D., Moss Beach, CA, United States
 Nissen, Jeffrey S., Indianapolis, IN, United States
 Mabry, Thomas E., Indianapolis, IN, United States
 Latimer, Lee H., Oakland, CA, United States
 John, Varghese, San Francisco, CA, United States
 Fang, Lawrence Y., Foster City, CA, United States
 Audia, James E., Indianapolis, IN, United States
 PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
 Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6313152 B1 20011106
 AI US 1999-390692 19990907 (9)
 RLI Division of Ser. No. US 1997-976179, filed on 21 Nov 1997, now patented, Pat. No. US 6117901
 PRAI US 1996-98551P 19961122 (60)
 US 1996-19790P 19960614 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3130
 INCL INCLM: 514/357.000
 INCLS: 514/375.000; 514/379.000; 514/438.000; 514/439.000; 514/461.000; 514/469.000
 NCL NCLM: 514/357.000
 NCLS: 514/375.000; 514/379.000; 514/438.000; 514/439.000; 514/461.000; 514/469.000
 IC [7]
 ICM: A61K031-44
 ICS: A61K031-425
 EXF 514/357; 514/375; 514/379; 514/438; 514/439; 514/461; 514/469
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 266 OF 325 USPATFULL on STN
 AN 2001:185264 USPATFULL
 TI Modified VEGF oligonucleotides for treatment of skin disorders
 IN Smyth, Adrienne P., Charlton, MA, United States
 Robinson, Gregory S., Acton, MA, United States
 PA Hybridon, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 6306829 B1 20011023
 AI US 1996-761708 19961206 (8)
 RLI Continuation-in-part of Ser. No. US 1996-629730, filed on 9 Apr 1996, now abandoned Continuation-in-part of Ser. No. US 1995-569926, filed on 8 Dec 1995, now patented, Pat. No. US 5641756

FS GRANTED
LN.CNT 1365
INCL INCLM: 514/044.000
INCLS: 536/024.500; 536/023.100; 536/023.500; 435/375.000; 435/455.000;
435/006.000
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/375.000; 435/455.000; 536/023.100; 536/023.500;
536/024.500
IC [7]
ICM: A61K031-70
ICS: C07H021-04; C12N005-00
EXF 514/44; 435/375; 435/61; 435/377; 435/455; 536/24.5; 536/23.1; 536/23.5;
536/24.31; 536/24.3; 536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 267 OF 325 USPATFULL on STN
AN 2001:176227 USPATFULL
TI Anti-cryptosporidium parvum preparations
IN Riggs, Michael W., Tucson, AZ, United States
Perryman, Lance E., Cary, NC, United States
PA North Carolina State University, Raleigh, NC, 27695 (U.S. corporation)
PI US 2001028882 A1 20011011
US 6730307 B2 20040504
AI US 2001-832888 A1 20010412 (9)
RLI Continuation of Ser. No. US 2000-557324, filed on 25 Apr 2000, PENDING
Continuation of Ser. No. US 1997-828943, filed on 27 Mar 1997, GRANTED,
Pat. No. US 6110463
PRAI US 1996-14410P 19960329 (60)
US 1996-21465P 19960710 (60)
DT Utility
FS APPLICATION
LN.CNT 1401
INCL INCLM: 424/151.100
NCL NCLM: 424/266.100
NCLS: 424/184.100; 424/265.100; 424/151.100; 424/269.100; 424/535.000;
424/807.000; 435/007.220; 435/329.000; 435/342.000; 435/947.000;
530/350.000; 530/388.600; 530/389.100; 530/395.000; 530/822.000;
530/832.000

IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 268 OF 325 USPATFULL on STN
AN 2001:173325 USPATFULL
TI Protein/(poly)peptide libraries
IN Knappik, Achim, Grafelfing, Germany, Federal Republic of
Pack, Peter, Munchen, Germany, Federal Republic of
Ge, Liming, Munchen, Germany, Federal Republic of
Moroney, Simon, Munchen, Germany, Federal Republic of
Pluckthun, Andreas, Zurich, Switzerland
PA Morphosys AG, Munich, Germany, Federal Republic of (non-U.S.
corporation)
PI US 6300064 B1 20011009
AI US 1998-25769 19980218 (9)
RLI Continuation of Ser. No. WO 1996-EP3647, filed on 19 Aug 1996
PRAI EP 1995-113021 19950818
DT Utility
FS GRANTED
LN.CNT 7901
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/320.100; 435/440.000; 435/455.000; 435/471.000;
435/328.000; 435/069.100; 435/069.300; 435/DIG.002; 435/DIG.003;
435/DIG.015; 435/DIG.017; 435/DIG.051; 536/023.100; 536/024.100;
514/044.000
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 435/069.300; 435/320.100; 435/328.000;
435/440.000; 435/455.000; 435/471.000; 435/DIG.002; 435/DIG.003;
435/DIG.015; 435/DIG.017; 435/DIG.051; 514/044.000; 536/023.100;
536/024.100
IC [7]
ICM: G01N033-53
ICS: A61K039-29
EXF 435/6; 435/71.1; 435/69.7; 435/69.1; 435/7.1; 435/320.1; 435/440;
435/455; 435/471; 435/328; 435/69.3; 435/DIG.2; 435/DIG.3; 435/DIG.15;
435/DIG.17; 435/DIG.51; 536/23.1; 536/24.1; 514/44

L3 ANSWER 269 OF 325 USPATFULL on STN
 AN 2001:150648 USPATFULL
 TI N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS
 COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE
 AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
 IN AUDIA, JAMES E., INDIANAPOLIS, IN, United States
 FOLMER, BEVERLY K., NEWARK, DE, United States
 JOHN, VARGHESE, SAN FRANCISCO, CA, United States
 LATIMER, LEE H., OAKLAND, CA, United States
 NISSEN, JEFFREY S., INDIANAPOLIS, IN, United States
 PORTER, WARREN J., INDIANAPOLIS, IN, United States
 THORSETT, EUGENE D., MOSS BEACH, CA, United States
 WU, JING, SAN MATEO, CA, United States
 PI US 2001020097 A1 20010906
 US 6495693 B2 20021217
 AI US 1999-280966 A1 19990330 (9)
 RLI Continuation of Ser. No. US 1997-976191, filed on 21 Nov 1997, GRANTED,
 Pat. No. US 6096782
 DT Utility
 FS APPLICATION
 LN.CNT 3729
 INCL INCLM: 546/162.000
 INCLS: 514/313.000; 514/367.000; 514/400.000; 514/419.000; 514/616.000;
 514/620.000; 514/506.000; 514/399.000; 560/039.000; 560/043.000;
 560/041.000; 564/156.000; 564/157.000; 564/163.000; 564/168.000;
 548/161.000; 548/178.000; 548/338.100; 548/495.000; 546/163.000
 NCL NCLM: 546/162.000
 NCLS: 546/163.000; 548/161.000; 548/178.000; 548/338.100; 548/495.000;
 560/039.000; 560/041.000; 560/043.000; 564/156.000; 564/157.000;
 564/163.000; 564/168.000
 IC [7]
 ICM: C07D277-82
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 270 OF 325 USPATFULL on STN
 AN 2001:142468 USPATFULL
 TI Hybridoma and anti-KC-4 humanized monoclonal ***antibody***
 IN do Couto, F. J. R., Pleasanton, CA, United States
 Ceriani, R. L., Lafayette, CA, United States
 Peterson, J. A., Lafayette, CA, United States
 PA Coulter Corporation, Miami, FL, United States (U.S. corporation)
 PI US 6281335 B1 20010828
 AI US 1993-134346 19931008 (8)
 DT Utility
 FS GRANTED
 LN.CNT 2039
 INCL INCLM: 530/388.850
 INCLS: 530/388.800; 424/009.100; 424/133.100; 436/518.000; 435/007.950;
 435/328.000
 NCL NCLM: 530/388.850
 NCLS: 424/009.100; 424/133.100; 435/007.950; 435/328.000; 436/518.000;
 530/388.800
 IC [7]
 ICM: C07K016-30
 ICS: A61K049-00; C12N005-16; G01N033-53
 EXF 530/388.8; 530/388.85; 424/9.1; 424/133.1; 436/518; 435/7.95; 435/328
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 271 OF 325 USPATFULL on STN
 AN 2001:121591 USPATFULL
 TI HIV-vaccines
 IN Katinger, Hermann, Vienna, Austria
 Buchacher, Andrea, Vienna, Austria
 Ernst, Wolfgang, Vienna, Austria
 Ballaun, Claudia, Vienna, Austria
 Purtscher, Martin, Vienna, Austria
 Trkola, Alexandra, Vienna, Austria
 Predl, Renate, Deutsch-Wagram, Austria
 Schmatz, Christine, Vienna, Austria
 Klima, Annelies, Vienna, Austria
 Steindl, Franz, Vienna, Austria
 Muster, Thomas, Vienna, Austria
 PA Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria
 (non-U.S. corporation)

AI US 1998-124900 19980730 (9)
 RLI Division of Ser. No. US 1995-478536, filed on 7 Jun 1995, now patented,
 Pat. No. US 5911989 Continuation-in-part of Ser. No. WO 1995-EP1481,
 filed on 19 Apr 1995
 DT Utility
 FS GRANTED
 LN.CNT 804
 INCL INCLM: 530/388.350
 INCLS: 424/192.100; 424/208.100; 435/005.000; 435/007.100; 435/339.100
 NCL NCLM: 530/388.350
 NCLS: 424/192.100; 424/208.100; 435/005.000; 435/007.100; 435/339.100
 IC [7]
 ICM: C07K016-00
 ICS: A61K039-00; A61K039-21; C12Q001-70; G01N033-53
 EXF 424/192.1; 424/208.1; 530/388.35; 435/5; 435/7.1; 435/339.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 272 OF 325 USPATFULL on STN
 AN 2001:116835 USPATFULL
 TI Method and device for detection of specific target cells in specialized
 or mixed cell populations and solutions containing mixed cell
 populations
 IN Fodstad, .O slashed.ystein, Oslo, Norway
 H.o slashed.if.o slashed.dt, Hanne Kleppe, Hvalstad, Norway
 Rye, Philip, Oslo, Norway
 PA Oystein Fodstad, Oslo, Norway (non-U.S. corporation)
 PI US 6265229 B1 20010724
 WO 9524648 19950914
 AI US 1996-704619 19961104 (8)
 WO 1995-NO52 19950310
 19961104 PCT 371 date
 19961104 PCT 102(e) date
 PRAI NO 1994-866 19940310
 DT Utility
 FS GRANTED
 LN.CNT 1694
 INCL INCLM: 436/526.000
 INCLS: 422/101.000; 435/007.200; 435/007.210; 435/007.230; 435/007.240;
 435/033.000; 435/395.000; 436/518.000; 436/525.000; 436/526.000;
 436/809.000
 NCL NCLM: 436/526.000
 NCLS: 422/101.000; 435/007.200; 435/007.210; 435/007.230; 435/007.240;
 435/033.000; 435/395.000; 436/518.000; 436/525.000; 436/809.000
 IC [7]
 ICM: G01N033-553
 ICS: B01L011-00
 EXF 422/101; 435/7.1; 435/7.2-7.32; 435/29; 435/30; 435/33; 435/383;
 435/395; 435/401; 435/975; 436/518; 436/525; 436/526; 436/808; 436/809
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 273 OF 325 USPATFULL on STN
 AN 2001:116789 USPATFULL
 TI Direct molecular cloning of foreign genes into poxviruses and methods
 for the preparation of recombinant proteins
 IN Dorner, Friedrich, Vienna, Austria
 Scheifflinger, Friedrich, Orth/Donau, Austria
 Falkner, Falko Gunter, Mannsdorf, Austria
 Pfleiderer, Michael, Breitstetten, Austria
 PA Baxter Aktiengesellschaft, Vienna, Australia (non-U.S. corporation)
 PI US 6265183 B1 20010724
 AI US 1994-358928 19941219 (8)
 RLI Continuation-in-part of Ser. No. US 1992-914738, filed on 20 Jul 1992,
 now abandoned Continuation-in-part of Ser. No. US 1991-750080, filed on
 26 Aug 1991, now patented, Pat. No. US 5445953
 DT Utility
 FS GRANTED
 LN.CNT 5471
 INCL INCLM: 435/069.100
 INCLS: 435/320.100; 424/232.100; 424/199.100; 424/208.100
 NCL NCLM: 435/069.100
 NCLS: 424/199.100; 424/208.100; 424/232.100; 435/320.100
 IC [7]
 ICM: C12P021-06
 ICS: C12N015-00; A61K039-275
 EXF 435/67.1; 435/70.1; 435/71.1; 435/172.3; 424/188.1; 424/208.1

L3 ANSWER 274 OF 325 USPATFULL on STN
 AN 2001:112566 USPATFULL
 TI N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
 IN Wu, Jing, San Mateo, CA, United States
 Tung, Jay S., Belmont, CA, United States
 Nissen, Jeffrey S., Indianapolis, IN, United States
 Mabry, Thomas E., Indianapolis, IN, United States
 Latimer, Lee H., Oakland, CA, United States
 Eid, Clark N., Cheshire, CT, United States
 Audia, James E., Indianapolis, IN, United States
 PA Elan Pharmaceuticals, Inc., S. San Francisco, CA, United States (U.S. corporation)
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6262302 B1 20010717
 AI US 1999-398211 19990917 (9)
 RLI Continuation of Ser. No. US 1997-976295, filed on 21 Nov 1997, now patented, Pat. No. US 6153652
 PRAI US 1996-98551P 19961122 (60)
 US 1997-113671P 19970228 (60)
 DT Utility
 FS GRANTED
 LN.CNT 4050
 INCL INCLM: 564/152.000
 INCLS: 564/155.000; 564/158.000; 564/168.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 549/303.000; 549/304.000; 548/471.000; 548/475.000; 546/309.000; 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000; 514/535.000; 514/539.000; 514/619.000
 NCL NCLM: 564/152.000
 NCLS: 546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/155.000; 564/158.000; 564/168.000
 IC [7]
 ICM: C07C229-38
 ICS: C07C233-64; C07D307-00; C07D211-00; C07D213-00
 EXF 560/43; 560/45; 560/47; 560/39; 560/41; 560/42; 514/349; 514/352; 514/357; 514/417; 514/470; 514/535; 514/539; 514/619; 564/152; 564/168; 564/155; 564/158; 549/303; 549/304; 548/471; 548/475; 546/309
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 275 OF 325 USPATFULL on STN
 AN 2001:59667 USPATFULL
 TI .beta.-secretase ***antibody***
 IN Chrysler, Susanna M. S., San Bruno, CA, United States
 Sinha, Sukanto, San Francisco, CA, United States
 Keim, Pamela S., San Mateo, CA, United States
 Anderson, John P., San Francisco, CA, United States
 Tan, Hua, Daly City, CA, United States
 McConlogue, Lisa Clair, San Francisco, CA, United States
 PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 6221645 B1 20010424
 AI US 1996-660531 19960607 (8)
 RLI Continuation-in-part of Ser. No. US 1995-480498, filed on 7 Jun 1995, now patented, Pat. No. US 5744346
 DT Utility
 FS Granted
 LN.CNT 1908
 INCL INCLM: 435/226.000
 INCLS: 435/212.000; 435/219.000; 530/387.100; 530/388.100; 530/388.150; 530/388.260
 NCL NCLM: 435/226.000
 NCLS: 435/212.000; 435/219.000; 530/387.100; 530/388.100; 530/388.150; 530/388.260
 IC [7]
 ICM: C07K016-00
 EXF 435/226; 435/219; 435/212; 530/387.1; 530/388.26; 530/388.1; 530/388.15
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 276 OF 325 USPATFULL on STN
 AN 2001:51568 USPATFULL
 TI Hepatocyte growth factor receptor antagonists and uses thereof
 IN Schwall, Ralph H., Pacifica, CA, United States

PA Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 6214344 B1 20010410

AI US 1998-6776 19980114 (9)

RLI Continuation of Ser. No. US 1995-459849, filed on 2 Jun 1995, now abandoned

DT Utility

FS Granted

LN.CNT 1428

INCL INCLM: 424/174.100
INCLS: 424/130.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100; 424/155.100; 424/172.100; 530/387.700; 530/388.220; 530/388.800; 530/388.850; 530/389.700

NCL NCLM: 424/174.100
NCLS: 424/130.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100; 424/155.100; 424/172.100; 530/387.700; 530/388.220; 530/388.800; 530/388.850; 530/389.700

IC [7]
ICM: C07K016-28
ICS: C07K016-30; A61K039-395

EXF 424/138.1; 424/143.1; 424/152.1; 424/130.1; 424/141.1; 424/155.1; 424/172.1; 424/174.1; 530/388.8; 530/388.88; 530/389.7; 530/387.7; 530/388.22

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 277 OF 325 USPATFULL on STN

AN 2001:48108 USPATFULL

TI Compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis

IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Reel, Jon K., Carmel, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Folmer, Beverly K., Newark, DE, United States
Droste, James J., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States

PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IL, United States (U.S. corporation)

PI US 6211235 B1 20010403

AI US 1998-164448 19980930 (9)

RLI Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997

PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-98558P 19970228 (60)

DT Utility

FS Granted

LN.CNT 14056

INCL INCLM: 514/534.000
INCLS: 574/619.000; 560/041.000; 560/040.000; 564/163.000

NCL NCLM: 514/534.000
NCLS: 514/019.000; 514/619.000; 544/162.000; 546/233.000; 546/336.000; 548/479.000; 548/496.000; 560/040.000; 560/041.000; 564/163.000

IC [7]
ICM: A01N037-12
ICS: C07C229-00; C07C233-00

EXF 514/534; 514/619; 564/163; 560/40; 560/41

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 278 OF 325 USPATFULL on STN

AN 2001:44268 USPATFULL

TI Compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis

IN Audia, James E., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Droste, James J., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
Huffman, George W., Carmel, IN, United States
John, Varghese, San Francisco, CA, United States

Mabry, Thomas E., Indianapolis, IN, United States
 Nissen, Jeffrey S., Indianapolis, IN, United States
 Porter, Warren J., Indianapolis, IN, United States
 Reel, Jon K., Carmel, IN, United States
 Thorsett, Eugene D., Moss Beach, CA, United States
 Tung, Jay S., Belmont, CA, United States
 Wu, Jing, San Mateo, CA, United States
 PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6207710 B1 20010327
 AI US 1998-164385 19980930 (9)
 RLI Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997
 PRAI US 1996-108166P 19961122 (60)
 US 1997-64859P 19970228 (60)
 US 1997-108161P 19970228 (60)
 US 1997-98558P 19970228 (60)
 DT Utility
 FS Granted
 LN.CNT 12026
 INCL INCLM: 514/551.000
 INCLS: 514/534.000; 514/563.000; 560/037.000; 560/038.000; 560/040.000;
 560/041.000; 654/123.000; 654/155.000
 NCL NCLM: 514/551.000
 NCLS: 514/534.000; 514/563.000; 530/331.000; 560/037.000; 560/038.000;
 560/040.000; 560/041.000; 564/123.000; 564/155.000
 IC [7]
 ICM: A01N037-12
 ICS: C07C229-00; C07C233-00
 EXF 514/551; 514/534; 514/563; 560/37; 560/38; 560/40; 560/41; 564/123;
 564/155
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 279 OF 325 USPATFULL on STN
 AN 2001:43710 USPATFULL
 TI Hepatocyte growth factor receptor antagonists and uses thereof
 IN Schwall, Ralph H., Pacifica, CA, United States
 Taber, Kelly H., Hillsborough, CA, United States
 PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)
 PI US 6207152 B1 20010327
 WO 9638557 19961205
 AI US 1998-952235 19980217 (8)
 WO 1996-US8094 19960531
 19980217 PCT 371 date
 19980217 PCT 102(e) date
 RLI Continuation-in-part of Ser. No. US 1995-460368, filed on 2 Jun 1995,
 now patented, Pat. No. US 5686292
 DT Utility
 FS Granted
 LN.CNT 2855
 INCL INCLM: 424/130.100
 INCLS: 424/133.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100;
 424/155.100; 424/156.100; 424/174.100; 530/387.100; 530/387.300;
 530/388.220; 530/388.880; 530/388.850; 530/389.100; 530/389.700;
 435/007.100; 435/007.200; 435/007.210; 435/007.230
 NCL NCLM: 424/130.100
 NCLS: 424/133.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100;
 424/155.100; 424/156.100; 424/174.100; 435/007.100; 435/007.200;
 435/007.210; 435/007.230; 530/387.100; 530/387.300; 530/388.220;
 530/388.800; 530/388.850; 530/389.100; 530/389.700
 IC [7]
 ICM: C07K016-18
 ICS: C07K016-28; A61K039-395
 EXF 530/388.22; 530/387.1; 530/387.3; 530/388.88; 530/388.85; 530/389.1;
 530/389.7; 424/130.1; 424/133.1; 424/138.1; 424/141.1; 424/143.1;
 424/152.1; 424/155.1; 424/156.1; 424/174.1; 435/7.1; 435/7.2; 435/7.21;
 435/7.23
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 280 OF 325 USPATFULL on STN
 AN 2001:25931 USPATFULL
 TI Methods and compounds for inhibiting .beta.-amyloid peptide release
 and/or its synthesis
 IN Audia, James E., Indianapolis, IN, United States
 Britton, Thomas C., Carmel, IN, United States

Folmer, Beverly K., Newark, DE, United States
 Huffman, George W., Carmel, IN, United States
 Varghese, John, San Francisco, CA, United States
 Latimer, Lee H., Oakland, CA, United States
 Mabry, Thomas E., Indianapolis, IN, United States
 Nissen, Jeffrey S., Indianapolis, IN, United States
 Porter, Warren J., Indianapolis, IN, United States
 Reel, Jon K., Carmel, IN, United States
 Thorsett, Eugene D., Moss Beach, CA, United States
 Tung, Jay S., Belmont, CA, United States
 Wu, Jing, San Mateo, CA, United States
 Eid, Clark Norman, Cheshire, CT, United States
 Scott, William Leonard, Indianapolis, IN, United States
 PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6191166 B1 20010220
 AI US 1997-976289 19971121 (8)
 PRAI US 1996-108166P 19961122 (60)
 US 1997-64859P 19970228 (60)
 US 1997-108161P 19970228 (60)
 US 1997-698556P 19970228 (60)
 DT Utility
 FS Granted
 LN.CNT 12827
 INCL INCLM: 514/534.000
 INCLS: 514/535.000; 514/616.000; 514/619.000
 NCL NCLM: 514/534.000
 NCLS: 514/535.000; 514/616.000; 514/619.000
 IC [7]
 ICM: A01N037-12
 EXF 574/534; 574/535; 574/616; 574/619
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 281 OF 325 USPATFULL on STN
 AN 2001:18290 USPATFULL
 TI Method for detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
 IN Fodstad, .O slashed.ystein, Frits Kiers v. 28, N-0383 Oslo, Norway
 Kvalheim, Gunnar, .ang.sstubben 13, N-0381 Oslo, Norway
 PI US 6184043 B1 20010206
 AI US 1997-881393 19970624 (8)
 RLI Division of Ser. No. US 403844
 PRAI WO 1992-NO151 19920914
 DT Utility
 FS Granted
 LN.CNT 1107
 INCL INCLM: 436/526.000
 INCLS: 435/002.000; 435/007.100; 435/007.200; 435/007.230; 435/007.240; 435/007.250; 435/007.500; 435/007.800; 435/007.940; 435/040.000; 435/052.000; 435/174.000; 435/181.000; 435/961.000; 436/513.000; 436/518.000; 436/523.000; 436/532.000; 436/534.000; 436/538.000; 436/540.000; 436/824.000; 436/828.000
 NCL NCLM: 436/526.000
 NCLS: 435/002.000; 435/007.100; 435/007.200; 435/007.230; 435/007.240; 435/007.250; 435/007.500; 435/007.800; 435/007.940; 435/040.000; 435/052.000; 435/174.000; 435/181.000; 435/961.000; 436/513.000; 436/518.000; 436/523.000; 436/532.000; 436/534.000; 436/538.000; 436/540.000; 436/824.000; 436/828.000
 IC [7]
 ICM: G01N033-553
 EXF 435/2; 435/7.1; 435/7.2; 435/7.23; 435/7.24; 435/7.25; 435/7.5; 435/7.8; 435/7.94; 435/40.52; 435/174; 435/181; 435/961; 436/513; 436/518; 436/523; 436/526; 436/532; 436/534; 436/538; 436/540; 436/824; 436/828
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 282 OF 325 USPATFULL on STN
 AN 2001:8223 USPATFULL
 TI Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
 IN Mucke, Lennart, Foster City, CA, United States
 Wyss-Coray, Tony, Berkeley, CA, United States
 Masliah, Eliezer, Chula Vista, CA, United States
 PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

AI US 1997-947295 19971008 (8)
 DT Utility
 FS Granted
 LN.CNT 1697
 INCL INCLM: 800/012.000
 INCLS: 800/003.000; 800/018.000; 424/009.200
 NCL NCLM: 800/012.000
 NCLS: 424/009.200; 800/003.000; 800/018.000
 IC [7]
 ICM: A01K067-00
 ICS: A01K067-033; G01N033-00
 EXF 800/3; 800/8; 800/9; 800/12; 800/13; 800/18; 424/9.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 283 OF 325 USPATFULL on STN
 AN 2001:4473 USPATFULL
 TI Monoclonal ***antibodies*** reactive with defined regions of the T
 cell antigen receptor
 IN Skibbens, Robert V., Brookline, MA, United States
 Henry, Larry D., Brookline, MA, United States
 Rittershaus, Charles W., Malden, MA, United States
 Tian, Wei-Tao, Allston, MA, United States
 Ip, Stephen H., Sudbury, MA, United States
 Kung, Patrick C., Lexington, MA, United States
 Snider, Mary Ellen, Ledyard, CT, United States
 Ko, Jone-Long, Cambridge, MA, United States
 Wood, Nancy L., Cambridge, MA, United States
 PA Astra AB, Sodertalje, Sweden (non-U.S. corporation)
 PI US 6171799 B1 20010109
 AI US 1995-450275 19950525 (8)
 RLI Division of Ser. No. US 1993-83408, filed on 25 Jun 1993, now patented,
 Pat. No. US 6048526 Division of Ser. No. US 1989-449692, filed on 11 Dec
 1989, now patented, Pat. No. US 5223426 Continuation-in-part of Ser. No.
 US 1989-343189, filed on 25 Apr 1989, now abandoned Continuation-in-part
 of Ser. No. US 1988-284511, filed on 15 Dec 1988, now abandoned
 DT Patent
 FS Granted
 LN.CNT 3046
 INCL INCLM: 435/007.100
 INCLS: 436/503.000; 436/548.000; 436/063.000; 436/804.000; 436/811.000
 NCL NCLM: 435/007.100
 NCLS: 436/063.000; 436/503.000; 436/548.000; 436/804.000; 436/811.000
 IC [7]
 ICM: G01N033-53
 EXF 424/144.1; 530/388.22; 530/388.75; 435/240.27; 435/172.3; 435/70.21;
 435/7.1; 436/503; 436/548; 436/63; 436/804; 436/811
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 284 OF 325 USPATFULL on STN
 AN 2000:161048 USPATFULL
 TI N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical
 compositions comprising same, and methods for inhibiting .beta.-amyloid
 peptide release and/or its synthesis by use of such compounds
 IN Wu, Jing, San Mateo, CA, United States
 Tung, Jay S., Belmont, CA, United States
 Nissen, Jeffrey S., Indianapolis, IN, United States
 Mabry, Thomas E., Indianapolis, IN, United States
 Latimer, Lee H., Oakland, CA, United States
 Eid, Clark N., Cheshire, CT, United States
 Audia, James E., Indianapolis, IN, United States
 PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6153652 20001128
 AI US 1997-976295 19971121 (8)
 PRAI US 1996-1551P 19961122 (60)
 US 1997-113671P 19970228 (60)
 DT Utility
 FS Granted
 LN.CNT 3652
 INCL INCLM: 514/619.000
 INCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000;
 514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000;
 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000;
 560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000

NCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000;
514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000;
549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000;
560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000

IC [7]

ICM: A01N037-18

ICS: A01N037-12; A01N037-44; A61K031-165

EXF 564/155; 564/158; 564/152; 564/168; 546/309; 548/471; 548/475; 549/303;
549/304; 560/39; 560/41; 560/42; 560/43; 514/349; 514/352; 514/357;
514/417; 514/470; 514/535; 514/539; 514/619

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 285 OF 325 USPATFULL on STN

AN 2000:121544 USPATFULL

TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
comprising same, and methods for use

IN Wu, Jing, San Mateo, CA, United States

Thorsett, Eugene D., Moss Beach, CA, United States

Nissen, Jeffrey S., Indianapolis, IN, United States

Mabry, Thomas E., Indianapolis, IN, United States

Latimer, Lee H., Oakland, CA, United States

John, Varghese, San Francisco, CA, United States

Fang, Lawrence Y., Foster City, CA, United States

Audia, James E., Indianapolis, IN, United States

PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
corporation)

Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)

PI US 6117901 20000912

AI US 1997-976179 19971121 (8)

PRAI US 1996-98551P 19961122 (60)

US 1996-19790P 19960614 (60)

DT Utility

FS Granted

LN.CNT 3321

INCL INCLM: 514/513.000

NCL NCLM: 514/513.000

IC [7]

ICM: A61K031-16

EXF 514/513

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 286 OF 325 USPATFULL on STN

AN 2000:113492 USPATFULL

TI Anti-Cryptosporidium parvum preparations

IN Riggs, Michael W., Tucson, AZ, United States

Perryman, Lance E., Cary, NC, United States

PA North Carolina State University, Raleigh, NC, United States (U.S.
corporation)

The Arizona Board of Regents, Tucson, AZ, United States (U.S.
corporation)

PI US 6110463 20000829

AI US 1997-828943 19970327 (8)

PRAI US 1996-14410P 19960329 (60)

US 1996-21465P 19960710 (60)

DT Utility

FS Granted

LN.CNT 1611

INCL INCLM: 424/151.100

INCLS: 424/535.000; 424/807.000; 435/007.220; 435/070.210; 435/172.200;
435/342.000; 530/388.600; 530/822.000; 530/832.000

NCL NCLM: 424/151.100

NCLS: 424/535.000; 424/807.000; 435/007.220; 435/070.210; 435/342.000;
530/388.600; 530/822.000; 530/832.000

IC [7]

ICM: A61K039-395

ICS: A61K035-20; C07K016-20; C12N005-20

EXF 424/130.1; 424/151.1; 424/265.1; 424/266.1; 424/269.1; 424/535; 424/807;
435/7.22; 435/70.21; 435/172.2; 435/947; 435/342; 530/388.6; 530/389.1;
530/822; 530/832; 935/104; 935/107; 935/108

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 287 OF 325 USPATFULL on STN

AN 2000:105429 USPATFULL

TI Methods for generating immune responses employing modified vaccinia of
fowlpox viruses

Scheifflinger, Friedrich, Orth/Donau, Austria
Falkner, Falko Gunter, Mannsdorf, Austria
Pfleiderer, Michael, Breitstetten, Austria
PA Immuno AG., Vienna, Austria (non-U.S. corporation)
PI US 6103244 20000815
AI US 1996-651472 19960522 (8)
RLI Division of Ser. No. US 1994-358928, filed on 19 Dec 1994 which is a
continuation-in-part of Ser. No. US 1992-914738, filed on 20 Jul 1992,
now abandoned which is a continuation-in-part of Ser. No. US
1991-750080, filed on 26 Aug 1991, now patented, Pat. No. US 5445953
DT Utility
FS Granted
LN.CNT 7208
INCL INCLM: 424/199.100
INCLS: 424/188.100; 424/232.100
NCL NCLM: 424/199.100
NCLS: 424/188.100; 424/232.100
IC [7]
ICM: A61K039-12
ICS: A61K039-21; A61K039-275
EXF 435/320.1; 424/184.1; 424/199.1; 424/204.1; 424/207.1; 424/208.1;
424/232.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 288 OF 325 USPATFULL on STN
AN 2000:101874 USPATFULL
TI Hepatocyte growth factor receptor agonists and uses thereof
IN Hillan, Kenneth J., San Francisco, CA, United States
Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly H., Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6099841 20000808
AI US 1997-884669 19970627 (8)
PRAI US 1996-21215P 19960703 (60)
DT Utility
FS Granted
LN.CNT 1908
INCL INCLM: 424/143.100
INCLS: 424/134.100; 424/135.100; 424/136.100; 424/138.100; 435/334.000;
530/387.700; 530/387.300; 530/388.220; 530/389.100; 530/389.200;
530/389.700; 530/350.000
NCL NCLM: 424/143.100
NCLS: 424/134.100; 424/135.100; 424/136.100; 424/138.100; 435/334.000;
530/350.000; 530/387.300; 530/387.700; 530/388.220; 530/389.100;
530/389.200; 530/389.700
IC [7]
ICM: C07K016-28
ICS: C12N015-06; A61K039-395
EXF 530/388.22; 530/389.1; 530/387.3; 530/350; 530/387.7; 530/389.7;
530/389.2; 435/334; 435/7.1; 514/2; 424/143.1; 424/134.1; 424/135.1;
424/136.1; 424/138.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 289 OF 325 USPATFULL on STN
AN 2000:98466 USPATFULL
TI N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions
comprising same and methods for inhibiting .beta.-amyloid peptide
release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Wu, Jing, San Mateo, CA, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6096782 20000801
AI US 1997-976191 19971121 (8)
PRAI US 1996-77175P 19961122 (60)
DT Utility
FS Granted

INCL INCLM: 514/506.000
INCLS: 514/399.000; 548/335.500; 560/041.000
NCL NCLM: 514/506.000
NCLS: 514/399.000; 548/335.500; 560/041.000
IC [7]
ICM: A01N037-20
ICS: A01N043-50; C07C229-24; C07D233-61
EXF 560/41; 514/506; 514/399; 548/335.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 290 OF 325 USPATFULL on STN
AN 2000:43767 USPATFULL
TI Monoclonal ***antibodies*** reactive with defined regions of the T
cell antigen receptor
IN Skibbens, Robert V., Chapel Hill, NC, United States
Henry, Larry D., Brookline, MA, United States
Rittershaus, Charles W., Malden, MA, United States
Tian, Wei-Tao, Allston, MA, United States
Ip, Stephen H., Sudbury, MA, United States
Kung, Patrick C., Lexington, MA, United States
Snider, Mary Ellen, Ledyard, CT, United States
Ko, Jone-Long, Cambridge, MA, United States
Wood, Nancy L., Cambridge, MA, United States
PA Astra AB, United States (non-U.S. corporation)
PI US 6048526 20000411
AI US 1993-83408 19930625 (8)
RLI Division of Ser. No. US 1989-449692, filed on 11 Dec 1989, now patented,
Pat. No. US 5223426 which is a continuation-in-part of Ser. No. US
1989-343189, filed on 25 Apr 1989, now abandoned which is a
continuation-in-part of Ser. No. US 1988-284511, filed on 15 Dec 1988,
now abandoned
DT Utility
FS Granted
LN.CNT 3237
INCL INCLM: 424/144.100
INCLS: 530/388.750
NCL NCLM: 424/144.100
NCLS: 530/388.750
IC [7]
ICM: A61K039-395
ICS: C12P021-08
EXF 424/144.1; 424/144.4; 530/388.22; 530/388.75; 435/240.27; 435/172.3;
435/70.21; 435/7.1; 435/7.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 291 OF 325 USPATFULL on STN
AN 2000:34194 USPATFULL
TI Peptides derived from immunodominant epitopes of myelin basic protein
IN Weiner, Howard L., Brookline, MA, United States
Hafler, David A., West Newton, MA, United States
PA Autoimmune, Inc., Lexington, MA, United States (U.S. corporation)
PI US 6039947 20000321
AI US 1994-297395 19940811 (8)
RLI Continuation of Ser. No. US 1993-59189, filed on 6 May 1993, now
abandoned which is a continuation of Ser. No. US 1990-502559, filed on
30 Mar 1990, now abandoned which is a continuation-in-part of Ser. No.
WO 1988-US2139, filed on 24 Jun 1988, now abandoned And a
continuation-in-part of Ser. No. US 1987-65734, filed on 24 Jun 1987,
now abandoned
DT Utility
FS Granted
LN.CNT 1507
INCL INCLM: 424/184.100
INCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000;
530/326.000
NCL NCLM: 424/184.100
NCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000;
530/326.000
IC [7]
ICM: A61K039-00
ICS: A61K038-17; C07K007-08; C07K014-47
EXF 424/184.1; 530/300; 530/350; 530/324; 530/325; 530/326; 514/12; 514/13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 292 OF 325 USPATFULL on STN

TI Protein sequences of serrate gene products
 IN Ish-Horowicz, David, Oxford, United Kingdom
 Henrique, Domingos Manuel Pinto, Oxford, United Kingdom
 Lewis, Julian Hart, Oxford, United Kingdom
 Myat, Anna Mary, Oxford, United Kingdom
 Fleming, Robert J., Rochester, NY, United States
 Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
 Mann, Robert S., Hamden, CT, United States
 Gray, Grace E., New Haven, CT, United States
 PA Imperial Cancer Research Technology, Ltd., London, United Kingdom
 (non-U.S. corporation)
 Yale University, New Haven, CT, United States (U.S. corporation)
 PI US 6004924 19991221
 AI US 1996-611729 19960306 (8)
 RLI Continuation-in-part of Ser. No. US 1995-400159, filed on 7 Mar 1995
 which is a continuation-in-part of Ser. No. US 1994-255102, filed on 7
 Jun 1994, now abandoned which is a continuation of Ser. No. US
 1993-121979, filed on 14 Sep 1993, now abandoned which is a continuation
 of Ser. No. US 1991-808458, filed on 11 Dec 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 6539
 INCL INCLM: 514/002.000
 INCLS: 514/013.000; 514/015.000; 530/300.000; 530/326.000; 530/328.000;
 530/350.000
 NCL NCLM: 514/002.000
 NCLS: 514/013.000; 514/015.000; 530/300.000; 530/326.000; 530/328.000;
 530/350.000
 IC [6]
 ICM: A01N037-18
 ICS: A61K037-00; C07K014-00
 EXF 530/300; 530/326; 530/328; 530/350; 514/15; 514/13; 514/2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 293 OF 325 USPATFULL on STN
 AN 1999:141299 USPATFULL
 TI Monoclonal ***antibodies*** reactive with defined regions of the T
 cell antigen receptor
 IN Skibbens, Robert V., Chapel Hill, NC, United States
 Henry, Larry D., Brookline, MA, United States
 Rittershaus, Charles W., Malden, MA, United States
 Tian, Wei-Tao, Allston, MA, United States
 Ip, Stephen H., Sudbury, MA, United States
 Kung, Patrick C., Lexington, MA, United States
 Snider, Mary Ellen, Ledyard, CT, United States
 Ko, Jone-Long, Cambridge, MA, United States
 Wood, Nancy L., Cambridge, MA, United States
 PA Astra AB, Sodertalje, Sweden (non-U.S. corporation)
 PI US 5980892 19991109
 AI US 1995-450425 19950525 (8)
 RLI Division of Ser. No. US 1993-83408, filed on 25 Jun 1993 which is a
 division of Ser. No. US 1989-449692, filed on 11 Dec 1989, now patented,
 Pat. No. US 5223426 which is a continuation-in-part of Ser. No. US
 1989-343189, filed on 25 Apr 1989, now abandoned which is a
 continuation-in-part of Ser. No. US 1988-284511, filed on 15 Dec 1988,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 3139
 INCL INCLM: 424/144.100
 INCLS: 424/154.100; 435/007.100; 435/007.240
 NCL NCLM: 424/144.100
 NCLS: 424/154.100; 435/007.100; 435/007.240
 IC [6]
 ICM: A61K039-395
 EXF 435/7.1; 435/7.24; 424/144.1; 424/154.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 294 OF 325 USPATFULL on STN
 AN 1999:136967 USPATFULL
 TI Monoclonal ***antibodies*** which identify the glycoprotein carrying
 the CA 125 epitope
 IN O'Brien, Timothy J., Little Rock, AR, United States
 PA The Board of Trustees of The University of Arkansas, Little Rock, AR,
 United States (U.S. corporation)

AI US 1996-626675 19960402 (8)
RLI Continuation of Ser. No. US 1994-343357, filed on 22 Nov 1994, now
abandoned which is a continuation of Ser. No. US 1991-808219, filed on
16 Dec 1991
DT Utility
FS Granted
LN.CNT 595
INCL INCLM: 435/007.230
INCLS: 435/007.900; 435/007.920; 436/063.000; 436/064.000; 530/388.800
NCL NCLM: 435/007.230
NCLS: 435/007.900; 435/007.920; 436/063.000; 436/064.000; 530/388.800
IC [6]
ICM: G01N033-574
ICS: G01N033-53; G01N033-542; G01N033-48
EXF 530/387.7; 530/388.8; 436/63; 436/64; 435/7.23; 435/7.9; 435/7.92;
435/7.94
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 295 OF 325 USPATFULL on STN
AN 1999:136683 USPATFULL
TI Monoclonal ***antibodies*** reactive with defined regions of the T
cell antigen receptor
IN Skibbens, Robert V., Chapel Hill, NC, United States
Henry, Larry D., Brookline, MA, United States
Rittershaus, Charles W., Malden, MA, United States
Tian, Wei-Tao, Allston, MA, United States
Ip, Stephen H., Sudbury, MA, United States
Kung, Patrick C., Lexington, MA, United States
Snider, Mary Ellen, Ledyard, CT, United States
Ko, Jone-Long, Cambridge, MA, United States
Wood, Nancy L., Cambridge, MA, United States
PA Astra AB, Sodertalje, Sweden (non-U.S. corporation)
PI US 5976533 19991102
AI US 1995-449890 19950525 (8)
RLI Division of Ser. No. US 1993-83408, filed on 25 Jun 1993 which is a
division of Ser. No. US 1989-449692, filed on 11 Dec 1989, now patented,
Pat. No. US 5223426 which is a continuation-in-part of Ser. No. US
1989-343189, filed on 25 Apr 1989, now abandoned which is a
continuation-in-part of Ser. No. US 1988-284511, filed on 15 Dec 1988,
now abandoned
DT Utility
FS Granted
LN.CNT 3019
INCL INCLM: 424/144.100
INCLS: 435/070.210; 530/388.220; 530/388.750
NCL NCLM: 424/144.100
NCLS: 435/070.210; 530/388.220; 530/388.750
IC [6]
ICM: A61K039-395
ICS: C12N005-16
EXF 424/144.1; 530/388.22; 530/388.75; 435/240.27; 435/172.3; 435/70.21;
435/325; 435/372.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 296 OF 325 USPATFULL on STN
AN 1999:124950 USPATFULL
TI N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions
comprising same, and methods for inhibiting .beta.-amyloid peptide
release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Whitesitt, Celia A., Greenwood, IN, United States
PA Athena Neurosciences, Inc., United States (U.S. corporation)
PI US 5965614 19991012
AI US 1997-975977 19971121 (8)
PRAI US 1996-104593P 19961122 (60)
DT Utility
FS Granted
LN.CNT 2939
INCL INCLM: 514/538.000

NCL NCLM: 514/538.000
NCLS: 514/508.000; 560/035.000; 560/043.000
IC [6]
ICM: A01N037-12
ICS: A01N037-52; C07C229-28
EXF 514/538; 514/508; 560/43; 560/35
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 297 OF 325 USPATFULL on STN
AN 1999:99548 USPATFULL
TI Assays for detecting .beta.-secretase
IN Anderson, John P., San Francisco, CA, United States
Jacobson-Croak, Kirsten L., San Bruno, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5942400 19990824
AI US 1996-659984 19960607 (8)
RLI Continuation-in-part of Ser. No. US 1995-485152, filed on 7 Jun 1995 And
a continuation-in-part of Ser. No. US 1995-480498, filed on 7 Jun 1995,
now patented, Pat. No. US 5744346
DT Utility
FS Granted
LN.CNT 2312
INCL INCLM: 435/007.100
INCLS: 435/023.000; 435/961.000; 436/063.000; 436/161.000
NCL NCLM: 435/007.100
NCLS: 435/023.000; 435/961.000; 436/063.000; 436/161.000
IC [6]
ICM: G01N033-53
EXF 435/7.1; 435/7.2; 435/23; 435/325; 435/961; 436/515; 436/516; 436/161;
436/63
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 298 OF 325 USPATFULL on STN
AN 1999:67010 USPATFULL
TI HIV-vaccines
IN Katinger, Hermann, Vienna, Austria
Buchacher, Andrea, Vienna, Austria
Ernst, Wolfgang, Vienna, Austria
Ballaun, Claudia, Vienna, Austria
Purtscher, Martin, Vienna, Austria
Trkola, Alexandra, Vienna, Austria
Predl, Renate, Deutsch-Wagram, Austria
Schmatz, Christine, Vienna, Austria
Klima, Annelies, Vienna, Austria
Steindl, Franz, Vienna, Austria
Muster, Thomas, Vienna, Austria
PA Polynum Scientific Immunbiologische Forschung GmbH, Vienna, Austria
(non-U.S. corporation)
PI US 5911989 19990615
AI US 1995-478536 19950607 (8)
RLI Continuation-in-part of Ser. No. WO 1995-EP1481, filed on 19 Apr 1995
DT Utility
FS Granted
LN.CNT 857
INCL INCLM: 424/160.100
INCLS: 530/388.350; 424/208.100; 435/005.000
NCL NCLM: 424/160.100
NCLS: 424/208.100; 435/005.000; 530/388.350
IC [6]
ICM: A61K039-42
ICS: A61K039-21; C12Q001-70; C07K016-00
EXF 424/160.1; 424/208.1; 530/388.35; 435/5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 299 OF 325 USPATFULL on STN
AN 1999:18950 USPATFULL
TI Nucleotide and protein sequences of the serrate gene and methods based
thereon
IN Ish-Horowicz, David, Oxford, England
Henrique, Domingos Manuel Pinto, Oxford, England
Lewis, Julian Hart, Oxford, England
Myat, Anna Mary, Oxford, England
Fleming, Robert J., Rochester, NY, United States

Mann, Robert S., Hamden, CT, United States
 Gray, Grace E., New Haven, CT, United States
 PA Imperial Cancer Research Technology, Ltd., London, England (non-U.S. corporation)
 Yale University, Haven, CT, United States (U.S. corporation)
 PI US 5869282 19990209
 AI US 1995-400159 19950307 (8)
 RLI Continuation-in-part of Ser. No. US 1994-255102, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. US 1993-121979, filed on 14 Sep 1993, now abandoned which is a continuation of Ser. No. US 1991-808458, filed on 11 Dec 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 5411
 INCL INCLM: 435/069.100
 INCLS: 435/325.000; 435/252.300; 435/320.100; 536/023.100; 536/024.300; 530/300.000; 530/350.000
 NCL NCLM: 435/069.100
 NCLS: 435/252.300; 435/320.100; 435/325.000; 530/300.000; 530/350.000; 536/023.100; 536/024.300
 IC [6]
 ICM: C12P021-00
 ICS: C12N015-00; C07H017-00; C07K014-00
 EXF 536/23.1; 536/24.3; 435/69.1; 435/320.1; 435/240.1; 435/252.3; 435/325; 530/300; 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 300 OF 325 USPATFULL on STN
 AN 1998:135175 USPATFULL
 TI Human monoclonal anti-HIV-I- ***antibodies***
 IN Katinger, Hermann, Heiligenstadterstrasse 131-139, A-1190 Vienna, Austria
 Jungbauer, Alois, Vienna, Austria
 Steindl, Franz, Vienna, Austria
 Buchacher, Andrea, Vienna, Austria
 PA Katinger, Hermann, Austria (non-U.S. individual)
 PI US 5831034 19981103
 AI US 1994-293842 19940822 (8)
 RLI Continuation of Ser. No. US 1991-693730, filed on 30 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1987-120489, filed on 13 Nov 1987, now abandoned
 DT Utility
 FS Granted
 LN.CNT 506
 INCL INCLM: 530/388.350
 INCLS: 435/005.000; 435/069.100; 530/413.000; 536/023.530; 536/024.200
 NCL NCLM: 530/388.350
 NCLS: 435/005.000; 435/069.100; 530/413.000; 536/023.530; 536/024.200
 IC [6]
 ICM: C07K016-00
 ICS: C12Q001-70; C12P021-06; A23J001-00
 EXF 435/5; 435/69.1; 536/23.53; 536/24.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 301 OF 325 USPATFULL on STN
 AN 1998:108026 USPATFULL
 TI Modified ***antibodies*** with human milk fat globule specificity
 IN do Couto, Fernando J. R., Pleasanton, CA, United States
 Ceriani, Roberto L., Lafayette, CA, United States
 Peterson, Jerry A., Lafayette, CA, United States
 PA Cancer Research Fund of Contra Costa, Walnut Creek, CA, United States (U.S. corporation)
 PI US 5804187 19980908
 AI US 1993-129930 19930930 (8)
 RLI Continuation-in-part of Ser. No. US 1992-977696, filed on 16 Nov 1992
 DT Utility
 FS Granted
 LN.CNT 5440
 INCL INCLM: 424/134.100
 INCLS: 424/133.100; 424/138.100; 435/007.230; 435/328.000; 435/330.000; 530/387.300; 530/387.700
 NCL NCLM: 424/134.100
 NCLS: 424/133.100; 424/138.100; 435/007.230; 435/328.000; 435/330.000; 530/387.300; 530/387.700
 IC [6]

ICS: A61K039-40; A61K039-42; G01N033-574
 EXF 530/387.3; 530/388.85; 424/133.1; 424/134.1; 424/156.1; 424/1.11;
 435/240.27
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 302 OF 325 USPATFULL on STN
 AN 1998:95622 USPATFULL
 TI Polynucleotides encoding modified ***antibodies*** with human milk
 fat globule specificity
 IN do Couto, Fernando J. R., Pleasanton, CA, United States
 Ceriani, Roberto L., Lafayette, CA, United States
 Peterson, Jerry A., Lafayette, CA, United States
 Padlan, Eduardo A., Kensington, MD, United States
 PA Cancer Research Fund of Contra Costa, Walnut Creek, CA, United States
 (U.S. corporation)
 PI US 5792852 19980811
 AI US 1992-977696 19921116 (7)
 DT Utility
 FS Granted
 LN.CNT 5011
 INCL INCLM: 536/023.530
 INCLS: 536/023.500; 530/387.300; 424/133.100; 424/134.100; 424/135.100
 NCL NCLM: 536/023.530
 NCLS: 424/133.100; 424/134.100; 424/135.100; 530/387.300; 536/023.500
 IC [6]
 ICM: C07H021-04
 ICS: C12P021-08; A61K039-695; A61K039-40
 EXF 530/387.3; 530/387.7; 530/388.15; 530/388.8; 424/133.1; 424/134.1;
 424/135.1; 424/136.1; 424/138.1; 424/155.1; 536/23.5; 536/23.53
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 303 OF 325 USPATFULL on STN
 AN 1998:68799 USPATFULL
 TI Kit containing d-arabinitol dehydrogenase and NAD+ for determining
 d-arabinitol
 IN Miyada, Charles Garrett, Mountainview, CA, United States
 Switchenko, Arthur C., Palo Alto, CA, United States
 Quong, Melanie W., La Jolla, CA, United States
 Wong, Man-Ying Laurie, Fremont, CA, United States
 PA Syntex (USA) Inc., San Jose, CA, United States (U.S. corporation)
 PI US 5766874 19980616
 AI US 1995-479069 19950607 (8)
 RLI Division of Ser. No. US 1995-400417, filed on 3 Mar 1995, now patented,
 Pat. No. US 5451517 which is a continuation of Ser. No. US 1994-184764,
 filed on 21 Jan 1994, now abandoned which is a continuation of Ser. No.
 US 1991-731218, filed on 12 Jul 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1094
 INCL INCLM: 435/026.000
 INCLS: 435/190.000; 435/255.400; 435/810.000; 435/921.000; 435/924.000
 NCL NCLM: 435/026.000
 NCLS: 435/190.000; 435/255.400; 435/810.000; 435/921.000; 435/924.000
 IC [6]
 ICM: C12Q001-32
 ICS: C12N009-04; C12N001-16
 EXF 435/190; 435/255.4; 435/921; 435/924; 435/810; 435/26
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 304 OF 325 USPATFULL on STN
 AN 1998:45086 USPATFULL
 TI .beta.-secretase
 IN Chrysler, Susanna M. S., San Bruno, CA, United States
 Sinha, Sukanto, San Francisco, CA, United States
 Keim, Pamela S., San Mateo, CA, United States
 Anderson, John P., San Francisco, CA, United States
 PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 PI US 5744346 19980428
 AI US 1995-480498 19950607 (8)
 DT Utility
 FS Granted
 LN.CNT 689
 INCL INCLM: 435/226.000
 INCLS: 435/219.000; 435/212.000

IC NCLS: 435/212.000; 435/219.000
[6]
ICM: C12N009-64
ICS: C12N009-50; C12N006-48
EXF 435/226; 435/219; 435/212
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 305 OF 325 USPATFULL on STN
AN 1998:33788 USPATFULL
TI Complexes of nucleic acid and polymer, their process of preparation and
their use for the transfection of cells
IN Midoux, Patrick, Orleans, France
Erbacher, Patrick, Orleans, France
Roche-Degremont, Annie-Claude, Sandillon, France
Monsigny, Michel, Saint-Cyr-En-Val, France
PA I.D.M. Immuno-Designed Molecules, France (non-U.S. corporation)
PI US 5733762 19980331
AI US 1996-741678 19961031 (8)
RLI Continuation-in-part of Ser. No. US 1995-505068, filed on 21 Jul 1995,
now abandoned which is a continuation-in-part of Ser. No. US
1994-288681, filed on 10 Aug 1994, now patented, Pat. No. US 5595897,
issued on 21 Jan 1997
PRAI FR 1994-5174 19940428
DT Utility
FS Granted
LN.CNT 2545
INCL INCLM: 435/172.300
INCLS: 435/325.000; 514/044.000; 530/300.000; 530/345.000; 530/350.000;
530/395.000; 530/402.000; 536/023.200; 536/023.500; 536/024.500;
536/023.700
NCL NCLM: 435/458.000
NCLS: 435/325.000; 514/044.000; 530/300.000; 530/345.000; 530/350.000;
530/395.000; 530/402.000; 536/023.200; 536/023.500; 536/023.700;
536/024.500

IC [6]
ICM: C07K001-00
ICS: C07K001-107; C12N015-00; C12N015-88
EXF 435/6; 435/69.1; 435/91.1; 435/172.3; 435/172.1; 435/240.2; 435/183;
435/189; 435/193; 435/194; 435/207; 435/325; 435/375; 435/91.3;
435/91.31; 435/320.1; 530/345; 530/395; 530/402; 530/300; 530/350;
536/23.1; 536/23.2; 536/23.5; 536/23.7; 536/23.72; 536/23.74; 536/24.5;
514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 306 OF 325 USPATFULL on STN
AN 97:120717 USPATFULL
TI Immunogenic peptide antigen corresponding to plasmodium vivax
circumsporozoite protein
IN Arnot, David E., New York, NY, United States
Enea, Vincenzo, New York, NY, United States
Nussenzweig, Ruth S., New York, NY, United States
Nussenzweig, Victor, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 5700906 19971223
WO 8700533 19870129
AI US 1987-43550 19870409 (7)
WO 1986-US1373 19860624
19870409 PCT 371 date
19870409 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1985-754645, filed on 12 Jul 1985,
now abandoned
DT Utility
FS Granted
LN.CNT 1827
INCL INCLM: 530/324.000
INCLS: 530/326.000; 530/300.000; 530/350.000
NCL NCLM: 530/324.000
NCLS: 530/300.000; 530/326.000; 530/350.000
IC [6]
ICM: C07K007-08
ICS: C07K014-445
EXF 530/328; 530/403; 530/324; 530/326; 530/300; 530/350; 435/172.3;
435/69.1; 435/71.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 97:104323 USPATFULL
 TI Hepatocyte growth factor receptor antagonist ***antibodies*** and
 uses thereof
 IN Schwall, Ralph H., Pacifica, CA, United States
 Tabor, Kelly Helen, Hillsborough, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 PI US 5686292 19971111
 AI US 1995-460368 19950602 (8)
 DT Utility
 FS Granted
 LN.CNT 1406
 INCL INCLM: 435/240.270
 INCLS: 424/133.100; 424/143.100; 530/387.300; 530/387.700; 530/388.100;
 530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100;
 530/389.700
 NCL NCLM: 424/143.100
 NCLS: 424/133.100; 435/334.000; 530/387.300; 530/387.700; 530/388.100;
 530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100;
 530/389.700
 IC [6]
 ICM: C12N005-12
 ICS: A61K039-395; C07K016-28
 EXF 530/387.7; 530/388.1; 530/388.2; 530/388.8; 530/388.85; 530/389.1;
 530/389.7; 530/387.3; 424/133.1; 424/143.1; 435/240.27
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 308 OF 325 USPATFULL on STN
 AN 97:75973 USPATFULL
 TI Immortalized human cell lines containing exogenous cytochrome P450 genes
 IN Harris, Curtis C., 8402 Thornden Terr., Bethesda, MD, United States
 20817
 Gelboin, Harry V., 2806 Abilene Dr., Chevy Chase, MD, United States
 20815
 Gonzalez, Frank J., 5000 Battery La., Apt. #101, Bethesda, MD, United
 States 20814
 Mace, Katharine C., Rue Haldimand 10, 1003 Lausanne, Switzerland
 Pfeifer, Andrea M. A., Chemin de Chaponeyres 6, 1800 Vevey, Switzerland
 PI US 5660986 19970826
 AI US 1995-462998 19950605 (8)
 RLI Division of Ser. No. US 1993-65201, filed on 19 May 1993, now patented,
 Pat. No. US 5506131 which is a continuation-in-part of Ser. No. US
 1992-869818, filed on 13 Apr 1992, now patented, Pat. No. US 5356806
 which is a continuation-in-part of Ser. No. US 1991-787777, filed on 6
 Nov 1991, now patented, Pat. No. US 5164313 which is a
 continuation-in-part of Ser. No. US 1987-58387, filed on 5 Jun 1987, now
 abandoned, said Ser. No. US -869818 which is a continuation-in-part
 of Ser. No. US 1991-636712, filed on 2 Jan 1991, now patented, Pat. No.
 US 5443954 which is a continuation-in-part of Ser. No. US 1988-265883,
 filed on 1 Nov 1988, now abandoned which is a continuation-in-part of
 Ser. No. US 1987-114508, filed on 30 Oct 1987, now patented, Pat. No. US
 4885238
 DT Utility
 FS Granted
 LN.CNT 1057
 INCL INCLM: 435/006.000
 INCLS: 435/172.100; 435/029.000; 435/032.000
 NCL NCLM: 435/006.000
 NCLS: 435/029.000; 435/032.000; 435/441.000
 IC [6]
 ICM: C12Q001-68
 EXF 435/6; 435/172.1; 435/240.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 309 OF 325 USPATFULL on STN
 AN 97:59098 USPATFULL
 TI Nucleic acids encoding hepatocyte growth factor receptor antagonist
 antibodies
 IN Schwall, Ralph H., Pacifica, CA, United States
 Tabor, Kelly Helen, Hillsborough, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 PI US 5646036 19970708
 AI US 1995-459388 19950602 (8)
 DT Utility

LN.CNT 1402
INCL INCLM: 435/252.300
INCLS: 435/240.200; 435/320.100; 536/023.530; 530/387.700; 530/388.220;
530/388.800; 530/388.850; 530/389.100; 530/389.700
NCL NCLM: 435/252.300
NCLS: 435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800;
530/388.850; 530/389.100; 530/389.700; 536/023.530
IC [6]
ICM: C12N015-13
ICS: C12N015-85; C12N001-21; C07K016-28
EXF 536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85;
530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 310 OF 325 USPATFULL on STN
AN 97:54206 USPATFULL
TI Modified VEGF oligonucleotides
IN Robinson, Gregory S., Acton, MA, United States
PA Hybridon, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5641756 19970624
AI US 1995-569926 19951208 (8)
RLI Continuation-in-part of Ser. No. US 1995-398945, filed on 2 Mar 1995
which is a continuation-in-part of Ser. No. US 1995-378860, filed on 26
Jan 1995 which is a continuation-in-part of Ser. No. US 1993-98942,
filed on 27 Jul 1993

DT Utility
FS Granted
LN.CNT 1264
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/375.000; 536/024.500; 536/023.500; 536/024.300;
536/024.310; 536/024.330
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/375.000; 536/023.500; 536/024.300; 536/024.310;
536/024.330; 536/024.500
IC [6]
ICM: A61K031-70
ICS: C07H021-00; C12N005-10; C12Q001-68
EXF 536/24.5; 536/23.5; 536/24.3; 536/24.31; 536/24.33; 514/44; 435/6;
435/240.2; 435/172.3; 935/33; 935/34; 935/36; 935/8; 935/9; 935/11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 311 OF 325 USPATFULL on STN
AN 97:51892 USPATFULL
TI Resurfacing of rodent ***antibodies***
IN Pedersen, Jan T., Bath, United Kingdom
Searle, Stephen M. J., Bath, United Kingdom
Rees, Anthony R., Bath, United Kingdom
Roguska, Michael A., Ashland, MA, United States
Guild, Braydon C., Concord, MA, United States
PA Immunogen Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5639641 19970617
AI US 1992-942245 19920909 (7)
DT Utility
FS Granted
LN.CNT 2777
INCL INCLM: 435/069.600
INCLS: 435/172.100; 530/387.300; 530/387.700; 530/388.300
NCL NCLM: 435/069.600
NCLS: 530/387.300; 530/387.700; 530/388.300
IC [6]
ICM: C12N015-00
ICS: C07K016-00; A61K039-395
EXF 530/387.3; 530/387.7; 530/388.8; 435/69.6; 435/172.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 312 OF 325 USPATFULL on STN
AN 97:1549 USPATFULL
TI Detection of complexes which include basement membrane components as
diagnostic of cancer and other diseases
IN Van Aken, Morgan, Bainbridge Island, WA, United States
Paskell, Stefan L., Bainbridge Island, WA, United States
PA Bainbridge Sciences, Inc., Redmond, WA, United States (U.S. corporation)
PI US 5591830 19970107
AI US 1995-456855 19950601 (8)
RLI Continuation of Ser. No. US 1994-178219, filed on 6 Jan 1994, now

1993-96490, filed on 23 Jul 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1991-721756, filed on 26 Jun 1991,
now patented, Pat. No. US 5264370, issued on 23 Nov 1993 which is a
continuation-in-part of Ser. No. US 1988-283397, filed on 12 Dec 1988,
now abandoned
DT Utility
FS Granted
LN.CNT 1908
INCL INCLM: 530/388.850
INCLS: 530/387.100; 530/388.100; 530/388.200; 435/007.230
NCL NCLM: 530/388.850
NCLS: 435/007.230; 530/387.100; 530/388.100; 530/388.200
IC [6]
ICM: C07K016-00
ICS: C07K016-18
EXF 530/387.1; 530/388.1; 530/388.2; 530/388.85; 435/7.23
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 313 OF 325 USPATFULL on STN
AN 97:1325 USPATFULL
TI Detection of complexes which include basement membrane components as
diagnostic of cancer and other diseases
IN Van Aken, Morgan, Bainbridge Island, WA, United States
Paskell, Stefan L., Bainbridge Island, WA, United States
PA Bainbridge Sciences, Inc., Redmond, WA, United States (U.S. corporation)
PI US 5591595 19970107
AI US 1995-457285 19950601 (8)
RLI Continuation of Ser. No. US 1994-178219, filed on 6 Jan 1994, now
patented, Pat. No. US 5512657 which is a continuation of Ser. No. US
1993-96490, filed on 23 Jul 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1991-721756, filed on 26 Jun 1991,
now patented, Pat. No. US 5264370, issued on 23 Nov 1993 which is a
continuation-in-part of Ser. No. US 1988-283397, filed on 12 Dec 1988,
now abandoned
DT Utility
FS Granted
LN.CNT 2087
INCL INCLM: 435/007.230
INCLS: 435/007.100; 435/007.200; 435/007.900; 435/007.920; 436/501.000;
436/064.000; 436/813.000
NCL NCLM: 435/007.230
NCLS: 435/007.100; 435/007.200; 435/007.900; 435/007.920; 436/064.000;
436/501.000; 436/813.000
IC [6]
ICM: G01N033-574
ICS: G01N033-53
EXF 435/7.23; 435/7.1; 435/7.2; 435/7.9; 435/7.92; 436/501; 436/64; 436/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 314 OF 325 USPATFULL on STN
AN 96:113802 USPATFULL
TI Agglutination assay
IN Hillyard, Carmel J., Queensland, Australia
Rylatt, Dennis B., Queensland, Australia
PA Agen Limited, Queensland, Australia (non-U.S. corporation)
PI US 5583003 19961210
AI US 1994-351105 19941130 (8)
RLI Continuation of Ser. No. US 1992-842343, filed on 25 Mar 1992, now
abandoned
PRAI AU 1989-6558 19890925
DT Utility
FS Granted
LN.CNT 1912
INCL INCLM: 435/007.250
INCLS: 435/007.400; 435/972.000; 435/973.000
NCL NCLM: 435/007.250
NCLS: 435/007.400; 435/972.000; 435/973.000
IC [6]
ICM: G01N033-53
ICS: G01N033-555; G01N033-567
EXF 435/972; 435/973; 435/7.4; 435/7.25
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 315 OF 325 USPATFULL on STN
AN 96:101449 USPATFULL

IN Janda, Kim D., San Diego, CA, United States
 PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
 PI US 5571681 19961105
 AI US 1994-209525 19940310 (8)
 DT Utility
 FS Granted
 LN.CNT 3030
 INCL INCLM: 435/007.600
 INCLS: 435/188.500; 435/041.000
 NCL NCLM: 435/007.600
 NCLS: 435/041.000; 435/188.500; 435/DIG.004; 435/DIG.021; 435/DIG.035
 IC [6]
 ICM: C12Q001-25
 ICS: C12N009-00
 EXF 435/188.5; 435/7.6; 435/7.71; 435/7.72; 435/41
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 316 OF 325 USPATFULL on STN
 AN 96:67898 USPATFULL
 TI Methods for determining the invasiveness of a bladder tumor
 IN Houghton, Raymond L., Bothell, WA, United States
 Van Aken, Morgan, Bainbridge Island, WA, United States
 Jones, Tobin K., Bainbridge Island, WA, United States
 PA Bard Diagnostic Sciences, Inc., Redmond, WA, United States (U.S. corporation)
 PI US 5541076 19960730
 AI US 1995-460496 19950602 (8)
 RLI Continuation-in-part of Ser. No. US 1994-178219, filed on 6 Jan 1994
 which is a continuation of Ser. No. US 1993-96490, filed on 23 Jul 1993,
 now abandoned which is a continuation-in-part of Ser. No. US
 1991-721756, filed on 26 Jun 1991, now patented, Pat. No. US 5264370
 which is a continuation-in-part of Ser. No. US 1988-283397, filed on 12
 Dec 1988, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1489
 INCL INCLM: 435/007.230
 INCLS: 435/007.900; 436/064.000; 436/813.000
 NCL NCLM: 435/007.230
 NCLS: 435/007.900; 436/064.000; 436/813.000
 IC [6]
 ICM: G01N033-574
 ICS: G01N033-53
 EXF 435/7.23; 435/7.9; 436/64; 436/813
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 317 OF 325 USPATFULL on STN
 AN 96:36652 USPATFULL
 TI Detection of complexes which include basement membrane components as
 diagnostic of cancer and other diseases
 IN Van Aken, Morgan, Bainbridge Island, WA, United States
 Paskell, Stefan L., Bainbridge Island, WA, United States
 PA Bainbridge Sciences, Inc., Redmond, WA, United States (U.S. corporation)
 PI US 5512657 19960430
 AI US 1994-178219 19940106 (8)
 RLI Continuation of Ser. No. US 1993-96490, filed on 23 Jul 1993, now
 abandoned which is a continuation-in-part of Ser. No. US 1991-721756,
 filed on 26 Jun 1991, now patented, Pat. No. US 5264370, issued on 23
 Nov 1993 which is a continuation-in-part of Ser. No. US 1988-283397,
 filed on 12 Dec 1988, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1885
 INCL INCLM: 530/350.000
 INCLS: 530/412.000; 530/413.000; 530/416.000; 436/064.000; 436/811.000;
 436/813.000; 436/820.000; 435/004.000; 435/029.000
 NCL NCLM: 530/350.000
 NCLS: 435/004.000; 435/029.000; 436/064.000; 436/811.000; 436/813.000;
 436/820.000; 530/412.000; 530/413.000; 530/416.000
 IC [6]
 ICM: C07K014-435
 ICS: C07K001-22; G01N033-483; G01N033-493
 EXF 530/350; 530/412; 530/413; 530/416; 435/4; 435/29; 436/63; 436/64;
 436/811; 436/813; 436/820

L3 ANSWER 318 OF 325 USPATFULL on STN
 AN 96:29461 USPATFULL
 TI Immortalized human cell lines containing exogenous cytochrome P450 genes
 IN Harris, Curtis C., Bethesda, MD, United States
 Gelboin, Harry V., Chevy Chase, MD, United States
 Gonzalez, Frank J., Bethesda, MD, United States
 Mace, Katharine C., Lousanne, Switzerland
 Pfeifer, Andrea M. A., Vevey, Switzerland
 PA The United States of America as represented by the Department of Health
 and Human Services, Washington, DC, United States (U.S. government)
 PI US 5506131 19960409
 AI US 1993-65201 19930519 (8)
 RLI Continuation-in-part of Ser. No. US 1992-869818, filed on 13 Apr 1992,
 now patented, Pat. No. US 5356806 which is a continuation-in-part of
 Ser. No. US 1991-787777, filed on 6 Nov 1991, now patented, Pat. No. US
 5164313 which is a continuation-in-part of Ser. No. US 1987-58387, filed
 on 5 Jun 1987, now abandoned, said Ser. No. US -869818 which is a
 continuation-in-part of Ser. No. US 1991-636712, filed on 2 Jan 1991,
 now patented, Pat. No. US 5443954 which is a continuation-in-part of
 Ser. No. US 1988-265883, filed on 1 Nov 1988, now abandoned which is a
 continuation-in-part of Ser. No. US 1987-114508, filed on 30 Oct 1987,
 now patented, Pat. No. US 4885238
 DT Utility
 FS Granted
 LN.CNT 1259
 INCL INCLM: 435/240.200
 INCLS: 435/006.000
 NCL NCLM: 435/006.000
 NCLS: 435/371.000
 IC [6]
 ICM: C12N005-10
 EXF 435/6; 435/7.21; 435/69.1; 435/172.2; 435/172.3; 435/240.2; 935/70
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 319 OF 325 USPATFULL on STN
 AN 95:84315 USPATFULL
 TI D-arabinitol dehydrogenase from Candida tropicalis ATCC 750 or Candida
 shehatae
 IN Miyada, Charles G., Mountain View, CA, United States
 Switchenko, Arthur C., Palo Alto, CA, United States
 Quong, Melanie W., La Jolla, CA, United States
 Wong, Man-Ying L., Fremont, CA, United States
 PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5451517 19950919
 AI US 1995-400417 19950303 (8)
 RLI Continuation of Ser. No. US 1994-184764, filed on 21 Jan 1994, now
 abandoned which is a continuation of Ser. No. US 1991-731218, filed on
 12 Jul 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1085
 INCL INCLM: 435/190.000
 INCLS: 435/255.400; 435/921.000; 435/924.000
 NCL NCLM: 435/190.000
 NCLS: 435/255.400; 435/921.000; 435/924.000
 IC [6]
 ICM: C12N009-04
 ICS: C12N001-16; C12N001-00
 EXF 435/190; 435/255.4; 435/921; 435/924
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 320 OF 325 USPATFULL on STN
 AN 95:40851 USPATFULL
 TI Erythrocyte agglutination assay
 IN Hillyard, Carmel J., Brisbane, Australia
 Rylatt, Dennis B., Rosalie, Australia
 Kemp, Bruce E., Kew, Australia
 Bundesen, Peter G., Fig Tree Pocket, Australia
 PA Agen Biomedical, Ltd., Acadia Ridge, Australia (non-U.S. corporation)
 PI US 5413913 19950509
 AI US 1994-191064 19940203 (8)
 RLI Continuation of Ser. No. US 1991-770845, filed on 4 Oct 1991, now
 abandoned which is a continuation of Ser. No. US 1989-324500, filed on
 16 Mar 1989, now patented, Pat. No. US 5086002 which is a

now patented, Pat. No. US 4894347 which is a continuation-in-part of
Ser. No. US 1987-111313, filed on 22 Oct 1987, now abandoned
PRAI AU 1987-4400 19870907
AU 1987-5018 19871022
DT Utility
FS Granted
LN.CNT 1176
INCL INCLM: 435/007.250
INCLS: 435/002.000; 435/975.000; 436/519.000; 436/520.000; 436/819.000;
530/388.700; 530/391.100
NCL NCLM: 435/007.250
NCLS: 435/002.000; 435/975.000; 436/519.000; 436/520.000; 436/819.000;
530/388.700; 530/391.100
IC [6]
ICM: G01N033-555
EXF 435/2; 435/7.5; 435/70.21; 435/975; 436/501; 436/519; 436/520; 436/547;
436/548; 436/819; 530/388.1; 530/388.2; 530/388.7; 530/391.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 321 OF 325 USPATFULL on STN
AN 93:106926 USPATFULL
TI Assay by enzyme-catalyzed isotopic exchange
IN Switchenko, Arthur C., Sunnyvale, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5272054 19931221
AI US 1992-857883 19920326 (7)
DT Utility
FS Granted
LN.CNT 1476
INCL INCLM: 435/004.000
INCLS: 435/007.720; 435/007.900; 435/015.000; 435/026.000; 435/189.000;
435/191.000; 435/810.000; 435/814.000; 435/968.000; 435/975.000;
436/504.000; 436/542.000; 436/545.000; 436/804.000; 424/001.100
NCL NCLM: 435/004.000
NCLS: 435/007.720; 435/007.900; 435/015.000; 435/026.000; 435/189.000;
435/191.000; 435/810.000; 435/814.000; 435/968.000; 435/975.000;
436/504.000; 436/542.000; 436/545.000; 436/804.000
IC [5]
ICM: C12Q001-00
ICS: G01N033-567
EXF 435/4; 435/7.72; 435/7.9; 435/15; 435/26; 435/189; 435/191; 435/810;
435/814; 435/968; 435/975; 436/504; 436/542; 436/545; 436/804; 424/1.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 322 OF 325 USPATFULL on STN
AN 93:52504 USPATFULL
TI Monoclonal ***antibodies*** reactive with defined regions of the
T-cell antigen receptor
IN Skibbens, Robert V., Chapel Hill, NC, United States
Henry, Larry D., Brookline, MA, United States
Rittershaus, Charles W., Malden, MA, United States
Tian, Wei-Tao, Allston, MA, United States
Ip, Stephen H., Sudbury, MA, United States
Kung, Patrick C., Lexington, MA, United States
Snider, Mary Ellen, Ledyard, CT, United States
Ko, Jone-Long, Cambridge, MA, United States
Wood, Nancy L., Cambridge, MA, United States
PA T Cell Sciences, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5223426 19930629
AI US 1989-449692 19891211 (7)
RLI Continuation-in-part of Ser. No. US 1989-343189, filed on 25 Apr 1989
which is a continuation-in-part of Ser. No. US 1988-284511, filed on 15
Dec 1988, now abandoned
DT Utility
FS Granted
LN.CNT 2972
INCL INCLM: 435/240.270
INCLS: 530/387.100; 530/387.900; 424/085.800
NCL NCLM: 435/331.000
NCLS: 424/144.100; 424/154.100; 530/387.100; 530/387.900; 530/388.220;
530/388.750
IC [5]
ICM: A61K039-00
ICS: A61K035-16

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 323 OF 325 USPATFULL on STN
AN 92:9052 USPATFULL
TI Erythrocyte agglutination assay
IN Hillyard, Carmel J., Brisbane, Australia
Rylatt, Dennis B., Rosalie, Australia
Kemp, Bruce E., Kew, Australia
Bundesen, Peter G., Fig Tree Pocket, Australia
PA Agen Biomedical, Ltd., Acacia Ridge, Australia (non-U.S. corporation)
PI US 5086002 19920204
AI US 1989-324500 19890316 (7)
RLI Continuation-in-part of Ser. No. US 1988-143343, filed on 13 Jan 1988,
now patented, Pat. No. US 4894347 which is a continuation-in-part of
Ser. No. US 1987-111313, filed on 22 Oct 1987, now abandoned
PRAI AU 1987-4400 19870907
AU 1987-5018 19871022
DT Utility
FS Granted
LN.CNT 1284
INCL INCLM: 436/540.000
INCLS: 436/501.000; 436/519.000; 422/061.000; 530/387.000
NCL NCLM: 436/540.000
NCLS: 422/061.000; 435/007.250; 436/501.000; 436/519.000; 530/387.300;
530/388.700; 530/389.100; 530/866.000
IC [5]
ICM: G01N033-541
EXF 530/387; 530/389; 422/61; 436/519; 436/520; 436/540; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 324 OF 325 USPATFULL on STN
AN 90:4355 USPATFULL
TI Erythrocyte agglutination assay
IN Hillyard, Carmel J., Brisbane, Australia
Rylatt, Dennis B., Rosalie, Australia
Kemp, Bruce E., Kew, Australia
Bundesen, Peter G., Fig Tree Pocket, Australia
PA Agen Limited, Australia (non-U.S. corporation)
PI US 4894347 19900116
AI US 1988-143343 19880113 (7)
RLI Continuation-in-part of Ser. No. US 1989-111313, filed on 22 Oct 1989
PRAI AU 1987-4400 19870917
DT Utility
FS Granted
LN.CNT 701
INCL INCLM: 436/540.000
INCLS: 436/501.000; 436/519.000; 422/061.000; 530/387.000
NCL NCLM: 436/540.000
NCLS: 422/061.000; 436/501.000; 436/519.000; 530/387.300; 530/388.700
IC [4]
ICM: G01N033-541
EXF 530/387; 530/389; 422/61; 436/519; 436/520; 436/540; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 325 OF 325 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1992-390692 [48] WPIDS
DNC C1992-173320
TI Prod'n. of human immunodeficiency virus gp-41 derivs. - using plasmid
contg. FR-coat proteins, 2N-terminal aminoacid(s) and HIV gene AA474-647,
to produce immunologically active gp-41.
DC B04 D16
IN DREILINJA, D; KOZLOVSKAJA, T; OZOLS, J; PORSTMANN, T; PUMPEN, P; PUSHKO,
P; ULRICH, R
PA (ALOR) AS LATV ORGANIC SYNTHESIS INST; (UYBE) UNIV BERLIN HUMBOLDT
CYC 1
PI DD 300690 A5 19920702 (199248)* 4 C12N015-48
ADT DD 300690 A5 DD 1990-338996 19900323
PRAI DD 1990-338996 19900323
IC ICM C12N015-48
ICS C07K015-04; C12N015-62; C12P021-02
STN INTERNATIONAL LOGOFF AT 12:04:10 ON 17 MAY 2004

Connecting via Winsock to STN
Welcome to STN International! Enter x:x
***** Welcome to STN International *****
***** STN Columbus *****

FILE 'HOME' ENTERED AT 15:53:05 ON 17 MAY 2004

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:53:14 ON 17 MAY 2004

FILE 'ANABSTR' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:53:14 ON 17 MAY 2004

FILE 'CAPLUS' ENTERED AT 15:53:14 ON 17 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:53:14 ON 17 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 15:53:14 ON 17 MAY 2004

COPYRIGHT (C) 2004 Proquest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 15:53:14 ON 17 MAY 2004

FILE 'FOMAD' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:53:14 ON 17 MAY 2004

FILE 'HEALSAFE' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:53:14 ON 17 MAY 2004

FILE 'NIOSHTIC' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:53:14 ON 17 MAY 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.

All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 15:53:14 ON 17 MAY 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:53:14 ON 17 MAY 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 15:53:14 ON 17 MAY 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 15:53:14 ON 17 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:53:14 ON 17 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 15:53:14 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S 3D6
64 FILES SEARCHED...
L1 2786 3D6

=> DUP REM L1
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY 98% COMPLETE FOR L1
PROCESSING COMPLETED FOR L1
L2 2449 DUP REM L1 (337 DUPLICATES REMOVED)

=> S L2 AND antibody
22 FILES SEARCHED...
46 FILES SEARCHED...
L3 325 L2 AND ANTIBODY

=> S L3 AND PY<=2000
'2000' NOT A VALID FIELD CODE
6 FILES SEARCHED...
9 FILES SEARCHED...
13 FILES SEARCHED...
17 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
29 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
40 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
44 FILES SEARCHED...
49 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
57 FILES SEARCHED...
64 FILES SEARCHED...
L4 160 L3 AND PY<=2000

=> D L4 1-160

L4 ANSWER 1 OF 160 AGRICOLA Compiled and distributed by the National
Agricultural Library of the Department of Agriculture of the United States
of America. It contains copyrighted materials. All rights reserved.
(2004) on STN

AN 2000:4580 AGRICOLA

DN IND22009396

TI Monoclonal ***antibody*** production in murine ascites. II. Production
characteristics.

AU Jackson, L.R.; Trudel, L.J.; Fox, J.G.; Lipman, N.S.

CS Biogen, Inc., Cambridge, MA.

SO Laboratory animal science, ***Feb 1999.*** Vol. 49, No. 1. p. 81-86
Publisher: Cordova, Tenn. : American Association for Laboratory Animal
Science.

CODEN: LBASAE; ISSN: 0023-6764

NTE Includes references

CY Tennessee; United States

DT Article

FS U.S. Imprints not USDA, Experiment or Extension

LA English

L4 ANSWER 2 OF 160 AGRICOLA Compiled and distributed by the National
Agricultural Library of the Department of Agriculture of the United States
of America. It contains copyrighted materials. All rights reserved.
(2004) on STN

AN 92:115808 AGRICOLA

DN IND92071156

TI Demonstration of peptidoglycan-associated Brucella outer-membrane proteins
by use of monoclonal ***antibodies***.

AU Cloeckaert, A.; Zygmunt, M.S.; Wergifosse, P. de; Dubray, G.; Limet, J.N.

CS Catholic University of Louvain, Brussels, Belgium

AV DNAL (448.3 J823)

SO The Journal of general microbiology, ***July 1992.*** Vol. 138, No.
pt.7. p. 1543-1550

Publisher: Reading : Society for General Microbiology.

CODEN: JGMIAN; ISSN: 0022-1287

NTE Includes references.

DT Article

FS Non-U.S. Imprint other than FAO

LA English

L4 ANSWER 3 OF 160 BIOBUSINESS COPYRIGHT 2004 BIOSIS on STN

AN 85:580 BIOBUSINESS

DN 0010784

TI A MORE SPECIFIC, SIMILAR RADIOIMMUNOASSAY FOR CARCINOEMBRYONIC ANTIGEN,
WITH USE OF MONOCLONAL ***ANTIBODIES***.

AU LIU Y-S V; TOBIAS R J; ZURAWSKI V R JR

CS CENTOCOR, 244 GREAT VALLEY PARKWAY, MALVERN, PA. 19355.

SO CLINICAL CHEMISTRY, (***1985***) VOL.31, NO.2, P.191-195.

FS NONUNIQUE

LA ENGLISH

L4 ANSWER 4 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:121222 BIOSIS
DN PREV200100121222
TI Intraneuronal Abeta42 immunoreactivity in Down syndrome brain.
AU Mori, C. [Reprint author]; Spooner, E. T.; Lu, M.; Wisniewski, K.;
Wisniewski, T.; Yamaguchi, H.; Saido, T. C.; Selkoe, D. J.; Lemere, C. A.
CS Brigham " Women's Hospital, Harvard Medical School, Boston, MA, USA
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
No.-764.7. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New
Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 7 Mar 2001
Last Updated on STN: 15 Feb 2002

L4 ANSWER 5 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:80301 BIOSIS
DN PREV200100080301
TI Dissociation between age-related and age-independent memory deficits in
the PDAPP mouse.
AU Morris, R. G.; Chen, G.; Chen, K. S.; Knox, J.; Inglis, J.; Martin, S. J.;
Justice, A.; Games, D.; Freedman, S. B.
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
No.-275.4. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New
Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Feb 2001
Last Updated on STN: 12 Feb 2002

L4 ANSWER 6 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:368395 BIOSIS
DN PREV200000368395
TI Antineoplastic effect of intracellular expression of a single-chain
antibody directed against type IV collagenase.
AU Wang, Weigang; Zhou, Jinghua; Xu, Linna; Zhen, Yongsu [Reprint author]
CS Department of Oncology, Institute of Medicinal Biotechnology, Chinese
Academy of Medical Sciences and Peking Union Medical College, Beijing,
100050, China
SO Journal of Environmental Pathology Toxicology and Oncology, (2000) Vol.
19, No. 1-2, pp. 61-68. print.
CODEN: JEPOEC. ISSN: 0731-8898.
DT Article
LA English
ED Entered STN: 23 Aug 2000
Last Updated on STN: 8 Jan 2002

L4 ANSWER 7 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:245001 BIOSIS
DN PREV200000245001
TI Antitumor effects of novel immunoconjugates with downsized-molecule
prepared by linking lidamycin to Fab' and scFv ***antibody*** .
AU Liu, Xiao Yun [Reprint author]; Li, S. Q.; Jiang, M.; Zhen, Y. S.
CS Inst for Med Bio, Chinese Acad of Med Sci, Beijing, China
SO Proceedings of the American Association for Cancer Research Annual
Meeting, (March, 2000) No. 41, pp. 290-291. print.
Meeting Info.: 91st Annual Meeting of the American Association for Cancer
Research. San Francisco, California, USA. April 01-05, 2000.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Jun 2000
Last Updated on STN: 5 Jan 2002

L4 ANSWER 8 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:76243 BIOSIS
DN PREV200000076243

TI A human anti-HIV autoantibody enhances EBV transformation and HIV infection.
 AU Cavacini, Lisa A. [Reprint author]; Wisniewski, Adam [Reprint author]; Peterson, Jennifer E. [Reprint author]; Montefiori, David; Emes, Charlotte [Reprint author]; Duval, Mark [Reprint author]; Kingsbury, Gillian [Reprint author]; Wang, Anlai [Reprint author]; Scadden, David [Reprint author]; Posner, Marshall R. [Reprint author]
 CS Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA, USA
 SO Clinical Immunology (Orlando), (Dec., 1999) Vol. 93, No. 3, pp. 263-273. print.
 ISSN: 1521-6616.
 DT Article
 LA English
 ED Entered STN: 23 Feb 2000
 Last Updated on STN: 3 Jan 2002

L4 ANSWER 9 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1999:209028 BIOSIS
 DN PREV199900209028
 TI Monoclonal ***antibody*** production in murine ascites: I. Clinical and pathologic features.
 AU Jackson, Lynn R. [Reprint author]; Trudel, Laura J.; Fox, James G.; Lipman, Neil S.
 CS Biogen, Inc., 14 Cambridge Center, Cambridge, MA, 02142, USA
 SO Laboratory Animal Science, (Feb., 1999) Vol. 49, No. 1. print.
 CODEN: LBASAE. ISSN: 0023-6764.
 DT Article
 LA English
 ED Entered STN: 26 May 1999
 Last Updated on STN: 26 May 1999

L4 ANSWER 10 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1999:13917 BIOSIS
 DN PREV199900013917
 TI Capture of human monoclonal ***antibodies*** from cell culture supernatant by ion exchange media exhibiting high charge density.
 AU Necina, Roman; Amatschek, Karin; Jungbauer, A. [Reprint author]
 CS Inst. Appl. Microbiol., Univ. Agric. For. Biotechnol., Nussdorferlaende 11, A-1190 Vienna, Austria
 SO Biotechnology and Bioengineering, (Dec. 20, 1998) Vol. 60, No. 6, pp. 689-698. print.
 CODEN: BIBIAU. ISSN: 0006-3592.
 DT Article
 LA English
 ED Entered STN: 11 Jan 1999
 Last Updated on STN: 11 Jan 1999

L4 ANSWER 11 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1998:480733 BIOSIS
 DN PREV199800480733
 TI Functional and molecular characterization of human monoclonal ***antibody*** reactive with immunodominant region of HIV type 1 glycoprotein 41.
 AU Cavacini, Lisa A. [Reprint author]; Emes, Charlotte L.; Wisniewski, Adam V.; Power, Jennifer; Lewis, George; Montefiori, David; Posner, Marshall R.
 CS Beth Israel Deaconess Med. Cent., 21-27 Burlington Ave., P.O. Box 15709, Boston, MA 02215, USA
 SO AIDS Research and Human Retroviruses, (Sept. 20, 1998) Vol. 14, No. 14, pp. 1271-1280. print.
 CODEN: ARHRE7. ISSN: 0889-2229.
 DT Article
 LA English
 ED Entered STN: 5 Nov 1998
 Last Updated on STN: 5 Nov 1998

L4 ANSWER 12 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1998:443408 BIOSIS
 DN PREV199800443408
 TI Molecular characterization of five neutralizing anti-HIV type 1 ***antibodies*** : Identification of nonconventional D segments in the human monoclonal ***antibodies*** 2G12 and 2F5.
 AU Kunert, Renate [Reprint author]; Ruker, Florian; Katinger, Hermann
 CS Inst. Applied Microbiol., Univ. Agricultural Sciences, Muthgasse 18, Haus B, A-1190 Vienna, Austria
 SO AIDS Research and Human Retroviruses, (Sept. 1, 1998) Vol. 14, No. 13, pp.

1115-1128. print.
 CODEN: ARHRE7. ISSN: 0889-2229.

DT Article
 LA English
 ED Entered STN: 21 Oct 1998
 Last Updated on STN: 21 Oct 1998

L4 ANSWER 13 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1997:61863 BIOSIS
 DN PREV199799361066
 TI Molecular identification of a novel fibrinogen binding site on the first
 domain of ICAM-1 regulating leukocyte-endothelium bridging.
 AU Duperray, Alain; Languino, Lucia R.; Plescia, Janet; McDowall, Alison;
 Hogg, Nancy; Craig, Alister G.; Berendt, Anthony R.; Altieri, Dario C.
 [Reprint author]
 CS Yale Univ. Sch. Med., BCM 436B, 295 Congress Ave., New Haven, CT 06536,
 USA
 SO Journal of Biological Chemistry, (1997) Vol. 272, No. 1, pp. 435-441.
 CODEN: JBCHA3. ISSN: 0021-9258.

DT Article
 LA English
 ED Entered STN: 11 Feb 1997
 Last Updated on STN: 11 Feb 1997

L4 ANSWER 14 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1995:438091 BIOSIS
 DN PREV199598452391
 TI Interaction between a Fab fragment against gp41 of human immunodeficiency
 virus 1 and its peptide epitope: Characterization using a peptide epitope
 library and molecular modeling.
 AU Stigler, Rolf-Dietrich; Rueker, Florian; Katinger, Dietmar; Elliott,
 Graham; Hoehne, Wolfgang; Henklein, Peter; Ho, Joseph X.; Keeling, Kim;
 Carter, Dan C.; Nügel, Elsa; Kramer, Achim; Porstmann, Tomas;
 Schneider-Mergener, Jens [Reprint author]
 CS Inst. Med. Immunologie, Universitätsklinik Charité, Humboldt-Univ. zu
 Berlin, Schumannstrasse 20-21, 10098 Berlin, Germany
 SO Protein Engineering, (1995) Vol. 8, No. 5, pp. 471-479.
 CODEN: PRENE9. ISSN: 0269-2139.

DT Article
 LA English
 ED Entered STN: 10 Oct 1995
 Last Updated on STN: 10 Oct 1995

L4 ANSWER 15 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1994:271698 BIOSIS
 DN PREV199497284698
 TI HIV-1 gp41 shares a common immunologic determinant with human T, B and
 monocyte cell lines.
 AU Chen, Ying-Hua; Susanna, Alex; Boeck, Guenther; Steindl, Franz; Katinger,
 Hermann; Dierich, Manfred P. [Reprint author]
 CS Inst. Hygiene, Fritz-Pregl-Strasse 3, A-6010 Innsbruck, Austria
 SO Immunology Letters, (1994) Vol. 39, No. 3, pp. 219-222.
 CODEN: IMLED6. ISSN: 0165-2478.

DT Article
 LA English
 ED Entered STN: 24 Jun 1994
 Last Updated on STN: 24 Jun 1994

L4 ANSWER 16 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1994:128940 BIOSIS
 DN PREV199497141940
 TI Stable, continuous large-scale production of human monoclonal HIV-1
 antibody using a computer-controlled pilot plant.
 AU Unterluggauer, F. [Reprint author]; Doblhoff-Dier, O.; Tauer, C.;
 Jungbauer, A.; Gaida, T.; Reiter, M.; Schmatz, C.; Zach, N.; Katinger, H.
 CS Inst. Applied Microbiol., Univ. Agric. and Forestry, Nussdorfer Laende 11,
 A-1190 Vienna, Austria
 SO Biotechniques, (1994) Vol. 16, No. 1, pp. 140-144, 146-147.
 CODEN: BTNQD0. ISSN: 0736-6205.

DT Article
 LA English
 ED Entered STN: 24 Mar 1994
 Last Updated on STN: 24 Mar 1994

L4 ANSWER 17 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1993:587931 BIOSIS

DN PREV199497007301
 TI Expression of colorectal carcinoma-associated antigens in colonic polyps.
 AU Salem, Ronald R. [Reprint author]; Wolf, Barbara C. [Reprint author];
 Sears, Henry F. [Reprint author]; Lavin, Philip T. [Reprint author];
 Ravikumar, Thanjavur S. [Reprint author]; Decoste, Deborah [Reprint
 author]; D'Emilia, John C. [Reprint author]; Herlyn, Meenhard; Schlom,
 Jeffrey
 CS Dep. Surg., Lab. Cancer Biol., New England Deaconess Hosp., Harvard Med.
 Sch., Boston, MA 02138, USA
 SO Journal of Surgical Research, (1993) Vol. 55, No. 3, pp. 249-255.
 CODEN: JSGRA2. ISSN: 0022-4804.
 DT Article
 LA English
 ED Entered STN: 28 Dec 1993
 Last Updated on STN: 28 Dec 1993

L4 ANSWER 18 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1993:410131 BIOSIS
 DN PREV199396075856
 TI HIV-1 and HIV-2 isolates differ in their ability to activate the
 complement system on the surface of infected cells.
 AU Marschang, Peter [Reprint author]; Guertler, Lutz; Toetsch, Martin;
 Thielens, Nicole M.; Arlaud, Gerard J.; Hittmair, Anton; Katinger,
 Hermann; Dierich, Manfred P.
 CS Inst. Hygiene, Fritz-Pregl-Str. 3, 6020 Innsbruck, Austria
 SO AIDS (Philadelphia), (1993) Vol. 7, No. 7, pp. 903-910.
 CODEN: AIDSET. ISSN: 0269-9370.
 DT Article
 LA English
 ED Entered STN: 8 Sep 1993
 Last Updated on STN: 8 Sep 1993

L4 ANSWER 19 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1992:504534 BIOSIS
 DN PREV199294123059; BA94:123059
 TI GLOBAL FOREBRAIN ISCHEMIA RESULTS IN DECREASED IMMUNOREACTIVITY OF
 CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II.
 AU CHURN S B [Reprint author]; YAGHMAI A; POVLISHOCK J; RAFIQ A; DELORENZO R
 J
 CS DEP NEUROLOGY, MED COLL VA, BOX 599 MCV STATION, RICHMOND, VA 23298, USA
 SO Journal of Cerebral Blood Flow and Metabolism, (1992) Vol. 12, No. 5, pp.
 784-793.
 CODEN: JCBMDN. ISSN: 0271-678X.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 9 Nov 1992
 Last Updated on STN: 10 Nov 1992

L4 ANSWER 20 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1992:391924 BIOSIS
 DN PREV199294064099; BA94:64099
 TI MONOCLONAL ***ANTIBODIES*** AND RABBIT ANTISERA RECOGNIZING 4
 AMINOBIIPHENYL-DNA ADDUCTS AND APPLICATION TO IMMUNOAFFINITY
 CHROMATOGRAPHY.
 AU GROOPMAN J D [Reprint author]; SKIPPER P L; DONAHUE P R; TRUDEL L J;
 WILDSCHUTTE M; KADLUBAR F F; TANNENBAUM S R
 CS DEP ENVIRONMENTAL HEALTH SCIENCES, JOHNS HOPKINS UNIV, SCH HYGIENE PUBLIC
 HEALTH, 615 NORTH WOLFE STREET, BALTIMORE, MD 21205, USA
 SO Carcinogenesis (Oxford), (1992) Vol. 13, No. 6, pp. 917-922.
 CODEN: CRNGDP. ISSN: 0143-3334.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 24 Aug 1992
 Last Updated on STN: 24 Aug 1992

L4 ANSWER 21 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1992:119275 BIOSIS
 DN PREV199293065075; BA93:65075
 TI ANALYSIS OF VARIOUS ANTIGENS IN GOLDEN HAMSTER TESTIS BY MONOCLONAL
 ANTIBODIES.
 AU OHSAKO S [Reprint author]; KUROHMARU M; NISHIDA T; HAYASHI Y
 CS DEP VETERINARY ANATOMY, FAC AGRIC, UNIVERSITY TOKYO, BUNKYO-KU, TOKYO 113,
 JAPAN
 SO Journal of Veterinary Medical Science, (1991) Vol. 53, No. 6, pp. 969-974.

CODEN: JVMSEQ. ISSN: 0916-7250.

DT Article
FS BA
LA ENGLISH
ED Entered STN: 1 Mar 1992
Last Updated on STN: 1 Mar 1992

L4 ANSWER 22 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1990:517848 BIOSIS
DN PREV199090135124; BA90:135124
TI CHARACTERIZATION OF MONOCLONAL ***ANTIBODIES*** TO HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 GP41 BY HIV-1 POLYPEPTIDES EXPRESSED IN
ESCHERICHIA-COLI.
AU LARCHER C [Reprint author]; BROEKER M; HUEMER H P; SOELDER B; SCHULZ T F;
HOFBAUER J M; WACHTER H; DIERICH M P
CS INST HYGIENE, UNIV INNSBRUCK, FRITZ-PREGL-STR 3, A-6020 INNSBRUCK, AUSTRIA
SO FEMS (Federation of European Microbiological Societies) Microbiology
Immunology, (1990) Vol. 64, No. 2, pp. 103-110.
ISSN: 0920-8534.

DT Article
FS BA
LA ENGLISH
ED Entered STN: 19 Nov 1990
Last Updated on STN: 19 Nov 1990

L4 ANSWER 23 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1989:514312 BIOSIS
DN PREV198988130455; BA88:130455
TI T-CELL RECEPTOR V-BETA-5 USAGE DEFINES REACTIVITY TO A HUMAN T-CELL
RECEPTOR MONOCLONAL ***ANTIBODY***
AU LIPOLDOVA M [Reprint author]; BOYLSTON A W; YSSEL H; OWEN M J
CS IMPERIAL CANCER RES FUND, ST BARTHOLOMEW'S HOSP, DOMINION HOUSE,
BARTHOLOMEW CLOSE, LONDON EC1A 7BE, UK
SO Immunogenetics, (1989) Vol. 30, No. 3, pp. 162-168.
CODEN: IMNGBK. ISSN: 0093-7711.

DT Article
FS BA
LA ENGLISH
ED Entered STN: 15 Nov 1989
Last Updated on STN: 15 Nov 1989

L4 ANSWER 24 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1989:495013 BIOSIS
DN PREV198988121550; BA88:121550
TI THE EXPRESSION OF COLORECTAL CARCINOMA-ASSOCIATED ANTIGENS IN THE NORMAL
COLONIC MUCOSA AN IMMUNOHISTOCHEMICAL ANALYSIS OF REGIONAL DISTRIBUTION.
AU WOLF B C [Reprint author]; SALEM R R; SEARS H F; HORST D A; LAVIN P T;
HERLYN M; ITZKOWITZ S H; SCHLOM J; STEEL G D JR
CS LAB CANCER BIOL, NEW ENGLAND DEACONESS HOSP, 50 BINNEY ST, BOSTON, MASS
02115, USA
SO American Journal of Pathology, (1989) Vol. 135, No. 1, pp. 111-120.
CODEN: AJPAA4. ISSN: 0002-9440.

DT Article
FS BA
LA ENGLISH
ED Entered STN: 2 Nov 1989
Last Updated on STN: 2 Nov 1989

L4 ANSWER 25 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1989:27208 BIOSIS
DN PREV198987015208; BA87:15208
TI PRODUCTION OF MONOCLONAL ***ANTIBODIES*** AGAINST HUMAN ERYTHROPOIETIN
AND THEIR USE IN THE PURIFICATION OF HUMAN URINARY ERYTHROPOIETIN.
AU MIYAZAKI H [Reprint author]; KOZUTSUMI H; KATO T; HOSHI S; TAMURA S;
KUBOTA M; SUZUKI T
CS PHARM LAB, KIRIN BREWERY CO LTD, MAEBASHI, GUNMA 371, JPN
SO Journal of Immunological Methods, (1988) Vol. 113, No. 2, pp. 261-268.
CODEN: JIMMBG. ISSN: 0022-1759.

DT Article
FS BA
LA ENGLISH
ED Entered STN: 20 Dec 1988
Last Updated on STN: 20 Dec 1988

L4 ANSWER 26 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1988:439941 BIOSIS

DN PREV198886092039; BA86:92039
 TI ANTIGEN- ***ANTIBODY*** INTERACTION SYNTHETIC PEPTIDES DEFINE LINEAR
 ANTIGENIC DETERMINANTS RECOGNIZED BY MONOCLONAL ***ANTIBODIES***
 DIRECTED TO THE CYTOPLASMIC CARBOXYL TERMINUS OF RHODOPSIN.
 AU HODGES R S [Reprint author]; HEATON R J; PARKER J M R; MOLDAY L; MOLDAY R
 S
 CS DEP BIOCHEM, UNIV ALBERTA, EDMONTON, ALBERTA T6G 2H7, CAN
 SO Journal of Biological Chemistry, (1988) Vol. 263, No. 24, pp. 11768-11775.
 CODEN: JBCHA3. ISSN: 0021-9258.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 4 Oct 1988
 Last Updated on STN: 4 Oct 1988

L4 ANSWER 27 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1987:85748 BIOSIS
 DN PREV198783044326; BA83:44326
 TI A FAMILY OF T CELL RECEPTOR MOLECULES EXPRESSED ON T CELL CLONES WITH
 DIFFERENT SPECIFICITIES FOR ALLOMAJOR HISTOCOMPATIBILITY ANTIGENS.
 AU BORST J [Reprint author]; SPITS H; VOORDOUW A; DE VRIES E; BOYLSTON A; DE
 VRIES J E
 CS DIV IMMUNOL, NETHERLANDS CANCER INST PLESMANLAAN 121, 10666 CX AMSTERDAM,
 NETHERLANDS
 SO Human Immunology, (1986) Vol. 17, No. 4, pp. 426-442.
 CODEN: HUIMDQ. ISSN: 0198-8859.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 7 Feb 1987
 Last Updated on STN: 7 Feb 1987

L4 ANSWER 28 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1987:65782 BIOSIS
 DN PREV198783034108; BA83:34108
 TI T CELL CLONES WHICH SHARE T CELL RECEPTOR EPITOPES DIFFER IN PHENOTYPE
 FUNCTION AND SPECIFICITY.
 AU YSSEL H [Reprint author]; BLANCHARD D; BOYLSTON A; DE VRIES J E; SPITS H
 CS UNICET, CENTRE DE RECHERCHES, 27 CHEMIN DES PEUPLIERS, BP 11, F-69572
 DARDILLY, FR
 SO European Journal of Immunology, (1986) Vol. 16, No. 10, pp. 1187-1194.
 CODEN: EJIMAF. ISSN: 0014-2980.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 24 Jan 1987
 Last Updated on STN: 24 Jan 1987

L4 ANSWER 29 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1986:378452 BIOSIS
 DN PREV198682073428; BA82:73428
 TI PROPERTIES OF A PANEL OF MONOCLONAL ***ANTIBODIES*** WHICH REACT WITH
 THE HUMAN T CELL ANTIGEN RECEPTOR ON THE LEUKEMIC LINE HPB-ALL AND A
 SUBSET OF NORMAL PERIPHERAL BLOOD T LYMPHOCYTES.
 AU BOYLSTON A W [Reprint author]; BORST J; YSSEL H; BLANCHARD D; SPITS H; DE
 VRIES J E
 CS PATHOL DEP, ST MARY'S HOSP MED SCH, LONDON W2 1PG, ENGLAND, UK
 SO Journal of Immunology, (1986) Vol. 137, No. 2, pp. 741-744.
 CODEN: JOIMA3. ISSN: 0022-1767.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 20 Sep 1986
 Last Updated on STN: 20 Sep 1986

L4 ANSWER 30 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1986:286053 BIOSIS
 DN PREV198682029916; BA82:29916
 TI THE USE OF A MONOCLONAL ***ANTIBODY*** SPECIFIC FOR THE AMINO-TERMINAL
 REGION OF SOUTHERN BEAN MOSAIC VIRUS AS A PROBE OF VIRUS STRUCTURE.
 AU MACKENZIE D J [Reprint author]; TREMAINE J H
 CS RESEARCH STN, AGRIC CAN, 6660 NW MARINE DR, VANCOUVER, BRITISH COLUMBIA,
 CAN V6T 1X2
 SO Journal of General Virology, (1986) Vol. 67, No. 4, pp. 727-736.
 CODEN: JGVIAY. ISSN: 0022-1317.
 DT Article

FS BA
LA ENGLISH
ED Entered STN: 4 Jul 1986
Last Updated on STN: 4 Jul 1986

L4 ANSWER 31 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1986:258982 BIOSIS
DN PREV198682013731; BA82:13731
TI DIFFERENTIAL IMMUNOGOLD-DEXTRAN LABELING OF BOVINE AND FROG ROD AND CONE
CELLS USING MONOCLONAL ****ANTIBODIES**** AGAINST BOVINE RHODOPSIN.
AU HICKS D [Reprint author]; MOLDAV R S
CS DEPARTMENT BIOCHEMISTRY, UNIVERSITY BRITISH COLUMBIA, VANCOUVER, BC V6T
1W5, CANADA
SO Experimental Eye Research, (1986) Vol. 42, No. 1, pp. 55-72.
CODEN: EXERA6. ISSN: 0014-4835.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 21 Jun 1986
Last Updated on STN: 21 Jun 1986

L4 ANSWER 32 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1986:171816 BIOSIS
DN PREV198681082232; BA81:82232
TI HUMAN T CELL LINES DIFFERING IN PHENOTYPE AND SPECIFICITY ARE REACTIVE
WITH THE SAME ANTI-IDIOTYPIC ****ANTIBODY**** .
AU BORST J [Reprint author]; BOYLSTON A W; DE VRIES J E; SPITS H
CS DIV IMMUNOLOGY, NETH CANCER INST, ANTONI VAN LEEUWENHOEK HUIS, PLESMANLAAN
121, 1066 CX AMSTERDAM, NETH
SO Journal of Immunology, (1986) Vol. 136, No. 2, pp. 601-608.
CODEN: JOIMA3. ISSN: 0022-1767.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 26 Apr 1986
Last Updated on STN: 26 Apr 1986

L4 ANSWER 33 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1985:407367 BIOSIS
DN PREV198580077359; BA80:77359
TI GROWTH OF NORMAL HUMAN T LYMPHOCYTES INDUCED BY MONOCLONAL
ANTIBODY TO THE T CELL ANTIGEN RECEPTOR.
AU BOYLSTON A W [Reprint author]; COSFORD P
CS DEP PATHOLOGY, ST MARY'S HOSPITAL MED SCH, NORFOLK PLACE, PADDINGTON,
LONDON W21PG, GB, UK
SO European Journal of Immunology, (1985) Vol. 15, No. 7, pp. 738-742.
CODEN: EJIMAF. ISSN: 0014-2980.
DT Article
FS BA
LA ENGLISH

L4 ANSWER 34 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1985:388721 BIOSIS
DN PREV198580058713; BA80:58713
TI DETERMINANT HETEROGENEITY OF L-1 L-2 AND L-3 ANTIGEN MOLECULES ON HUMAN T
CELLS AS DEFINED BY MONOCLONAL ***ANTIBODIES*** AND THEIR ROLES IN T
CELL-MEDIATED IMMUNE FUNCTIONS.
AU TAKEI T [Reprint author]; ISHII Y
CS DEP PATHOL, SAPPORO MED COLL
SO Sapporo Medical Journal, (1985) Vol. 54, No. 3, pp. 281-300.
CODEN: SIZSAR. ISSN: 0036-472X.
DT Article
FS BA
LA JAPANESE

L4 ANSWER 35 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1985:308182 BIOSIS
DN PREV198579088178; BA79:88178
TI A MORE SPECIFIC SIMILAR RADIOIMMUNOASSAY FOR CARCINOEMBRYONIC ANTIGEN WITH
USE OF MONOCLONAL ****ANTIBODIES**** .
AU LIU Y-S V [Reprint author]; TOBIAS R J; ZURAWSKI V R JR
CS CENTOCOR, 244 GREAT VALLEY PARKWAY, MALVERN, PA 19355, USA
SO Clinical Chemistry, (1985) Vol. 31, No. 2, pp. 191-195.
CODEN: CLCHAU. ISSN: 0009-9147.
DT Article
FS BA

LA ENGLISH

L4 ANSWER 36 OF 160 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1983:195706 BIOSIS
DN PREV198375045706; BA75:45706
TI ORGANIZATION OF RHOD OPSIN AND A HIGH MOLECULAR WEIGHT GLYCO PROTEIN IN
ROD PHOTO RECEPTOR DISC MEMBRANES USING MONO CLONAL ****ANTIBODIES****
AU MACKENZIE D [Reprint author]; MOLDAY R S
CS DEP BIOCHEMISTRY, UNIV BRITISH COLUMBIA, VANCOUVER, BRITISH COLUMBIA V6T
1W5 CANADA
SO Journal of Biological Chemistry, (1982) Vol. 257, No. 12, pp. 7100-7105.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
FS BA
LA ENGLISH

L4 ANSWER 37 OF 160 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 1996-02092 BIOTECHDS
TI Isolated ligand for T cell surface molecule, especially CTLA4;
antigen-specific apoptosis using a T-lymphocyte CTLA4 human monoclonal
****antibody****, for application in graft rejection inhibition and in
autoimmune disease therapy
AU Gribben J G; Freeman G J; Nadler L M; Rennert P; Jellis C L; Greenfield
E; Gray G
PA Repligen; Dana-Farber-Cancer-Inst.
LO Cambridge, MA, USA; Boston, MA, USA.
PI WO 9533770 ****14 Dec 1995****
AI WO 1995-US6726 2 Jun 1995
PRAI US 1994-253783 3 Jun 1994
DT Patent
LA English
OS WPI: 1996-040187 [04]

L4 ANSWER 38 OF 160 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 1993-09567 BIOTECHDS
TI Isoprotein analysis by ionexchange chromatography using a linear pH
gradient combined with a salt gradient;
monoclonal ****antibody**** purification (conference paper)
AU Kaltenbrunner O; Tauer C; Brunner J; Jungbauer A
LO Institut fuer angewandte Mikrobiologie, Universitaet fuer Bodenkultur,
Nussdorfer Laende 11, A-1190 Vienna, Austria.
SO J.Chromatogr.; (****1993****) 639, 1, 41-49
CODEN: JOCRAM
DT Journal
LA English

L4 ANSWER 39 OF 160 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 1993-04124 BIOTECHDS
TI New D-arabinitol-dehydrogenase enzyme;
produced by Candida shehatae or Candida tropicalis, which is incapable
of oxidizing D-mannitol, is useful for detecting Candida infections;
monoclonal ****antibody****
PA Syntex
PI EP 522875 ****13 Jan 1993****
AI EP 1992-306371 10 Jul 1992
PRAI US 1991-731218 12 Jul 1991
DT Patent
LA English
OS WPI: 1993-010684 [02]

L4 ANSWER 40 OF 160 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 1992-08168 BIOTECHDS
TI Microencapsulation of hybridomas by cellulose sulfate-
polydimethyldiallylammonium chloride procedure;
hybridoma encapsulation and cell culture for mouse and human
monoclonal ****antibody**** preparation
AU Groot-Wassink T; Dautzenberg H; Grunow R; von Baehr R
LO Bereich Medizin (Charite) der Humboldt-Universitaet zu Berlin, Institut
fuer Medizinische Immunologie, Schumannstrasse 20/21, PSF 150, O-1040
Berlin, Germany.
SO Acta Biotechnol.; (****1992****) 12, 3, 169-78
CODEN: ACBTDD
DT Journal
LA English

L4 ANSWER 41 OF 160 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN

AN 1992-07605 BIOTECHDS
 TI Expression of a human monoclonal anti-HIV-1 ***antibody*** in CHO cells;
 production of human recombinant monoclonal ***antibody*** specific for HIV virus-1 gp41 by expression of heavy chain and light chain from vector pair in CHO cell culture (conference paper)

AU Rueker F; Ebert V; Kohl J; Steindl F; Riegler H; Katinger H
 LO Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur, Nussdorfer Laende 11, A-1190 Vienna, Austria.
 SO Ann.N.Y.Acad.Sci.; (***1991***) 646, 212-19
 CODEN: ANYAA9
 DT Journal
 LA English

L4 ANSWER 42 OF 160 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 1992-07389 BIOTECHDS
 TI Cloning and expression of an HIV-1 specific single-chain Fv region fused to Escherichia coli alkaline phosphatase;
 anti-HIV virus-1 recombinant monoclonal ***antibody*** fragment production and purification following ***antibody*** engineering (conference paper)

AU Kohl J; *Rueker F; Himmeler G; Razazzi E; Katinger H
 LO Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur, Nussdorfer Laende 11, A-1190 Vienna, Austria.
 SO Ann.N.Y.Acad.Sci.; (***1991***) 646, 106-14
 CODEN: ANYAA9
 DT Journal
 LA English

L4 ANSWER 43 OF 160 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 1992-03259 BIOTECHDS
 TI Recombinant protein which binds to complex viral antigen of HIV virus-1; human recombinant ***antibody*** containing variable region of human monoclonal ***antibody*** ; DNA sequence; useful in detection, quantification, purification of HIV virus-1 antigen

PA Jungbauer A
 PI WO 9118983 ***12 Dec 1991***
 AI WO 1991-AT67 28 May 1991
 PRAI AT 1990-1178 29 May 1990
 DT Patent
 LA German
 OS WPI: 1992-007468 [01]

L4 ANSWER 44 OF 160 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 1990-12830 BIOTECHDS
 TI Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-chains of a human monoclonal ***antibody*** specific to HIV-1 - gp41;
 HIV virus-1 gp41; heavy and light chain DNA sequence

AU Flegenhauer M; Kohl J; *Rueker F
 LO Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur, Peter Jordanstrasse 82, A-1190 Wien, Austria.
 SO Nucleic Acids Res.; (***1990***) 18, 16, 4927
 CODEN: NARHAD
 DT Journal
 LA English

L4 ANSWER 45 OF 160 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
 AN 2000:31001699 BIOTECHNO
 TI Standardization of measurement of .beta.-amyloid((1-42)) in cerebrospinal fluid and plasma

AU Vanderstichele H.; Van Kerschaver E.; Hesse C.; Davidsson P.; Buyse M.-A.; Andreasen N.; Minthon L.; Wallin A.; Blennow K.; Vanmechelen E.
 CS Dr. H. Vanderstichele, Innogenetics NV, Box 4, Industriepark Zwijnaarde 7, B-9052 Ghent, Belgium.
 E-mail: hugovdr@innogenetics.be
 SO Amyloid, (***2000***), 7/4 (245-258), 51 reference(s)
 CODEN: AIJIET ISSN: 1350-6129
 DT Journal; Article
 CY United Kingdom
 LA English
 SL English

L4 ANSWER 46 OF 160 BIOTECHNO COPYRIGHT 2004 Elsevier science B.V. on STN
 AN 1991:22266099 BIOTECHNO
 TI Expression of a human monoclonal anti-HIV-1 ***antibody*** in CHO

cells
 AU Ruker F.; Ebert V.; Kohl J.; Steindl F.; Riegler H.; Katinger H.
 CS Inst. fur Angewandte Mikrobiologie, Universitat fur Bodenkultur,
 Nussdorfer Lande 11,A-1190 Vienna, Austria.
 SO Annals of the New York Academy of Sciences, (***1991***), 646/-
 (212-219)
 CODEN: ANYAAO ISSN: 0077-8923
 DT Journal; Conference Article
 CY United States
 LA English
 SL English

L4 ANSWER 47 OF 160 CABA COPYRIGHT 2004 CABI on STN
 AN 97:137303 CABA
 DN 19972214088
 TI Antigen analysis of egg drop syndrome 76 virus by using monoclonal
 antibodies
 AU Yang KeJun; Kong DeYing; Xin ChaoAn; Yang, K. J.; Kong, D. Y.; Xin, C. A.
 CS Department of Animal Medicine, South China Agricultural University,
 Guangzhou, Guangdong 510642, China.
 SO Chinese Journal of Veterinary Medicine, (***1996***) Vol. 22, No. 5,
 pp. 3-6. 12 ref.
 DT Journal
 LA Chinese
 SL English
 ED Entered STN: 19971112
 Last Updated on STN: 19971112

L4 ANSWER 48 OF 160 CANCERLIT on STN
 AN 93114405 CANCERLIT
 DN 93114405 PubMed ID: 7678090
 TI Characterization of hemopoietic cell populations from human cord blood
 expressing c-kit.
 AU Reisbach G; Bartke I; Kempkes B; Kostka G; Ellwart J; Birner A; Thalmeier
 K; Mailhammer R; Bornkamm G W; Ullrich A; +
 CS GSF-Institute of Experimental Hematology, Munich, Germany.
 SO EXPERIMENTAL HEMATOLOGY, ***1993 Jan*** 21 (1) 74-9.
 Journal code: 0402313. ISSN: 0301-472X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS MEDLINE; Priority Journals
 OS MEDLINE 93114405
 EM 199301
 ED Entered STN: 19941107
 Last Updated on STN: 19960517

L4 ANSWER 49 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:231762 CAPLUS
 DN 134:227345
 TI Anti-matrix metalloprotease monoclonal ***antibody*** Fab'-medicine
 conjugate and its antitumor action
 IN Zhen, Yongsu; Liu, Xiaoyun; Xu, Linna; Shang, Boyang
 PA Inst. of Medicinal Biological Technology, Chinese Academy of Medical
 Sciences, Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 14 pp.
 CODEN: CNXXEV

DT Patent
 LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1268377	A	20001004	CN 2000-103497	20000315 <--
PRAI	CN 2000-103497		20000315		

L4 ANSWER 50 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:65029 CAPLUS
 DN 134:91120
 TI Monoclonal ***antibody*** Fab'-pingyangmycin conjugate and its
 anticancer action
 IN Zhen, Yongsu; Liu, Xiaoyun; Wang, Weigang; Liu, Xiujun
 PA Inst. of Biomedical Technology, Chinese Academy of Medical Sciences,
 Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 9 pp.
 CODEN: CNXXEV
 DT Patent

LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1255378	A	20000607	CN 1999-110806	19990721 <--
	CN 1110322	B	20030604		
PRAI	CN 1999-110806		19990721		

L4 ANSWER 51 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:249109 CAPLUS

DN 130:293622

TI Process for detecting, extracting or removing human or mammalian cells with a disturbed cellular cycle regulation or unlimited proliferation or tumor-forming ability

IN Abken, Hinrich

PA Germany

SO PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9918235	A1	19990415	WO 1998-EP6384	19981007 <--
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 19821506	A1	19990415	DE 1998-19821506	19980513 <--
	EP 1021564	A1	20000726	EP 1998-954373	19981007 <--
	R: AT, CH, DE, DK, ES, FR, GB, IT, LI				
	JP 2001519169	T2	20011023	JP 2000-515027	19981007
PRAI	DE 1997-19744335	A	19971007		
	DE 1997-19749118	A	19971106		
	DE 1998-19821506	A	19980513		
	WO 1998-EP6384	W	19981007		

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 52 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:184272 CAPLUS

DN 130:223588

TI Preparation and properties of biomolecules containing an elastomeric peptide

IN Reiersen, Herald; Rees, Anthony; Korsnes, Lars

PA Dynal As, Norway

SO PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911661	A1	19990311	WO 1998-GB2602	19980828 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2301981	AA	19990311	CA 1998-2301981	19980828 <--
	AU 9888755	A1	19990322	AU 1998-88755	19980828 <--
	AU 759080	B2	20030403		
	EP 1009761	A1	20000621	EP 1998-940427	19980828 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, PT, IE, FI				
	BR 9811421	A	20000822	BR 1998-11421	19980828 <--
	JP 2001514263	T2	20010911	JP 2000-508699	19980828
	NZ 503097	A	20020328	NZ 1998-503097	19980828
PRAI	GB 1997-18463	A	19970829		
	WO 1998-GB2602	W	19980828		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 53 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:291603 CAPLUS

DN 129:94197
 TI Production of monoclonal ***antibodies*** against bovine parvovirus
 AU Mahmoud, Mervat M.; Karim, Ikram A.; Shalaby, M. A.
 CS Animal Health Research Institute, Giza, Egypt
 SO Veterinary Medical Journal Giza (***1997***), 45(4), 449-455
 CODEN: VMJGEA; ISSN: 1110-1423
 PB Cairo University, Faculty of Veterinary Medicine
 DT Journal
 LA English
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 54 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:59054 CAPLUS
 DN 128:124544
 TI Hepatocyte growth factor receptor agonists and uses thereof
 IN Hillan, Kenneth J.; Schwall, Ralph H.; Tabor, Kelly H.
 PA Genentech, Inc., USA
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9800543	A1	19980108	WO 1997-US10688	19970620 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2258153	AA	19980108	CA 1997-2258153	19970620 <--
AU 9734949	A1	19980121	AU 1997-34949	19970620 <--
AU 729029	B2	20010125		
EP 922102	A1	19990616	EP 1997-931275	19970620 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000515735	T2	20001128	JP 1998-504193	19970620 <--
US 6099841	A	20000808	US 1997-884669	19970627 <--
ZA 9705851	A	19990104	ZA 1997-5851	19970701 <--
PRAI US 1996-21215P	P	19960703		
WO 1997-US10688	W	19970620		

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 55 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1995:950241 CAPLUS
 DN 124:6696
 TI BiP binding sequences in ***antibodies***
 AU Knarr, Gerhard; Gething, Mary-Jane; Modrow, Susanne; Buchner, Johannes
 CS Inst. Biophys. Physikalische Biochemie, Univ. Regensburg, Regensburg, 93040, Germany
 SO Journal of Biological Chemistry (***1995***), 270(46), 27589-94
 CODEN: JBCHA3; ISSN: 0021-9258
 PB American Society for Biochemistry and Molecular Bio logy
 DT Journal
 LA English

L4 ANSWER 56 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:467394 CAPLUS
 DN 115:67394
 TI The effect of a monoclonal ***antibody*** on specific steps of the reaction sequence of the calcium-magnesium ATPase from sarcoplasmic reticulum
 AU Mata, Ana M.; Colyer, John; Michelangeli, Francesco; Lee, Anthony G.; East, J. Malcolm
 CS Dep. Biochem., Univ. Southampton, Southampton, SO9 3TU, UK
 SO Biochemical Society Transactions (***1991***), 19(2), 205s
 CODEN: BCSTB5; ISSN: 0300-5127
 DT Journal
 LA English

L4 ANSWER 57 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:196651 CAPLUS
 DN 112:196651
 TI Pilot production of human monoclonal ***antibodies*** against HIV-1
 AU Jungbauer, Alois; Steindl, Franz; Grunow, Roland; Porstmann, Tomas; Ernst, Wolfgang; Purtscher, Martin; Reiter, Manfred; Tauer, Christa; Wenisch, Elisabeth; Katinger, Hermann
 CS Inst. Angew. Mikrobiol., Univ. Bodenkult., Vienna, A-1190, Austria
 SO Zeitschrift fuer Klinische Medizin (1985) (***1990***), 45(4), 351-4
 CODEN: ZKMEEF; ISSN: 0233-1608
 DT Journal
 LA German

L4 ANSWER 58 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:137344 CAPLUS

DN 112:137344

TI Human monoclonal anti-human immunodeficiency virus type 1 (anti-HIV-1) ***antibodies***

IN Katinger, Hermann; Von Baehr, Ruediger; Jungbauer, Alois; Porstmann, Tomas; Steindl, Franz J.; Grunow, Roland; Buchacher, Andrea

PA CL Pharma A.-G., Austria

SO PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8904370	A1	19890518	WO 1988-EP1072	19881114 <--
	W: JP, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 355140	A1	19900228	EP 1989-900809	19881114 <--
	EP 355140	B1	19960320		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02502251	T2	19900726	JP 1989-500718	19881114 <--
	AT 135743	E	19960415	AT 1989-900809	19881114 <--
	US 5831034	A	19981103	US 1994-293842	19940822 <--
	US 5753503	A	19980519	US 1994-347966	19941201 <--
PRAI	US 1987-120489	A	19871113		
	WO 1988-EP1072	W	19881114		
	US 1990-583505	B1	19900917		
	US 1991-693730	B1	19910430		
	US 1993-97170	B1	19930723		
	US 1993-105360	B1	19930810		

L4 ANSWER 59 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1988:524927 CAPLUS

DN 109:124927

TI The mechanism of inhibition of the calcium-magnesium-ATPase by monoclonal ***antibodies***

AU Colyer, J.; Michelangeli, F.; Lee, A. G.; East, J. M.

CS Dep. Biochem., Univ. Southampton, Southampton, SO9 3TU, UK

SO Biochemical Society Transactions (***1988***), 16(6), 967-8

CODEN: BCSTB5; ISSN: 0300-5127

DT Journal

LA English

L4 ANSWER 60 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1988:488831 CAPLUS

DN 109:88831

TI Effect of monoclonal ***antibodies*** raised against calcium-magnesium ATPase from rabbit skeletal muscle sarcoplasmic reticulum on ATPase activity and its correlation with epitope location

AU Mata, Ana M.; Colyer, John; Tunwell, Richard E. A.; Lee, Anthony G.; East, J. Malcolm

CS Dep. Biochem., Univ. Southampton, Southampton, SO9 3TU, UK

SO Biochemical Society Transactions (***1988***), 16(5), 771-2

CODEN: BCSTB5; ISSN: 0300-5127

DT Journal

LA English

L4 ANSWER 61 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1987:634639 CAPLUS

DN 107:234639

TI Immunometric assay for high-molecular-weight carcinoembryonic antigen, kits for the immunoassay, and their use in colorectal cancer diagnosis

IN Schoemaker, Hubert J. P.; Brennan, Suzanne E.; Schlom, Jeffrey; Brock,

Paul
PA Centocor, Inc., USA
SO Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 225709	A2	19870616	EP 1986-308212	19861022 <--
	EP 225709	A3	19880907		
	EP 225709	B1	19920527		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 790261	A0	19880601	US 1985-790261	19851022 <--
	JP 62201364	A2	19870905	JP 1986-251574	19861022 <--
	CA 1291422	A1	19911029	CA 1986-521283	19861022 <--
	AT 76690	E	19920615	AT 1986-308212	19861022 <--
PRAI	US 1985-790261		19851022		
	EP 1986-308212		19861022		

L4 ANSWER 62 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1987:420274 CAPLUS
DN 107:20274
TI Detection in plasma of derivatives of crosslinked fibrin, using monoclonal
antibodies
AU Whitaker, A. N.; Masci, P. P.; Dunstan, A.; Elms, M. J.; Bunce, I. H.;
Bundesen, P. J.; Rylatt, D. B.; Webber, A. J.
CS Princess Alexandra Hosp., Univ. Queensland, Queensland, Australia
SO International Congress Series (***1986***), 722(Fibrinogen Its
Deriv.), 265-72
CODEN: EXMDA4; ISSN: 0531-5131
DT Journal
LA English

L4 ANSWER 63 OF 160 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1969:479219 CAPLUS
DN 71:79219
TI Quantitative studies of the specificity of antipneumococcal
antibodies, types III and VIII. IV. Binding of labeled
hexasaccharides derived from S3 by anti-S3 ***antibodies*** and their
Fab fragments
AU Katz, Moshe; Pappenheimer, Alwin M., Jr.
CS Harvard Univ., Cambridge, MA, USA
SO Journal of Immunology (***1969***), 103(3), 491-5
CODEN: JOIMA3; ISSN: 0022-1767
DT Journal
LA English

L4 ANSWER 64 OF 160 DISSABS COPYRIGHT (C) 2004 ProQuest Information and
Learning Company; All Rights Reserved on STN
AN 93:59597 DISSABS Order Number: AARC313016 (not available for sale by
UMI)
TI CLONING AND EXPRESSION OF A SINGLE-CHAIN PROTEIN IN ESCHERICHIA COLI
KOLONIERUNG UND EXPRESSION EINES ANTIGENBINDENDEN PROTEINS IN ESCHERICHIA
COLI
AU KOHL, JOHANN [DR.NAT.]
CS UNIVERSITAET FUER BODENKULTUR WIEN (AUSTRIA) (5808)
SO Dissertation Abstracts International, (***1991***) vol. 54, No. 4C, p.
1078. Order No.: AARC313016 (not available for sale by UMI). 58 pages.
DT Dissertation
FS DAI
LA English
ED Entered STN: 19931214
Last Updated on STN: 19931214

L4 ANSWER 65 OF 160 DISSABS COPYRIGHT (C) 2004 ProQuest Information and
Learning Company; All Rights Reserved on STN
AN 93:38865 DISSABS Order Number: AAR9320691
TI APPLICATION OF MONOCLONAL ***ANTIBODIES*** IN THE STUDY OF MYCOPLASMA
GALLISEPTICUM SURFACE EPITOPES AND AS A DIAGNOSTIC TOOL
AU GARCIA, MARICARMEN [PH.D.]; KLEVEN, STANLEY H. [advisor]
CS UNIVERSITY OF GEORGIA (0077)
SO Dissertation Abstracts International, (***1993***) vol. 54, No. 3B, p.
1314. Order No.: AAR9320691. 118 pages.
DT Dissertation
FS DAI

LA English
ED Entered STN: 19930817
Last Updated on STN: 19930817

L4 ANSWER 66 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW19507 protein DGENE
TI Testing compounds for an effect on an Alzheimer's disease marker - uses
non-human transgenic animals which can control expression of major forms
of beta-amyloid precursor protein
IN Games K D; McConlogue L C; Rydel R E; Schenk D B; Seubert P A
PA (ATHE-N) ATHENA NEUROSCIENCES INC.
PI ***WO 9640896 A1 19961219 139p***
AI WO 1996-US9857 19960607
PRAI US 1995-480653 19950607
DT Patent
LA English
OS 1997-052309 [05]
DESC Immunogen for raising monoclonal ***antibody*** ***3D6*** for
A-beta recognition.

L4 ANSWER 67 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW19494 protein DGENE
TI Transgenic mammal comprising DNA encoding A-beta-contg. protein - useful
as animal model to test potential Alzheimer's disease treatments
IN McConlogue L C; Seubert P A
PA (ATHE-N) ATHENA NEUROSCIENCES INC.
PI ***WO 9640895 A1 19961219 116p***
AI WO 1996-US9679 19960607
PRAI US 1995-486538 19950607
US 1995-486018 19950607
DT Patent
LA English
OS 1997-052308 [05]
DESC Immunogen for raising monoclonal ***antibody*** ***3D6*** for
A-beta recognition.

L4 ANSWER 68 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52521 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 CDR-H2.

L4 ANSWER 69 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52537 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 heavy chain complementarity determining region 1.

L4 ANSWER 70 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52536 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 heavy chain complementarity determining region 1.

L4 ANSWER 71 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52535 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 heavy chain complementarity determining region 1.

L4 ANSWER 72 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52534 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ***3D6*** light chain complementarity determining region 3.

L4 ANSWER 73 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52533 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 light chain complementarity determining region 3.

L4 ANSWER 74 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52532 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English

OS 1994-120230 [15]
DESC D1.3 light chain complementarity determining region 3.

L4 ANSWER 75 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52531 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 light chain complementarity determining region 3.

L4 ANSWER 76 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52530 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ***3D6*** light chain complementarity determining region 2.

L4 ANSWER 77 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52529 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 light chain complementarity determining region 2.

L4 ANSWER 78 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52528 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 light chain complementarity determining region 2.

L4 ANSWER 79 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52527 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on

V-region
 IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI ***EP 592106 A1 19940413 230p***
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC Gloop-2 light chain complementarity determining region 2.

L4 ANSWER 80 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52526 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region
 IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI ***EP 592106 A1 19940413 230p***
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC ***3D6*** light chain complementarity determining region 1.

L4 ANSWER 81 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52525 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region
 IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI ***EP 592106 A1 19940413 230p***
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC 36-71 light chain complementarity determining region 1.

L4 ANSWER 82 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52524 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region
 IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI ***EP 592106 A1 19940413 230p***
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent
 LA English
 OS 1994-120230 [15]
 DESC D1.3 light chain complementarity determining region 1.

L4 ANSWER 83 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAR52523 Peptide DGENE
 TI Method of resurfacing of rodent ***antibodies*** to produce humanised
 antibody forms - for producing non-human ***antibodies***
 with improved therapeutic efficiency by presenting human surface on
 V-region
 IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
 PA (PEDE-I) PEDERSEN J T.
 (IMMU-N) IMMUNOGEN INC.
 PI ***EP 592106 A1 19940413 230p***
 AI EP 1993-307051 19930907
 PRAI US 1992-942245 19920909
 DT Patent

LA English
OS 1994-120230 [15]
DESC Gloop-2 light chain complementarity determining region 1.

L4 ANSWER 84 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52522 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC F19.9 CDR-H2.

L4 ANSWER 85 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52546 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ****3D6*** heavy chain complementarity determining region 3.

L4 ANSWER 86 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52545 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 heavy chain complementarity determining region 3.

L4 ANSWER 87 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52544 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 heavy chain complementarity determining region 3.

L4 ANSWER 88 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52543 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***

with improved therapeutic efficiency by presenting human surface on V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 heavy chain complementarity determining region 3.

L4 ANSWER 89 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52542 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ***3D6*** heavy chain complementarity determining region 2.

L4 ANSWER 90 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52541 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC 36-71 heavy chain complementarity determining region 2.

L4 ANSWER 91 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52540 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC D1.3 heavy chain complementarity determining region 2.

L4 ANSWER 92 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52539 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on V-region

IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909

DT Patent
LA English
OS 1994-120230 [15]
DESC Gloop-2 heavy chain complementarity determining region 2.

L4 ANSWER 93 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR52538 Peptide DGENE
TI Method of resurfacing of rodent ***antibodies*** to produce humanised
antibody forms - for producing non-human ***antibodies***
with improved therapeutic efficiency by presenting human surface on
V-region
IN Guild B C; Pedersen J T; Rees A R; Roguska M A; Searle S M J
PA (PEDE-I) PEDERSEN J T.
(IMMU-N) IMMUNOGEN INC.
PI ***EP 592106 A1 19940413 230p***
AI EP 1993-307051 19930907
PRAI US 1992-942245 19920909
DT Patent
LA English
OS 1994-120230 [15]
DESC ***3D6*** heavy chain complementarity determining region 1.

L4 ANSWER 94 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR20059 Protein DGENE
TI Recombinant protein which binds to complex viral antigen and HIV-1 -
contains variable region of ***antibody*** derived from ***3D6***
cell line, used for detecting HIV-1 antigen
IN Felgenhauer M; Himmler G; Kohl J; Steindl F
PA (JUNG-I) JUNGBAUER A.
PI ***WO 9118983 A 19911212 52p***
AI WO 1991-1000067 19910528
PRAI AT 1990-1178 19900529
DT Patent
LA German
OS 1992-007468 [01]
CR N-PSDB: AAQ20068
DESC Recombinant sc3D6 anti-HIV gp160 ***antibody*** .

L4 ANSWER 95 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR20058 Protein DGENE
TI Recombinant protein which binds to complex viral antigen and HIV-1 -
contains variable region of ***antibody*** derived from ***3D6***
cell line, used for detecting HIV-1 antigen
IN Felgenhauer M; Himmler G; Kohl J; Steindl F
PA (JUNG-I) JUNGBAUER A.
PI ***WO 9118983 A 19911212 52p***
AI WO 1991-1000067 19910528
PRAI AT 1990-1178 19900529
DT Patent
LA German
OS 1992-007468 [01]
CR N-PSDB: AAQ20067
DESC Light chain of ***3D6*** anti-HIV ***antibody*** .

L4 ANSWER 96 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR20057 Protein DGENE
TI Recombinant protein which binds to complex viral antigen and HIV-1 -
contains variable region of ***antibody*** derived from ***3D6***
cell line, used for detecting HIV-1 antigen
IN Felgenhauer M; Himmler G; Kohl J; Steindl F
PA (JUNG-I) JUNGBAUER A.
PI ***WO 9118983 A 19911212 52p***
AI WO 1991-1000067 19910528
PRAI AT 1990-1178 19900529
DT Patent
LA German
OS 1992-007468 [01]
CR N-PSDB: AAQ20066
DESC Heavy chain of ***3D6*** anti-HIV ***antibody*** .

L4 ANSWER 97 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAQ20068 DNA DGENE
TI Recombinant protein which binds to complex viral antigen and HIV-1 -
contains variable region of ***antibody*** derived from ***3D6***
cell line, used for detecting HIV-1 antigen
IN Felgenhauer M; Himmler G; Kohl J; Steindl F

PA (JUNG-I) JUNGBAUER A.
 PI ***WO 9118983 A 19911212 52p***
 AI WO 1991-1000067 19910528
 PRAI AT 1990-1178 19900529
 DT Patent
 LA German
 OS 1992-007468 [01]
 CR P-PSDB: AAR20059
 DESC Encodes recombinant sc3D6 anti-HIV gp160 ***antibody*** .

L4 ANSWER 98 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAQ20067 DNA DGENE
 TI Recombinant protein which binds to complex viral antigen and HIV-1 -
 contains variable region of ***antibody*** derived from ***3D6***
 cell line, used for detecting HIV-1 antigen
 IN Felgenhauer M; Himmler G; Kohl J; Steindl F
 PA (JUNG-I) JUNGBAUER A.
 PI ***WO 9118983 A 19911212 52p***
 AI WO 1991-1000067 19910528
 PRAI AT 1990-1178 19900529
 DT Patent
 LA German
 OS 1992-007468 [01]
 CR P-PSDB: AAR20058
 DESC Encodes light chain of ***3D6*** anti-HIV ***antibody*** .

L4 ANSWER 99 OF 160 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAQ20066 DNA DGENE
 TI Recombinant protein which binds to complex viral antigen and HIV-1 -
 contains variable region of ***antibody*** derived from ***3D6***
 cell line, used for detecting HIV-1 antigen
 IN Felgenhauer M; Himmler G; Kohl J; Steindl F
 PA (JUNG-I) JUNGBAUER A.
 PI ***WO 9118983 A 19911212 52p***
 AI WO 1991-1000067 19910528
 PRAI AT 1990-1178 19900529
 DT Patent
 LA German
 OS 1992-007468 [01]
 CR P-PSDB: AAR20057
 DESC Encodes heavy chain of ***3D6*** ***antibody*** .

L4 ANSWER 100 OF 160 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2000-36596 DRUGU P
 TI Peripherally administered ***antibodies*** against amyloid
 beta-peptide enter the central nervous system and reduce pathology in a
 mouse model of Alzheimer disease.
 AU Bard F; Cannon C; Barbour R; Burke R L; Games D; Grajeda H; Guido T; Hu
 K; Huang J; Johnson Wood K
 LO San Francisco, Cal., USA
 SO Nat.Med. (6, No. 8, 916-19, 2000) 3 Fig. 1 Tab. 10 Ref.
 CODEN: MAMEF ISSN: 1078-8956
 AV Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco,
 California 94080, U.S.A. (23 authors). (e-mail: fbard@elanpharma.com).
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature

L4 ANSWER 101 OF 160 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2000-31155 DRUGU P
 TI Antitumor effects of novel immunoconjugates with downsized-molecule
 prepared by linking lidamycin to Fab' and scFv ***antibody*** .
 AU Liu X Y; Li S Q; Jiang M; Zhen Y S
 CS Chinese-Acad.Med.Sci.
 LO Beijing, China
 SO Proc.Am.Assoc.Cancer Res. (41, 91 Meet., 290-91, 2000) ISSN:
 0197-016X
 AV Inst. for Med Bio, Chinese Acad of Med Sci, China.
 LA English
 DT Journal
 FA AB; LA; CT
 FS Literature

L4 ANSWER 102 OF 160 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 1985-37973 DRUGU P M

TI Rationale for Development of a Synthetic Vaccine Against Plasmodium
 Falciparum Malaria.
 AU Zavala F; Tam J P; Hollingdale M R; Cochrane A H; Quakyi I; Nussenzweig R
 S
 LO New York, New York, Rockville, Maryland, United States; Legon, Gha
 SO Science (228, No. 4706, 1436-40, 1985) 2 Fig. 2 Tab. 23 Ref.
 CODEN: SCIEAS ISSN: 0036-8075
 AV Department of Medical and Molecular Parasitology, New York University
 Medical Center, New York 10021, U.S.A. (7 authors).
 LA English
 DT Journal
 FA AB; LA; CT; MPC
 FS Literature

L4 ANSWER 103 OF 160 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): MUSIGVHC GenBank (R)
 GenBank ACC. NO. (GBN): D14172
 GenBank VERSION (VER): D14172.1 GI:784932
 CAS REGISTRY NO. (RN): 384577-20-2
 SEQUENCE LENGTH (SQL): 341
 MOLECULE TYPE (CI): mRNA; linear
 DIVISION CODE (CI): Rodents
 DATE (DATE): 24 Jan 2003
 DEFINITION (DEF): Mus musculus mRNA, immunoglobulin heavy chain variable
 region (anti-CD8 monoclonal ***antibody***),
 partial sequence, clone:TD- ***3D6*** .

KEYWORDS (ST): VH region
 SOURCE: Mus musculus (house mouse)
 ORGANISM (ORGN): Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
 Euteleostomi; Mammalia; Eutheria; Rodentia;
 Sciurognathi; Muridae; Murinae; Mus

NUCLEIC ACID COUNT (NA): 97 a 83 c 89 g 72 t

COMMENT:

On Apr 26, 1995 this sequence version replaced gi:498370.

REFERENCE: 1 (bases 1 to 341)

AUTHOR (AU): Sato,T.; Kon,S.

TITLE (TI): Analysis of the immunoglobulin heavy chain variable
 region of hybridomas producing anti-CD8 monoclonal
 antibodies

JOURNAL (SO): Sapporo Med. J., 62, 31-41 (***1993***)

OTHER SOURCE (OS): CA 121:80571

REFERENCE: 2 (bases 1 to 341)

AUTHOR (AU): Kon,S.

TITLE (TI): Direct Submission

JOURNAL (SO): Submitted (25-JAN-1993) Shinichiro Kon, Sapporo Medical
 College, Department of Pathology; South1, West17,
 Chuo-ku, Sapporo 060, Japan (Tel:011-611-2111(ex.2311),
 Fax:011-643-2310)

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..341	/organism="Mus musculus" /strain="BALB/c" /db-xref="taxon:10090" /clone="TD-3D6" /cell-type="hybridoma (TD series)"
V-region	<1..>341	/product="anti-CD8 monoclonal antibody" /db-xref="IMGT/LIGM:D14172"
misc-feature	1..89	/note="FR1"
misc-feature	90..104	/note="CDR1"
misc-feature	105..146	/note="FR2"
misc-feature	147..197	/note="CDR2"
misc-feature	198..293	/note="FR3"
misc-feature	294..317	/note="CDR3"
misc-feature	318..341	/note="FR4"

SEQUENCE (SEQ):

```

1 aggtccaact gcagcagtct ggagctgaac tgatgaagcc tggggcctca gtgaagatat
61 cctgcaaggc tactggcaac acattcagaa ccaactggat agagtgggta aaacagaggc
121 ctggacatgg ccttgagtgg attggagaga ttttacctgg aagtggtagt accaactacc
181 atgagaagtt caaggataag gccacattca ctgcagacat atcctccaac acagcctaca
241 tacaactcag cagcctgaca tctgaggact ctgccgtcta ttactgtgca agactgagtg
  
```

301 attccaagtt tgcttactgg ggcgcaggga ccacgggtcac c

L4 ANSWER 104 OF 160 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): HS3D6LCV GenBank (R)
GenBank ACC. NO. (GBN): X53612
GenBank VERSION (VER): X53612.1 GI:23868
CAS REGISTRY NO. (RN): 140555-39-1
SEQUENCE LENGTH (SQL): 381
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Primates
DATE (DATE): 3 Apr 1995
DEFINITION (DEF): Human mRNA for ***3D6*** light chain variable region.
SOURCE: human.
ORGANISM (ORGN): Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo

NUCLEIC ACID COUNT (NA): 92 a 101 c 95 g 93 t

COMMENT:

This comes from serum of a HIV-1 positive individual.

REFERENCE: 1 (bases 1 to 381)

AUTHOR (AU): Rueker, F.

TITLE (TI): Direct Submission

JOURNAL (SO): Submitted (26-JUN-1990) Rueker F., Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur, Peter Jordanstr. 82, A-1190 Wien, Austria

REFERENCE: 2 (bases 1 to 381)

AUTHOR (AU): Felgenhauer, M.; Kohl, J.; Rucker, F.

TITLE (TI): Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-chains of a human monoclonal ***antibody*** specific to HIV-1-gp41

JOURNAL (SO): Nucleic Acids Res., 18 (16), 4927 (***1990***)

OTHER SOURCE (OS): CA 113:166692

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..381	/organism="Homo sapiens" /isolate="monoclonal antibody 3D6" /db-xref="taxon:9606" /cell-line="3D6." /cell-type="rearranged lymphoblastoid"
sig-peptide	1..66	
CDS	1..>381	/codon-start=1 /product="kappa light chain V-region" /protein-id="CAA37674.1" /db-xref="GI:762937" /translation="MDMRVPAQLLGLLLWLPGA KCDIQMTQSPSTLSASVGDRVIT CRASQSISRWLAWYQQKPGKVPKLLIYKASSLES GVPSRFSGSGSGTEFTLTISSLQP DDFATYYCQQYNSYSFGPGTKVDIK"
V-region	67..>381	/note="variable region (AA 23 - 127)"

SEQUENCE (SEQ):

```
1 atggacatga gggccccgc tcagctcctg gggctcctgc tgctctggct cccaggtgcc
61 aaatgtgaca tccagatgac ccagctcctt tccaccctgt ctgcatctgt aggagacaga
121 gtcaccatca cttgccgggc cagtcagagt attagtaggt ggttggcctg gtatcagcag
181 aaaccaggga aagtccttaa gctcctgac tataaggcat ctagtttaga aagtgggggc
241 ccatcaaggt tcagcggcag tggatctggg acagaattca ctctcaccat cagcagcctg
301 cagcctgatg attttgcaac ttattactgc caacagtata atagttattc tticggccct
361 gggaccaaaag tggatatcaa a
```

L4 ANSWER 105 OF 160 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): HS3D6HCV GenBank (R)
GenBank ACC. NO. (GBN): X53613
GenBank VERSION (VER): X53613.1 GI:23865
CAS REGISTRY NO. (RN): 139841-87-5
SEQUENCE LENGTH (SQL): 435
MOLECULE TYPE (CI): mRNA; linear

DIVISION CODE (CI): Primates
 DATE (DATE): 3 Apr 1995
 DEFINITION (DEF): Human mRNA for ***3D6*** heavy chain variable region.
 SOURCE: human.
 ORGANISM (ORGN): Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
 Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae; Homo

NUCLEIC ACID COUNT (NA): 99 a 87 c 130 g 119 t

COMMENT:
 This comes from serum of a HIV-1 positive individual.

REFERENCE: 1 (bases 1 to 435)
 AUTHOR (AU): Rueker, F.
 TITLE (TI): Direct Submission
 JOURNAL (SO): Submitted (26-JUN-1990) Rueker F., Institut fuer Angewandte Mikrobiologie, Universitaet fuer Bodenkultur, Peter Jordanstr. 82, A-1190 Wien, Austria
 REFERENCE: 2 (bases 1 to 435)
 AUTHOR (AU): Felgenhauer, M.; Kohl, J.; Ruer, F.
 TITLE (TI): Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-chains of a human monoclonal ***antibody*** specific to HIV-1-gp41
 JOURNAL (SO): Nucleic Acids Res., 18 (16), 4927 (***1990***)
 OTHER SOURCE (OS): CA 113:166692

FEATURES (FEAT):	Feature Key	Location	Qualifier
source	1..435		/organism="Homo sapiens" /isolate="monoclonal antibody 3D6" /db-xref="taxon:9606" /cell-line="3D6." /cell-type="rearranged lymphoblastoid"
sig-peptide	1..57		
CDS	1..>435		/codon-start=1 /product="kappa light chain V-region" /protein-id="CAA37675.1" /db-xref="GI:762936" /translation="MELGLSWIFLLAILKGVQCE VQLVESGGGLVQPGRSLRLSCAAS GFTFNDYAMHWVRQAPGKGLEWVSGISWDSSSIG YADSVKGRFTISRDNAKNSLYLQM NSLRAEDMALYYCVKGRDYYDSGGYFTVAFDIWG QGTMTVSS"
V-region	58..>435		/note="variable region (AA 20 - 145)"

SEQUENCE (SEQ):
 1 atggagttgg gactgagctg gattttcctt ttggctattt taaaagggtg ccagtgtgaa
 61 gtgcagctgg tggagctctg gggaggcttg gtacagcctg gcaggctccct gagactctcc
 121 tgtgcagcct ctggattcac cttaaatgat tatgccatgc actgggtccg gcaagctcca
 181 gggaagggcc tggagtgggt ctcaggtata agttgggata gtagtagtat aggctatgcg
 241 gactctgtga agggccgatt caccatctcc agagacaacg ccaagaactc cctgtatctg
 301 caaatgaaca gtctgagagc tgaggacatg gccttatatt actgtgtaaa aggcagagat
 361 tactatgata gtggtggtta ttacacggtt gcttttgata tctggggcca aggacaatg
 421 gtcaccgtct cttca

L4 ANSWER 106 OF 160 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 02981273 IFIPAT;IFIUDB;IFICDB
 TI HUMAN MONOCLONAL ANTI-HIV-I- ***ANTIBODIES*** ; CAPABLE OF SELECTIVELY BINDING TO GP41 OF ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
 IN von Baehr Ruediger (DE); Grunow Roland (DE); Jungbauer Alois A (AT); Katinger Hermann W D (AT); Porstmann Tomas (DE); Steindl Franz J (AT)
 PA Unassigned Or Assigned To Individual (68000)
 PI US 5753503 A 19980519
 AI US 1994-347966 19941201
 RLI US 1990-583505 19900917 CONTINUATION ABANDONED
 US 1993-97170 19930723 CONTINUATION ABANDONED
 US 1993-105360 19930810 CONTINUATION ABANDONED
 US 1987-120489 19871113 DIVISION ABANDONED
 FI US 5753503 19980519
 DT Utility

FS CHEMICAL
GRANTED
CLMN 7
GI 5 Drawing Sheet(s), 8 Figure(s).

L4 ANSWER 107 OF 160 LIFESCI COPYRIGHT 2004 CSA on STN
AN 93:53806 LIFESCI
TI Demonstration of peptidoglycan-associated Brucella outer-membrane
proteins by use of monoclonal ***antibodies***
AU Coeckaert, A.; Zygmunt, M.S.; de Wergifosse, P.; Dubray, G.; Limet, J.N.
CS Unit Exp. Med., Catholic Univ. Louvain, 75 Ave. Hippocrate, B-1200
Brussels, Belgium
SO J. GEN. MICROBIOL., (***1992***) vol. 138, no. 7, pp. 1543-1550.
DT Journal
FS J; M; F
LA English
SL English

L4 ANSWER 108 OF 160 LIFESCI COPYRIGHT 2004 CSA on STN
AN 88:57297 LIFESCI
TI Production of monoclonal ***antibodies*** against human erythropoietin
and their use in the purification of human urinary erythropoietin.
AU Miyazaki, H.; Kozutsumi, H.; Kato, T.; Hoshi, S.; Tamura, S.; Kubota, M.;
Suzuki, T.
CS Pharm. Lab., Kirin Brewery Co., Ltd., Maebashi, Gunma 371, Japan
SO J. IMMUNOL. METHODS., (***1988***) vol. 113, no. 3, pp. 261-267.
DT Journal
FS F
LA English
SL English

L4 ANSWER 109 OF 160 LIFESCI COPYRIGHT 2004 CSA on STN
AN 86:33498 LIFESCI
TI Characterization of three different rat T-cell clones with specificity to
Listeria monocytogenes : Phenotype, specific proliferation, lymphokine
production, and protective capacity in vivo.
AU Stolpmann, R.M.; Sperling, U.; Hahn, H.
CS Inst. Med. Mikrobiol., Freie Univ., Berlin, FRG
SO CELL. IMMUNOL., (***1986***) vol. 101, no. 2, pp. 548-557.
DT Journal
FS J; F
LA English
SL English

L4 ANSWER 110 OF 160 MEDLINE on STN
AN 91077155 MEDLINE
DN PubMed ID: 1701654
TI Characterization of monoclonal ***antibodies*** to human
immunodeficiency virus type 1 gp41 by HIV-1 polypeptides expressed in
Escherichia coli.
AU Larcher C; Broker M; Huemer H P; Solder B; Schulz T F; Hofbauer J M;
Wachter H; Dierich M P
CS Institut fur Hygiene, University of Innsbruck, Austria.
SO FEMS microbiology immunology, *** (1990 Sep) *** 2 (2) 103-10.
Journal code: 8901230. ISSN: 0920-8534.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 199101
ED Entered STN: 19910322
Last Updated on STN: 19970203
Entered Medline: 19910129

L4 ANSWER 111 OF 160 PASCAL COPYRIGHT 2004 INIST-CNRS. ALL RIGHTS
RESERVED. on STN
AN 1992-0540032 PASCAL
TIEN Demonstration of peptidoglycan-associated Brucella outer-membrane
proteins by use of monoclonal ***antibodies***
AU CLOACKAERT A.; ZYGMUNT M. S.; DE WERGIFOSSE P.; DUBRAY G.; LIMET J. N.
CS Catholic univ. Louvain, unit exp. medicine, 1200 Brussels, Belgium
SO JGM. Journal of general microbiology, *** (1992) *** , 138(p.7),
1543-1550, refs. 1 p.
DT Journal
BL Analytic
CY United Kingdom

LA English
AV INIST-4410, 354000020157910310

L4 ANSWER 112 OF 160 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 94:100602 SCISEARCH
GA The Genuine Article (R) Number: MQ935
TI STABLE, CONTINUOUS LARGE-SCALE PRODUCTION OF HUMAN MONOCLONAL HIV-1
ANTIBODY USING A COMPUTER-CONTROLLED PILOT-PLANT
AU UNTERLUGGAUER F (Reprint); DOBLHOFFDIER O; TAUER C; JUNGBAUER A; GAIDA T;
REITER M; SCHMATZ C; ZACH N; KATINGER H
CS UNIV AGR & FORESTRY, INST APPL MICROBIOL, NUSSDORFER LANDE 11, A-1190
VIENNA, AUSTRIA (Reprint)
CYA AUSTRIA
SO BIOTECHNIQUES, (***JAN 1994***) Vol. 16, No. 1, pp. 140.
ISSN: 0736-6205.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 25
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 113 OF 160 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 93:5268 SCISEARCH
GA The Genuine Article (R) Number: KD862
TI GROWTH AND PRODUCTION KINETICS OF HUMAN X MOUSE AND MOUSE HYBRIDOMA CELLS
AT REDUCED TEMPERATURE AND SERUM CONTENT
AU BORTH N (Reprint); HEIDER R; ASSADIAN A; KATINGER H
CS UNIV AGR VIENNA, INST APPL MICROBIOL, NUSSDORFER LANDE 11, A-1190 VIENNA,
AUSTRIA (Reprint)
CYA AUSTRIA
SO JOURNAL OF BIOTECHNOLOGY, (***SEP 1992***) Vol. 25, No. 3, pp.
319-331.
ISSN: 0168-1656.
DT Article; Journal
FS AGRI
LA ENGLISH
REC Reference Count: 36
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 114 OF 160 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 2002:432063 TOXCENTER
DN EMIC-87667
TI Monoclonal ***antibodies*** and rabbit antisera recognizing
4-aminobiphenyl--DNA adducts and application to immunoaffinity
chromatography.
AU Groopman J D; Skipper P L; Donahue P R; Trudel L J; Wildschutte M;
Kadlubar F F; Tannenbaum S R
CS Department of Environmental Health Sciences, Johns Hopkins University,
School of Hygiene and Public Health, Baltimore, MD 21205.
NC K04 CA01517 (CA)
P01-ES00597 (ES)
SO Carcinogenesis, (***1992 Jun***) 13 (6) 917-22.
Journal Code: C9T. ISSN: 0143-3334.
DT Journal; Article; (JOURNAL ARTICLE)
FS EMIC
OS EMIC MED-92289027
LA English
ED Entered STN: 20021200
Last updated on STN: 20021200

L4 ANSWER 115 OF 160 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 1998:106834 TOXCENTER
CP Copyright 2004 ACS
DN CA12811124544M
TI Hepatocyte growth factor receptor agonists and uses thereof
AU Hillan, Kenneth J.; Schwall, Ralph H.; Tabor, Kelly H.
CS ASSIGNEE: Genentech, Inc.
PI WO 98543 A1 8 Jan 1998
SO (***1998***) PCT Int. Appl., 48 pp.
CODEN: PIXXD2.
CY UNITED STATES
DT Patent
FS CAPLUS
OS CAPLUS 1998:59054
LA English
ED Entered STN: 20011116

Last Updated on STN: 20020605

L4 ANSWER 116 OF 160 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 1990:125644 TOXCENTER
CP Copyright 2004 ACS
DN CA11215137344R
TI Human monoclonal anti-human immunodeficiency virus type 1 (anti-HIV-1)
antibodies

AU Katinger, Hermann; Von Baehr, Ruediger; Jungbauer, Alois; Porstmann,
Tomas; Steindl, Franz J.; Grunow, Roland; Buchacher, Andrea
CS ASSIGNEE: CL Pharma A.-G.
PI WO 894370 A1 18 May 1989
SO (***1989***) PCT Int. Appl., 35 pp.
CODEN: PIXXD2.
CY AUSTRIA
DT Patent
FS CAPLUS
OS CAPLUS 1990:137344
LA English
ED Entered STN: 20011116
Last Updated on STN: 20021022

L4 ANSWER 117 OF 160 USPATFULL on STN
AN 2001:116835 USPATFULL
TI Method and device for detection of specific target cells in specialized
or mixed cell populations and solutions containing mixed cell
populations
IN Fodstad, .O slashed.ystein, Oslo, Norway
H.o slashed.if.o slashed.dt, Hanne Kleppe, Hvalstad, Norway
Rye, Philip, Oslo, Norway
PA Oystein Fodstad, Oslo, Norway (non-U.S. corporation)
PI US 6265229 B1 20010724
WO 9524648 19950914 <--
AI US 1996-704619 19961104 (8)
WO 1995-NO52 19950310
19961104 PCT 371 date
19961104 PCT 102(e) date
PRAI NO 1994-866 19940310
DT Utility
FS GRANTED
LN.CNT 1694
INCL INCLM: 436/526.000
INCLS: 422/101.000; 435/007.200; 435/007.210; 435/007.230; 435/007.240;
435/033.000; 435/395.000; 436/518.000; 436/525.000; 436/526.000;
436/809.000
NCL NCLM: 436/526.000
NCLS: 422/101.000; 435/007.200; 435/007.210; 435/007.230; 435/007.240;
435/033.000; 435/395.000; 436/518.000; 436/525.000; 436/809.000
IC [7]
ICM: G01N033-553
ICS: B01L011-00
EXF 422/101; 435/7.1; 435/7.2-7.32; 435/29; 435/30; 435/33; 435/383;
435/395; 435/401; 435/975; 436/518; 436/525; 436/526; 436/808; 436/809
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 118 OF 160 USPATFULL on STN
AN 2001:43710 USPATFULL
TI Hepatocyte growth factor receptor antagonists and uses thereof
IN Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly H., Hillsborough, CA, United States
PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)
PI US 6207152 B1 20010327 <--
WO 9638557 19961205
AI US 1998-952235 19980217 (8)
WO 1996-US8094 19960531
19980217 PCT 371 date
19980217 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-460368, filed on 2 Jun 1995,
now patented, Pat. No. US 5686292
DT Utility
FS Granted
LN.CNT 2855
INCL INCLM: 424/130.100
INCLS: 424/133.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100;
424/155.100; 424/156.100; 424/174.100; 530/387.100; 530/387.300;
530/388.220; 530/388.880; 530/388.850; 530/389.100; 530/389.700;

NCL NCLM: 435/007.100; 435/007.200; 435/007.210; 435/007.230
NCLS: 424/130.100
424/133.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100;
424/155.100; 424/156.100; 424/174.100; 435/007.100; 435/007.200;
435/007.210; 435/007.230; 530/387.100; 530/387.300; 530/388.220;
530/388.800; 530/388.850; 530/389.100; 530/389.700

IC [7]

ICM: C07K016-18

ICS: C07K016-28; A61K039-395

EXF 530/388.22; 530/387.1; 530/387.3; 530/388.88; 530/388.85; 530/389.1;
530/389.7; 424/130.1; 424/133.1; 424/138.1; 424/141.1; 424/143.1;
424/152.1; 424/155.1; 424/156.1; 424/174.1; 435/7.1; 435/7.2; 435/7.21;
435/7.23

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 119 OF 160 USPATFULL on STN

AN 2000:161048 USPATFULL

TI N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical
compositions comprising same, and methods for inhibiting .beta.-amyloid
peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, United States

Tung, Jay S., Belmont, CA, United States

Nissen, Jeffrey S., Indianapolis, IN, United States

Mabry, Thomas E., Indianapolis, IN, United States

Latimer, Lee H., Oakland, CA, United States

Eid, Clark N., Cheshire, CT, United States

Audia, James E., Indianapolis, IN, United States

PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
corporation)

Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)

PI US 6153652 20001128 <--

AI US 1997-976295 19971121 (8)

PRAI US 1996-1551P 19961122 (60)

US 1997-113671P 19970228 (60)

DT Utility

FS Granted

LN.CNT 3652

INCL INCLM: 514/619.000

INCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000;

514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000;

549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000;

560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000

NCL NCLM: 514/619.000

NCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000;

514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000;

549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000;

560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000

IC [7]

ICM: A01N037-18

ICS: A01N037-12; A01N037-44; A61K031-165

EXF 564/155; 564/158; 564/152; 564/168; 546/309; 548/471; 548/475; 549/303;

549/304; 560/39; 560/41; 560/42; 560/43; 514/349; 514/352; 514/357;

514/417; 514/470; 514/535; 514/539; 514/619

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 120 OF 160 USPATFULL on STN

AN 2000:121544 USPATFULL

TI N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
comprising same, and methods for use

IN Wu, Jing, San Mateo, CA, United States

Thorsett, Eugene D., Moss Beach, CA, United States

Nissen, Jeffrey S., Indianapolis, IN, United States

Mabry, Thomas E., Indianapolis, IN, United States

Latimer, Lee H., Oakland, CA, United States

John, Varghese, San Francisco, CA, United States

Fang, Lawrence Y., Foster City, CA, United States

Audia, James E., Indianapolis, IN, United States

PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
corporation)

Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)

PI US 6117901 20000912 <--

AI US 1997-976179 19971121 (8)

PRAI US 1996-98551P 19961122 (60)

US 1996-19790P 19960614 (60)

DT Utility

FS Granted

LN.CNT 3321
INCL INCLM: 514/513.000
NCL NCLM: 514/513.000
IC [7]
ICM: A61K031-16
EXF 514/513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 121 OF 160 USPATFULL on STN
AN 2000:113492 USPATFULL
TI Anti-Cryptosporidium parvum preparations
IN Riggs, Michael W., Tucson, AZ, United States
Perryman, Lance E., Cary, NC, United States
PA North Carolina State University, Raleigh, NC, United States (U.S.
corporation)
The Arizona Board of Regents, Tucson, AZ, United States (U.S.
corporation)

PI US 6110463 20000829 <--
AI US 1997-828943 19970327 (8)
PRAI US 1996-14410P 19960329 (60)
US 1996-21465P 19960710 (60)

DT Utility
FS Granted

LN.CNT 1611

INCL INCLM: 424/151.100
INCLS: 424/535.000; 424/807.000; 435/007.220; 435/070.210; 435/172.200;
435/342.000; 530/388.600; 530/822.000; 530/832.000

NCL NCLM: 424/151.100
NCLS: 424/535.000; 424/807.000; 435/007.220; 435/070.210; 435/342.000;
530/388.600; 530/822.000; 530/832.000

IC [7]

ICM: A61K039-395
ICS: A61K035-20; C07K016-20; C12N005-20
EXF 424/130.1; 424/151.1; 424/265.1; 424/266.1; 424/269.1; 424/535; 424/807;
435/7.22; 435/70.21; 435/172.2; 435/947; 435/342; 530/388.6; 530/389.1;
530/822; 530/832; 935/104; 935/107; 935/108

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 122 OF 160 USPATFULL on STN
AN 2000:105429 USPATFULL
TI Methods for generating immune responses employing modified vaccinia of
fowlpox viruses
IN Dorner, Friedrich, Vienna, Austria
Scheiflinger, Friedrich, Orth/Donau, Austria
Falkner, Falko Gunter, Mannsdorf, Austria
Pfleiderer, Michael, Breitstetten, Austria
PA Immuno AG., Vienna, Austria (non-U.S. corporation)

PI US 6103244 20000815 <--
AI US 1996-651472 19960522 (8)

RLI Division of Ser. No. US 1994-358928, filed on 19 Dec 1994 which is a
continuation-in-part of Ser. No. US 1992-914738, filed on 20 Jul 1992,
now abandoned which is a continuation-in-part of Ser. No. US
1991-750080, filed on 26 Aug 1991, now patented, Pat. No. US 5445953

DT Utility
FS Granted

LN.CNT 7208

INCL INCLM: 424/199.100
INCLS: 424/188.100; 424/232.100

NCL NCLM: 424/199.100
NCLS: 424/188.100; 424/232.100

IC [7]

ICM: A61K039-12
ICS: A61K039-21; A61K039-275
EXF 435/320.1; 424/184.1; 424/199.1; 424/204.1; 424/207.1; 424/208.1;
424/232.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 123 OF 160 USPATFULL on STN
AN 2000:101874 USPATFULL
TI Hepatocyte growth factor receptor agonists and uses thereof
IN Hillan, Kenneth J., San Francisco, CA, United States
Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly H., Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)

PI US 6099841 20000808 <--

AI US 1997-884669 19970627 (8)
 PRAI US 1996-21215P 19960703 (60)
 DT Utility
 FS Granted
 LN.CNT 1908
 INCL INCLM: 424/143.100
 INCLS: 424/134.100; 424/135.100; 424/136.100; 424/138.100; 435/334.000;
 530/387.700; 530/387.300; 530/388.220; 530/389.100; 530/389.200;
 530/389.700; 530/350.000
 NCL NCLM: 424/143.100
 NCLS: 424/134.100; 424/135.100; 424/136.100; 424/138.100; 435/334.000;
 530/350.000; 530/387.300; 530/387.700; 530/388.220; 530/389.100;
 530/389.200; 530/389.700
 IC [7]
 ICM: C07K016-28
 ICS: C12N015-06; A61K039-395
 EXF 530/388.22; 530/389.1; 530/387.3; 530/350; 530/387.7; 530/389.7;
 530/389.2; 435/334; 435/7.1; 514/2; 424/143.1; 424/134.1; 424/135.1;
 424/136.1; 424/138.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 124 OF 160 USPATFULL on STN
 AN 2000:98466 USPATFULL
 TI N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions
 comprising same and methods for inhibiting .beta.-amyloid peptide
 release and/or its synthesis by use of such compounds
 IN Audia, James E., Indianapolis, IN, United States
 Folmer, Beverly K., Newark, DE, United States
 John, Varghese, San Francisco, CA, United States
 Latimer, Lee H., Oakland, CA, United States
 Nissen, Jeffrey S., Indianapolis, IN, United States
 Porter, Warren J., Indianapolis, IN, United States
 Thorsett, Eugene D., Moss Beach, CA, United States
 Wu, Jing, San Mateo, CA, United States
 PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6096782 20000801 <--
 AI US 1997-976191 19971121 (8)
 PRAI US 1996-77175P 19961122 (60)
 DT Utility
 FS Granted
 LN.CNT 3343
 INCL INCLM: 514/506.000
 INCLS: 514/399.000; 548/335.500; 560/041.000
 NCL NCLM: 514/506.000
 NCLS: 514/399.000; 548/335.500; 560/041.000
 IC [7]
 ICM: A01N037-20
 ICS: A01N043-50; C07C229-24; C07D233-61
 EXF 560/41; 514/506; 514/399; 548/335.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 125 OF 160 USPATFULL on STN
 AN 2000:43767 USPATFULL
 TI Monoclonal ***antibodies*** reactive with defined regions of the T
 cell antigen receptor
 IN Skibbens, Robert V., Chapel Hill, NC, United States
 Henry, Larry D., Brookline, MA, United States
 Rittershaus, Charles W., Malden, MA, United States
 Tian, Wei-Tao, Allston, MA, United States
 Ip, Stephen H., Sudbury, MA, United States
 Kung, Patrick C., Lexington, MA, United States
 Snider, Mary Ellen, Ledyard, CT, United States
 Ko, Jone-Long, Cambridge, MA, United States
 Wood, Nancy L., Cambridge, MA, United States
 PA Astra AB, United States (non-U.S. corporation)
 PI US 6048526 20000411 <--
 AI US 1993-83408 19930625 (8)
 RLI Division of Ser. No. US 1989-449692, filed on 11 Dec 1989, now patented,
 Pat. No. US 5223426 which is a continuation-in-part of Ser. No. US
 1989-343189, filed on 25 Apr 1989, now abandoned which is a
 continuation-in-part of Ser. No. US 1988-284511, filed on 15 Dec 1988,
 now abandoned
 DT Utility
 FS Granted

LN.CNT 3237
INCL INCLM: 424/144.100
INCLS: 530/388.750
NCL NCLM: 424/144.100
NCLS: 530/388.750
IC [7]
ICM: A61K039-395
ICS: C12P021-08
EXF 424/144.1; 424/144.4; 530/388.22; 530/388.75; 435/240.27; 435/172.3;
435/70.21; 435/7.1; 435/7.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 126 OF 160 USPATFULL on STN
AN 2000:34194 USPATFULL
TI Peptides derived from immunodominant epitopes of myelin basic protein
IN Weiner, Howard L., Brookline, MA, United States
Hafler, David A., West Newton, MA, United States
PA Autoimmune, Inc., Lexington, MA, United States (U.S. corporation)
PI US 6039947 20000321 <--
AI US 1994-297395 19940811 (8)
RLI Continuation of Ser. No. US 1993-59189, filed on 6 May 1993, now
abandoned which is a continuation of Ser. No. US 1990-502559, filed on
30 Mar 1990, now abandoned which is a continuation-in-part of Ser. No.
WO 1988-US2139, filed on 24 Jun 1988, now abandoned And a
continuation-in-part of Ser. No. US 1987-65734, filed on 24 Jun 1987,
now abandoned

DT Utility
FS Granted

LN.CNT 1507
INCL INCLM: 424/184.100
INCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000;
530/326.000
NCL NCLM: 424/184.100
NCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000;
530/326.000

IC [7]
ICM: A61K039-00
ICS: A61K038-17; C07K007-08; C07K014-47
EXF 424/184.1; 530/300; 530/350; 530/324; 530/325; 530/326; 514/12; 514/13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 127 OF 160 USPATFULL on STN
AN 1999:166965 USPATFULL
TI Protein sequences of serrate gene products
IN Ish-Horowicz, David, Oxford, United Kingdom
Henrique, Domingos Manuel Pinto, Oxford, United Kingdom
Lewis, Julian Hart, Oxford, United Kingdom
Myat, Anna Mary, Oxford, United Kingdom
Fleming, Robert J., Rochester, NY, United States
Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
Mann, Robert S., Hamden, CT, United States
Gray, Grace E., New Haven, CT, United States
PA Imperial Cancer Research Technology, Ltd., London, United Kingdom
(non-U.S. corporation)
Yale University, New Haven, CT, United States (U.S. corporation)
PI US 6004924 19991221 <--
AI US 1996-611729 19960306 (8)
RLI Continuation-in-part of Ser. No. US 1995-400159, filed on 7 Mar 1995
which is a continuation-in-part of Ser. No. US 1994-255102, filed on 7
Jun 1994, now abandoned which is a continuation of Ser. No. US
1993-121979, filed on 14 Sep 1993, now abandoned which is a continuation
of Ser. No. US 1991-808458, filed on 11 Dec 1991, now abandoned

DT Utility
FS Granted

LN.CNT 6539
INCL INCLM: 514/002.000
INCLS: 514/013.000; 514/015.000; 530/300.000; 530/326.000; 530/328.000;
530/350.000
NCL NCLM: 514/002.000
NCLS: 514/013.000; 514/015.000; 530/300.000; 530/326.000; 530/328.000;
530/350.000

IC [6]
ICM: A01N037-18
ICS: A61K037-00; C07K014-00
EXF 530/300; 530/326; 530/328; 530/350; 514/15; 514/13; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 128 OF 160 USPATFULL on STN
 AN 1999:141299 USPATFULL
 TI Monoclonal ***antibodies*** reactive with defined regions of the T
 cell antigen receptor
 IN Skibbens, Robert V., Chapel Hill, NC, United States
 Henry, Larry D., Brookline, MA, United States
 Rittershaus, Charles W., Malden, MA, United States
 Tian, Wei-Tao, Allston, MA, United States
 Ip, Stephen H., Sudbury, MA, United States
 Kung, Patrick C., Lexington, MA, United States
 Snider, Mary Ellen, Ledyard, CT, United States
 Ko, Jone-Long, Cambridge, MA, United States
 Wood, Nancy L., Cambridge, MA, United States
 PA Astra AB, Sodertalje, Sweden (non-U.S. corporation)
 PI US 5980892 19991109 <--
 AI US 1995-450425 19950525 (8)
 RLI Division of Ser. No. US 1993-83408, filed on 25 Jun 1993 which is a
 division of Ser. No. US 1989-449692, filed on 11 Dec 1989, now patented,
 Pat. No. US 5223426 which is a continuation-in-part of Ser. No. US
 1989-343189, filed on 25 Apr 1989, now abandoned which is a
 continuation-in-part of Ser. No. US 1988-284511, filed on 15 Dec 1988,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 3139
 INCL INCLM: 424/144.100
 INCLS: 424/154.100; 435/007.100; 435/007.240
 NCL NCLM: 424/144.100
 NCLS: 424/154.100; 435/007.100; 435/007.240
 IC [6]
 ICM: A61K039-395
 EXF 435/7.1; 435/7.24; 424/144.1; 424/154.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 129 OF 160 USPATFULL on STN
 AN 1999:136967 USPATFULL
 TI Monoclonal ***antibodies*** which identify the glycoprotein carrying
 the CA 125 epitope
 IN O'Brien, Timothy J., Little Rock, AR, United States
 PA The Board of Trustees of The University of Arkansas, Little Rock, AR,
 United States (U.S. corporation)
 PI US 5976818 19991102 <--
 AI US 1996-626675 19960402 (8)
 RLI Continuation of Ser. No. US 1994-343357, filed on 22 Nov 1994, now
 abandoned which is a continuation of Ser. No. US 1991-808219, filed on
 16 Dec 1991
 DT Utility
 FS Granted
 LN.CNT 595
 INCL INCLM: 435/007.230
 INCLS: 435/007.900; 435/007.920; 436/063.000; 436/064.000; 530/388.800
 NCL NCLM: 435/007.230
 NCLS: 435/007.900; 435/007.920; 436/063.000; 436/064.000; 530/388.800
 IC [6]
 ICM: G01N033-574
 ICS: G01N033-53; G01N033-542; G01N033-48
 EXF 530/387.7; 530/388.8; 436/63; 436/64; 435/7.23; 435/7.9; 435/7.92;
 435/7.94
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 130 OF 160 USPATFULL on STN
 AN 1999:136683 USPATFULL
 TI Monoclonal ***antibodies*** reactive with defined regions of the T
 cell antigen receptor
 IN Skibbens, Robert V., Chapel Hill, NC, United States
 Henry, Larry D., Brookline, MA, United States
 Rittershaus, Charles W., Malden, MA, United States
 Tian, Wei-Tao, Allston, MA, United States
 Ip, Stephen H., Sudbury, MA, United States
 Kung, Patrick C., Lexington, MA, United States
 Snider, Mary Ellen, Ledyard, CT, United States
 Ko, Jone-Long, Cambridge, MA, United States
 Wood, Nancy L., Cambridge, MA, United States
 PA Astra AB, Sodertalje, Sweden (non-U.S. corporation)
 PI US 5976533 19991102 <--

AI US 1995-449890 19950525 (8)
RLI Division of Ser. No. US 1993-83408, filed on 25 Jun 1993 which is a
division of Ser. No. US 1989-449692, filed on 11 Dec 1989, now patented,
Pat. No. US 5223426 which is a continuation-in-part of Ser. No. US
1989-343189, filed on 25 Apr 1989, now abandoned which is a
continuation-in-part of Ser. No. US 1988-284511, filed on 15 Dec 1988,
now abandoned
DT Utility
FS Granted
LN.CNT 3019
INCL INCLM: 424/144.100
INCLS: 435/070.210; 530/388.220; 530/388.750
NCL NCLM: 424/144.100
NCLS: 435/070.210; 530/388.220; 530/388.750
IC [6]
ICM: A61K039-395
ICS: C12N005-16
EXF 424/144.1; 530/388.22; 530/388.75; 435/240.27; 435/172.3; 435/70.21;
435/325; 435/372.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 131 OF 160 USPATFULL on STN
AN 1999:124950 USPATFULL
TI N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions
comprising same, and methods for inhibiting .beta.-amyloid peptide
release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Whitesitt, Celia A., Greenwood, IN, United States
PA Athena Neurosciences, Inc., United States (U.S. corporation) <--
PI US 5965614 19991012
AI US 1997-975977 19971121 (8)
PRAI US 1996-104593P 19961122 (60)
DT Utility
FS Granted
LN.CNT 2939
INCL INCLM: 514/538.000
INCLS: 514/508.000; 560/043.000; 560/035.000
NCL NCLM: 514/538.000
NCLS: 514/508.000; 560/035.000; 560/043.000
IC [6]
ICM: A01N037-12
ICS: A01N037-52; C07C229-28
EXF 514/538; 514/508; 560/43; 560/35
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 132 OF 160 USPATFULL on STN
AN 1999:99548 USPATFULL
TI Assays for detecting .beta.-secretase
IN Anderson, John P., San Francisco, CA, United States
Jacobson-Croak, Kirsten L., San Bruno, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
corporation) <--
PI US 5942400 19990824
AI US 1996-659984 19960607 (8)
RLI Continuation-in-part of Ser. No. US 1995-485152, filed on 7 Jun 1995 And
a continuation-in-part of Ser. No. US 1995-480498, filed on 7 Jun 1995,
now patented, Pat. No. US 5744346
DT Utility
FS Granted
LN.CNT 2312
INCL INCLM: 435/007.100
INCLS: 435/023.000; 435/961.000; 436/063.000; 436/161.000
NCL NCLM: 435/007.100
NCLS: 435/023.000; 435/961.000; 436/063.000; 436/161.000
IC [6]
ICM: G01N033-53
EXF 435/7.1; 435/7.2; 435/23; 435/325; 435/961; 436/515; 436/516; 436/161;
436/63
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 133 OF 160 USPATFULL on STN
 AN 1999:67010 USPATFULL
 TI HIV-vaccines
 IN Katinger, Hermann, Vienna, Austria
 Buchacher, Andrea, Vienna, Austria
 Ernst, Wolfgang, Vienna, Austria
 Ballaun, Claudia, Vienna, Austria
 Purtscher, Martin, Vienna, Austria
 Trkola, Alexandra, Vienna, Austria
 Predl, Renate, Deutsch-Wagram, Austria
 Schmatz, Christine, Vienna, Austria
 Klima, Annelies, Vienna, Austria
 Steindl, Franz, Vienna, Austria
 Muster, Thomas, Vienna, Austria
 PA Polynum Scientific Immunbiologische Forschung GmbH, Vienna, Austria
 (non-U.S. corporation)
 PI US 5911989 19990615 <--
 AI US 1995-478536 19950607 (8)
 RLI Continuation-in-part of Ser. No. WO 1995-EP1481, filed on 19 Apr 1995
 DT Utility
 FS Granted
 LN.CNT 857
 INCL INCLM: 424/160.100
 INCLS: 530/388.350; 424/208.100; 435/005.000
 NCL NCLM: 424/160.100
 NCLS: 424/208.100; 435/005.000; 530/388.350
 IC [6]
 ICM: A61K039-42
 ICS: A61K039-21; C12Q001-70; C07K016-00
 EXF 424/160.1; 424/208.1; 530/388.35; 435/5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 134 OF 160 USPATFULL on STN
 AN 1999:18950 USPATFULL
 TI Nucleotide and protein sequences of the serrate gene and methods based
 thereon
 IN Ish-Horowicz, David, Oxford, England
 Henrique, Domingos Manuel Pinto, Oxford, England
 Lewis, Julian Hart, Oxford, England
 Myat, Anna Mary, Oxford, England
 Fleming, Robert J., Rochester, NY, United States
 Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
 Mann, Robert S., Hamden, CT, United States
 Gray, Grace E., New Haven, CT, United States
 PA Imperial Cancer Research Technology, Ltd., London, England (non-U.S.
 corporation)
 Yale University, Haven, CT, United States (U.S. corporation)
 PI US 5869282 19990209 <--
 AI US 1995-400159 19950307 (8)
 RLI Continuation-in-part of Ser. No. US 1994-255102, filed on 7 Jun 1994,
 now abandoned which is a continuation of Ser. No. US 1993-121979, filed
 on 14 Sep 1993, now abandoned which is a continuation of Ser. No. US
 1991-808458, filed on 11 Dec 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 5411
 INCL INCLM: 435/069.100
 INCLS: 435/325.000; 435/252.300; 435/320.100; 536/023.100; 536/024.300;
 530/300.000; 530/350.000
 NCL NCLM: 435/069.100
 NCLS: 435/252.300; 435/320.100; 435/325.000; 530/300.000; 530/350.000;
 536/023.100; 536/024.300
 IC [6]
 ICM: C12P021-00
 ICS: C12N015-00; C07H017-00; C07K014-00
 EXF 536/23.1; 536/24.3; 435/69.1; 435/320.1; 435/240.1; 435/252.3; 435/325;
 530/300; 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 135 OF 160 USPATFULL on STN
 AN 1998:135175 USPATFULL
 TI Human monoclonal anti-HIV-I- ***antibodies***
 IN Katinger, Hermann, Heiligenstadterstrasse 131-139, A-1190 Vienna,
 Austria
 Jungbauer, Alois, Vienna, Austria

Steindl, Franz, Vienna, Austria
 Buchacher, Andrea, Vienna, Austria
 Katinger, Hermann, Austria (non-U.S. individual)
 PA US 5831034 19981103 <--
 PI US 1994-293842 19940822 (8)
 AI
 RLI Continuation of Ser. No. US 1991-693730, filed on 30 Apr 1991, now
 abandoned which is a continuation-in-part of Ser. No. US 1987-120489,
 filed on 13 Nov 1987, now abandoned
 DT Utility
 FS Granted
 LN.CNT 506
 INCL INCLM: 530/388.350
 INCLS: 435/005.000; 435/069.100; 530/413.000; 536/023.530; 536/024.200
 NCL NCLM: 530/388.350
 NCLS: 435/005.000; 435/069.100; 530/413.000; 536/023.530; 536/024.200
 IC [6]
 ICM: C07K016-00
 ICS: C12Q001-70; C12P021-06; A23J001-00
 EXF 435/5; 435/69.1; 536/23.53; 536/24.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 136 OF 160 USPATFULL on STN
 AN 1998:108026 USPATFULL
 TI Modified ***antibodies*** with human milk fat globule specificity
 IN do Couto, Fernando J. R., Pleasanton, CA, United States
 Ceriani, Roberto L., Lafayette, CA, United States
 Peterson, Jerry A., Lafayette, CA, United States
 PA Cancer Research Fund of Contra Costa, Walnut Creek, CA, United States
 (U.S. corporation)
 PI US 5804187 19980908 <--
 AI US 1993-129930 19930930 (8)
 RLI Continuation-in-part of Ser. No. US 1992-977696, filed on 16 Nov 1992
 DT Utility
 FS Granted
 LN.CNT 5440
 INCL INCLM: 424/134.100
 INCLS: 424/133.100; 424/138.100; 435/007.230; 435/328.000; 435/330.000;
 530/387.300; 530/387.700
 NCL NCLM: 424/134.100
 NCLS: 424/133.100; 424/138.100; 435/007.230; 435/328.000; 435/330.000;
 530/387.300; 530/387.700
 IC [6]
 ICM: A61K039-395
 ICS: A61K039-40; A61K039-42; G01N033-574
 EXF 530/387.3; 530/388.85; 424/133.1; 424/134.1; 424/156.1; 424/1.11;
 435/240.27
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 137 OF 160 USPATFULL on STN
 AN 1998:95622 USPATFULL
 TI Polynucleotides encoding modified ***antibodies*** with human milk
 fat globule specificity
 IN do Couto, Fernando J. R., Pleasanton, CA, United States
 Ceriani, Roberto L., Lafayette, CA, United States
 Peterson, Jerry A., Lafayette, CA, United States
 Padlan, Eduardo A., Kensington, MD, United States
 PA Cancer Research Fund of Contra Costa, Walnut Creek, CA, United States
 (U.S. corporation)
 PI US 5792852 19980811 <--
 AI US 1992-977696 19921116 (7)
 DT Utility
 FS Granted
 LN.CNT 5011
 INCL INCLM: 536/023.530
 INCLS: 536/023.500; 530/387.300; 424/133.100; 424/134.100; 424/135.100
 NCL NCLM: 536/023.530
 NCLS: 424/133.100; 424/134.100; 424/135.100; 530/387.300; 536/023.500
 IC [6]
 ICM: C07H021-04
 ICS: C12P021-08; A61K039-695; A61K039-40
 EXF 530/387.3; 530/387.7; 530/388.15; 530/388.8; 424/133.1; 424/134.1;
 424/135.1; 424/136.1; 424/138.1; 424/155.1; 536/23.5; 536/23.53
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 138 OF 160 USPATFULL on STN
 AN 1998:68799 USPATFULL

TI Kit containing d-arabinitol dehydrogenase and NAD+ for determining
d-arabinitol
 IN Miyada, Charles Garrett, Mountainview, CA, United States
Switchenko, Arthur C., Palo Alto, CA, United States
Quong, Melanie W., La Jolla, CA, United States
Wong, Man-Ying Laurie, Fremont, CA, United States
 PA Syntex (USA) Inc., San Jose, CA, United States (U.S. corporation)
 PI US 5766874 19980616 <--
 AI US 1995-479069 19950607 (8)
 RLI Division of Ser. No. US 1995-400417, filed on 3 Mar 1995, now patented,
Pat. No. US 5451517 which is a continuation of Ser. No. US 1994-184764,
filed on 21 Jan 1994, now abandoned which is a continuation of Ser. No.
US 1991-731218, filed on 12 Jul 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1094
 INCL INCLM: 435/026.000
INCLS: 435/190.000; 435/255.400; 435/810.000; 435/921.000; 435/924.000
 NCL NCLM: 435/026.000
NCLS: 435/190.000; 435/255.400; 435/810.000; 435/921.000; 435/924.000
 IC [6]
ICM: C12Q001-32
ICS: C12N009-04; C12N001-16
 EXF 435/190; 435/255.4; 435/921; 435/924; 435/810; 435/26
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L4 ANSWER 139 OF 160 USPATFULL on STN
 AN 1998:45086 USPATFULL
 TI .beta.-secretase
 IN Chrysler, Susanna M. S., San Bruno, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
Keim, Pamela S., San Mateo, CA, United States
Anderson, John P., San Francisco, CA, United States
 PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
corporation)
 PI US 5744346 19980428 <--
 AI US 1995-480498 19950607 (8)
 DT Utility
 FS Granted
 LN.CNT 689
 INCL INCLM: 435/226.000
INCLS: 435/219.000; 435/212.000
 NCL NCLM: 435/226.000
NCLS: 435/212.000; 435/219.000
 IC [6]
ICM: C12N009-64
ICS: C12N009-50; C12N006-48
 EXF 435/226; 435/219; 435/212
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L4 ANSWER 140 OF 160 USPATFULL on STN
 AN 1998:33788 USPATFULL
 TI Complexes of nucleic acid and polymer, their process of preparation and
their use for the transfection of cells
 IN Midoux, Patrick, Orleans, France
Erbacher, Patrick, Orleans, France
Roche-Degremont, Annie-Claude, Sandillon, France
Monsigny, Michel, Saint-Cyr-En-Val, France
 PA I.D.M. Immuno-Designed Molecules, France (non-U.S. corporation)
 PI US 5733762 19980331 <--
 AI US 1996-741678 19961031 (8)
 RLI Continuation-in-part of Ser. No. US 1995-505068, filed on 21 Jul 1995,
now abandoned which is a continuation-in-part of Ser. No. US
1994-288681, filed on 10 Aug 1994, now patented, Pat. No. US 5595897,
issued on 21 Jan 1997
 PRAI FR 1994-5174 19940428
 DT Utility
 FS Granted
 LN.CNT 2545
 INCL INCLM: 435/172.300
INCLS: 435/325.000; 514/044.000; 530/300.000; 530/345.000; 530/350.000;
530/395.000; 530/402.000; 536/023.200; 536/023.500; 536/024.500;
536/023.700
 NCL NCLM: 435/458.000
NCLS: 435/325.000; 514/044.000; 530/300.000; 530/345.000; 530/350.000;
530/395.000; 530/402.000; 536/023.200; 536/023.500; 536/023.700;

536/024.500

IC [6]
ICM: C07K001-00
ICS: C07K001-107; C12N015-00; C12N015-88
EXF 435/6; 435/69.1; 435/91.1; 435/172.3; 435/172.1; 435/240.2; 435/183;
435/189; 435/193; 435/194; 435/207; 435/325; 435/375; 435/91.3;
435/91.31; 435/320.1; 530/345; 530/395; 530/402; 530/300; 530/350;
536/23.1; 536/23.2; 536/23.5; 536/23.7; 536/23.72; 536/23.74; 536/24.5;
514/44

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 141 OF 160 USPATFULL on STN
AN 97:120717 USPATFULL
TI Immunogenic peptide antigen corresponding to plasmodium vivax
circumsporozoite protein
IN Arnot, David E., New York, NY, United States
Enea, Vincenzo, New York, NY, United States
Nussenzweig, Ruth S., New York, NY, United States
Nussenzweig, Victor, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 5700906 19971223 <--
WO 8700533 19870129 <--
AI US 1987-43550 19870409 (7)
WO 1986-US1373 19860624
19870409 PCT 371 date
19870409 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1985-754645, filed on 12 Jul 1985,
now abandoned
DT Utility
FS Granted
LN.CNT 1827
INCL INCLM: 530/324.000
INCLS: 530/326.000; 530/300.000; 530/350.000
NCL NCLM: 530/324.000
NCLS: 530/300.000; 530/326.000; 530/350.000

IC [6]
ICM: C07K007-08
ICS: C07K014-445
EXF 530/328; 530/403; 530/324; 530/326; 530/300; 530/350; 435/172.3;
435/69.1; 435/71.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 142 OF 160 USPATFULL on STN
AN 97:104323 USPATFULL
TI Hepatocyte growth factor receptor antagonist ***antibodies*** and
uses thereof
IN Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly Helen, Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5686292 19971111 <--
AI US 1995-460368 19950602 (8)
DT Utility
FS Granted
LN.CNT 1406
INCL INCLM: 435/240.270
INCLS: 424/133.100; 424/143.100; 530/387.300; 530/387.700; 530/388.100;
530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100;
530/389.700
NCL NCLM: 424/143.100
NCLS: 424/133.100; 435/334.000; 530/387.300; 530/387.700; 530/388.100;
530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100;
530/389.700

IC [6]
ICM: C12N005-12
ICS: A61K039-395; C07K016-28
EXF 530/387.7; 530/388.1; 530/388.2; 530/388.8; 530/388.85; 530/389.1;
530/389.7; 530/387.3; 424/133.1; 424/143.1; 435/240.27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 143 OF 160 USPATFULL on STN
AN 97:75973 USPATFULL
TI Immortalized human cell lines containing exogenous cytochrome P450 genes
IN Harris, Curtis C., 8402 Thornden Terr., Bethesda, MD, United States
20817
Gelboin, Harry V., 2806 Abilene Dr., Chevy Chase, MD, United States

20815
Gonzalez, Frank J., 5000 Battery La., Apt. #101, Bethesda, MD, United States 20814
Mace, Katharine C., Rue Haldimand 10, 1003 Lausanne, Switzerland
Pfeifer, Andrea M. A., Chemin de Chaponeyres 6, 1800 Vevey, Switzerland

PI US 5660986 19970826 <--
AI US 1995-462998 19950605 (8)
RLI Division of Ser. No. US 1993-65201, filed on 19 May 1993, now patented, Pat. No. US 5506131 which is a continuation-in-part of Ser. No. US 1992-869818, filed on 13 Apr 1992, now patented, Pat. No. US 5356806 which is a continuation-in-part of Ser. No. US 1991-787777, filed on 6 Nov 1991, now patented, Pat. No. US 5164313 which is a continuation-in-part of Ser. No. US 1987-58387, filed on 5 Jun 1987, now abandoned, said Ser. No. US -869818 which is a continuation-in-part of Ser. No. US 1991-636712, filed on 2 Jan 1991, now patented, Pat. No. US 5443954 which is a continuation-in-part of Ser. No. US 1988-265883, filed on 1 Nov 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-114508, filed on 30 Oct 1987, now patented, Pat. No. US 4885238

DT Utility
FS Granted
LN.CNT 1057
INCL INCLM: 435/006.000
INCLS: 435/172.100; 435/029.000; 435/032.000
NCL NCLM: 435/006.000
NCLS: 435/029.000; 435/032.000; 435/441.000
IC [6]
ICM: C12Q001-68
EXF 435/6; 435/172.1; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 144 OF 160 USPATFULL on STN
AN 97:59098 USPATFULL
TI Nucleic acids encoding hepatocyte growth factor receptor antagonist
antibodies
IN Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly Helen, Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5646036 19970708 <--
AI US 1995-459388 19950602 (8)
DT Utility
FS Granted
LN.CNT 1402
INCL INCLM: 435/252.300
INCLS: 435/240.200; 435/320.100; 536/023.530; 530/387.700; 530/388.220; 530/388.800; 530/388.850; 530/389.100; 530/389.700
NCL NCLM: 435/252.300
NCLS: 435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800; 530/388.850; 530/389.100; 530/389.700; 536/023.530
IC [6]
ICM: C12N015-13
ICS: C12N015-85; C12N001-21; C07K016-28
EXF 536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85; 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 145 OF 160 USPATFULL on STN
AN 97:54206 USPATFULL
TI Modified VEGF oligonucleotides
IN Robinson, Gregory S., Acton, MA, United States
PA Hybridon, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5641756 19970624 <--
AI US 1995-569926 19951208 (8)
RLI Continuation-in-part of Ser. No. US 1995-398945, filed on 2 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-378860, filed on 26 Jan 1995 which is a continuation-in-part of Ser. No. US 1993-98942, filed on 27 Jul 1993

DT Utility
FS Granted
LN.CNT 1264
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/375.000; 536/024.500; 536/023.500; 536/024.300; 536/024.310; 536/024.330
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/375.000; 536/023.500; 536/024.300; 536/024.310;

536/024.330; 536/024.500

IC [6]
ICM: A61K031-70
ICS: C07H021-00; C12N005-10; C12Q001-68
EXF 536/24.5; 536/23.5; 536/24.3; 536/24.31; 536/24.33; 514/44; 435/6;
435/240.2; 435/172.3; 935/33; 935/34; 935/36; 935/8; 935/9; 935/11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 146 OF 160 USPATFULL on STN
AN 97:51892 USPATFULL
TI Resurfacing of rodent ***antibodies***
IN Pedersen, Jan T., Bath, United Kingdom
Searle, Stephen M. J., Bath, United Kingdom
Rees, Anthony R., Bath, United Kingdom
Roguska, Michael A., Ashland, MA, United States
Guild, Braydon C., Concord, MA, United States
PA Immunogen Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5639641 19970617 <--
AI US 1992-942245 19920909 (7)
DT Utility
FS Granted
LN.CNT 2777
INCL INCLM: 435/069.600
INCLS: 435/172.100; 530/387.300; 530/387.700; 530/388.300
NCL NCLM: 435/069.600
NCLS: 530/387.300; 530/387.700; 530/388.300

IC [6]
ICM: C12N015-00
ICS: C07K016-00; A61K039-395
EXF 530/387.3; 530/387.7; 530/388.8; 435/69.6; 435/172.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 147 OF 160 USPATFULL on STN
AN 97:1549 USPATFULL
TI Detection of complexes which include basement membrane components as
diagnostic of cancer and other diseases
IN Van Aken, Morgan, Bainbridge Island, WA, United States
Paskell, Stefan L., Bainbridge Island, WA, United States
PA Bainbridge Sciences, Inc., Redmond, WA, United States (U.S. corporation)
PI US 5591830 19970107 <--
AI US 1995-456855 19950601 (8)
RLI Continuation of Ser. No. US 1994-178219, filed on 6 Jan 1994, now
patented, Pat. No. US 5512657 which is a continuation of Ser. No. US
1993-96490, filed on 23 Jul 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1991-721756, filed on 26 Jun 1991,
now patented, Pat. No. US 5264370, issued on 23 Nov 1993 which is a
continuation-in-part of Ser. No. US 1988-283397, filed on 12 Dec 1988,
now abandoned
DT Utility
FS Granted
LN.CNT 1908
INCL INCLM: 530/388.850
INCLS: 530/387.100; 530/388.100; 530/388.200; 435/007.230
NCL NCLM: 530/388.850
NCLS: 435/007.230; 530/387.100; 530/388.100; 530/388.200
IC [6]
ICM: C07K016-00
ICS: C07K016-18
EXF 530/387.1; 530/388.1; 530/388.2; 530/388.85; 435/7.23
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 148 OF 160 USPATFULL on STN
AN 97:1325 USPATFULL
TI Detection of complexes which include basement membrane components as
diagnostic of cancer and other diseases
IN Van Aken, Morgan, Bainbridge Island, WA, United States
Paskell, Stefan L., Bainbridge Island, WA, United States
PA Bainbridge Sciences, Inc., Redmond, WA, United States (U.S. corporation)
PI US 5591595 19970107 <--
AI US 1995-457285 19950601 (8)
RLI Continuation of Ser. No. US 1994-178219, filed on 6 Jan 1994, now
patented, Pat. No. US 5512657 which is a continuation of Ser. No. US
1993-96490, filed on 23 Jul 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1991-721756, filed on 26 Jun 1991,
now patented, Pat. No. US 5264370, issued on 23 Nov 1993 which is a
continuation-in-part of Ser. No. US 1988-283397, filed on 12 Dec 1988,

now abandoned
DT Utility
FS Granted
LN.CNT 2087
INCL INCLM: 435/007.230
INCLS: 435/007.100; 435/007.200; 435/007.900; 435/007.920; 436/501.000;
436/064.000; 436/813.000
NCL NCLM: 435/007.230
NCLS: 435/007.100; 435/007.200; 435/007.900; 435/007.920; 436/064.000;
436/501.000; 436/813.000
IC [6]
ICM: G01N033-574
ICS: G01N033-53
EXF 435/7.23; 435/7.1; 435/7.2; 435/7.9; 435/7.92; 436/501; 436/64; 436/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 149 OF 160 USPATFULL on STN
AN 96:113802 USPATFULL
TI Agglutination assay
IN Hillyard, Carmel J., Queensland, Australia
Rylatt, Dennis B., Queensland, Australia
PA Agen Limited, Queensland, Australia (non-U.S. corporation)
PI US 5583003 19961210 <--
AI US 1994-351105 19941130 (8)
RLI Continuation of Ser. No. US 1992-842343, filed on 25 Mar 1992, now
abandoned
PRAI AU 1989-6558 19890925
DT Utility
FS Granted
LN.CNT 1912
INCL INCLM: 435/007.250
INCLS: 435/007.400; 435/972.000; 435/973.000
NCL NCLM: 435/007.250
NCLS: 435/007.400; 435/972.000; 435/973.000
IC [6]
ICM: G01N033-53
ICS: G01N033-555; G01N033-567
EXF 435/972; 435/973; 435/7.4; 435/7.25
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 150 OF 160 USPATFULL on STN
AN 96:101449 USPATFULL
TI Chemical event selection by suicide substrate conjugates
IN Janda, Kim D., San Diego, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S.
corporation)
PI US 5571681 19961105 <--
AI US 1994-209525 19940310 (8)
DT Utility
FS Granted
LN.CNT 3030
INCL INCLM: 435/007.600
INCLS: 435/188.500; 435/041.000
NCL NCLM: 435/007.600
NCLS: 435/041.000; 435/188.500; 435/DIG.004; 435/DIG.021; 435/DIG.035
IC [6]
ICM: C12Q001-25
ICS: C12N009-00
EXF 435/188.5; 435/7.6; 435/7.71; 435/7.72; 435/41
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 151 OF 160 USPATFULL on STN
AN 96:67898 USPATFULL
TI Methods for determining the invasiveness of a bladder tumor
IN Houghton, Raymond L., Bothell, WA, United States
Van Aken, Morgan, Bainbridge Island, WA, United States
Jones, Tobin K., Bainbridge Island, WA, United States
PA Bard Diagnostic Sciences, Inc., Redmond, WA, United States (U.S.
corporation)
PI US 5541076 19960730 <--
AI US 1995-460496 19950602 (8)
RLI Continuation-in-part of Ser. No. US 1994-178219, filed on 6 Jan 1994
which is a continuation of Ser. No. US 1993-96490, filed on 23 Jul 1993,
now abandoned which is a continuation-in-part of Ser. No. US
1991-721756, filed on 26 Jun 1991, now patented, Pat. No. US 5264370
which is a continuation-in-part of Ser. No. US 1988-283397, filed on 12

Dec 1988, now abandoned
DT Utility
FS Granted
LN.CNT 1489
INCL INCLM: 435/007.230
INCLS: 435/007.900; 436/064.000; 436/813.000
NCLM: 435/007.230
NCLS: 435/007.900; 436/064.000; 436/813.000
IC [6]
ICM: G01N033-574
ICS: G01N033-53
EXF 435/7.23; 435/7.9; 436/64; 436/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 152 OF 160 USPATFULL on STN
AN 96:36652 USPATFULL
TI Detection of complexes which include basement membrane components as
diagnostic of cancer and other diseases
IN Van Aken, Morgan, Bainbridge Island, WA, United States
Paskell, Stefan L., Bainbridge Island, WA, United States
PA Bainbridge Sciences, Inc., Redmond, WA, United States (U.S. corporation)
PI US 5512657 19960430 <--
AI US 1994-178219 19940106 (8)
RLI Continuation of Ser. No. US 1993-96490, filed on 23 Jul 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1991-721756,
filed on 26 Jun 1991, now patented, Pat. No. US 5264370, issued on 23
Nov 1993 which is a continuation-in-part of Ser. No. US 1988-283397,
filed on 12 Dec 1988, now abandoned
DT Utility
FS Granted
LN.CNT 1885
INCL INCLM: 530/350.000
INCLS: 530/412.000; 530/413.000; 530/416.000; 436/064.000; 436/811.000;
436/813.000; 436/820.000; 435/004.000; 435/029.000
NCLM: 530/350.000
NCLS: 435/004.000; 435/029.000; 436/064.000; 436/811.000; 436/813.000;
436/820.000; 530/412.000; 530/413.000; 530/416.000
IC [6]
ICM: C07K014-435
ICS: C07K001-22; G01N033-483; G01N033-493
EXF 530/350; 530/412; 530/413; 530/416; 435/4; 435/29; 436/63; 436/64;
436/811; 436/813; 436/820
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 153 OF 160 USPATFULL on STN
AN 96:29461 USPATFULL
TI Immortalized human cell lines containing exogenous cytochrome P450 genes
IN Harris, Curtis C., Bethesda, MD, United States
Gelboin, Harry V., Chevy Chase, MD, United States
Gonzalez, Frank J., Bethesda, MD, United States
Mace, Katharine C., Lousanne, Switzerland
Pfeifer, Andrea M. A., Vevey, Switzerland
PA The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. government)
PI US 5506131 19960409 <--
AI US 1993-65201 19930519 (8)
RLI Continuation-in-part of Ser. No. US 1992-869818, filed on 13 Apr 1992,
now patented, Pat. No. US 5356806 which is a continuation-in-part of
Ser. No. US 1991-787777, filed on 6 Nov 1991, now patented, Pat. No. US
5164313 which is a continuation-in-part of Ser. No. US 1987-58387, filed
on 5 Jun 1987, now abandoned, said Ser. No. US -869818 which is a
continuation-in-part of Ser. No. US 1991-636712, filed on 2 Jan 1991,
now patented, Pat. No. US 5443954 which is a continuation-in-part of
Ser. No. US 1988-265883, filed on 1 Nov 1988, now abandoned which is a
continuation-in-part of Ser. No. US 1987-114508, filed on 30 Oct 1987,
now patented, Pat. No. US 4885238
DT Utility
FS Granted
LN.CNT 1259
INCL INCLM: 435/240.200
INCLS: 435/006.000
NCLM: 435/006.000
NCLS: 435/371.000
IC [6]
ICM: C12N005-10
EXF 435/6; 435/7.21; 435/69.1; 435/172.2; 435/172.3; 435/240.2; 935/70

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 154 OF 160 USPATFULL on STN
AN 95:84315 USPATFULL
TI D-arabinitol dehydrogenase from Candida tropicalis ATCC 750 or Candida shehatae
IN Miyada, Charles G., Mountain View, CA, United States
Switchenko, Arthur C., Palo Alto, CA, United States
Quong, Melanie W., La Jolla, CA, United States
Wong, Man-Ying L., Fremont, CA, United States
PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5451517 19950919 <--
AI US 1995-400417 19950303 (8)
RLI Continuation of Ser. No. US 1994-184764, filed on 21 Jan 1994, now abandoned which is a continuation of Ser. No. US 1991-731218, filed on 12 Jul 1991, now abandoned
DT Utility
FS Granted
LN.CNT 1085
INCL INCLM: 435/190.000
INCLS: 435/255.400; 435/921.000; 435/924.000
NCL NCLM: 435/190.000
NCLS: 435/255.400; 435/921.000; 435/924.000
IC [6]
ICM: C12N009-04
ICS: C12N001-16; C12N001-00
EXF 435/190; 435/255.4; 435/921; 435/924
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 155 OF 160 USPATFULL on STN
AN 95:40851 USPATFULL
TI Erythrocyte agglutination assay
IN Hillyard, Carmel J., Brisbane, Australia
Rylatt, Dennis B., Rosalie, Australia
Kemp, Bruce E., Kew, Australia
Bundesen, Peter G., Fig Tree Pocket, Australia
PA Agen Biomedical, Ltd., Acadia Ridge, Australia (non-U.S. corporation)
PI US 5413913 19950509 <--
AI US 1994-191064 19940203 (8)
RLI Continuation of Ser. No. US 1991-770845, filed on 4 Oct 1991, now abandoned which is a continuation of Ser. No. US 1989-324500, filed on 16 Mar 1989, now patented, Pat. No. US 5086002 which is a continuation-in-part of Ser. No. US 1988-143343, filed on 13 Jan 1988, now patented, Pat. No. US 4894347 which is a continuation-in-part of Ser. No. US 1987-111313, filed on 22 Oct 1987, now abandoned
PRAI AU 1987-4400 19870907
AU 1987-5018 19871022
DT Utility
FS Granted
LN.CNT 1176
INCL INCLM: 435/007.250
INCLS: 435/002.000; 435/975.000; 436/519.000; 436/520.000; 436/819.000; 530/388.700; 530/391.100
NCL NCLM: 435/007.250
NCLS: 435/002.000; 435/975.000; 436/519.000; 436/520.000; 436/819.000; 530/388.700; 530/391.100
IC [6]
ICM: G01N033-555
EXF 435/2; 435/7.5; 435/70.21; 435/975; 436/501; 436/519; 436/520; 436/547; 436/548; 436/819; 530/388.1; 530/388.2; 530/388.7; 530/391.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 156 OF 160 USPATFULL on STN
AN 93:106926 USPATFULL
TI Assay by enzyme-catalyzed isotopic exchange
IN Switchenko, Arthur C., Sunnyvale, CA, United States
Ullman, Edwin F., Atherton, CA, United States
PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5272054 19931221 <--
AI US 1992-857883 19920326 (7)
DT Utility
FS Granted
LN.CNT 1476
INCL INCLM: 435/004.000
INCLS: 435/007.720; 435/007.900; 435/015.000; 435/026.000; 435/189.000; 435/191.000; 435/810.000; 435/814.000; 435/968.000; 435/975.000;

NCL NCLM: 436/504.000; 436/542.000; 436/545.000; 436/804.000; 424/001.100
NCLS: 435/004.000
435/007.720; 435/007.900; 435/015.000; 435/026.000; 435/189.000;
435/191.000; 435/810.000; 435/814.000; 435/968.000; 435/975.000;
436/504.000; 436/542.000; 436/545.000; 436/804.000
IC [5]
ICM: C12Q001-00
ICS: G01N033-567
EXF 435/4; 435/7.72; 435/7.9; 435/15; 435/26; 435/189; 435/191; 435/810;
435/814; 435/968; 435/975; 436/504; 436/542; 436/545; 436/804; 424/1.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 157 OF 160 USPATFULL on STN
AN 93:52504 USPATFULL
TI Monoclonal ***antibodies*** reactive with defined regions of the
T-cell antigen receptor
IN Skibbens, Robert V., Chapel Hill, NC, United States
Henry, Larry D., Brookline, MA, United States
Rittershaus, Charles W., Malden, MA, United States
Tian, Wei-Tao, Allston, MA, United States
Ip, Stephen H., Sudbury, MA, United States
Kung, Patrick C., Lexington, MA, United States
Snider, Mary Ellen, Ledyard, CT, United States
Ko, Jone-Long, Cambridge, MA, United States
Wood, Nancy L., Cambridge, MA, United States
PA T Cell Sciences, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5223426 19930629 <--
AI US 1989-449692 19891211 (7)
RLI Continuation-in-part of Ser. No. US 1989-343189, filed on 25 Apr 1989
which is a continuation-in-part of ser. No. US 1988-284511, filed on 15
Dec 1988, now abandoned
DT Utility
FS Granted
LN.CNT 2972
INCL INCLM: 435/240.270
INCLS: 530/387.100; 530/387.900; 424/085.800
NCL NCLM: 435/331.000
NCLS: 424/144.100; 424/154.100; 530/387.100; 530/387.900; 530/388.220;
530/388.750
IC [5]
ICM: A61K039-00
ICS: A61K035-16
EXF 530/387; 530/381.1; 530/2; 530/395; 435/240.27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 158 OF 160 USPATFULL on STN
AN 92:9052 USPATFULL
TI Erythrocyte agglutination assay
IN Hillyard, Carmel J., Brisbane, Australia
Rylatt, Dennis B., Rosalie, Australia
Kemp, Bruce E., Kew, Australia
Bundesen, Peter G., Fig Tree Pocket, Australia
PA Agen Biomedical, Ltd., Acacia Ridge, Australia (non-U.S. corporation)
PI US 5086002 19920204 <--
AI US 1989-324500 19890316 (7)
RLI Continuation-in-part of Ser. No. US 1988-143343, filed on 13 Jan 1988,
now patented, Pat. No. US 4894347 which is a continuation-in-part of
ser. No. US 1987-111313, filed on 22 Oct 1987, now abandoned
PRAI AU 1987-4400 19870907
AU 1987-5018 19871022
DT Utility
FS Granted
LN.CNT 1284
INCL INCLM: 436/540.000
INCLS: 436/501.000; 436/519.000; 422/061.000; 530/387.000
NCL NCLM: 436/540.000
NCLS: 422/061.000; 435/007.250; 436/501.000; 436/519.000; 530/387.300;
530/388.700; 530/389.100; 530/866.000
IC [5]
ICM: G01N033-541
EXF 530/387; 530/389; 422/61; 436/519; 436/520; 436/540; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 159 OF 160 USPATFULL on STN
AN 90:4355 USPATFULL
TI Erythrocyte agglutination assay

IN Hillyard, Carmel J., Brisbane, Australia
 Rylatt, Dennis B., Rosalie, Australia
 Kemp, Bruce E., Kew, Australia
 Bundesen, Peter G., Fig Tree Pocket, Australia
 PA Agen Limited, Australia (non-U.S. corporation)
 PI US 4894347 19900116 <--
 AI US 1988-143343 19880113 (7)
 RLI Continuation-in-part of Ser. No. US 1989-111313, filed on 22 Oct 1989
 PRAI AU 1987-4400 19870917
 DT Utility
 FS Granted
 LN.CNT 701
 INCL INCLM: 436/540.000
 INCLS: 436/501.000; 436/519.000; 422/061.000; 530/387.000
 NCL NCLM: 436/540.000
 NCLS: 422/061.000; 436/501.000; 436/519.000; 530/387.300; 530/388.700
 IC [4]
 ICM: G01N033-541
 EXF 530/387; 530/389; 422/61; 436/519; 436/520; 436/540; 436/501
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 160 OF 160 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 1992-390692 [48] WPIDS
 DNC C1992-173320
 TI Prodn. of human immunodeficiency virus gp-41 derivs. - using plasmid
 contg. FR-coat proteins, 2N-terminal aminoacid(s) and HIV gene AA474-647,
 to produce immunologically active gp-41.
 DC B04 D16
 IN DREILINJA, D; KOZLOVSKAJA, T; OZOLS, J; PORSTMANN, T; PUMPEN, P; PUSHKO,
 P; ULRICH, R
 PA (ALOR) AS LATV ORGANIC SYNTHESIS INST; (UYBE) UNIV BERLIN HUMBOLDT
 CYC 1
 PI DD 300690 A5 19920702 (199248)* 4 C12N015-48 <--
 ADT DD 300690 A5 DD 1990-338996 19900323
 PRAI DD 1990-338996 19900323
 IC ICM C12N015-48
 ICS C07K015-04; C12N015-62; C12P021-02
 STN INTERNATIONAL LOGOFF AT 16:17:00 ON 17 MAY 2004